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ABSTRACT 
 
Thymic stromal lymphopoietin (TSLP) is an IL-7 like cytokine that has recently 
emerged as being critical in promoting T-2 mediated inflammatory responses in 
atopic disease via its unique activation of dendritic cells (DCs). However, its role in 
idiopathic pulmonary fibrosis (IPF), a non-allergen driven disease characterised by 
excessive fibroblast activation and a pro-fibrotic T-2 immune phenotype, is 
unknown.  
TSLP has traditionally been regarded as an epithelial-derived cytokine targeting 
cells of a haematopoietic lineage. However, the present work identifies fibroblasts 
as a potentially important source and cellular target in IPF. Primary human lung 
fibroblasts (pHLFs) express and release TSLP in a JNK/c-Jun dependent manner 
following exposure to TNF-α, a master cytokine strongly implicated in the 
pathogenesis of lung fibrosis. Moreover, this thesis demonstrates for the first time 
that lung fibroblasts express a functional TSLP-TSLPR signalling axis; following 
exposure to TSLP, these cells release the pro-fibrotic chemokine, CCL2, in a 
STAT3-dependent manner, thereby promoting chemotaxis of human monocytes. 
The work presented here further identifies TSLP as a key mediator of local DC 
activation and the generation of a T-2 immune phenotype in the bleomycin model of 
lung injury and fibrosis. However, neutralisation of TSLP activity in vivo did not 
attenuate bleomycin-induced fibrosis, suggesting that despite its essential role in 
DC activation and T-2 polarisation, TSLP may not play a significant role in the 
subsequent development of fibrosis in this model. Taken together, these studies 
extend our current understanding of TSLP as a master regulator of T-2 immune 
responses beyond that of allergic inflammatory conditions. The human expression 
and functional studies performed during the course of this PhD do not rule out a 
potential pathogenic role for TSLP in IPF. Extended studies are warranted to 
explore these observations further. 
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CHAPTER 1: INTRODUCTION 
 
1.1. Pulmonary Fibrosis 
Pulmonary fibrosis (PF) represents the end stage of a heterogeneous group of 
conditions that are characterised by the excessive deposition of extracellular matrix 
(ECM) proteins within the pulmonary interstitium. This interstitium is composed of 
the alveolar walls, including epithelial and endothelial cells, their septae and 
associated peri-lymphatic and peri-bronchiolar connective tissue. It is across this 
critical space that gas exchange occurs. The deposited ECM proteins, such as 
collagen, ultimately replace normal functional tissue in a disorganised fashion. This 
fibrosis is generally progressive and, in many cases, leads inexorably to respiratory 
failure, due to obliteration of functional alveolar units, and premature death.  
PF, to a greater or lesser degree, is a hallmark of the interstitial lung diseases 
(ILDs). Although individual disease patterns within this group of conditions share a 
number of clinical, radiographic and pathological features, mechanisms of disease 
and prognoses are often very different. A small number of ILDs have well defined 
aetiologies relating to occupational factors (eg. asbestosis) or drug exposure (eg. 
methotrexate); some are associated with systemic disorders such as rheumatoid 
arthritis or systemic sclerosis. The ILDs with known aetiologies have been grouped 
in Table 1.1. However, the vast majority are idiopathic, and are termed the 
Idiopathic Interstitial Pneumonias (IIPs). 
Ever since the fibrotic sequelae of ILDs were first described towards the end of the 
19th century, classification of IIPs has been marred by controversy and difficulty 
(Maher et al., 2007). However in 2002, the American Thoracic Society (ATS) and 
European Respiratory Society (ERS) consensus panels reclassified IIPs into seven 
distinct disease entities, distinguishable by their clinical, radiological and histological 
patterns, as illustrated in Table 1.2. 
1.2. Idiopathic Pulmonary Fibrosis 
Idiopathic pulmonary fibrosis (IPF) accounts for almost half of all the IIPs (ATS, 
2000). In the UK, it has a reported incidence of 4.6 per 100000 people in the 
general population (Gribbin et al., 2006), a figure which has increased annually by 
11% between 1991 and 2003 (Gribbin et al., 2006). In the UK alone, around 5000 
new cases are currently diagnosed each year and IPF accounts for over 1500 
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Aetiology 
 
 Clinical example 
Systemic 
disease 
Collagen vascular 
disease 
Systemic sclerosis 
  Rheumatoid arthritis 
 
  Sjorgren’s disease 
 
  Poly/dermatomyositis 
 
 Immunodeficiency Common variable immunodeficiency 
   
Exposures 
 
Environmental 
 
Hypersensitivity pneumonitis 
 Occupational 
 
Asbestosis 
  Berylliosis 
 
  Silicosis 
 
 Drug induced Amiodarone 
 
  Methotrexate 
 
Genetic  Familial interstitial pneumonia 
 
  Hermanski-Pudlack syndrome 
 
 
 
Table 1.1. Clinical classification of ILDs with known aetiologies (adapted 
from Laurent and Shapiro, 2007) 
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deaths per year (Hubbard et al., 1996), representing a disease burden comparable 
to small cell lung cancer. It is more common in men, and its incidence increases 
with age. There is no geographical pattern of disease distribution or racial 
predisposition. A number of clinical, radiological and physiological parameters have 
been identified as predictors of worse outcome – these include progressive 
dyspnoea, oxygen desaturation during a 6 minute walk test, the presence and 
extent of honeycombing on high resolution computed tomography (HRCT) of the 
thorax and the presence of pulmonary hypertension.  
The classical histological pattern of IPF is one of usual interstitial pneumonia (UIP): 
areas of normal lung are interspersed with regions of dense fibrosis, honeycombing 
and fibrotic foci (Figure 1.1.). Honeycombing occurs as a result of the destruction of 
lung parenchyma leading to enlarged and distorted airspaces. Fibrotic foci are 
aggregates of highly synthetic myofibroblasts often observed within the mura of 
microscopic honeycomb lesions underlying injured and reparative epithelium, as 
well as within the interstitium – these foci represent accumulations of fibroblasts and 
myofibroblasts within organizing ECM, and their presence and distribution, together 
with the spatial and temporal heterogeneity of epithelial damage and ECM 
deposition is crucial to defining a UIP pattern (Katzenstein et al., 1998). This is in 
contrast, for example, to the histological pattern of non-specific interstitial 
pneumonia (NSIP) in which honeycombing is absent and a marked inflammatory 
interstitial infiltrate is observed. The spatial heterogeneity of UIP is similarly seen on 
high-resolution CT scans of IPF lung, and the patchy, subpleural, predominantly 
lower lobe reticular opacities and honeycombing correlates well with UIP, often 
obviating recourse to a lung biopsy to achieve a definitive diagnosis.  
Following diagnosis, although the clinical course of IPF can be extremely variable, 
the median survival is less than 3 years (Kim et al., 2006a) – this is the poorest 
prognosis of all the IIPs, and reflects the progressive replacement of functional 
alveolar units with dense fibrotic tissue. The disease appears to be resistant to 
conventional anti-inflammatory and immunosuppressive treatment, but despite this, 
current gold standard therapy comprises low dose steroids and a steroid sparing 
immunosuppressive agent such as azathioprine, together with the recent addition of 
N-acetylcysteine (Demedts et al., 2005). Interestingly, a recent study demonstrated 
that pirfenidone, a novel anti-inflammatory and anti-fibrotic drug, reduces the
  
 
Figure 1.1. 
Fibrotic foci – a histological hallmark of idiopathic pulmonary fibrosis. (A) Histological analysis of human IPF tissue reveals 
the presence of dense collagen deposition within the interstitium (Martius Scarlet Blue staining; original magnification ×10). 
Fibroblastic foci are revealed as accumulations of fibroblasts and alpha-SMA+ myofibroblasts, which are highly synthetic for 
collagen and have a contractile phenotype (B: Martius Scarlet Blue staining; C: immunohistochemistry for alpha-SMA. Original 
magnification ×20). The overlying epithelium is often hyperplastic, with frequent apoptosis and areas of denudation. The presence 
and distribution of fibrotic foci, together with the spatial and temporal heterogeneity of the pathology is crucial to defining a UIP 
pattern. [reproduced from (Datta et al., 2011)] 
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Histological pattern 
 
 
Diagnosis based on clinical, radiological 
and histological findings 
 
Usual interstitial pneumonia (UIP) Idiopathic pulmonary fibrosis (IPF) 
 
Non-specific interstitial pneumonia 
(NSIP) 
Non-specific interstitial pneumonia 
(NSIP) 1 
 
Organizing pneumonia Cryptogenic organizing pneumonia  
 
Diffuse alveolar damage 
 
Acute interstitial pneumonia 
 
Respiratory bronchiolitis 
 
Respiratory bronchiolitis-associated 
interstitial lung disease 
 
Desquamative interstitial pneumonia  
 
Desquamative interstitial pneumonia  
 
Lymphoid interstitial pneumonia  Lymphoid interstitial pneumonia  
 
 
 
Table 1.2. Classification of Idiopathic Interstitial Pneumonias. 
(Table adapted from: American Thoracic Society / European Respiratory 
Society International multidisciplinary consensus classification of IIPs, 2002) 
1
 NSIP can be further sub-divided into cellular and fibrotic NSIP (Nicholson 
et al., 2000)  
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deterioration in lung function in IPF patients (Noble et al., 2011). The precise 
molecular mechanism of action of pirfenidone remains unknown, though its anti-
fibrotic potential may relate to its ability to inhibit fibroblast proliferation and 
extracellular matrix deposition (Di Sario et al., 2002; Hewitson et al., 2001), which 
may be secondary to inhibition of pro-fibrotic cytokine expression (Gurujeyalakshmi 
et al., 1999; Iyer et al., 1999). 
The aetiology of IPF remains unknown, although a number of risk factors have been 
identified. For example, cigarette smoking has been associated with an increased 
risk of developing IPF (Baumgartner et al., 1997), as have certain latent viral 
infections, including EBV and herpesvirus (Kelly et al., 2002; Tang et al., 2003). 
Three percent of IPF patients appear to have a familial form, and gene 
polymorphisms of tumour necrosis factor (TNF)-α and transforming growth factor 
beta (TGF)-β1, as well as mutations in surfactant protein C, appear to confer an 
increased risk of developing IPF (Lawson et al., 2004; Whyte et al., 2000; Xaubet et 
al., 2003). However, as only a small number of those individuals exposed to known 
risk factors develop IPF, the true aetiology is likely to be multi-factorial.  
1.3. Pathogenesis of pulmonary fibrosis 
Although significant advances have been made in our understanding of the 
pathogenesis of pulmonary fibrosis, the specific molecular and cellular mechanisms 
that contribute to disease progression remain unclear. Much of our understanding is 
derived from animal models of pulmonary fibrosis, the commonest of which involves 
the administration of bleomycin (BLM) to rodents to initiate lung injury, inflammation 
and subsequent fibrosis. This model was employed during the course of this PhD to 
study the pathogenesis of lung fibrosis in vivo, and will now be discussed in more 
detail. 
1.3.1. The bleomycin model of lung injury and fibrosis 
Lung fibrosis is observed in mice challenged with bleomycin via the intravenous 
(i.v.), intra-tracheal (i.t.), intra-peritoneal (i.p.) or oropharyngeal (o.p.) routes (Chua 
et al., 2005). Bleomycin binds to dsDNA and initiates DNA scission in an oxygen-
dependent manner in vitro; these findings are mirrored in animal models of 
bleomycin-induced lung injury, in which bleomycin challenge results in persistent 
and extensive DNA damage to lung cells (Harrison et al., 1989) resulting in 
epithelial injury, reflected by epithelial cell apoptosis. While the i.v. route may reflect 
the nature of lung fibrosis observed as a side-effect in humans receiving bleomycin 
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as part of chemotherapy, the development of fibrosis in mice occurs over a relatively 
long time-frame, rendering it unsuitable to work within the confines of the current 
studies. A similar issue is faced when employing an i.p. approach, which is 
additionally associated with increased morbidity. Bleomycin challenge to mice, via 
the airways, results in an initial non-allergen driven epithelial injury, with the 
development of a neutrophilic and lymphocytic inflammatory infiltrate during the first 
week (Janick-Buckner et al., 1989a). The transition to fibrosis is usually observed 
after two weeks (Scotton et al., 2009). Histological characteristics of BLM-induced 
fibrosis in rodents include epithelial cell injury with reactive hyperplasia, basement 
membrane damage and interstitial, as well as intra-alveolar, fibrosis (Usuki et al., 
1995). Furthermore, discrete clusters of mesenchymal cells are often observed in 
areas of repairing lung, reminiscent of fibrotic foci present in IPF. I.t. challenge is 
perhaps the most widely used, but does result in a bronchocentric distribution of 
fibrosis, in contrast to the peripheral and subpleural pattern of matrix deposition 
observed in IPF (Scotton et al., 2010). This pattern is mirrored more faithfully 
following o.p. challenge in the host laboratory. Fibrotic lung lesions in rodents have 
been reported to have completely resolved by 6 weeks following a single intra-
tracheal (i.t.) bleomycin challenge (Chung et al., 2003; Degryse et al., 2010). In 
contrast data from micro-CT imaging of murine lung ex-vivo suggest that fibrosis is 
maintained at 6 months following o.p. bleomycin-induced injury (unpublished data, 
Dr. C Scotton), more in keeping with the non-resolving nature of IPF. This lack of 
concordance may reflect subtle permutations of the model dependent on route of 
BLM administration (Chua et al., 2005) , but highlights a significant shortcoming in 
translating results obtained from this model to clinical outcomes in IPF (Scotton et 
al., 2010). Regardless of the issue of resolution, the lack of disease progression 
following single dose BLM injury represents a crucial difference between BLM-
induced fibrosis in mice and IPF and, together with a lack of restrictive physiology 
following injury in mice, highlights deficiencies of the model. Nonetheless, this 
model has proved invaluable in allowing the identification of a number of key 
pathways and cytokines involved in the fibroproliferative response to lung injury in 
vivo, and as such was employed in the current studies outlined in Section 1.9. 
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1.3.2. Current hypotheses regarding the pathogenesis of idiopathic 
pulmonary fibrosis 
An early and consistent feature of pulmonary fibrosis in humans is a change in the 
phenotype of the alveolar epithelial cell (AEC), suggesting that alveolar epithelial 
cell injury is a critical early step in the pathogenesis of pulmonary fibrosis (Chilosi et 
al., 2002; Kasper et al., 1996). The exact nature of this injury is unclear, but as 
alluded to earlier, the fibroproliferative response to injury is likely to be due to a 
combination of host-specific, genetic and environmental factors. 
Fibroblastic foci are the characteristic histological feature of UIP/IPF, and generally 
underlie areas of damaged or altered epithelium. They are composed of aggregates 
of myofibroblasts, which are the key effector cells in fibrosis, and this mesenchymal 
cell phenotype will be discussed in more detail in Section 1.3.2.3. Interestingly, 
recent evidence suggests that fibrotic foci are, in fact, interconnected, forming a 
continuous fibrotic reticulum which suggests that individual foci may not arise from 
discrete sites of lung injury (Cool et al., 2006). In lung fibrosis, it has been 
postulated that persistent and/or repetitive injurious stimuli result in a dysregulated 
wound healing response, characterised by impaired alveolar re-epithelialisation. 
Thereafter, persistent myofibroblast accumulation and activation contributes to the 
excessive deposition of ECM in the interstitium, characteristic of pulmonary fibrosis. 
Prevailing hypotheses regarding the pathogenesis of fibroproliferative lung disease 
have focused on dysregulated interactions between epithelial and mesenchymal 
cells (Selman et al., 2002). Moreover, there is increasing evidence that this 
defective crosstalk may be amplified by the immune response to injury (Wynn, 
2004). These concepts will now be discussed in more detail.  
1.3.2.1. Dysregulated epithelial – mesenchymal interactions in 
fibroproliferative disease 
Contemporary hypotheses propose that IPF arises as a result of a highly aberrant 
wound healing response in susceptible individuals following repetitive or persistent 
epithelial injury; it has been postulated that that IPF is an “epithelial-fibroblastic 
disease” in which fibroproliferative pathology is preceded by AEC injury and 
activation, with fibrotic foci representing the primary sites of injury and aberrant 
repair (Selman et al., 2002). The molecular mechanisms underlying the 
development of these foci, however, remain unclear – recent evidence suggests 
roles for the local proliferation, activation and differentiation into myofibroblasts from 
resident lung fibroblasts; recruitment of circulating fibrocytes; epithelial-
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mesenchymal transition and endothelial-mesenchymal transition. The derivation of 
(myo)fibroblasts will be discussed in greater detail in Section 1.3.2.3., but in all of 
these processes, a prominent role has been suggested for the overlying reactive 
and hyperplastic epithelium, resulting in a final common pathology characterized by 
the excessive and disordered deposition of ECM proteins with the destruction of 
alveolar-capillary units and the formation of cystic fibrotic spaces. The role of the 
epithelium and the mesenchyme in the pathogenesis of lung fibrosis will now be 
discussed in turn. 
1.3.2.2. The epithelium in IPF 
As alluded to earlier, an early feature of pulmonary fibrosis in humans is a change in 
the phenotype of the AEC, suggesting that AEC injury is a critical step in the 
pathogenesis of pulmonary fibrosis (Chilosi et al., 2002; Kasper et al., 1996). These 
changes include apoptosis (Kuwano et al., 1996; Plataki et al., 2005), regenerative 
hyperplasia (Corrin et al., 1985), bronchiolarization (Kawanami et al., 1982; Sutinen 
et al., 1980) and proliferation (Katzenstein, 1985). In IPF, epithelial cell apoptosis is 
a well-recognised histological finding (Barbas-Filho et al., 2001; Kuwano et al., 
1996; Maeyama et al., 2001; Plataki et al., 2005; Uhal et al., 1998). The 
mechanisms underlying this apoptosis, however, are unclear, though numerous 
mediators have been proposed, including TGF-β (Lee et al., 2004); angiotensin II 
(Marshall et al., 2004; Wang et al., 1999); reactive oxygen species (Waghray et al., 
2005) and Fas-signalling pathways (Maeyama et al., 2001). More recently, the 
alveolar epithelium of patients with IPF has been shown to express markers of 
endoplasmic reticulum stress and the unfolded protein response - activation of 
these pathways may result from altered surfactant protein processing or chronic 
herpesvirus infection (Korfei et al., 2008; Lawson et al., 2008).  
The persistent apoptosis and dysregulated proliferation of epithelial cells impairs 
adequate epithelial reconstitution following lung injury. A reconstituted epithelium 
appears to serve a homeostatic function that may be necessary to suppress the 
excessive fibroblast activation characteristic of an aberrant wound healing 
response. Prostaglandin E2 (PGE2), a cyclooxygenase (COX)-dependent 
arachidonic acid metabolite, is the major prostanoid produced in the lung. It is 
secreted by intact epithelial cells as well as fibroblasts (Maher et al., 2010a). Its anti-
fibrotic functions have been demonstrated both in vitro (Goldstein et al., 1982; 
Kolodsick et al., 2003; Lama et al., 2002) and in vivo (Keerthisingam et al., 2001) 
and levels of PGE2 have been reported to be reduced in IPF lung (Borok et al., 
 Chapter 1: Introduction 
 32   
 
1991). Furthermore, PGE2 has recently been implicated as playing a central role in 
promoting the ‘apoptosis paradox’ of IPF in which excessive epithelial cell apoptosis 
and (myo)fibroblast resistance to apoptosis contribute to dysregulated epithelial-
mesenchymal interaction (Maher et al., 2010b).  
As alluded to above, epithelial cell proliferation and regeneration following injury is 
critical to normal wound healing. In this regard, the anti-fibrotic activity of epithelial 
mitogens such as keratinocyte growth factor (KGF) (Aguilar et al., 2009) and 
hepatocyte growth factor (HGF) (Dohi et al., 2000) in vivo suggest that the 
promotion of appropriate re-epithelialisation may have therapeutic benefits in IPF. 
However, because IPF patients are at increased risk of developing lung 
malignancies (Ozawa et al., 2009), such a strategy would require further exploration 
before human trials are deemed ethical.  
Impaired epithelial reconstitution may further contribute to fibrogenesis through the 
generation of pro-fibrotic cytokines such as TGF-β (Xu et al., 2003) and TNF-α 
(Nash et al., 1993). TGF-β is regarded as a central mediator of pulmonary fibrosis in 
both murine models of fibrosis and human disease (Giri et al., 1993; Khalil et al., 
1989; Khalil et al., 1991). Its mechanisms of action are multitude and include the 
promotion of fibroblast to myofibroblast differentiation (Chambers et al., 2003; 
Subramanian et al., 2004), epithelial-mesenchymal transition (EMT) (Willis et al., 
2005) and the inhibition of myofibroblast apoptosis (Zhang et al., 1999). TGF-β is a 
potent inducer of collagen deposition, promoting both its synthesis (Raghow et al., 
1987) and inhibiting  its degradation (McAnulty et al., 1991; Overall et al., 1989). 
Furthermore, TGF-β is capable of upregulating the expression of a number of other 
pro-fibrotic mediators in fibroblasts, such as connective tissue growth factor (CTGF) 
(Igarashi et al., 1993). Interestingly, there is evidence of an overlapping relationship 
between the actions of TGF-β and TNF-α in the pathogenesis of lung fibrosis. 
Attenuation of experimentally-induced fibrosis in mice, using genetic or 
pharmacological tools to interfere with TNF-α signalling, is associated with reduced 
TGF-β expression (Liu et al., 1998; Phan et al., 1992; Piguet et al., 1994). 
Moreover, local over-expression of TNF-α in mice results in a patchy parenchymal 
fibrosis which is associated with increased TGF-β expression (Sime et al., 1998). In 
vitro studies have also highlighted the pro-fibrotic inter-relationship between TGF-β 
and TNF-α, demonstrating that TNF-α increases active TGF-β bioavailability both by 
increasing its transcription and mRNA stability (Sullivan et al., 2009; Sullivan et al., 
2005).  
 Chapter 1: Introduction 
 33   
 
Finally recent studies have demonstrated the importance of danger signals, derived 
from an injured epithelium, in promoting lung fibrosis in an interleukin (IL)-1β-
dependent / inflammasome dependent manner (Gasse et al., 2009; Riteau et al., 
2010). These non-antigenic danger signals, in addition to microbial products, alert 
the immune system to tissue stress or injury, and such detection is increasingly 
recognised as crucial to maintaining host integrity (Matzinger, 1994). It has 
previously been suggested that TNF-α be regarded as an endogenous danger 
signal (Efron et al., 2005), particularly in the context of its well documented capacity 
to modulate the innate and adaptive arms of the immune system (Kollias et al., 
1999). Although immune cells, such as alveolar macrophages have traditionally 
been regarded as the predominant source of TNF-α in the lung (Vassalli, 1992), 
injured epithelial cells are recognised as an important source of this master cytokine 
in fibroproliferative lung disease (Nash et al., 1993; Oikonomou et al., 2006; Piguet 
et al., 1993). Increased epithelial expression of TNF-α following epithelial injury may 
therefore be regarded as an initial danger signal to the immune system, and the role 
of TNF-α in the pathogenesis of lung fibrosis will be discussed in more detail in 
Section 1.8.2. 
1.3.2.3. The (myo)fibroblast in IPF 
The myofibroblast has long been regarded as the major cell involved in normal 
wound healing, and as the key effector cell in fibrogenesis. Myofibroblasts have 
characteristics intermediate between fibroblasts and smooth muscle cells (Gabbiani, 
2003). They are highly synthetic for collagen and other ECM components, and 
express α-smooth muscle actin (α-SMA) – the extent of such expression correlates 
with the increased contractility of this cell phenotype (Hinz et al., 2001), though the 
underlying mechanism of increased contractility is, as yet, not fully understood. 
Early studies observed the transient presence of the myofibroblast within 
granulation tissue, a cell phenotype exhibiting smooth muscle cell-like features 
including intracellular bundles of microfilaments and significant amounts of 
endoplasmic reticulum (Desmouliere et al., 2005). Other studies demonstrated the 
importance of myofibroblasts in a number of pathological conditions characterised 
by aberrant wound healing and excessive extracellular matrix deposition, such as 
fibrotic conditions of the heart (Brown et al., 2005), liver (Desmouliere et al., 2003) 
and lung (Adler et al., 1989).  
The presence of myofibroblasts in IPF lung, and in fibrotic lesions of animal models 
of fibrosis (Adler et al., 1989; Mitchell et al., 1989; Pache et al., 1998), supports the 
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notion that this mesenchymal phenotype contributes to the progression of fibrosis. 
Myofibroblasts have an increased synthetic capacity for collagen and other ECM 
components known to be associated with active disease such as fibronectin, 
vitronectin and laminin (Hetzel et al., 2005; Kuhn et al., 1991). Their presence in 
fibrotic lesions correlates with the development of active fibrosis in animal models, 
and their persistence and localisation to fibrotic foci in human disease is associated 
with disease progression (Kuhn et al., 1991; Zhang et al., 1994b). 
As well as demonstrating an increased synthetic capacity for collagen, 
myofibroblasts isolated from IPF lungs exhibit an enhanced migratory phenotype 
(Suganuma et al., 1995) and produce more pro-fibrotic mediators (Moodley et al., 
2003) when compared to mesenchymal cells isolated from healthy lungs. In 
addition, they appear more resistant to apoptosis (Moodley et al., 2004; Ramos et 
al., 2001) – failure of apoptosis following appropriate wound healing results in the 
persistence of this highly activated mesenchymal cell at the site of injury. In fact, 
TGF-β, whilst appearing to promote apoptosis of epithelial cells (Lee et al., 2004), 
promotes an anti-apoptotic phenotype in fibroblasts (Horowitz et al., 2006; Zhang et 
al., 1999). 
The myofibroblast itself may also induce epithelial apoptosis through paracrine 
signalling via extracellular hydrogen peroxide (Uhal et al., 1995; Waghray et al., 
2005), whilst autocrine signalling, mediated by growth factors, can activate cell 
survival pathways (Horowitz et al., 2004). The autocrine induction of TGF-β by 
myofibroblasts is mirrored by the decreased production of epithelial mitogens such 
as HGF and KGF (Marchand-Adam et al., 2003; Marchand-Adam et al., 2005), as 
well as anti-fibrotic mediators such as PGE2 (Keerthisingam et al., 2001).  
Classically, myofibroblasts in pulmonary fibrosis were thought to be derived from the 
local proliferation and subsequent differentiation of resident fibroblasts in the context 
of a highly pro-fibrotic cytokine milieu (Phan, 2002; Zhang et al., 1994b). However, 
this notion has recently been challenged, and it is now recognised that the key 
effector cell of fibrosis may have a number of other cellular sources. The concept of 
epithelial-mesenchymal transition (EMT) has been recognised as contributing to 
functional myofibroblasts in a number of other human fibrotic diseases (Carew et al., 
2012), and there is some evidence to support a role for EMT in IPF. During EMT, 
epithelial cells lose their characteristic markers (e.g. E-cadherin and zona 
occludens-1) and acquire mesenchymal markers (e.g. fibroblast-specific protein-1 
and α-SMA) (Grunert et al., 2003). AECs in vitro undergo EMT following prolonged 
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exposure to major fibrogenic mediators such as TGF-β when cultured on a 
provisional wound matrix – this process is further enhanced in the presence of TNF-
α (Willis et al., 2005). Lineage tracing studies have also provided strong support for 
EMT as a potential source of myofibroblasts during lung fibrogenesis (Kim et al., 
2006b; Kim et al., 2009). The observation that cells in IPF biopsy samples co-
express epithelial and mesenchymal markers (Kim et al., 2009) support the notion 
of EMT in human disease although it must be acknowledged that this has not been 
a universal finding (Yamada et al., 2008). The molecular pathways underlying the 
development of EMT are proving to be a fertile area of research, with current 
evidence suggesting roles for Wnt and Notch signalling pathways (Aoyagi-Ikeda et 
al., 2010; Chilosi et al., 2003; Konigshoff et al., 2009). 
A second hypothesis regarding the origin of (myo)fibroblasts in lung fibrosis 
proposes that these cells may be derived from circulating fibrocytes (Lama et al., 
2006). Fibrocytes were originally identified as collagen I + /CD34+/CD45RO+ cells 
that are likely derived from hematopoietic stem cells (Bucala et al., 1994). Support 
for a pathogenic role for fibrocytes in lung fibrosis has been provided from studies 
showing that blockade of fibrocyte recruitment is protective following experimental 
lung injury in rodents (Moore et al., 2005; Phillips et al., 2004). Specific chemokine 
receptor/chemokine ligand biological axes are critical to the recruitment of fibrocytes 
to sites of tissue injury and repair, where they may contribute to the propagation of 
the fibrotic response. A major role has been identified for the CXCR4/CXCL12 axis 
in this respect (Phillips et al., 2004) although several chemokines have been shown 
to be capable of recruiting fibrocytes in vivo. Whether fibrocyte-derived fibroblasts 
are capable of differentiating into fully activated myofibroblasts, especially in 
patients with IPF, remains the subject of an interesting debate, although recent 
evidence suggests that ~10% of fibrocytes express α-SMA in the bleomycin model 
(Mehrad et al., 2009). CXCR4/fibrocyte/mesenchymal marker co-expression studies 
further support the notion that circulating fibrocytes may contribute to the expansion 
of the fibroblast/myofibroblast population in IPF (Andersson-Sjoland et al., 2008). 
Finally, a recent report has shown that a >5% blood fibrocyte count is associated 
with poor survival in IPF (Moeller et al., 2009). In addition to the above cellular 
sources, there is very recent experimental evidence that lung capillary endothelial 
cells may also give rise to fibroblasts through endothelial–mesenchymal transition in 
a bleomycin-induced lung fibrosis model (Hashimoto et al., 2010).  
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As has been alluded to earlier in this section, dysregulated epithelial-mesenchymal 
interactions following lung injury, driven by mediators derived from these two cellular 
compartments, result in persistent activation of fibroblasts. However, there remains 
good evidence that these pro-fibrotic interactions may be further amplified by 
concomitant inflammatory and immune responses. Exciting new research has 
highlighted the role of danger signals, reflecting cellular injury, in potentiating the 
innate and adaptive immune response to epithelial injury. The nature and role of 
such cells and mediators in activating the immune response and thus enhancing the 
fibrotic response to injury will be discussed in Section 1.5. However, in the first 
instance, a brief overview of the role of the inflammatory and immune system in the 
pathogenesis of IPF will now be provided. 
1.3.3. The role of inflammation in the pathogenesis of fibrosis 
The role of inflammation per say in the pathogenesis of pulmonary fibrosis is 
controversial and continues to be the subject of much debate. For many years, 
chronic inflammation of the epithelial and vascular compartments was felt to be the 
dominant mechanism driving fibrogenesis, and IPF was regarded as primarily a 
chronic inflammatory condition. The failure of anti-inflammatory and 
immunosuppressive therapy to have any impact on the mortality of patients with 
IPF, together with the lack of any significant inflammatory histology on IPF lung 
specimens, prompted a paradigm shift in the postulated mechanisms involved in the 
pathogenesis of fibroproliferative lung disease. This has been supported by 
observations from animal models of fibrosis, where significant bleomycin-induced 
inflammation in αvβ6 integrin knockout mice (which are unable to activate TGF-β 
effectively) does not progress to fibrosis (Munger et al., 1999). Nonetheless, leading 
investigators continue to argue that inflammation does play a role in the early 
initiating (sub-clinical) stages of IPF (Strieter, 2008), and the evidence in support of 
this position will now be discussed. 
The lung occupies a unique position between the host and the external 
environment, with the alveolar space being separated from the vasculature by a 
barrier of only 4–8 µm, the alveolar-capillary membrane (ACM). Clearly, this 
anatomical structure is ideal for gas exchange, but leads to increasing host 
vulnerability to environmental insults and subsequent injury. The lung must be able 
to initiate a rapid (innate) host response to any offending insults, while maintaining 
its ability to facilitate effective gas exchange. Following lung injury, the complex 
interplay between humoral, cellular and ECM networks, in a sequential and 
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overlapping manner, is designed to restore baseline integrity to the ACM. Initially, 
haemorrhage and extravasation of plasma into the alveolar space results in 
activation of both the intrinsic and extrinsic coagulation cascade resulting in fibrin 
generation and the initiation of a provisional wound matrix. Concomitant platelet 
activation leads to the generation of numerous chemokines and cytokines, whose 
function include to promote the influx of appropriate inflammatory and mesenchymal 
cells and to elaborate the provisional matrix in such a manner as to facilitate the 
repair process. The initial influx of neutrophils is followed by the appearance of 
mononuclear cells, orchestrated to a degree by neutrophil-derived mediators 
(Keane MP, 2005). This second wave of inflammatory cell influx is crucial to the 
generation of further inflammatory and reparative mediators responsible for 
maturation of the ECM (Sibille et al., 1990). The immature provisional matrix is 
primarily composed of fibrin, fibronectin and a preponderance of type III collagen 
over type I, in contrast to the mature ECM, whose predominant collagen is type I 
(Keane MP, 2005). In instances where the basement membrane (BM) of the ACM 
has not been breached, resorption of the mature ECM allows appropriate re-
epithelialization (facilitated by contraction of myofibroblasts) and re-
endothelialization of the ACM, with restoration of a functioning alveolar unit (Wallace 
et al., 2007). Subsequent apoptosis of mesenchymal cells ensures the cessation of 
matrix deposition with minimal residual tissue damage.  
It has been argued that inflammation-induced loss of ACM BM integrity represents 
“a point of no return” in fibroproliferative lung disease, as adequate re-
epithelialization and re-endothelialization cannot occur on a persistently denuded 
BM (Strieter, 2008). Due to a combination of host and environmental factors, 
inappropriate proliferation of type II pneumocytes, in concert with persistent 
activation of (myo)fibroblasts and continuing deposition of mature ECM, leads to the 
histological appearance of UIP. This loss of integrity of the BM is consistently seen 
in ultrastructural analysis of UIP, as is the intra-alveolar deposition of ECM 
associated with myofibroblast accumulation (Basset et al., 1986; Corrin et al., 1985; 
Wallace et al., 2007).  
Importantly, UIP, whilst characteristic of IPF in the correct clinical context, can also 
represent end-stage pathology in a number of inflammatory conditions of the lung, 
including hypersensitivity pneumonitis, as well the pulmonary manifestation of 
chronic systemic inflammatory conditions such as rheumatoid arthritis and systemic 
sclerosis (Wallace et al., 2007). These conditions are characterised by the 
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persistence of an injurious insult, be it an exogenous or endogenous antigen. These 
observations suggest that UIP may occur in the context of preceding inflammation, 
and that our current snapshot view of this disease, almost always at late to end-
stage at presentation (King et al., 2001), precludes the detection of any antecedent 
inflammation. In fact, lung inflammation is seen in unaffected family members of 
patients with an autosomal dominant form of IPF, though it is unclear if these 
individuals will go on to develop a UIP lung histology (Bitterman et al., 1986). 
Moreover, even within IPF lung, the more inflammatory histology of NSIP is seen in 
26% of patients (Flaherty et al., 2001), suggesting that the two disease profiles may 
share a common origin. Indeed, no differences are observed in the global gene 
expression profiles of these conditions (Rosas et al., 2007). Recent gene microarray 
studies have demonstrated that, in addition to the expected increase in gene 
expression of proteins associated with extracellular matrix turnover, expression of 
genes traditionally associated with inflammatory process such as cytokines and 
chemokines is increased in IPF (Zuo et al., 2002). In an attempt to bring together 
two extremes of opinion, it has been suggested that while inflammation is necessary 
for fibrosis to develop, it is not sufficient in itself. Transient overexpression of the 
pro-inflammatory cytokine IL-1β leads to an acute inflammatory response which 
progresses to fibrosis in the context of sustained TGF-β expression (Kolb et al., 
2001) – it has been proposed that  the initial inflammatory response following tissue 
injury induces dysregulation of the epithelial-mesenchymal interaction resulting in 
failure of re-epithelialisation and persistence of myofibroblasts driven by cytokines 
such as TGF-β (Zhang et al., 1999). 
More recently, the potential role of the adaptive immune response in the 
pathogenesis of IPF has been highlighted. In particular, a cytokine milieu dominated 
by T-helper 2 (Th2), or Type-2 (T-2), cytokines, such as IL-4 and IL-13, following 
injury is widely regarded as being pro-fibrotic (Wynn, 2004). Crucial to polarisation 
of the immune response towards a T-2 phenotype are activated dendritic cells 
(DCs), through their interactions with naïve CD4 T-cells and memory Th2 cells. 
Activation of immature DCs had previously been thought to be related to their ability 
to sense the presence of foreign microbial products, allowing them to present 
foreign antigen, following intracellular processing, to naïve T-cells. However, it is 
increasingly appreciated that such activation may be induced by non-microbial 
danger signals, reflecting cellular injury or disruption to tissue architecture (Johnson 
et al., 2002; Matzinger, 1994; Shi et al., 2003), in addition to pathogen-associated 
molecular patterns (PAMPs) (Pulendran, 2004).  Thymic stromal lymphopoietin 
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(TSLP) is a recently discovered IL-7 like cytokine that has emerged as a key 
regulator of inflammatory responses characterised by increased expression of T-2 
cytokines, via its activation of immature DCs. However, its role in the pathogenesis 
of non-allergen driven lung diseases characterised by increased T-2 cytokine 
expression has not been explored. In this regard, the work presented in this thesis 
will attempt to address this issue, highlighting the potential role of TSLP as a T-2 
polarising signal relayed from the mesenchyme to immune cells, reflecting epithelial 
injury. 
These concepts will now be explored in more detail, beginning with a more 
extensive description of TSLP, its signalling pathways and its activation of immature 
DCs. The importance of mature DCs in the pathogenesis of IPF, in particular 
highlighting the importance of their activation by danger signals reflecting epithelial 
injury, will then be addressed.  Thereafter, a brief summary of evidence supporting 
the notion that increased T-2 cytokine expression can amplify the fibroproliferative 
response to injury will be provided. A major part of the work contributing to this 
thesis has explored the importance of TNF-α in mediating TSLP expression, and 
this introduction will conclude by highlighting the importance of this master cytokine 
in mediating the defective epithelial-mesenchymal crosstalk, considered crucial in 
the pathogenesis of lung fibrosis.  
1.4 Thymic stromal lymphopoietin (TSLP) 
Thymic stromal lymphopoietin (TSLP) is a novel IL-7-like cytokine that has recently 
been shown to be a critical regulator of atopic inflammatory responses in the lung 
characterised by increased expression of T-2 cytokines. The work in this thesis 
evaluates the role of TSLP in fibrotic lung disease. A more extensive description of 
TSLP, its expression and signalling pathways, and its effect on promoting the 
differentiation of naïve T cells into Th2 cells will now be discussed. 
 
1.4.1. Structure  
TSLP is a type I cytokine that belongs to the IL-2 cytokine family; this family 
includes IL-2, IL-4, IL-7 and IL-13 (Leonard, 2001). Of these members, TSLP is 
regarded as being most similar in function to IL-7. It was initially identified as a 
factor in the supernatants of a thymic stromal cell line that was capable of 
supporting the growth and development of murine fetal liver and adult bone marrow 
derived B cell progenitors (Friend et al., 1994; Sims et al., 2000), much like IL-7. 
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Conditioned medium from this cell line supported the long term growth of the 
NAG8/7 pre-B cell line and enhanced the proliferation of thymocytes to sub-optimal 
concentrations of anti-CD3 antibodies in vitro. However, unlike IL-7, TSLP is 
capable of promoting B cell development to a more mature B220+ / IgM+ stage, 
compared to a B220+ / IgM- stage (Levin et al., 1999). In fact, TSLP appears to 
influence B cell progenitor cells to varying degrees, dependent upon their origin – 
bone marrow derived pro-B cells, unlike fetal liver derived pro-B cells, must develop 
to a pre-B cell stage before they can respond to TSLP, despite expressing the TSLP 
receptor complex (Vosshenrich et al., 2004). 
Characterisation of this murine factor revealed a four-helix bundle 140 amino acid 
cytokine (Sims et al., 2000), and a human orthologue of TSLP was identified 
thereafter (Quentmeier et al., 2001). Human TSLP exhibits a similar four-helix 
structure with two N-glycosylation sites and six cysteine residues. Interestingly, the 
human TSLP gene is located in close proximity to a gene cluster encoding T-2 
cytokines on chromosome 5 (Quentmeier et al., 2001). Although human TSLP and 
murine TSLP share poor sequence homology of 43%, they are both expressed by 
similar cells and seem to exert similar biological functions (Liu et al., 2007b).  
1.4.2. TSLP receptor complex and signalling pathway 
The TSLP receptor complex (TSLPR) is a heterodimeric receptor consisting of a 
TSLPα-binding chain (referred to as TSLPRα) and the IL-7Rα chain (Park et al., 
2000). The former is a member of the haematopoietin receptor family and binds to 
TSLP with low affinity. It is an atypical type I cytokine receptor, with 24% homology 
to the common γc receptor chain, but has significant differences to other type I 
cytokine receptor chains, both in its intracellular and extracellular regions – 
intracellularly, for instance, while it contains a conserved cytoplasmic Box 1 domain, 
it lacks the conserved Box 2 domain, both of which regulate Janus protein tyrosine 
kinase (JAK) binding (Liu et al., 2007b). To date, expression of the human TSLP 
receptor complex has been identified in activated CD4+ cells, myeloid DCs and 
mast cells (Omori et al., 2007; Soumelis et al., 2002). More recently, structural cells 
have also been demonstrated to be capable of responding to TSLP (Semlali et al., 
2010; Shan et al., 2010)and TSLPR expression has been documented in human 
skin, kidney, liver and skeletal muscle (Tonozuka et al., 2001).  
Dimerization with the IL-7Rα chain allows high affinity binding and the initiation of 
downstream cell signalling pathways with functional effects (Park et al., 2000; 
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Reche et al., 2001). In particular, ligand-induced cross-linking of TSLPRα and IL-
7Rα results in functional activation of signal transducer and activator of transcription 
(STAT) 5 and 3 (Isaksen et al., 1999; Quentmeier et al., 2001; Wohlmann et al., 
2010) (Figure 1.2). Ordinarily, cytokine receptor-induced aggregation induces JAK 
transphosphorylation and subsequent phosphorylation of target tyrosine residues of 
the receptor. These then act as docking sites for -SH2 domain containing signalling 
molecules including STATs. STAT binding results in JAK-induced phosphorylation 
of tyrosine residues, inducing conformational shifts which permit dimerization and 
subsequent translocation to the nucleus to initiate transcription of target genes. 
Certainly, the IL-7 receptor complex, comprising the common γc chain and IL-7Rα, 
recruits JAK3 via the IL-7Rα Box 1 domain, leading to STAT5 activation, and 
subsequent target gene regulation (Hofmeister et al., 1999). However, activated 
JAK kinases do not exhibit specificity for particular STATs, as different receptors 
may activate common STATs, despite engaging with different JAKs (Kohlhuber et 
al., 1997). In fact specificity for STAT activation seems to be determined by the 
docking sites present on the receptor chains themselves. In addition, STATs may 
also be phosphorylated in a JAK-independent manner by receptor kinases directly, 
as in the case of the epidermal growth factor receptor (David et al., 1996), or by 
non-receptor associated kinases, such as Src family kinases (Chaturvedi et al., 
1998). 
Initial studies suggested that TSLPR ligation appeared to drive STAT5 and 3 
activation without involving any known JAKs (Isaksen et al., 1999; Levin et al., 
1999), despite the presence in both chains of conserved residues of typical Box1 
motifs – these sequences mediate the association of type I cytokine receptor chains 
with JAKS (Tanner et al., 1995). Mutations in the Box 1 domains from either chain 
abrogates TSLP-induced STAT activity (Isaksen et al., 2002) suggesting an 
involvement of JAK downstream of receptor ligation. However, TSLP did not appear 
to induce any JAK phosphorylation, despite the induction of functional STAT activity 
(Levin et al., 1999). Moreover, reconstitution studies demonstrated that expression 
of dominant-negative forms of JAK1 and JAK2 were unable to block TSLP-induced 
STAT5 phosphorylation, in contrast to IL-7 signalling (Isaksen et al., 1999). 
However, partial inhibition of TSLP-induced STAT5 activation was observed in the 
presence of a dominant-negative version of Tec, a cytoplasmic Src-related tyrosine 
kinase, suggesting a role for this kinase family upstream of STAT5 (Isaksen et al., 
1999). Further complexity to the TSLP signalling pathway is demonstrated by 
apparent uncoupling of STAT5 activation and TSLP-induced proliferation in pre B 
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cell lines - inhibition of the Src family kinases blocks TSLP-induced proliferation but 
has no effect on STAT5 activation (Isaksen et al., 2002).  
However, more recent studies have attempted to reconcile these unexpected 
findings. Earlier work evaluated JAK-STAT signalling pathways in murine pre-B cell 
lines in contrast to studies demonstrating a requirement for JAK1 and JAK2 in 
TSLP-induced STAT activation and downstream cellular effects in murine primary T 
cells (Rochman et al., 2010). These observations are supported by studies 
demonstrating a clear requirement for JAK1 and JAK2 in mediating STAT 
phosphorylation downstream of human TSLP receptor ligation (Wohlmann et al., 
2010). These latter differences may be explained by differences in downstream 
signalling pathways between mice and humans, supported by the fact that murine 
and human TSLPR share only 39% sequence homology – in particular, the highly 
conserved Box1 domain is located in different positions in these species.  
In summary, the mechanisms involved in TSLP signalling via the heterodimeric 
TSLPRα / IL-7Rα complex remain unclear. The unexpected findings that TSLP-
induced STAT phosphorylation in the absence of JAK phosphorylation have recently 
been addressed, though additional studies are required to fully delineate the 
signalling pathways downstream of TSLP receptor ligation and it is possible that 
unidentified kinases upstream of STAT are also involved in signal transduction. 
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1.4.3. TSLP expression in pulmonary cells 
TSLP expression has been most extensively studied in the context of archetypal T-2 
cytokine dominated diseases, such as atopic asthma and atopic dermatitis, with 
much of our understanding of the mechanisms involved in regulating its expression 
in vivo coming from studies of animal models of these conditions.  
In humans, baseline TSLP mRNA transcripts have been detected  for a number of 
key pulmonary cells, including bronchial and small airway epithelial cells, smooth 
muscle cells, fibroblasts and mast cells (Soumelis et al., 2002). Confirmation of 
expression at the protein level has been confirmed for epithelial cells (Lee et al., 
2007a), but not for fibroblasts. In vitro work has identified a number of mediators 
capable of inducing TSLP expression by lung epithelial and smooth muscle cells, 
and these are outlined in Table 1.3. However, the signal transduction systems 
underlying induction of TSLP expression remain unclear and are likely to vary 
between cell types. Recognised signalling pathways leading to TSLP production will 
now be discussed in more detail. 
1.4.3.1. Role of mitogen-activated protein kinase pathways in 
regulating TSLP expression 
Activation of mitogen-activated protein kinase (MAPK) signalling represents a major 
signal transduction pathway responsible for relaying extracellular stimuli allowing 
regulation of intracellular function. The MAPK family consists of 3 major sub-groups 
of highly conserved, eukaryote specific serine-threonine kinases, including the c-Jun 
amino-terminal kinases (JNK 1/2/3), extracellular signal-regulated kinases (ERK 
1/2) and p38 kinases. Briefly, the MAP kinases are sequentially phosphorylated by 
upstream kinases (Kyriakis et al., 2001), beginning with MAPK kinase kinases 
(MAPKKKs or MEKKs). These then activate downstream MAPK kinases (MAPKKs 
or MEKs) by phosphorylation of specific serine and threonine residues (Widmann et 
al., 1999). MEKs in turn phosphorylate MAPKs facilitating MAPK translocation to the 
nucleus where they can interact with transcription factors and histone proteins to 
regulate transcription of target genes (Treisman, 1996).  
The ERK1/2 pathway is important in mediating a number of responses in fibroblasts, 
such as proliferation and collagen production (Yoshida et al., 2002). This pathway 
has also been shown to mediate TNF-α induced TSLP protein production by human 
airway smooth muscle cells (HASMCs) – pharmacological inhibition of ERK1/2 
resulted in a significant inhibition of IL-1β and TNF-α induced TSLP expression  
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Stimulant Cell type TSLP expression 
 
References 
mRNA 
 
protein  
Poly I:C 
 
Bacterial 
peptidoglycan 
 
Primary 
small airway 
epithelial 
cells 
+ 
 
+ 
 
+ 
 
+ 
 
 
(Allakhverdi et 
al., 2007b) 
IL-4 
 
IL-13 
 
NHBE  + 
 
+ 
 
- 
 
- 
(Kato et al., 
2007) 
IL-4 + TNF-α 
 
IL-13 + TNF-α 
 
NHBE + 
 
+ 
 
+ 
 
+ 
 
(Kato et al., 
2007) 
IL-1β 
 
TNF-α 
 
NHBE 
 
A549 
+ 
 
+ 
 
+ 
 
+ 
 
(Lee et al., 
2007a) 
IL-1β 
 
TNF-α 
 
Primary 
airway 
smooth 
muscle cells  
+ 
 
+ 
 
+ 
 
+ 
 
(Zhang et al., 
2007) 
TLRL 2/3/8/9 
 
NHBE  + - (Lee et al., 
2007a; Zhang 
et al., 2007) 
TLRL 3 + IL-4 
 
NHBE  + + (Kato et al., 
2007) 
 
+/-:  increased / unchanged expression 
NHBE:  normal human bronchial epithelial cells 
TLRL:  toll like receptor ligand 
 
 
 
Table 1.3.  
 
Summary of known inducers of TSLP expression in pulmonary cells 
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(Zhang et al., 2007), suggesting that TSLP expression in these cells is controlled via 
MAPK pathways. 
The primary role of p38 has been considered to be in mediating inflammatory 
responses in disease settings (Schindler et al., 2007), and this kinase has been 
implicated in mediating the airway inflammation found in asthma, COPD and cystic 
fibrosis (de Boer et al., 2007; Konstan et al., 2002; Pelaia et al., 2005). 
Pharmacological inhibition of the p38 pathway suppresses TNF-α induced TSLP 
secretion by HASMCs (Zhang et al., 2007). The potential importance of this member 
of the MAPK family in mediating TSLP expression is further highlighted by studies 
performed in normal human bronchial epithelial cells (NHBEs). Respiratory syncitial 
virus (RSV) infection is a well-documented trigger of asthmatic exacerbations and 
can upregulate TSLP expression by NHBEs. Such induction is attenuated by 
inhibition of the p38 pathway (Tu et al., 2007).  
 
Three isoforms of JNK are recognized; JNK1 and JNK2 are broadly expressed in 
many tissues, whereas JNK3 is exclusively expressed by neurons, cardiac 
myocytes and testes. Therefore, only JNK1 and JNK2 are relevant to respiratory 
pathobiology (Bennett, 2006). JNK is the enzyme responsible for phosphorylating 
critical serine residues in the N-terminus of c-Jun, a component of AP-1. TSLP 
expression in NHBEs is upregulated following infection with rhinovirus and 
respiratory syncitial virus, and this effect is attenuated by pre-treatment of cells with 
inhibitors of the JNK pathway, implicating the JNK pathway in mediating TSLP 
expression in this cell type (Tu et al., 2007).  
1.4.3.2. The role of AP-1 in mediating TSLP expression 
The transcription factor, AP-1, is a heterodimeric protein complex composed of c-
Jun and c-Fos components. Regulation of AP-1 activity is achieved via a number of 
mechanisms including changes in transcription of genes encoding AP-1 subunits, 
control of the stability of their mRNAs and specific interactions between AP-1 
proteins and other transcription factors and cofactors [reviewed in (Hess et al., 
2004)]. Post-translational control has been most extensively documented for 
MAPKs; differential phosphorylation of c-Jun and c-Fos is essential for AP-1 
directed transcription of target genes and is achieved primarily by activation of 
kinases of the MAPK family of enzymes, in particular, JNK. With respect to the 
present studies, the importance of this transcription factor in mediating the 
expression of TSLP is suggested by the identification of a single nucleotide 
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polymorphism (SNP) in the promoter region of a long splice variant of the human 
Tslp gene in human bronchial epithelial cells,  facilitating the creation of a functional 
AP-1 binding site (Harada et al., 2009). Furthermore, a putative AP-1 binding site 
has been identified in the Tslp gene promoter region of a lung epithelial cell line and 
mutations in this motif result in a reduction in IL-1β induced promoter activity (Lee et 
al., 2007a). In human airway smooth muscle cells, transfection with a TSLP 
promoter plasmid harboring mutations in AP-1 binding sites abrogated TSLP 
promoter activity following TNF-α exposure (Redhu et al., 2011), further supporting 
a role for this transcription factor in mediating TSLP expression. 
1.4.3.3. Role of the NFκB in regulating TSLP expression 
The transcription factor NFκB is activated by numerous stimuli, and once activated, 
participates in the regulation of various target genes in different cells to exert its 
biological functions. 
Briefly, the NFκB family of transcription factors comprises a group of dimeric factors 
that are involved in the regulation of a huge range of inflammatory responses. NFκB 
proteins are retained within the cytoplasm bound to cellular IκB proteins which mask 
the former’s nuclear location sequence. Liberation of NFκB from this ternary 
complex is achieved following phosphorylation, ubiquitination and degradation of the 
IκB proteins allowing the translocation of NFκB homodimers into the nucleus where 
they can bind to regulatory components of target genes (Roff et al., 1996; Sen et al., 
1986). For full activation, NFκB must be further phosphorylated, and a number of 
different kinases have been implicated including the mitogen activated protein 
kinases (MAPKs) and protein kinase C (PKC) (Wajant et al., 2003). Phosphorylation 
of IκB is performed by the IκB kinase (IKK) complex, which is composed of two 
catalytic sub-units, IKKα and IKKβ (Mercurio et al., 1997), as well as a regulatory 
sub-unit, NFκB essential modulator (NEMO) (Yamaoka et al., 1998) and a kinase 
specific chaperone (Chen et al., 2002).  
Previous work has demonstrated a the presence of a DNA fragment upstream of the 
transcriptional start site of the TSLP gene containing a cis element required for 
transcriptional induction by IL-1β. This sequence contains a consensus cognate 
element for NFκB, and mutations within this element result in a reduction in IL-1β 
induced upregulation of TSLP expression in a human lung epithelial cell line (Lee et 
al., 2007a). EMSA studies further demonstrated IL-1β-stimulation of these cells 
results in binding of the p65/p50 heterodimer of NFκB to the human TSLP gene 
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promoter. In addition, expression of a dominant negative mutant of IκB in the same 
epithelial cell line also inhibits IL-1β mediated TSLP expression (Lee et al., 2007a). 
1.4.3.4. Role of cooperative signaling in regulating TSLP 
expression 
The induction of TSLP at the protein level in NHBEs by IL-4 and IL-13 requires the 
presence of TNF-α, suggesting cooperative signalling between STAT6 and TNF-α 
related pathways (Kato et al., 2007). Stimulation of TSLP expression evoked by 
rhinoviral dsDNA and RSV proteins via TLRs is also synergistically enhanced by IL-
4, suggesting cooperative signalling between JAK/STAT and NFκB pathways. This 
synergy between T-2 cytokines and TNF-α in inducing TSLP expression has also 
been demonstrated in human keratinocytes (Bogiatzi et al., 2007). In support of the 
notion that STAT6 may be an important transcription factor in mediating TSLP 
expression is the observation that siRNA targeted against STAT6 attenuates the 
enhancement of dsRNA induced TSLP expression by IL-4 in NHBEs (Kato et al., 
2007). 
A number of cellular targets of TSLP have been identified, including DCs, 
lymphocytes and granulocytes, as well as the more recent identification of structural 
cells that respond to TSLP. The relevance of these cells to the physiological and 
pathological roles of TSLP will now be discussed. 
1.4.4. The physiological role of TSLP 
Since TSLP was originally identified in conditioned media from a thymic stromal cell 
line, early studies focused on its potential role in lymphocyte development. 
However, Tslpr -/- mice display normal T and B cell development, although mice 
deficient in both the TSLPR chain and the IL-2 receptor chain (Tslpr -/- Il2rg -/- ) mice 
do show a more severe phenotype than Il2rg -/- mice, suggesting a non-redundant 
influence of TSLP on lymphocyte development in mice (Al-Shami et al., 2004; 
Carpino et al., 2004). However, there exists evidence that, in humans at least, TSLP 
may play a role in the thymic selection of regulatory T-cells (Tregs) and in peripheral 
homeostasis of T cells. 
TSLP is expressed by epithelial cells of Hassall’s corpuscles (HCs) within the thymic 
medulla where it appears to activate a sub population of DCs (Watanabe et al., 
2005). It has been postulated that these DCs serve to positively select high-affinity 
self-reactive Tregs in the thymic medulla. Ordinarily, when high-affinity self-reactive 
T cells receive strong TCR signalling from epithelial cells within the thymic medulla, 
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they die by negative selection. In contrast, it is hypothesised that if these cells 
receive co-stimulatory signals, such as CD86, they will be converted into Tregs by 
secondary positive selection. DCs activated by TSLP express CD86 and in vitro, 
TSLP-activated DCs (TSLP-DCs) induce proliferation of CD4+CD8-CD25- cells, of 
which 50% subsequently differentiate into CD4+CD8-CD25-FoxP3+ Tregs 
(Watanabe et al., 2005). This hypothesis is also consistent with the in vivo 
localisation of Tregs within the thymic medulla in close proximity to activated DCs. 
In this regard, TSLP represents the only known activator DC maturation in the 
thymic medulla. However, further work is needed to clarify this postulated role.  
TSLP-DCs are also capable of inducing a strong proliferation of naïve CD4+ cells 
(Watanabe et al., 2004) and are found in close association with TSLP-expressing 
tonsillar epithelial cells. A further postulated physiological role for TSLP is in the 
peripheral homeostasis of T cells by peripheral mucosa lymphoid tissue (Watanabe 
et al., 2004). The expansion of autologous naïve CD4 T cells by TSLP-DCs displays 
features of homeostatic expansion mediated by self-pMHC complexes, including 
dependence on MHC II and co-stimulatory molecules, but not on IL-7. Moreover, 
this expansion is a polyclonal expansion and importantly, the expanded population 
has the potential to further differentiate into Th1 or Th2 cells (Watanabe et al., 
2004). Once again, however, further studies are required in this field, and the 
remainder of this discussion will now focus on the role of TSLP in disease.  
Briefly, as alluded to earlier, co-culture experiments with TSLP-DCs and naïve 
syngeneic CD4+ cells suggest a role for TSLP in T cell homeostasis. However, in 
allogeneic culture systems, T cells ultimately display characteristic features of 
differentiated inflammatory Th2 cells (Soumelis et al., 2002), Moreover, TSLP-DCs 
are capable of supporting the maintenance and further polarisation of Th2 memory 
cells (Wang et al., 2006), further supporting a role for TSLP in the development of T-
2 inflammatory phenotype. These concepts will now be discussed in more detail, 
beginning with a summary of current understanding of Th2 cell differentiation.  
1.4.5. Current concepts regarding the differentiation of CD4+ T 
lymphocytes 
While T-cells, together with B-cells, are the key effector cells of the adaptive 
immune response, the initiation and subsequent modulation of their functions are 
achieved by DCs. These cells are professional antigen-presenting cells, and in this 
regard, their interaction with naïve T-cells is critical to activation of the latter, as T-
cells cannot recognize antigen directly – rather, for activation and antigen-driven 
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proliferation, CD4+ T-cells require antigen to be processed and presented to their T-
cell receptor (TCR) by MHC class II molecules on DCs. DCs have the capacity to 
polarise an immune response towards either a T-1 phenotype or a T-2 phenotype, 
depending on signals received at an immature stage from their microenvironment.  
Naïve CD4+ cells have the potential to differentiate into Th1 or Th2 cells, in addition 
to Th17 and Tregs. These former 2 subsets are characterised by expression of their 
signature cytokines, IFN-γ and IL-4 respectively, following activation. The avidity of 
the TCR to the antigen/MHC complex presented on the DC, the nature of co-
stimulatory molecules and the cytokine environment all influence the fate of a naïve 
CD4+ Th precursor cell, and the mechanisms involved in the differentiation of these 
cells into Th1 or Th2 lymphocytes will now be briefly discussed. 
The initiation of Th1 differentiation begins with stimulation of naïve CD4 cells by 
antigen presenting cells, in particular activated DCs, via cognate TCRs. Critical to 
the development of Th1 cells is a cytokine milieu dominated by IL-12. Microbe-
derived molecules can activate pattern recognition receptors on DCs, such as TLRs, 
leading to upregulation of IL-12 expression. In turn, IL-12 can act upon both natural 
killer (NK) cells and T cells to promote Th1 differentiation. IL-12 upregulates IFN-γ 
expression by NK cells (Yoshimoto et al., 1998) which, via a STAT1 dependent 
mechanism, upregulates T-bet expression in naïve CD4 cells (Lighvani et al., 2001). 
T-bet is a Th1 master transcription factor which induces IFN-γ production by CD4+ 
cells, as well as upregulating IL-12Rβ2 expression (Mullen et al., 2001). These T-
bethi IL-12Rβ2 expressing cells can therefore be selected for survival through the 
actions of IL-12, which via STAT4, further induces IFN-γ expression in this cell 
population. This integration of instructive and selective processes ultimately results 
in the clonal expansion of fully differentiated Th1 cells (Murphy et al., 2000). 
In terms of Th2 differentiation, IL-4 has long been recognised as a key cytokine 
involved in promoting the development of this CD4 subset in vitro (Le Gros et al., 
1990). More recently, the importance of IL-2 has also been highlighted in this 
differentiation program (Cote-Sierra et al., 2004). As in Th1 differentiation, DC-
derived signals are thought to influence the development of Th2 cells. However, 
activated DCs do not produce IL-4, and the primordial source of IL-4 in vivo remains 
unclear. It has been suggested that naive T-cells themselves can produce limited 
amounts of IL-4 following interaction with low-strength signals (Grogan et al., 2001; 
Yamane et al., 2005). The strength of signal may be modulated by a number of 
means, including the presence or absence of co-stimulatory molecules such as 
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CD28; variations in the affinity of the peptide/MHC complex for the TCR and the 
duration of the DC-T cell interaction (Boyton et al., 2002; Constant et al., 1997; Iezzi 
et al., 1999). Other possible cellular sources of IL-4 include NKT cells and basophils 
(Leite-de-Moraes et al., 1997; Nouri-Aria et al., 2001) though there remains 
insufficient evidence to invoke a role for these cells in the differentiation of Th2 cells.  
IL-4 exerts its cellular effects via activation of STAT6, and a critical role for STAT6 in 
mediating the Th2-differentiating properties of IL-4 is illustrated by a severe block of 
Th2 differentiation in mice deficient in STAT6 (Takeda et al., 1996). In addition to 
binding to the IL-4 promoter and 3’ enhancer (Avni et al., 2002), STAT6 promotes 
the expression of the Th2 master regulatory transcription factor, GATA-3 (Ouyang et 
al., 2000). GATA-3 is a Th2-cell specific transcription factor which was identified as 
regulating the expression of a variety of Th2 cytokines, including IL-4, IL-5 and IL-13 
(Zheng et al., 1997). Its critical role in Th2 cell differentiation is demonstrated by 
observations that treatment with antisense oligonucleotide against GATA-3 
represses Th2 development in vivo (Finotto et al., 2001) and deletion of GATA-3 in 
vivo eliminates Th2 responses in mice (Zhu et al., 2004). Importantly, GATA-3 has 
been reported to induce its own expression once its levels have reached a threshold 
level (Ouyang et al., 2000). This feedback of transcriptional activation stabilizes 
GATA-3 levels within the cell. It has been postulated that non-IL-4/STAT6 
mechanisms may serve to induce GATA-3 expression beyond this threshold. Thus, 
differentiating Th2 cells, following TCR engagement and activation of co-stimulatory 
signalling pathways, could themselves represent the initial source of IL-4 for 
amplification of this process. Such redundant signalling pathways include the CD28 
and inducible T-cell co-stimulator (ICOS) pathways (Greenwald et al., 2002). The 
mechanisms underlying GATA-3 regulation of Th2 gene expression is an expanding 
field and beyond the scope of this thesis. Briefly, however, GATA-3 binds directly to 
critical elements in the Il5 and Il13 promoters to upregulate their expression 
(Kishikawa et al., 2001; Schwenger et al., 2001). With respect to modulating Il4 
gene expression, GATA-3 creates heritable epigenetic patterns followed by the 
appearance of Th2-exclusive DNase hypersensitivity sites in the Il4 locus (V/VA) 
and Il4 / Il13 intergenic region (conserved non-coding sequence (CNS)-1) (Zhu et 
al., 2008). In addition, GATA-3 induces changes in the chromatin structure of the Il4 
gene (Lee et al., 2000; Ouyang et al., 2000).  
These observations lend credence to the hypothesis that this master Th2 
transcription factor mediates Il4 gene expression, not by directly binding to promoter 
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regions, but rather, by chromatin remodelling and subsequent epigenetic 
modulation. De-repression of the Il4 locus, renders it amenable to direct and 
immediate transcriptional control by non-Th2 specific transcription factors such as 
NFAT (Murphy et al., 2002). The mechanisms described above do not, however, 
necessarily explain the clonal expansion of Th2 cells. GATA-3 mediates Th2 
cytokine expression rather than cell growth, but the selective component to Th2 cell 
development may be explained by studies demonstrating that STAT6 induces 
expression of the zinc finger protein, GFI1, which in turn mediates clonal expansion 
(Zhu et al., 2002). Furthermore, GFI1 only drives the proliferation of GATA-3hi cells, 
though the interaction between GATA-3 and GFI1 remains unclear (Zhu et al., 
2002). Despite the indispensability of GATA-3 in the development of Th2 responses 
in vivo, GATA-3 expression alone is not sufficient to induce IL-4 expression. As 
alluded to earlier, IL-2 is also critical to Th2 cell differentiation, and IL-2 mediated 
activation of STAT5a/STAT5b plays a critical role in inducing/maintaining 
accessibility at DNase hypersensitive sites of the Il4 locus (Zhu et al., 2003). Thus, it 
is likely that a tightly regulated collaboration between STAT5 and GATA-3 accounts 
for full Th2 differentiation in vitro. Finally, cross-regulation by cytokines and 
transcription factors reflects a further level of complexity to the differentiation of 
Th1/2 cells. For instance, GATA-3 downregulates STAT4 (Usui et al., 2003), 
whereas T-bet can suppress GATA-3 expression (Usui et al., 2006). 
In summary, Th1 responses seem to be driven primarily by active signals derived 
from activated innate immune sources, such DCs. However, the mechanisms 
underlying DC-mediated Th2 cell differentiation is less well delineated. The 
primordial source of IL-4, critical to an instructive and selective program of Th2 cell 
expansion, remains unknown, though it has been suggested that activated DCs that 
produce low amounts of IL-12 promote Th2 differentiation (Georas et al., 2005). 
Environmental signals that lead to the maturation and activation of IL-12lo DCs 
include low-dose endotoxin and TLR2 ligands (Georas et al., 2005).  
In an effort to delineate the signalling pathways upstream of significant IL-4 
production by differentiating T cells, recent work has identified TSLP as a critical 
regulator of T-2 cytokine associated inflammatory diseases. TSLP is believed to be 
capable of instructing a programme of Th2 differentiation and proliferation via its 
unique actions on dendritic cells such that their subsequent interaction with naïve T-
cells results in Th2 differentiation, independent of IL-4. These effects will now be 
discussed in more detail. 
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1.4.6. The role of TSLP in activating dendritic cells into a T-2 polarising 
phenotype 
Activation of DCs is a critical step in engagement of the adaptive immune system to 
tissue injury or stress. Such activation may occur in an antigen-driven manner or, as 
has been described, in a non-antigenic manner, by danger signals reflecting tissue 
injury (Matzinger, 1994). Human myeloid DCs (mDCs) express the TSLP receptor 
complex (Soumelis et al., 2002). TSLP strongly upregulates the expression of 
MHCII, CD80, CD83 and CD86 on human mDCs. In this regard, it is no different to 
other activators of DCs, such as CD40L, LPS, poly I:C and TLR ligands. Unlike 
these stimuli, however, TSLP does not stimulate mDCs to produce the Th1-
polarizing cytokine, IL-12 (Ito et al., 2005; Soumelis et al., 2002). The molecular 
mechanisms underlying TSLP’s ability to promote DC maturation without inducing 
IL-12 production remains unknown though the signalling pathways are likely to be 
independent of MyD88 and NFκB transcription factors, both of which are required 
for the response to Th-1-promoting stimuli (Liu et al., 2007b).  
In allogeneic co-culture systems, TSLP-DCs induce the differentiation of naïve 
CD4+ T cells into inflammatory Th2 cells. In addition to the classical Th2 cytokines, 
IL-4, IL-5 and IL-13, these T cells secrete significant amounts of TNF-α. In contrast, 
they secrete little IFN-γ or IL-10, an anti-inflammatory cytokine (Soumelis et al., 
2002). Although not considered a Th2 cytokine, expression of TNF-α is often 
increased in inflammatory conditions associated with increased expression of T-2 
cytokines (Moffatt et al., 1997). 
Recent studies have afforded some insight into the molecular mechanisms by which 
TSLP-DCs induce naïve CD4+ T cells to differentiate into inflammatory Th2 cells. 
TSLP is the only known activator of DCs to upregulate expression of OX40L, a 
member of the TNF superfamily (Ito et al., 2005). Neutralisation of OX40L with an 
anti-OX40L antibody inhibits the production of T-2 cytokines and TNF-α by T-cells. 
Moreover, treatment of naïve CD4+ cells with human recombinant OX40L induces 
the expression of T-2 cytokines by naïve T cells, confirming that OX40L is the 
downstream molecule by which TSLP-DCs induce differentiation of inflammatory 
Th2 cells (Ito et al., 2005). The signalling pathways downstream of OX40 ligation on 
naïve T cells remains unclear, though one study has demonstrated that OX40 
signalling directly induces Th2 lineage commitment by activating nuclear factor of 
activated T cell (NFAT) c1 (So et al., 2006). This triggers IL-4 production, which as 
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described in Section 1.4.5., can then induce Th2 differentiation in a GATA-3 
dependent manner (So et al., 2006). 
The ability of OX40L to induce differentiation of Th2 cells depends upon the 
absence of IL-12. In the presence of IL-12, OX40L loses this capability and instead, 
naïve T cells are directed towards Th1 differentiation (Ito et al., 2005). Thus, the 
creation of a Th2-permissive microenvironment, through the absence of IL-12, 
represents a key characteristic of TSLP activation of DCs. These findings suggest 
that Th2 differentiation requires a negative signal (the absence of IL-12) and a 
positive signal (OX40L). Moreover, the observation that IL-12 is dominant over 
OX40L is compatible with the hygiene theory which postulates that microbial 
infections that trigger Th1 immune responses decrease the frequency of Th2-driven 
atopic conditions.  
Although anti-OX40L antibody reduces the frequency with which naïve T cells 
differentiate into Th2 cells, this effect is not completely blocked. However, a 
complete switch to a Th1 phenotype is achieved when an anti-IL4 antibody is 
added. As TSLP-DCs do not produce IL-4, these findings suggest that while OX40L 
represents the initial Th2 polarising trigger, IL-4 functions as a key autocrine 
stabiliser and enhancer of developing Th2 cells.  
TSLP also upregulates expression of CCL17 and macrophage derived chemokine 
(MDC) / CCL22 by immature mDCs (Soumelis et al., 2002). These two chemokines 
are important in attracting Th2 cells [reviewed in (Homey et al., 1999)], and may 
serve to amplify the Th2 cellular response at the site of initial activation of the DC. In 
addition, TSLP-DCs can induce a robust expansion of human Th2 memory cells, 
which maintain their central memory phenotype and capacity for effector cytokine 
function (Wang et al., 2006), further supporting the notion that TSLP represents a 
critical regulator of pathological Th2 inflammatory responses.  
1.4.7. Direct effects of TSLP on T cells 
The manner by which TSLP can polarise the immune response by influencing the 
interactions between activated dendritic cells and naïve T cells has been described 
in Section 1.4.6. However, recent studies have also demonstrated that TSLP exerts 
direct effects on T cells in vitro. TSLP, in conjunction with TCR activation, is capable 
of driving Th2 differentiation of murine naïve CD4+ cells directly, in the absence of 
DCs and exogenous IL-4 (Omori et al., 2007). These effects appear to be mediated 
by IL-4 acting downstream of TSLP and are compatible with previous work 
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demonstrating that TSLP can induce proliferation of CD4+ T cells (Al-Shami et al., 
2004). These findings have also been translated to human T cells, which are 
capable of proliferating in response to TSLP (Rochman et al., 2007). 
Aside from the aforementioned effects on naïve CD4+ cells, TSLP also exerts 
effects on Th2 effector cells. Recent studies have demonstrated that TSLP induces 
proliferation of murine effector Th2 cells and, together with TCR activation, is able to 
induce expression of IL-4 by effector Th2 cells (Kitajima et al., 2011).  
1.4.8. The role of TSLP in T-2 mediated inflammation: relevance to lung 
disease 
Much of the work discussed in the preceding sections is supported by evidence 
from animal models of T-2 cytokine dominated diseases, and in certain instances, 
human disease relevance has been established, particularly in the context of 
allergic airways disease.  
Pulmonary TSLP expression is increased in an ovalbumin (OVA)-induced murine 
model of allergic airways disease (Zhou et al., 2005). Furthermore, in mice 
selectively expressing TSLP in alveolar epithelial cells, spontaneous T-2 biased 
airway inflammation is observed, with a predominantly eosinophilic alveolar 
infiltrate, accompanied by airway remodelling characterised by epithelial cell 
hyperplasia, subepithelial fibrosis and mucus metaplasia (Zhou et al., 2005). In 
addition, TSLPR knockout mice, sensitized and challenged with OVA, demonstrate 
an attenuated airway inflammatory response (Zhou et al., 2005). In these mice, 
reconstitution with TSLPR-sufficient T cells restores inflammatory disease, 
suggesting that TSLP is both necessary and sufficient for the development of a T-2 
cytokine dominated inflammatory phenotype (Al-Shami et al., 2005). In support of 
the notion that TSLP plays a crucial role in directing Th2 dominated inflammation is 
the observation that blockade of TSLP signalling in an OVA model of asthma, by the 
administration of anti-TSLPR antibodies (Shi et al., 2008) or anti-TSLP neutralizing 
antibody (Li et al., 2010) , attenuated OVA-challenge induced airway inflammation – 
this attenuation was associated with reduced production of T-2 cytokines. 
As mentioned above, in humans, atopic asthma represents a classical T-2 
inflammatory condition. TSLP expression is significantly increased in the airways of 
asthmatic patients compared with normal control patients, and this increase 
correlates with the expression of T-2 chemokines and disease severity (Ying et al., 
2005).  
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However, the potential role of TSLP in promoting a cytokine milieu dominated by T-
2 cytokines in non-allergen driven lung disease remains unknown. In light of the 
evidence presented above that TSLP is a key activator of DCs into a T-2 polarizing 
phenotype, the role of this cell type in IPF will now be discussed in more detail.  
1.5 The role of dendritic cells in IPF 
Immature DCs are widely distributed in vivo to optimize antigen capture, and given 
the extremely large alveolar space that is at the interface between the host and the 
environment, they have a critical role in orchestrating the adaptive immune 
response to antigens presented to the lung. DCs are widely distributed throughout 
the normal lung, continuously sampling exogenous antigen, before trafficking to 
local lymph nodes to present them to naïve T-cells. An increase in the lung DC 
population is seen in a number of respiratory diseases, including COPD, lung 
cancer and lung transplant rejection (Vermaelen et al., 2005), though they have 
been most extensively studied in atopic asthma, where a clear pathogenetic role 
has been identified (van Rijt et al., 2005). As mentioned earlier, DCs have the 
capacity to polarise the immune response towards a T-1 or T-2 phenotype, 
depending upon signals received at an immature stage from their 
microenvironment, and while these signals had initially been thought to be solely 
antigen-derived, recent work suggests that DCs may also be activated by non-
antigenic danger signals (Matzinger, 1994), via purinergic receptors and TLRs 
[reviewed in (Skoberne et al., 2004)]. Such signals may be endogenous, and related 
to cellular degradation eg. heat shock proteins (HSPs) (Srivastava, 2002), ATP 
(Wilkin et al., 2001) and uric acid (Shi et al., 2003); endogenous and related to 
disruption of normal tissues architecture e.g. heparin-sulphate proteoglycans 
(Johnson et al., 2002); or exogenous pathogen-derived TLR ligands, such as viral 
dsRNA and LPS (Kaisho et al., 2003).  
As alluded to in Section 1.3.2.2., the importance of inflammasome activation by 
danger signals released following lung injury in promoting lung fibrosis has recently 
been demonstrated (Gasse et al., 2009). In these studies, NALP3 inflammasome 
activation, and subsequent maturation of IL-1β, following lung injury was 
demonstrated to be dependent upon the release of uric acid from injured cells. 
Strategies designed to lower uric acid levels, such as allopurinol or uricase 
administration, prevented activation of the inflammasome and attenuated 
bleomycin-induced lung fibrosis (Gasse et al., 2009).  The potential importance of 
this pathway in human disease is supported by the observation that uric acid levels 
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are elevated in IPF lung compared with non-fibrotic control lung (Markart et al., 
2009) . Moreover, uric acid has been demonstrated to be an important endogenous 
danger signal released from injured cells that activates immature dendritic cells and 
subsequent downstream immune responses (Shi et al., 2003). Another danger 
signal common to activation of the NALP-3 inflammasome (Aymeric et al., 2010), 
fibrogenesis (Riteau et al., 2010) and dendritic cell activation (Wilkin et al., 2001) is 
extracellular ATP (eATP). Levels of eATP are elevated in broncho-alveolar lavage 
fluid (BALF) specimens from IPF patients compared to non-fibrotic control lung and 
eATP promotes maturation of IL-1β and evolution of inflammation to fibrosis in an 
animal model of lung injury - the source of eATP in this model was postulated to be 
injured epithelial cells (Riteau et al., 2010). Collectively, these data support the 
notion that danger signals released from injured epithelium, not only activate the 
innate immune system but are additionally perceived by dendritic cells, thus 
engaging the adaptive immune system. 
In light of the importance attached to chronic epithelial cell injury in the 
pathogenesis of IPF, this thesis will address the overarching hypothesis that DCs, 
activated by these danger signals, may promote a local pro-fibrotic immune 
response at sites of tissue damage. The IPF lung has been reported to be infiltrated 
by mature/activated dendritic cells (Marchal-Somme et al., 2006), located adjacent 
to T-cell aggregates in a peri-vascular distribution. Moreover, these activated DCs 
were observed to be located in close proximity to T-cells expressing CD40L, a 
terminal maturation marker to DCs (Quezada et al., 2004), suggesting that such 
maturation might occur in situ. Recent work has also demonstrated that the IPF lung 
is also heavily infiltrated by immature DCs, expressing Specific Intercellular 
adhesion molecule-3-Grabbing Non-Integrin (DC-SIGNs), in a peri-bronchovascular 
distribution, in close proximity to endothelial cells expressing ICAM-2, critical for DC-
SIGN mediated DC trafficking (Geijtenbeek et al., 2000). In addition, DC-SIGN 
expressing DCs were observed at the periphery of T-cell aggregates expressing 
ICAM-3 (Marchal-Somme et al., 2007a), another important SIGN ligand (van Kooyk 
et al., 2002). Furthermore, hyperplastic epithelial cells and fibroblasts in IPF lung 
displayed strong immunoreactivity for chemokines known to be important in 
mediating DC recruitment, including CCL19, CCL22 and CXCL12 (Caux et al., 
2000). These latter findings support the notion of a “stromal address code” (Buckley 
et al., 2001) the aberrant expression of which leads to the accumulation of DCs and 
lymphocytes within inflamed organs. This phenomenon is well-recognised in other 
human auto-immune diseases such as rheumatoid arthritis (Parsonage et al., 2005). 
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Traditionally, the interaction between DCs and naïve T-cells has been thought to 
occur in local lymph nodes, to where the recently activated and maturing DCs traffic; 
certainly, mature DCs rapidly accumulate in lymph nodes under inflammatory 
conditions (Cook et al., 2007). However, the accumulation of such cells in the lung 
following BLM challenge suggests that they have the potential to interact with T-
cells in tertiary lymphoid structures, consistent with previous reports that migration 
of DCs to lymph nodes is not a prerequisite for lung T-cell activation (Constant et 
al., 2002; Wakim et al., 2008).  
As described above, mature DCs play a critical role in the activation of T-
lymphocytes, and their subsequent polarisation into Type 1 or Type 2 T-cells. The 
following section will address the potential role of T-cells in the pathogenesis of lung 
fibrosis.  
1.6. The role of the adaptive immune response in lung 
fibrosis 
T-lymphocytes are a key cellular component of the inflammatory response and, in 
particular, of the adaptive immune response. While their role in orchestrating 
immune responses linked to fibroproliferation in other organs in well established 
(Marrack et al., 2001), evidence regarding their involvement in lung fibrosis is less 
clear. The basis for their immune function is selective clonal expansion following 
specific antigen exposure. Such oligoclonal expansion is seen in fibroproliferative 
diseases of the lung, such as berylliosis, where a clear role for T-cells has been 
established (Fontenot et al., 1999), and such findings have recently been observed 
in IPF patients (Feghali-Bostwick et al., 2007; Shimizudani et al., 2002). Evidence 
regarding their potential role in the pathogenesis of IPF will now be discussed.  
1.6.1. T-cells in animal models of pulmonary fibrosis 
Data from animal models provide conflicting evidence as to the potential importance 
of T-cells of lung fibrosis. Lung T-cell accumulation has been reported to be 
increased in mice following bleomycin challenge from day 6 onwards compared to 
saline-treated controls (Izbicki et al., 2002; Zhu et al., 1996). Lung collagen 
accumulation in a bleomycin model of fibrosis is attenuated in athymic nude mice 
compared to wild type controls (Schrier et al., 1983). A similar attenuation in seen in 
rag -/- mice (Oikonomou et al., 2006), which are completely devoid of both T and B 
cells, and lymphocyte recruitment is associated with the development of bleomycin-
induced fibrosis, suggesting a role for the cellular immune system in this model 
 Chapter 1: Introduction 
59 
 
(Oikonomou et al., 2006). Furthermore, mice that lack CD28, a critical co-
stimulatory molecule required for full T-cell activation, are protected from BLM-
induced fibrosis; susceptibility is restored following the adoptive transfer of CD28 
expressing T cells (Okazaki et al., 2001), strongly suggesting that T-cell activation is 
required for the development of fibrosis following lung injury. 
Systemic depletion of T-cells in mice can be achieved by the administration of anti-
CD3, anti-CD4 and/or anti-CD8 antibody, and in these instances, mice are protected 
from BLM-induced fibrosis (Huaux et al., 2003b; Piguet et al., 1989; Sharma et al., 
1996). However, these findings are not universal (Janick-Buckner et al., 1989b) and 
a number of groups have failed to demonstrate any protection from bleomycin-
induced fibrosis in mice lacking T-cells (Helene et al., 1999; Szapiel et al., 1979) – 
one possible explanation for these discrepancies may be that severe combined 
immunodeficiency (SCID) mice, used in a number of these studies, are somewhat 
leaky, with residual circulating lymphocytes. It must also be noted that the dose of 
bleomycin, as well as the route of its administration varied from study to study. It is 
also plausible that variability of results from studies using knockout mice is due to 
the development of compensatory immune and repair mechanisms in an 
environment-dependent manner. Furthermore, the conflicting results observed with 
studies employing anti-CD3, anti-CD4 and/or anti-CD8 antibody administration may 
be due to variability in efficiency in terms of T-cell depletion. A limitation of the 
genetic models and those employing systemic depletion of T-cells, as described 
above, is that T-cells accumulate as part of a complex inflammatory response, thus 
confounding any specific role they may play in fibrogenesis. This issue may be 
circumvented by the selective attraction of T-cells to healthy lung. Transgenic mice 
overexpressing CCL18, a highly specific T-cell chemoattractant develop lung 
fibrosis in close association with T-cell infiltrates and importantly this effect is 
attenuated by the systemic depletion of T-cells (Luzina et al., 2006).  
Although the precise profile of T-cells that have been reported to accumulate in the 
lung following experimentally-induced lung injury remains unclear, recent work 
suggests that, in the bleomycin, they are predominantly of a memory phenotype, 
(Bantsimba-Malanda et al., 2010), consistent with the hypothesis that lymphocytes 
in the lung are memory cells whose population is maintained by continuous 
recruitment (Ely et al., 2006). Such memory T cells have the potential to be 
reactivated locally by DCs under inflammatory conditions (Heath et al., 2009), and 
importantly retain the capacity for effector cytokine generation (Harris et al., 2002). 
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Furthermore, these T cells also express CD40L, a marker of recently activated T-
cells (Quezada et al., 2004), but not KI67, a marker of proliferation, suggesting 
activation prior to recruitment to the aggregates (Bantsimba-Malanda et al., 2010). 
1.6.2. T-cells in IPF 
Despite controversy surrounding the role of inflammation in IPF, there are numerous 
reports to suggest a role for T-cells in the pathogenesis of IPF. The presence of T 
cells is consistently observed in lung tissue and BALF of IPF patients (Daniil et al., 
2005; Papiris et al., 2005; Parra et al., 2007) and their presence has been reported 
to correlate with worse lung function and poor survival (Daniil et al., 2005). 
Accumulation of T-cells appears to correlate with the degree of fibrosis, with 
relatively few T cells observed in areas of normal lung architecture (Parra et al., 
2007). Their distribution is variable and ranges from a diffuse infiltration throughout 
alveolar spaces and interstitium to focal perivascular aggregates (Luzina et al., 
2008). 
Recent work has demonstrated that peripheral CD4+ T-cells from IPF patients are 
more frequently activated than similar cells from healthy volunteers, with increased 
surface expression of MHC II and CD40L (Feghali-Bostwick et al., 2007). 
Interestingly, analysis of the TCR repertoires of these cells suggests that observed 
abnormal TCR-variable beta (TCRBV) expansions were due to clonal proliferation, 
suggesting oligoclonal expansions of these activated CD4 T-cells (Feghali-Bostwick 
et al., 2007). Similar analyses of BALF T-cells from IPF patients (Shimizudani et al., 
2002) support the notion that IPF is associated with an oligoclonal expansion of T-
lymphocytes, suggesting antigenic stimulation of these cells (Becker et al., 2000).  
The presence of lymphoid follicles, resembling germinal centres, in IPF lung has 
been noted for some time (Campbell et al., 1985; Wallace et al., 1996). Germinal 
centres are essential for lymphoid neogenesis, and consist of proliferating B cells 
and T-cells (Weyand et al., 2001) When occurring ectopically, they are termed 
tertiary lymphoid follicles. These follicles are found in a number of chronic 
inflammatory human diseases (Hjelmstrom, 2001), but only recently have their 
structure and function been evaluated in IPF. As alluded to earlier, recent work has 
demonstrated significant peri-vascular lymphocytic infiltration in IPF lung in which 
the lymphocytes were organized in follicular-type structures (Marchal-Somme et al., 
2006). Within these structures, T-lymphocytes were predominantly CD4+, 
expressing a CD45RO+ memory phenotype. Importantly, the vast majority were 
 Chapter 1: Introduction 
61 
 
also CD40L +. As described above, expression of this ligand is upregulated soon 
after T-cell activation and serves as a key maturation signal to dendritic cells 
(Quezada et al., 2004). This preponderance of CD40L+ memory T-cells, in both 
animal models of fibrosis, as well as in IPF lung, suggests that the T-lymphocytes 
infiltrating IPF lung are activated and antigen-experienced, hinting at a possible role 
for the adaptive immune response to the fibrogenesis, and in this regard, the role of 
auto-immunity in IPF will now be discussed.  
1.6.3. Auto-immunity in IPF 
In support of the notion that autoimmunity might be involved in the pathogenesis of 
IPF are reports of circulating immune complexes and autoantibodies against a 
variety of self-antigens in IPF patients (Chapman et al., 1984; Dobashi et al., 2000; 
Feghali-Bostwick et al., 2007; Yang et al., 2002). It has been postulated that the 
AEC represents a potential target of an autoimmune process in IPF, as a number of 
these circulating antibodies are directed against epithelial cells, including those very 
recently identified targeting periplakin (PPL) (Taille et al., 2010), a member of the 
plakin protein family which localises to desmosomes and intermediate filaments. 
The interaction between PPL and intermediate filaments is required for closure of 
experimental wounds in epithelial monolayers (Long et al., 2006) - the observation 
that anti-PPL antibodies inhibited epithelial cell repair in vitro supports the 
hypothesis that impaired epithelial reconstitution following injury might be a key step 
in the pathogenesis of lung fibrosis (Taille et al., 2010).  
Importantly, in vitro co-culture experiments have demonstrated that IPF lung extract 
stimulates proliferation of autologous CD4+ T-cells in contrast to preparations from 
healthy controls, strongly suggestive of an underlying autoimmune phenomenon in 
IPF patients (Feghali-Bostwick et al., 2007). Two recent studies provide further 
support for a role of the adaptive immune response in the pathogenesis of IPF. 
First, marked downregulation of CD28 expression has been demonstrated on 
circulating CD4+ T-lymphocytes from IPF patients , in contrast to T-cells derived 
from healthy individuals, almost all of which express CD28 (Gilani et al., 2010). As 
alluded to Section 1.6.1., CD28 serves as a key co-stimulatory molecule to ensure 
complete activation of naïve CD4+ T-cells. However, following repeated cycles of 
antigen-driven proliferation, human CD4+ T-cells develop a number of phenotypic 
and functional characteristics, including loss of CD28 expression (Hirokawa et al., 
2001; Studer et al., 2008); these activated CD4+ T-cells, or memory T-cells, do not 
require CD28 for further activation and effector cytokine function (Fontenot et al., 
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2003). The loss of CD28 expression by circulating CD4+ T-cells in IPF is strongly 
suggestive of an underlying chronic adaptive immune response, suggesting the 
presence of an offending antigen as an initiating injurious stimulus, in the 
pathogenesis of IPF. Indeed, the downregulation of CD28 expression appears to be 
associated with poor outcomes in these patients (Gilani et al., 2010). Second, 
circulating and BALF FoxP3+ Tregs, which are essential for the control of 
immunological tolerance and the dampening of the adaptive immune response 
against antigen, are reduced in number in IPF patients compared with non-IPF 
controls (Kotsianidis et al., 2009). Importantly, the suppression of experimentally-
induced T-2 immune responses in vitro by Tregs derived from IPF BALF is 
significantly impaired. Moreover, this degree of impairment correlates with lung 
function parameters (Kotsianidis et al., 2009). Such quantitative and qualitative 
defects in Treg populations are well described in other human autoimmune 
diseases(Ehrenstein et al., 2004), pointing to a similar pathogenetic process in IPF. 
1.7. Mechanism of action of T-cells in pulmonary fibrosis 
While a defect in Treg number and function suggests a deficiency in immune 
tolerance that may contribute to the pathogenesis of IPF, the mechanism of action 
of non-Treg CD4+ T-cells in this condition remains unclear. Several studies have 
demonstrated that activated T-cells can directly induce collagen synthesis by 
fibroblasts (Cathcart et al., 1987; Selman et al., 1990; Yamamura et al., 2001). One 
possible mechanism may involve the CD40 ligand (CD40L)-CD40 activation 
pathway. CD40L expression is higher on IPF CD4+ T-cells, compared to control 
cells (Feghali-Bostwick et al., 2007), and interaction between CD40L and its 
cognate receptor, CD40, results in increased collagen synthesis by CD40 
expressing lung fibroblasts (Sempowski et al., 1997).  In addition to membrane-
dependent interactions, T-cells may regulate fibrogenesis via the generation 
chemokine gradients promoting the recruitment of fibrocytes to the lung. For 
instance, activated CD4+ T-cells can elaborate CCL3 (Grob et al., 2003), and CCL3 
-/- mice, as well as mice lacking its receptor, CCR5, are protected from BLM-induced 
fibrosis, with an associated attenuation in lung fibrocyte recruitment (Ishida et al., 
2007). An expansion of a functional fibrocyte population may also be achieved 
through differentiation of monocytes, and the attenuation of experimentally-induced 
renal fibrosis observed with anti-CD4 antibody treatment is associated with a 
reduction in fibrocyte differentiation, suggesting that both fibrocyte recruitment and 
differentiation is critically dependent on CD4+ T cell activity (Niedermeier et al., 
2009). However, most attention regarding the role of T-cells in fibrosis have focused 
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on their expression of soluble T-2 cytokines. The pro-fibrotic potential of these 
cytokines will now be discussed in more detail.  
1.7.1. The T-2 hypothesis of fibrosis 
There is a growing body of evidence to suggest that the cytokine phenotype of the 
immune response to an inciting stimulus determines whether injury progresses to 
fibrosis or resolves. This hypothesis proposes that progressive fibrosis results from 
a maladaptive immune response to a chronic or persistent antigen or inciting 
agent(s). The fibroproliferative response to injury can therefore be considered a 
result of an inappropriate shift towards a more T-2 phenotype characterised by a 
relative increase in expression of T-2 cytokines, such as IL-13, over T-1 cytokines 
such as IFN-γ (Wynn et al., 1995). This polarisation is independent of the potency of 
inflammation as potent inflammatory responses dominated by IFN-γ induced in 
animal models of schistosomiasis do not result in fibrosis (Hoffmann et al., 2000). 
Rather, this hypothesis proposes that fibrogenesis is regulated by the nature of the 
cytokine phenotype of the immune response. Moreover, it has been argued that a 
switch to T-2 cytokine expression may be in the interests of the host organism when 
faced with persistent T-1 dominated responses to prevent excessive inflammation-
induced damage and death (Wynn, 2004). In a murine model of schistosomiasis, IL-
10/IL-4 knockout mice, which develop a highly polarised T-1 phenotype, 
demonstrate 100% mortality at week 9 following egg-laying, strongly linked to IFN-γ 
levels, in contrast to T-2 biased mice, which display only 30% mortality at the same 
time point (Hoffmann et al., 2000). In this regard, the development of organ fibrosis 
may be an acceptable compromise to ensure survival, and thus be viewed as an 
adaptive wound healing mechanism.  
1.7.2. The role of IL-13 in pulmonary fibrosis 
Of all the T-2 cytokines, IL-13 has received most attention in the context of several 
fibrotic conditions [reviewed in (Wynn, 2004)]. IL-13 is predominantly secreted by 
Th2 cells, but other cellular sources include mast cells, basophils and eosinophils. 
More recently, human alveolar epithelial cells and macrophages have also been 
identified as significant sources of IL-13 (Allahverdian et al., 2008; Hancock et al., 
1998). 
The hallmark of lung fibrosis is the inappropriate deposition of excessive ECM 
proteins present in the interstitium, and the predominant such protein is collagen. 
This net excess reflects increased synthesis, though reduced turnover is also 
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contributory (McAnulty et al., 1987). In addition to being mitogenic for human 
fibroblasts (Saito et al., 2003), IL-13 induces the upregulation of total collagen 
production and upregulates collagen type I gene expression by this key effector cell 
of fibrosis (Oriente et al., 2000). Furthermore, IL-13 can promote differentiation of 
fibroblasts into myofibroblasts (Saito et al., 2003). IL-13 may also promote a non-
degradative micro-environment within the pulmonary interstitium, by its ability to 
inhibit IL-1β induced expression of matrix metalloproteinase (MMP)-1 by fibroblasts 
and by upregulating tissue inhibitor of metalloproteinase (TIMP)-1 expression 
(Oriente et al., 2000). More recently, IL-13 has been identified as a mediator of 
epithelial cell apoptosis in vitro (Borowski et al., 2008), suggesting a role for this T-2 
cytokine in amplifying the dysregulated crosstalk between the epithelium and the 
mesenchyme.  
In animal models, bleomycin-induced lung injury induces upregulation of IL-13 
protein expression. The time of maximal upregulation appears to be between 12 
and 28 days post challenge (Belperio et al., 2002; Jakubzick et al., 2003). Moreover, 
IL-13 -/- mice are protected from bleomycin-induced fibrosis at day 21 (Liu et al., 
2004b), whereas selective airway expression of IL-13 in mice promotes the 
development of sub-epithelial fibrosis at one month of age and of parenchymal 
fibrosis by three months (Lee et al., 2001). Further support for a role for IL-13 in 
fibroproliferative lung disease in animal models, comes from studies targeting IL-13 
or IL-13 responsive cells. Attenuation of bleomycin-induced fibrosis in mice is 
observed by passive neutralization of IL-13 with anti-IL-13 antibodies (Belperio et 
al., 2002), and a similar observation is seen following the therapeutic administration 
of an IL-13 immunotoxin chimeric molecule (IL13-PE) comprised of human IL-13 
and a mutated form of Pseudomonas aeruginosa exotoxin A (Jakubzick et al., 
2003).  
As well as exerting direct effects on epithelial cells and fibroblasts, IL-13 may 
promote a fibrotic phenotype via a number of other mediators. IL-13 induction of 
TGF-β expression has been demonstrated in macrophages (Fichtner-Feigl et al., 
2006), and IL-13 also seems capable of activating latent TGF-β via a plasmin/serine 
and MMP-9 dependent manner (Lee et al., 2001). Found in Inflammatory Zone 
(FIZZ) -1 is a protein that belongs to a novel family of cysteine rich secreted proteins 
termed resistin-like molecules (RELMs). FIZZ-1 is a potent inducer of fibroblast to 
myofibroblast differentiation in vitro (Liu et al., 2004a), and its expression is 
significantly upregulated in epithelial cells following bleomycin-induced lung injury in 
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mice. However, this upregulation is completely abrogated in IL-13 knockout mice 
which are protected from bleomycin-induced fibrosis (Liu et al., 2004b). 
In humans, elevated levels of macrophage-derived IL-13 have been observed in 
BALF samples from IPF compared to control (Hancock et al., 1998). Since then, 
elevated IL-13 mRNA and protein levels have been reported in lung biopsies of 
patients with IPF compared to non-fibrotic control biopsies (Jakubzick et al., 2004b). 
This latter group also demonstrated a significant increase in IL-13 receptor 
expression in IPF lung compared to non-fibrotic control, localising in particular to 
fibrotic foci leading to the suggestion that this may facilitate increased 
responsiveness to IL-13 of the cellular components of such foci. Indeed, lung 
fibroblasts derived from IPF lung exhibit greater IL-13 receptor expression than non-
fibrotic control cells and display greater susceptibility to IL-13PE-mediated 
cytotoxicity in vitro (Jakubzick et al., 2004a) Collectively, these findings support the 
notion that IL-13 may play a significant role in the pathogenesis of IPF which is 
reflected by an on-going interest in targeting IL-13 as a novel therapeutic strategy in 
IPF and other fibrotic conditions (Datta et al., 2011). IL-13PE has recently been 
granted orphan drug status in the USA, and an IL-13 neutralising antibody is 
currently being evaluated in IPF patients (Novartis, USA).  
1.7.3. The role of IL-4 in fibroproliferative disease 
Although IL-13 has received most attention of the T-2 cytokines in the pathogenesis 
of fibrotic conditions, several studies have also demonstrated the potential 
importance of the prototypic T-2 cytokine, IL-4, in such diseases. IL-4 exerts a wide 
range of effects on a number of different cell types. For example, it is a key cytokine 
involved in driving the differentiation of naïve Th cells into Th2 cells, and is crucial 
for eosinophil chemotaxis. IL-4 exerts a number of regulatory effects on human 
fibroblasts, including promoting chemotaxis, proliferation, collagen synthesis and 
differentiation into myofibroblasts (Postlethwaite et al., 1992; Postlethwaite et al., 
1991; Sempowski et al., 1994). IL-4 expression is upregulated in mice following 
bleomycin-induced lung injury (Gharaee-Kermani et al., 2001), and human disease 
relevance is suggested by the observation of enhanced IL-4 immunoreactivity in  
IPF lung sections, compared to normal controls (Ando et al., 1999; Wallace et al., 
1995). However, the role of IL-4 in the pathogenesis of lung fibrosis appears more 
complex than previously thought. For example, it appears to possess 
immunosuppressive and anti-inflammatory properties, and has been demonstrated 
to inhibit TNF-α synthesis by macrophages (Levings et al., 1999). In accordance 
with this, IL-4 appears to perform a dual role following lung injury in murine models : 
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at early time points following bleomycin-induced injury, it is immunosuppressive and 
anti-inflammatory contributing to limited T-cell recruitment and reduced TNF-α 
generation, but thereafter appears to be pro-fibrotic (Huaux et al., 2003a).  
1.7.4. The role of T-2 chemokines in fibroproliferative disease 
It is increasingly recognised that chemokines can cooperate with pro-fibrotic T-2 
cytokines in the development of fibrosis, via the recruitment of lymphocytes, 
macrophages and other effector cells to sites of tissue damage. Together with their 
receptors, chemokines are an essential component of T-1 and T-2 mediated 
immune responses, and their importance in the polarisation and subsequent 
amplification of a particular immune response is reflected by the differential 
expression of chemokine receptors on Th1 and Th2 cells: CXCR3 and CCR5 are 
predominantly expressed by Th1 cells whereas Th2 cells are characterised by 
increased CCR4 and CCR8 expression (Sallusto et al., 1998). It is likely that 
numerous chemokine signalling pathways are involved in fibrogenesis, but the CC-
chemokine family has been most extensively studied. Pathogenic roles for CCL6 
and CCL17 have been proposed on the basis of animal studies demonstrating 
attenuated fibrotic responses to bleomycin following passive neutralization of these 
chemokines (Belperio et al., 2002; Belperio et al., 2004). The attenuation in 
bleomycin-induced fibrosis observed with anti-CCL6 antibody administration is 
associated with a reduction in macrophage infiltration (Belperio et al., 2002). The 
importance of macrophages to the development of pulmonary fibrosis is well 
documented and beyond the scope of this thesis. Briefly, however, macrophages 
are felt to be a major cellular source of pro-fibrotic cytokines such as TGF-β and 
PDGF (Keane MP, 2000) as well as MMPs, important mediators of ECM 
remodelling (Riches, 2000). Indeed, macrophages appear to be the predominant 
cellular source of CCL6 in this model, downstream of IL-13 activity, suggesting an 
autocrine pathway to amplify the inflammatory response to lung injury. A similar 
association between reduced macrophage infiltration and fibrosis following 
bleomycin-induced lung injury has also been observed following neutralisation of 
CCL17 (Belperio et al., 2004). Interestingly, this was also associated with a 
significant reduction in lymphocyte accumulation and indeed, expression of CCR4, 
the cognate CCL17 receptor, was increased in this model. Conversely, CXCR3 -/- 
knockout mice demonstrate increased mortality with progressive fibrosis in a 
bleomycin model of lung injury compared to wild type controls (Jiang et al., 2004). 
Importantly, human disease relevance for the importance of CCR4 in the 
pathogenesis of IPF has recently been suggested by the observation of increased 
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CCR4 expression on BALF CD4+ T-cells In IPF lung compared to control, with a 
concomitant reduction in CXCR3 expression on the same T-cell population (Pignatti 
et al., 2006). 
Arguably the most intensively studied CC-chemokine in lung fibrosis, however, is 
CCL2. This chemokine is produced by a number of cell types, including epithelial 
cells and fibroblasts (Puneet et al., 2005) and is a potent chemoattractant for T 
cells, immature dendritic cells and mononuclear cells (Rose et al., 2003). Indeed, 
fibroblast-derived CCL2 has recently been demonstrated to play a critical role in 
dendritic cell trafficking in the lung following experimentally-induced airway 
inflammation and remodelling (Kitamura et al., 2011). Lung CCL2 expression is 
increased in mice following bleomycin challenge (Zhang et al., 1994a), and mice 
deficient in the unique CCL2 receptor, CCR2, are protected from BLM-induced lung 
fibrosis (Gharaee-Kermani et al., 2003). Elevated CCL2 expression has been 
reported in IPF (Antoniades et al., 1992; Mercer et al., 2009) and lung fibroblasts 
derived from fibrotic lesions of IPF patients display a greater ability express CCL2 
compared to normal control fibroblasts (Standiford et al., 1993).  
As discussed in Section 1.3.2.3., fibrocytes have been proposed to contribute to the 
myofibroblast population in IPF. Fibrocytes have been reported to accumulate in the 
lung following bleomycin-induced lung injury. In this model, the protection afforded 
from fibrosis in mice deficient in the receptor for CCL2, CCR2, is associated with 
reduced fibrocyte and monocyte recruitment (Moore et al., 2005), highlighting the 
importance of CCR2 signalling axis in this regard. CCL2 may further contribute to 
excessive matrix deposition by stimulating fibroblast collagen production via TGF-β 
(Gharaee-Kermani et al., 1996). CCL2 has also been reported to engage in a 
tripartite relationship with TGF-β and IL-13, with interplay between these three 
cytokines promoting a pro-fibrotic response (Murray et al., 2008). 
In addition, recent studies have suggested that CCL2 may amplify the dysregulated 
epithelial-mesenchymal crosstalk following lung injury via its ability to regulate 
apoptosis. As discussed in Section 1.3.2.3., resistance of lung (myo)fibroblasts to 
apoptosis may contribute to the persistence of this key effector cell in lung fibrosis; 
CCL2 mediates such resistance in vitro in an IL-6 dependent manner (Liu et al., 
2007a). 
Over the past 15 years, it has become increasingly apparent that chemokines may 
also contribute to regulation of the immune response (Luther et al., 2001). T-cell 
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activation in the presence of CCL2 results in enhanced T-2 cytokine generation 
(Karpus et al., 1997). Moreover, neutralization of fibroblast-derived CCL2 attenuates 
IL-4 expression by T-cells with a concomitant increase in expression of the 
prototypic T-1 cytokine, interferon (IFN)-γ (Hogaboam et al., 1998). These findings, 
demonstrating the T-enhancing properties of CCL2, are supported by in vivo studies 
in which CCL2-/- mice are unable to mount T-2 immune responses (Gu et al., 2000).  
Taken together, these findings suggest that CCL2 represents an important mediator 
in fibrotic lung disease by promoting a range of cellular responses.  
1.8. The role of TNF-α in fibroproliferative disease 
The work presented in this thesis focuses on TNF-α as a regulator of TSLP 
expression. An overview of TNF-α biology will therefore now be provided. TNF-α is 
a pluripotent cytokine that has traditionally been viewed as being pro-inflammatory. 
However, it may be more appropriately regarded as a master cytokine involved in a 
wide range of cellular processes including differentiation, proliferation and 
apoptosis. Its basic biology and relevance to fibroproliferative disease of the lung 
will now be discussed. 
1.8.1. TNF-α : a brief overview of biology 
In humans, TNF-α is initially synthesised as a 26kDa pro-protein which is integrated 
into the cell membrane (mTNF) existing as a stable homotrimer (Tang et al., 1996). 
This cell associated form is biologically active and is thought to be involved in 
juxtacrine signalling following initiation of cell-cell contact (Kriegler et al., 1988). In 
addition, a further biologically active form is created by the action of matrix 
metalloproteinases which cleave the extracellular domain releasing a mature 17kDa 
soluble protein (sTNF) which also exists in a homotrimeric form (Black et al., 1997) . 
The major enzyme involved in releasing sTNF from mTNF is TNF-α converting 
enzyme (TACE) (Moss et al., 1997). The particular functions of mTNF and sTNF 
remain unclear, though recent evidence suggests in certain instances they may play 
distinct roles. For instance, sTNF knockout mice are protected from endotoxin-
induced lethality (Josephs et al., 2000) but are sensitive to the development of 
chronic inflammatory conditions such as rheumatoid arthritis (Alexopoulou et al., 
1997) and the relevance of this to fibroproliferative disease of the lung will be 
discussed in more detail in Section 1.8.2. To a certain degree this may reflect a 
preference for sTNF to signal via one of 2 structurally distinct TNF-α receptors, TNF 
receptor type 1 (TNFRI), over TNFRII (Grell et al., 1995), as TNFRI knockout mice 
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are also resistant to endotoxin-induced lethality (Evans et al., 1994). The reason for 
this remains unclear, though may reflect differing on-off kinetics of the two receptors 
– TNF-α binding to TNFRI is essentially irreversible, whereas binding to TNFRII is 
associated with rapid on-off kinetics (Grell et al., 1998).  
The distribution of these receptor sub-types varies between different tissues and cell 
types. TNFRI is constitutively expressed in most tissues whereas TNFRII 
expression is tightly regulated and is typically limited to cells of the immune system. 
The majority of cellular processes induced by TNF-α are mediated via TNFRI. The 
binding of TNF-α to TNFRI triggers a series of intracellular events which ultimately 
result in the activation of two major transcription factors, NFκB and AP-1. As 
discussed in Section 1.4.3., these transcription factors are responsible for the 
inducible expression of genes important for a wide range of cellular processes 
including cell growth and development as well as host immune and inflammatory 
responses. 
As discussed in Section 1.4.3.3., liberation of NFκB from IκB is achieved following 
the phosphorylation-induced degradation of IκB, to which it is bound in the 
cytoplasm. This phosphorylation of IκB is performed by the IκB kinase (IKK) 
complex. The initial step in TNF-induced activation of the IKK complex is a 
conformational shift of the TNF-R1 complex, resulting in release of the inhibitory 
protein, silencer of death domain (SODD) (Jiang et al., 1999). TNFRI possess an 
intra-cellular protein-protein interaction domain termed death-domain (DD). This DD 
can recruit other DD-containing proteins. Following SODD dissociation,  the DD-
containing adaptor protein, tumour necrosis factor receptor type 1-associated death 
domain protein (TRADD), is recruited to the death domain (DD) of TNFRI by 
homophilic interactions between these DDs (Hsu et al., 1995). TRADD, in turn, 
serves as a scaffold for the binding of TNF receptor-associated  factor (TRAF)-2, 
and the death-domain-containing serine-threonine kinase receptor-interacting 
kinase (RIP) (Hsu et al., 1996) . A complete review of the subsequent molecular 
interactions that lead to IKK phosphorylation is beyond the scope of this thesis, but 
briefly it appears that TRAF-2 promotes recruitment of the IKK complex to RIP, 
which activates the kinases of IKK (Devin et al., 2000). Subsequent phosphorylation 
of IκB allows release of NFκB and unmasking of their nuclear location sequence. 
Thereafter, translocation of the NFκB, into the nucleus permits binding of this 
transcription factor to regulatory sequences of target genes.  
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The second major transcription factor commonly activated following binding of TNF-
α to its receptors is AP-1. As discussed in Section 1.4.3.2., regulation of AP-1 
directed transcription of target genes may be regulated in a post-translational 
manner by differential phosphorylation of its c-Jun and c-Fos components. This is 
achieved primarily by JNK following ligation of TNFRI by TNF-α. Evidence from 
studies employing knockout mice and/or mice expressing dominant-negative 
enzyme forms, suggest that TNF-α-induced activation of JNK, and therefore of c-
Jun phosphorylation, occurs via a non-apoptotic TRAF-2 dependent pathway (Lee 
et al., 1997; Reinhard et al., 1997; Yeh et al., 1997). TRAF-2 appears necessary for 
coupling the JNK pathway to TNFRI, via MEK7 and MEK4 (Tournier et al., 2001). 
However, the MEKK linking TRAF-2 and MEK7/4 remains undefined. Potential roles 
have been postulated for MEKK1 and apoptosis-signal-regulating kinase (ASK)-1 
(Baud et al., 1999; Hoeflich et al., 1999), as well for members of the germinal centre 
kinase (GSK) family (Yuasa et al., 1998) ], which are recognised proximal activators 
of MAPK pathways via phosphorylation of MEKKs (Kyriakis, 1999). These latter 
kinases may serve to link TNFRI ligation to JNK activation by promoting a functional 
interaction between TRAF-2 and MEKK1 (Shi et al., 1999). However, unlike the 
NFκB pathway, there appears no functional role for RIP, as RIP knockdown fails to 
inhibit TRAF-2-induced JNK activation (Yuasa et al., 1998).  
In contrast, good evidence exists to suggest an axis that TNF-induced activation of 
the p38 MAPK cascade relies on a functional interaction between the adaptor 
protein TRAF-2 and RIP (Yuasa et al., 1998), though there is clearly a degree of 
redundancy in this pathway, as ASK1 and MEKK1 have also been strongly 
implicated in its activation (Carpentier et al., 1998). Mechanisms underlying ERK1/2 
activation following engagement of TNFRI by TNF-α are far less well understood, 
though the recruitment of a protein containing a low DD homology termed MAPK-
activating death domain protein (MADD) to the DD of TNFRI has been implicated 
(Schievella et al., 1997). 
It is clear that signalling mechanisms downstream of TNF-α binding to its receptors 
is extremely complex, with extensive cross-talk between pro-apoptotic pathways 
(not discussed in this thesis), NFκB and MAPK signalling cascades. The molecular 
basis for this cross talk remains unclear, and aside from cell to cell variation, the 
importance of signal intensity and duration in promoting differential activation of one 
of these pathways is only now becoming clear. 
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1.8.2. The role of TNF-α in lung fibrosis 
As alluded to earlier, epithelium-derived TNF-α may be regarded as an endogenous 
danger signal indicative of cellular injury. This “early wave” alarm-type cytokine is 
upregulated soon after injury in many tissues, including the lung. Although, 
haematopoietic cells, especially macrophages, have previously been regarded as 
the major TNF-α-producing cell, in fibroproliferative lung disease, the epithelium 
also appears to be a major contributor. Indeed, there exists good evidence that 
TNF-α plays an important role in the pathogenesis of IPF. Functional TNF-α 
polymorphisms are associated with an increased risk of developing IPF (Whyte et 
al., 2000). TNF-α immunoreactivity in IPF lungs is significantly greater than in non-
fibrotic control lungs (Kapanci et al., 1995; Nash et al., 1993; Piguet et al., 1993; 
Ziegenhagen et al., 1998), localising in particular to injured epithelial cells and 
macrophages. These findings are supported by animal models of lung fibrosis, 
where increased expression of TNF-α is observed following bleomycin-induced 
injury (Phan et al., 1992; Piguet et al., 1989), localising to apoptosing epithelial cells 
(Oikonomou et al., 2006). Interestingly, mice which lack TNF-α expression in 
haematopoietic cells are not protected from bleomycin-induced fibrosis – in contrast, 
abolishing TNF-α expression by non- haematopoietic cells results in complete 
disease protection (Oikonomou et al., 2006). These data are consistent with the 
hypothesized mechanism of action of bleomycin in this model, which is to induce 
breaks to double-stranded DNA in epithelial cells – the co-localisation of TNF-α to 
apoptosing epithelial cells strongly support the notion that  epithelium-derived TNF-
α has an important role in the pathogenesis of lung fibrosis. In support of a pro-
fibrotic role for TNF-α are observations that therapies targeting TNF-α attenuate 
experimentally-induced fibrosis in animal models (Piguet et al., 1989; Piguet et al., 
1994). Moreover, mice deficient in both TNFRI and TNFRII are protected from 
bleomycin-induced fibrosis (Ortiz et al., 1998), though more recent studies have 
suggested a degree of redundancy in these receptors (Oikonomou et al., 2006). 
As discussed in Section 1.8.1., human TNF-α exists in two forms which may have 
distinct roles. This notion is supported by the observation that mice which express 
only the transmembrane form (mTNF) are capable of mounting an inflammatory 
response consisting mainly of macrophages in response to bleomycin. However, 
these mice are protected from the subsequent development of fibrosis which is 
associated with a significant impairment in lymphocyte recruitment. Importantly, 
administration of sTNF-α restores lymphocyte recruitment and susceptibility to 
fibrosis in this model (Oikonomou et al., 2006). These data suggest that sTNF-α is 
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required for lymphocyte accumulation and the transition from an inflammatory 
response to one of fibrosis, and is in accordance with previous studies examining 
the effect of over-expression of TNF-α in the lung. These mice, over-expressing 
TNF-α under the control of surfactant protein C, develop a lymphocytic alveolitis 
associated with collagen deposition over the ensuing months (Miyazaki et al., 1995). 
Transient over-expression of TNF-α also results in a significant lymphocytosis, with 
a subsequent fibrotic distortion of lung architecture (Sime et al., 1998), further 
supporting the hypothesis that TNF-α plays a critical role in lung fibrogenesis.  
However, the molecular mechanisms underlying the pro-fibrotic potential of TNF-α 
are unclear. Indeed, up-regulation of TNF-α expression has been documented in 
other inflammatory and immune lung pathologies in which normal lung repair 
processes ensue without evidence of fibrotic reactions, suggesting that TNF-α may 
be acting via a number of other directly pro-fibrotic cytokines, such as TGF-β. 
Moreover, it is possible that the pro-fibrotic potential of TNF-α is only realised in the 
context of a damaged basement membrane, reflecting persistent and repetitive 
epithelial injury, features felt to be critical to fibroproliferative disease in the lung. In 
addition, the dysregulated epithelial-mesenchymal crosstalk, characteristic of lung 
fibrosis, may serve to amplify the pro-fibrotic nature of TNF-α, - these effects may 
be enhanced in the presence of other pro-fibrotic mediators entrapped within a 
disordered extracellular matrix (Bringardner et al., 2008).  
A common feature of fibrotic disease in animal models where TNF-α is felt to have a 
prominent role is an inflammatory cell infiltrate, particularly of lymphocytes (Miyazaki 
et al., 1995; Oikonomou et al., 2006). The mechanisms of this TNF-α-mediated 
accumulation of inflammatory cells, including lymphocytes, are likely to involve both 
direct effects of TNF-α itself on regulation of adhesion molecule expression and 
induction of other cytokines and growth factors capable of mediating leukocyte 
chemotaxis and survival (Ulrich, 1993). In addition, it appears that expression of 
TGF-β is upregulated in lung pathology where TNF-α is associated with fibrosis 
(Phan et al., 1992; Sime et al., 1998). Indeed, TNF-α has been reported to 
upregulate activity of lung fibroblast-derived-TGF-β in vitro both by increasing 
transcription and stabilising mRNA levels. TNF-α may further  promote fibrosis by 
inducing fibroblast chemotaxis and proliferation, the latter occurring in a PDGF-
dependent manner (Battegay et al., 1995; Leibovich et al., 1987).   
The potential of TNF-α to act as an endogenous danger signal, promoting 
maturation and activation of dendritic cells, has previously been documented (Efron 
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et al., 2005). Furthermore, ample evidence indicates that TNF-α may also directly 
influence the adaptive immune response. In particular, TNF-α has been shown to 
enhance T cell proliferation in response to antigens, alloantigens and mitogens 
(Hackett et al., 1988; Shalaby et al., 1988; Yokota et al., 1988) and in this regard, 
TNF-α is very similar to IL-1β. Interestingly, the potential importance of danger 
signals, including IL1β and eATP, released from injured epithelium, in the 
pathogenesis of fibrosis has recently garnered much interest (Gasse et al., 2009; 
Riteau et al., 2010). One may therefore postulate that in the context of epithelial cell 
injury, TNF-α represents a danger signal to resident or infiltrating cells, the sequelae 
of which may be to promote a pro-fibrotic microenvironment. In addition, TNF-α has 
been demonstrated to play a critical role in the mediation of T-2 cytokine host 
responses (Artis et al., 1999) and it has been hypothesised  that TNF-α functions in 
this regard through regulation of T-2 cytokine receptor expression (Lugli et al., 
1997). 
Despite the success of anti-TNF therapy in attenuating experimentally-induced 
fibrosis, an exploratory trial of etanercept, a soluble decoy TNF-α receptor, in 
patients with IPF did not demonstrate any significant improvement in primary 
outcome measures (Raghu et al., 2008). However, this trial was relatively small, 
compared to recent drug trials in IPF: 88 patients compared to over 700 patients 
combined in the recent CAPACITY trials evaluating the use of pirfenidone. This 
small size may have limited the ability of the trial to detect statistically significant 
differences in the primary end points. Moreover, the non-significant trend to 
improvement in a number of secondary parameters, including post hoc analysis of 
rate of disease progression by death, may become more apparent with larger 
patient groups. Furthermore, it is becoming increasingly apparent that IPF is likely to 
represent the end stage of “multiple hits to multiple pathways”. The success of 
pirfenidone in reducing the rate of deterioration in lung function in IPF patients 
reflects this point. Pirfenidone is a pyridine derivative which possesses numerous 
anti-fibrotic (Gurujeyalakshmi et al., 1999; Hewitson et al., 2001), anti-inflammatory 
(Oku et al., 2002) and anti-oxidant properties (Giri et al., 1999). With respect to the 
work presented in this thesis, it is interesting to note that pirfenidone possesses 
potent anti-TNF-α activity both in vitro (Nakazato et al., 2002) and in vivo (Iyer et al., 
2003; Oku et al., 2002; Oku et al., 2008), as well being capable of attenuating T-2 
cytokine expression and airway remodelling in experimentally-induced lung 
inflammation (Hirano et al., 2006).  
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The success of future therapeutic strategies in IPF may depend, therefore, on the 
simultaneous targeting of multiple pathways, the predominance of which may further 
vary from patient to patient, as well as temporally within an individual. Advances in 
molecular profiling technologies, including genetic testing and the identification of 
disease biomarkers, may facilitate a greater degree of personalised drug delivery, 
thus affording the scientific community an opportunity to make a significant impact in 
reducing the morbidity and mortality of complex end-stage pathologies such as 
fibrosis.  
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1.9. Summary and hypothesis 
Pulmonary fibrosis is the end stage of a heterogeneous group of conditions 
characterised by excessive and disordered ECM deposition within the pulmonary 
interstitium. Current evidence suggests that defective cross-talk between epithelial 
cells and mesenchymal cells following repetitive lung injury is a central mechanism 
contributing to the persistence of activated and highly synthetic myofibroblasts, the 
key effector cells of fibrogenesis. This defective crosstalk may be further influenced 
by the immune response to injury and a cytokine milieu dominated by T-2 cytokines 
is widely regarded as being pro-fibrotic.  
Recent evidence has highlighted TSLP as a critical cytokine involved in the 
polarisation of immune responses towards a T-2 phenotype through its unique 
activation of dendritic cells as well as direct effects on naïve CD4+ T cells. In 
addition, recent studies have demonstrated the importance of non-antigenic 
endogenous danger signals in engaging the adaptive immune response to 
inflammatory responses following epithelial injury. 
Although TSLP has traditionally been regarded as an epithelium-derived cytokine, 
other potential cellular sources include airway smooth muscle cells. However, the 
mechanisms underlying TSLP expression by mesenchymal cells remains unclear. 
Moreover, the role of TSLP in the development of a pro-fibrotic T-2 immune 
response in non-allergen driven lung disease is unknown.  
This thesis will therefore address the following hypothesis: 
 
The induction of TSLP following epithelial lung injury contributes to the 
development of pulmonary fibrosis by promoting a T-helper 2 immune 
response 
 
The specific aims of this thesis are to: 
 
1. Examine the immunolocalisation of TSLP and its receptor in human IPF lung 
tissue and in a murine model of bleomycin-induced lung fibrosis;  
 
2. Determine the role of TNF-α as a danger signal in promoting TSLP 
expression by alveolar / lung structural cells in vitro and in vivo; 
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3. Evaluate the contribution of TSLP to the development of a T-2 immune 
response following lung epithelial injury; 
 
4. Establish a causal relationship between TSLP and the induction of lung 
fibrosis following lung epithelial injury.  
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CHAPTER 2: MATERIALS AND METHODS 
 
MATERIALS 
 
2.1. Chemicals, solvents and tissue culture materials 
All chemicals were of analytical grade and were obtained from Sigma Aldrich (UK) 
unless otherwise stated. All water used for the preparation of buffers was distilled 
and deionised using a Millipore Water Purification System (Millipore RO10 followed 
by Milli-Q Plus; Millipore Ltd, UK). Solvents used for the preparation of high 
pressure liquid chromatography (HPLC) buffers and solutions were of HPLC grade 
and obtained from BDH-Merck Ltd (UK). Sterile tissue culture flasks and plates, 
polypropylene centrifuge tubes and pipettes were obtained from Nunc (Denmark). 
All sterile tissue culture media, sterile tissue culture grade trypsin/EDTA, antibiotics 
(penicillin/streptomycin) and glutamine were obtained from Invitrogen (UK). Foetal 
bovine serum (FBS) was obtained from Invitrogen (UK). Dulbecco’s Modified Eagle 
Medium (DMEM) and RPMI-1640 were purchased from Gibco (UK). 
2.2 Cytokines 
Human recombinant (hr) TNF-α was purchased from Peprotech (NJ, USA) and was 
dissolved in PBS/0.1% BSA (w/v), aliquoted and stored (1 µg/ml) at -80°C. hrTSLP, 
murine TSLP and hrCCL2 were purchased from R&D Systems (UK) and prepared 
as above. Prior to use, aliquots of appropriate cytokines were thawed and diluted in 
serum-free medium. Bleomycin was purchased from Kyowa-Hakka (UK) and was 
dissolved in normal (0.9%) saline prior to use. 
2.3. Inhibitors, antibodies and peptides 
All the inhibitors used for cell signalling studies were purchased from Calbiochem 
(USA) unless otherwise stated. All were dissolved in 100% DMSO, aliquoted and 
stored at -80°C, and were added to cells 30 mins prior to stimulation.  
The monoclonal rat anti-mouse TSLP antibody (28F12) was employed for in vivo 
studies in mice to neutralize TSLP, and was a kind gift from GlaxoSmithKline (GSK; 
UK). The isotype control antibody used in this study was a rat-derived IgG2a 
targeting the plant protein Avena phytochrome, and was also a kind gift from GSK. 
These antibodies were used at a concentration of 15 mg/kg body weight, and were 
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dissolved in DPBS. The antibodies use for immunohistochemical localization studies 
are described in Table 2.1. The blocking peptides used for immunohistochemical 
studies were purchased from Pro-Sci (CA, USA). The antibodies used for Western 
blotting analysis and flow cytometry are listed in Table 2.2. and Table 2.3. 
respectively. All other antibodies used for experimental work are listed in Table 2.4. 
2.4. Primary cells and cell lines 
A human type II alveolar epithelial cell line (A549) and a human 
monocyte/macrophage cell line (THP-1) were obtained from the American Type 
Culture Collection (ATCC) and were used at no more than passage 30. Although 
the A549 cell line was originally obtained through explant culture of lung carcinoma 
tissue, it is nevertheless widely used as a model of alveolar epithelial cell behaviour 
as it expresses many characteristic markers of this cell type (Foster et al., 1998; 
Lieber et al., 1976). For the experimental work described in this thesis, A459 cells 
were maintained in F12K (Gibco, UK) with 10% FBS (v/v), 200 units/ml 
penicillin/streptomycin and 4 mM glutamine. The human monocyte/macrophage cell 
line (THP-1), which was initially derived from a patient with acute monocytic 
leukaemia, possesses a number of phenotypic features characteristic of human 
monocytes (Tsuchiya et al., 1980). THP-1 cells were grown and maintained in 
RPMI-1640 (Gibco, UK) with 10% FBS (v/v), 200 units/ml penicillin/streptomycin 
and 4 mM glutamine, but were transferred into DMEM for chemotaxis experiments 
to enable meaningful comparison with conditioned media from treated primary 
human lung fibroblasts (pHLFs).  
Primary human Type II alveolar epithelial cells used in these studies were prepared 
from normal human lung and were a kind gift from Mr. Robert Alexander in our 
laboratory. 
Fibroblasts used in these studies were primary human lung fibroblasts (pHLFs), and 
were a kind gift from Dr. Robin McAnulty in our laboratory. These fibroblasts had 
initially been grown from ~1 mm3 explants dissected from normal human lung tissue. 
The explants were then cultured in DMEM supplemented with 10% FBS (v/v). The 
culture medium was replaced with fresh medium one day after isolation, and every 
three days thereafter for three weeks. Cells were collected by trypsinisation.
  
 
Target Target 
species 
Host 
species 
Company Secondary 
(species) - 
HRP 
Company Primary 
concentration 
Antigen 
extraction 
TSLP Human Sheep 1 R&D n/a n/a 2 µg/ml Citrate 
TSLPR Human Rabbit Pro-Sci Goat Invitrogen 5 µg/ml Saponin 
TSLP Mouse Rabbit Pro-Sci Goat Invitrogen 5 µg/ml None 
TSLPR Mouse Rabbit Pro-Sci Goat Invitrogen 0.3125 µg/ml None  
TNF-α Human Rabbit AbCam Goat Invitrogen 5 µg/ml Saponin 
CD11c Human Rabbit Epitomics Goat Invitrogen 1 in 50 Proteinase K 
Isotype 
control 
Human Sheep Santa Cruz n/a n/a As per primary As per primary 
Isotype 
control 
Human Rabbit Dako Goat Invitrogen As per primary As per primary 
Isotype 
control 
Mouse Rabbit Santa Cruz Goat Invitrogen As per primary As per primary 
 
Table 2.1. Antibodies used for immunohistochemical analysis of human and mouse lung tissue. 1 biotinylated antibody, 
therefore no secondary required.
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Target Host species Dilution Company 
Phospho c-Jun 
 
Rabbit 1 in 2000 Cell Signalling Technology 
MA, USA 
Total c-Jun Rabbit 1 in 2000 Cell Signalling Technology 
Phospho ERK1/2 
 
Rabbit 1 in 2000 Cell Signalling Technology 
Total ERK1/2 Rabbit 1 in 2000 Cell Signalling Technology 
Phospho HSP27 
 
Rabbit 1 in 2000 Cell Signalling Technology 
Total HSP27 Mouse 1 in 2000 Cell Signalling Technology 
IκB Rabbit 1 in 2000 Cell Signalling Technology 
Phospho STAT3 
 
Rabbit 1 in 2000 Cell Signalling Technology 
Total STAT3 Rabbit 1 in 2000 Cell Signalling Technology 
Phospho STAT5 
 
Rabbit 1 in 2000 Cell Signalling Technology 
Total STAT3 Rabbit 1 in 2000 Cell Signalling Technology 
Total ERK2 Goat 1 in 2000 Santa Cruz 
Anti-rabbit 
secondary 
Goat 1 in 2000 Dako 
Anti-goat 
secondary 
Rabbit 1 in 2000 Dako 
 
Table 2.2. Antibodies used for Western blotting
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Target Target 
species 
Host 
species 
Company Dilution Conjugate 
CD11c Mouse Hamster λ BD Biosciences 1 in 200 APC Cy7 
MHC II Mouse Rat κ eBiosciences 1 in 200 Pacific Blue 
CD86 Mouse Rat κ BD Biosciences 1 in 200 PE Cy7 
TCRβ Mouse Hamster λ BD Biosciences 1 in 200 APC Cy7 
CD4 Mouse Rat κ BD Biosciences 1 in 200 FITC 
CD8 Mouse Rat κ BD Biosciences 1 in 200 Pacific Blue 
IL4 Mouse Rat κ BD Biosciences 1 in 200 PE 
IFN-γ Mouse Rat κ BD Biosciences 1 in 200 APC 
OX40L Mouse Rat κ eBiosciences 1 in 200 PE 
 
Table 2.3. Antibodies used for flow cytometry on lung single cell 
suspensions. 
  
 
  
Chemotaxis assay 
 
Immunofluorescence 
 
Table 2.4. Antibodies used for chemotaxis assays and immunocytofluorescence. 1 PFA, paraformaldehyde 
 
Target Host species Dilution / 
Concentration 
Company Secondary 
species 
Dilution Company 
Human CCL2 Goat Please refer to 
text for each 
experiment in 
Results section 
 
R&D N/A N/A N/A 
Target Target 
species 
Host 
species 
Concentration Company Fixation1 Secondary 
antibody 
Company Conjugate 
IL7R Human Goat 2.5 µg/ml Santa Cruz PFA  Donkey Invitrogen AF555 
TSLPR Human Rabbit 2.5 µg/ml Pro-Sci PFA  Donkey Invitrogen AF488 
Isotype 
control 
Human Goat 2.5 µg/ml Santa Cruz PFA  Donkey Invitrogen AF555 
Isotype 
control 
Human Rabbit 2.5 µg/ml Santa Cruz PFA  Donkey Invitrogen AF488 
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Fibroblasts were identified by morphological characterisation, and by differential 
immunocytochemical staining for a selection of smooth muscle cell, endothelial and 
fibroblast markers such as α-smooth muscle actin (α-SMA), von Willebrand factor, 
vimentin and myosin. They were used at no more than passage 7. During the 
course of this PhD, I contributed to the generation of multiple other such lines of 
pHLFs. Primary mouse lung fibroblasts (pMLFs) were a kind gift from Dr. Paul 
Mercer in our laboratory. 
METHODS 
2.5. Animals 
Male C57Bl/6J mice (Charles River, UK) were housed in a specific pathogen-free 
facility in individually ventilated cages, with free access to food and water (12 hour 
light/dark cycle, normal sodium dry fishmeal diet, temperature 18-20°C). All 
procedures were performed on mice between 8 and 12 weeks of age, in accordance 
with the UK Home Office Scientific Procedures Act (1986). Animals were weighed 
prior to investigation, and then every few days until the end of the experiment. 
2.6. Animal model of pulmonary fibrosis 
Bleomycin (2 mg/kg body weight in 50 µl of saline) or saline was administered by 
oropharyngeal instillation as previously described (Lakatos et al., 2006). Briefly, 
following light halothane-induced anaesthesia, mice were hung by their teeth from 
an elastic band, and had their noses pinched shut while their tongue was held. This 
prevented the swallow reflex and forced the mouse to breathe through its mouth. 
Consequently, saline or bleomycin administered to the back of the animal’s throat 
was aspirated. Mice were sacrificed by intraperitoneal injection of phenobarbitone 
and severing of the abdominal inferior vena cava. For measurement of total lung 
collagen and real time RT-PCR analysis, lungs were removed and blotted. The 
trachea and major airways were excised before the separated lobes were 
immediately snap frozen in liquid nitrogen, weighed and pulverised in liquid 
nitrogen. Total lung collagen was determined by measuring hydroxyproline content 
in aliquots of pulverized lung, as described in Section 2.8. For RNA extraction, 1 ml 
of TRIzol (Gibco, UK) was added to a small aliquot of frozen pulverised lung and 
stored at -80°C until required, as described in Section 2.9. For histological and 
immunohistochemical analysis, the trachea was cannulated and the lungs were 
insufflated with 4% paraformaldehyde (PFA) in PBS at a pressure of 20 cm H2O. 
Thereafter, the heart and lungs were removed en bloc and placed in fresh fixative 
 Chapter 2: Materials and Methods 
84 
 
for 4 hrs. They were subsequently transferred to 15% sucrose in PBS and left 
overnight, before being washed in 50% ethanol and final transferred to 70% ethanol. 
For flow cytometric analysis, lungs were placed in RPMI on ice prior to the 
generation of lung single cell suspensions, as described in Section 2.10. 
Time-course data for this model was evaluated over a 28 day period. Parameters 
evaluated included total lung collagen and Col1A mRNA levels, and lung sections 
were prepared for immunohistochemical analysis; for details, please refer to each 
individual results section as appropriate. Time-points evaluated were days 7, 10, 14, 
21 and 28.  
2.7. TSLP neutralization in vivo using 28F12 
The contribution of TSLP to bleomycin-induced polarisation of the immune response 
and lung collagen accumulation in vivo was investigated using a neutralizing 
antibody to circulating TSLP, 28F12. A prophylactic schedule of administration was 
employed for each experiment as shown in Figure 2.1. Bleomycin or saline was 
administered by oropharyngeal administration as described in Section 2.6. 28F12 
or the isotype (IC) control antibody was administered by intraperitoneal injection at a 
dose of 15 mg/kg body weight in 100 µl DPBS every 4 days, starting at day -1. 
Serum samples from mice were also taken at the time of sacrifice in the 14 day 
bleomycin model for measurement of circulating 28F12 and IC antibody 
concentrations at GSK by ELISA of IgG (Appendix A1). Initial mouse numbers and 
mouse losses are shown in Figure 2.1. 
2.8. Determination of total lung collagen 
Total lung collagen was determined by measuring hydroxyproline (Hyp) content in 
aliquots of pulverised lung as described previously (Chambers et al., 1994) 
assuming that lung collagen contains 12.2 % w/w hydroxyproline (Laurent et al., 
1981). Hydroxyproline was quantified by reverse-phase high performance liquid 
chromatography (HPLC) of 7-chloro-4-nitrobenzo-oxa-1,3-diazole (NBD-Cl)-
derivatised acid hydrolysates. Secondary amino acids such as Hyp react with NBD-
Cl to generate a chromophore with maximum light absorbance at 490 nm. NBD-Cl 
also reacts with primary amino acids, but these amino acids have only limited 
absorbance at these wavelengths. In addition, the reactions with Hyp and proline 
occur one order of magnitude faster than with primary amino acids (Ahnoff et al., 
1981), Interference from primary amino acids is therefore minimised by keeping the 
derivation time to 20 mins, a timepoint at which the extent of Hyp derivatisation with 
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NBD-Cl at 37°C was previously shown to be maximal for up to 20 nmol Hyp (Campa 
et al., 1990).  
2.8.1. Pre-Column Derivatisation 
For each sample, approximately 20 mg of lung powder was accurately weighed and 
hydrolysed in 2 ml of 6 M HCl for 16 hrs at 110 °C in a pyrex tube. Hydrolysates 
were decolourised with activated charcoal, filtered through a 0.65 µm filter (Millipore 
Ltd, UK) and diluted 1 in 50. 200 µl aliquots of each hydrolysate were transferred to 
a microfuge tube and evaporated to dryness under vacuum on a Speedvac 
(Thermo-Electron Corporation, UK). The residue was re-dissolved in 100 µl HPLC 
grade water, buffered with 0.45 M potassium tetraborate (pH 9.5) and reacted with 
100 µl 36 mM NBD-Cl (in methanol) to a final concentration of 12 mM NBD-Cl. The 
samples were then incubated in a hot block at 37°C for 20 mins. The reaction was 
stopped by the addition of 50 µl 1.5 M HCl. At this point, 150 µl of 3.33x Buffer A 
(please refer to Table 2.5. for buffer composition) was also added. Samples 
were then filtered through an HPLC low dead-volume filter (pore size 0.22 µm, type 
GV; Millipore Ltd, UK) into a polypropylene tube insert within an Amber Snap Seal 
vial (Laboratory Sales Ltd., UK). These vials were then loaded onto the HPLC 
apparatus and the samples were sequentially injected onto the HPLC column and 
eluted with an acetonitrile gradient as described below. 
. 
  
 
Figure 2.1. TSLP neutralisation in vivo. Mice were administered anti-TSLP or isotype control antibody (15 mg/kg body weight) 
via the intra-peritoneal route every 4 days, starting at day -1 (red dash). Bleomycin (2 mg/kg body weight) or saline was 
administered at day 0 via the oro-pharyngeal route (o.p.). Mice were sacrificed at day 10, 14 or 28. Mice loss and final numbers are 
shown on the right. Numbers used for each different analysis are indicated in the relevant figure legend in the Results section. 
0 7 10 
7 14 28 21 
7 14 
Bleomycin (2 
mg/kg) or saline, 
o.p. 
sacrifice 
sacrifice 
sacrifice 
days 
days 
days 
Saline / IC: 2 (8) 
Saline / Ab: 2 (8) 
BLM / IC: 4 (6) 
BLM / Ab: 2 (8) 
 
 
Mice sacrificed early due to fighting wounds 
and/or ill health (final n): 
 
Saline / IC: 0 (3) 
Saline / Ab: 0 (3) 
BLM / IC: 0 (3) 
BLM / Ab: 0 (3) 
 
 
Saline / IC: 0 (8) 
Saline / Ab: 0 (8) 
BLM / IC: 3 (10) 
BLM / Ab: 0 (13) 
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2.8.2.  Instrumentation and chromatography conditions 
The HPLC apparatus employed for these measurements was a Beckman System 
Gold HPLC (Beckman Coulter, UK) with a reverse-phase cartridge column 
(LiChroCARTLiChrospher, 250 mm length x 4 mm diameter, 5 µm particle size, 100 
RP-18; BDH-Merk, UK) protected by a directly coupled pre-column (LiChrosorb, 4 
mm x 4 mm, 5 µm, 100RP-18; BDH/Merck, UK). Columns were continuously 
maintained at 40 °C in a heated column oven. At the beginning of each experiment, 
the running buffers were degassed with helium (BOC Ltd, UK), and the HPLC 
system equilibrated in running buffer A for 40 mins. The first two samples 
derivatised were Hyp standard solutions (equivalent to 50 pmol Hyp, Sigma, UK) 
which were then used for calibration. NBD-Cl derivatives in samples and standards 
were eluted with an acetonitrile gradient, which was achieved by changing the 
relative proportions of running buffers A and B over time. Chromatographic 
conditions and buffers employed in this process are summarised in Table 2.5. 
Post column detection was achieved by monitoring absorbance at 495 nm using a 
flow through variable wavelength monitor. Hyp elutes as a discrete peak between 
five and seven mins following its injection onto the column, between glutamine (3.5 
mins) and serine (7 to 9 mins), and just prior to the mobile phase becoming organic. 
Remaining amino acid derivatives in the sample were eluted as the hydrophobicity 
of the acetonitrile organic buffer was increased. The column running and 
regeneration time was 25 mins. 
Quantification of the hydroxyproline content in each 100 µl sample injected into the 
column was determined by comparing peak areas of chromatograms obtained for 
each sample to those generated from the standard solutions derivatised and 
separated under identical conditions at the beginning of each experiment. Total lung 
collagen was expressed as mg/lung.  
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Column 
 
LiChrosopher, 100 RP-18, 250 x 4 mm, 5 µm 
Mobile phase Buffer A – aqueous acetonitrile (8% v/v) 
 
50mM sodium acetate, pH 6.4 
 
 Buffer B - aqueous acetonitrile (75% v/v) 
 
Column flow rate 
 
1.0 ml/min 
Column 
temperature 
 
40°C 
Detection 
wavelength 
 
495 nm 
Elution gradient 
 
Time (min) % Buffer B 
 0 
 
0 
 5 
 
5 
 6 
 
80 
 12 
 
80 
 12.5 
 
0 
 25 
 
 
 
0 
 
Table 2.5. Conditions and buffers for the separation of hydroxyproline by 
reverse-phase HPLC 
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2.9. RT-PCR and qRT-PCR analysis 
2.9.1. Precautions taken to prevent RNA degradation 
For all experiments involving RNA isolation, deionised water was pre-treated with 
0.1% (v/v) diethylpyrocarbonate (DEPC) overnight at room temperature (RT); the 
treated water was then autoclaved to inactivate the DEPC. All subsequent reagents 
were made from molecular biology grade chemicals in DEPC-treated deionised 
water. All equipment was cleaned thoroughly using RNaseZap (Sigma Aldrich, UK), 
and nuclease-free pipette tips (Continental Lab Products, UK) were used throughout 
the extraction process.  
2.9.2. RNA extraction 
Total RNA from frozen lung tissue or cell cultures was isolated with TRIzol reagent 
as per the manufacturer’s protocol (Invitrogen, UK). TRIzol is a solution of phenol 
and guanidineisothiocyanate which disrupts cell membranes by dissolving cell 
components but maintaining the integrity of RNA. Briefly, 1 ml of TRIzol was added 
to 50-100 mg of lung tissue and this was further homogenized through a 25 gauge 
needle attached to a 1 ml syringe. For isolation from cell cultures, 1 ml of TRIzol 
was added to each well of cells that were grown in 6 well plates, and the well was 
scraped with a 1 ml pipette tip before transferring the solution to a 1.5 ml eppendorf 
tube. Subsequently, samples were left at RT for 5 mins, after which 200 µl of 
chloroform was added. Each tube was vortexed and left at RT temperature for 10 
mins to allow the solution to separate into an upper aqueous and a lower organic 
phase. Tubes were then centrifuged at 15000 g for 15 mins at 4°C in a microfuge, 
and the upper aqueous phase, containing the RNA, was transferred into a fresh 
tube with 500µl of isopropanol. Tubes were left at RT for 10 mins to allow the RNA 
to precipitate, and were then centrifuged at 15000 g for 15 mins at 4°C. The 
supernatants of each tube were discarded and 900 µl of 75% ethanol (BDH VWR 
International, UK) was added to the pelleted RNA and centrifuged for a further 15 
mins at 15000 g at 4°C. The supernatants in each tube were discarded and pellets 
were air dried and resuspended in 12.5 µl of nuclease-free water (Ambion, UK). 
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2.9.3. DNase treatment 
Total RNA was DNase-treated to remove contaminating genomic DNA, using an 
Ambion DNAfree kit. This kit comprised a 15 µl reaction in which total RNA, DNase I 
and RNase inhibitor were added and left to incubate at 37°C for 20 mins. The 
reaction was then stopped by the addition of an inactivating resin which binds the 
DNase. This resin was subsequently removed by centrifugation.  
RNA integrity was assessed by running samples on an agarose gel: a mixture of 1µl 
of total RNA and 11 µl DEPC-treated water was mixed with 3 µl of loading buffer 
(48% deionised formamide (v/v) [Gibco BRL, UK]; 6% formaldehyde (v/v) [BDH, 
UK]; 5% glycerol (v/v); 20 mM MOPS, 5mM sodium acetate and 1 mM EDTA pH 8.0 
made up in DEPC-treated water). The RNA was analysed by electrophoresis on a 
1% agarose-formaldehyde gel (6% formaldehyde (v/v); 1% agarose (w/v); 20mM 
MOPS, 5 mM sodium acetate, 1mM EDTA pH 8.0).  
Images of the RNA were captured using a Syngene Gene Genius Bio-imaging 
system (Synoptics, UK). A ratio of approximately 2:1 of the intensities of 28S rRNA 
to 18S rRNA bands confirmed that the RNA was not significantly degraded. The 
RNA concentration and protein contamination was measured on a Nanodrop 8000 
spectrophotometer (Thermo Scientific, UK), by measuring the A260 and A260/A280 
ratio respectively. The A260/A280 ratio was used as a guide to the purity of the RNA 
sample; ratios between 1.7 and 2.0 were considered acceptable.  
2.9.4. cDNA synthesis 
cDNA was prepared by reverse-transcription (RT) using a qScript cDNA SuperMix ® 
kit (Quanta Biosciences, USA), according to the manufacturer’s instructions. Briefly, 
up to a total of 1µg of RNA sample was made up to a volume of 16 µl with nuclease-
free water. 4 µl of qScript cDNA SuperMix ® (5X reaction buffer containing 
optimized concentrations of MgCl2, dNTPs [dATP, dCTP, dGTP, dTTP], 
recombinant RNase inhibitor protein, qScript reverse transcriptase, random primers, 
oligo(dT) primer and stabilizers) was then added to each sample, to achieve a final 
volume of 20 µl. Samples were then incubated for 5 mins at 25°C, 30 mins at 42°C 
and 5 mins at 85°C. 
For analysis of Tslpr and Il7r gene expression studies, PCR products (1 µg) were 
electrophoresed through a 1% agarose gel containing GelRed (Sigma, UK) diluted 
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at 1:10,000. Bands were visualised by UV transillumination and the size of the PCR 
products was estimated using a co-migrated DNA size marker (Roche Diagnostics). 
2.9.5. Primer design 
The primers were designed in conjunction with Dr. C. Scotton, using internet based 
software. The EntrezGene (http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene) 
database was used to locate accession numbers for the genomic DNA and RNA 
and then Spidey (http://www.ncbi.nlm.nih.gov/spidey/) was used to align the 
genomic and RNA sequences in order to locate intron/exon boundaries. Where 
possible, primers were designed to span introns, eliminating the possibility of 
amplifying genomic DNA. The mRNA sequence was copied into the primer 
designing software, Primer 3 (http://frodo.wi.mit.edu/primer3/). The program 
parameters were set at: 
 
Product size    85-130 bp 
Primer size    18-22 nucleotides long 
Primer melting temperature  58°C – 62°C, optimum temperature 60°C 
Max temperature difference  0.5°C 
Primer GC %    40-60%, optimum 50% 
Max self-complementarity  6.0 
Max 3’ complementarity  3.00 
Max poly-X    3 
The primers were then selected from the list. A BLAST search was also performed 
to check that the forward and reverse primers were specific for the intended 
sequence (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The primers were manufactured 
by Invitrogen, UK. The primers used in the present study are listed in Table 2.6. 
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Gene 
 
Forward primer Reverse primer 
hTslp 5’-TATGAGTGGGACCAAAAGTACCG-3’ 
 
5’-GGGATTGAAGGTTAGGCTCTGG-3’ 
 
hTslp (long 
splice 
variant  ) 
 
5’-GATTACATATATGAGTGGGAC-3’ 
 
5’-TTCATTGCCTGAGTAGCAT-3’ 
 
hTslp (short 
splice 
variant) 
 
5’-CGTAAACTTTGCCGCCTATGA-3’ 
 
5’-TTCTTCATTGCCTGAGTAGCATTTAT-3’ 
 
hTslpr 5’-GCAAGTCGCTGGATGGTTA-3’ 
 
5’-GTCAGAACACGTCACCGTCA-3’ 
hIl7r 5’-GGAGCCAATGACTTTGTGGT-3’ 
 
5’-AGTGTCAGCTTTGTGCTGGA-3’ 
hCccl2 5’-AGCAAGTGTCCCAAAGAAGC-3’ 
 
5’-CATGGAATCCTGAACCCTCT-3’ 
hHprt 
 
5’-TCATTATGCCGAGGATTTGG-3’ 5’-ACAGAGGGCCACAATGTGATGTTG-3’ 
mTslpr 
 
5’-GCTCCTTCCCTGGACTCTTT-3’ 
 
5’-TCCACCCTCTTAGCCTTGG-3’ 
 
mIl7r 
 
5’-CTTCTGGAGCGAGTGGAGTC-3’ 
 
5’-TGACACTTGGCAAGACAGGA-3’ 
 
mCol1A1  
 
5’-TCATGGCTTCTCTGGTCTC-3’ 5’-CCGTTGAGTCCGTCTTTGC-3’ 
mHprt 
 
5’-TCATTATGCCGAGGATTTGG-3’ 5’-ACAGAGGGCCACAATGTGATGTTG-3’ 
 
Table 2.6. Primers used for qRT-PCR 
h=human, m=murine 
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2.9.6. Real-time RT-PCR 
Real time RT-PCR was conducted using the Platinum SYBR Green qPCR SuperMix 
UDG (Invitrogen, UK) with cDNA samples diluted 1:3 or 1:4 in nuclease free water, 
and forward and reverse primers each at a final concentration of 800 nM (except 
mCol1A1 which was used at final concentrations of 400 nM), on a Mastercycler EP 
Realplex (Eppendorf, Germany). Cycling conditions were as follows: activation step 
of 95°C for 10 mins; 40 cycles of 95°C (10 seconds), 62°C (45 seconds), followed 
by melting curve analysis.  
The efficiency of each primer pair was also assessed by determining the crossing 
threshold (Ct) values for RT-PCR reactions using a series of 1:2 dilutions of 
template cDNA. Ct values were defined as the earliest point of the linear region of 
the logarithmic amplification plot reaching a threshold level of detection. 
Concentrations of samples were plotted against Ct values, and the slope of the plot 
determined, to determine the efficiency of the primers. Primers were only used if the 
PCR efficiency was greater than 95%. 
To examine the quantitative differences in target mRNA expression in each sample, 
Ct values were determined from the linear region of the logarithmic amplification 
plot. Each sample was also tested for the expression of the housekeeping gene, 
HPRT – the Ct value of which was used to normalise between samples. Fold 
changes were subsequently calculated using the standard 2-ΔΔCt approach and 
expressed relative to i) time 0 controls for time course studies in vitro, or ii) 
saline/isotype control for in vivo studies. The specificity of the products obtained by 
PCR was confirmed by analysis of the melting curves. A single melting curve was 
indicative of a single PCR product. Statistical analysis was performed using the ΔCt 
values. 
2.10. Flow cytometry 
2.10.1. Lung single cell suspension 
Following sacrifice of mice, as described in Section 2.6., the trachea and major 
airways were excised and lobes separated before being placed in RPMI-1640 
(Gibco, UK) on ice. Concomitantly, spleens were also harvested from each mouse, 
and similarly placed in RPMI-1640 on ice. Lungs were minced finely with scissors 
and incubated in RPMI-1640 containing Liberase TM (Roche, UK) and DNase 
(Roche, UK) at final concentrations of 0.15 mg/ml and 0.25 mg/ml respectively, for 
30 mins at 37°C. After digestion, single cell suspensions were generated by filtering 
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the digested lung through a 70 µm cell strainer (BD Biosciences, UK). For the 
generation of splenic single cell suspensions, no digestion was required and whole 
spleens were teased through a 70 µm cell strainer. All suspensions were spun at 
300 g for 5 mins, and cell pellets were resuspended in 1 ml of red blood cell lysis 
buffer (RBCLB) (Sigma, UK) and incubated at RT for 5 mins. Suspensions were 
then made up to a final volume of 15 ml with RPMI-1640 and spun at 300 g for 5 
mins. Cell pellets were resuspended in PBS/0.2% BSA (w/v) and used for 
experiments.  
2.10.2. FACS analysis 
Positive staining was confirmed by comparison with fluorescence minus one (FMO) 
controls for each fluorescence channel of interest. For unstained controls, single 
stain controls and FMO controls, cells were pooled from lungs or spleens as 
appropriate. The fluorochrome-conjugated antibodies used to characterise mouse 
lung dendritic cells and lymphocytes, together with their concentrations, are listed in 
Table 2.3. 
Prior to antibody staining of samples, non-specific antibody binding was blocked by 
pre-incubation with rat anti-mouse CD16/CD32 (1 in 200 in PBS/0.2% BSA [w/v]) for 
10 mins at RT. For staining of cell surface antigens, cells were incubated with 
antibody at 4 °C for 30 mins, before being washed in PBS/0.2% BSA (w/v) and fixed 
in 4% paraformaldehyde for 20 mins at RT. Samples were then stored at 4°C until 
analysed. For staining of intracellular cytokines, cell suspensions were incubated 
with phorbol myristate acetate (PMA), ionomycin and Brefeldin A (all Sigma, UK) in 
RPMI-1640 at final concentrations of 50 ng/ml, 500 ng/ml and 10 µg/ml respectively 
for 4 hrs at 37 °C. Thereafter, samples were washed in PBS/0.1% BSA (w/v)/0.1% 
sodium azide (w/v) (PBA) and incubated with antibodies targeted against cell 
surface antigens for 30 mins at 4°C. Cells were then washed in PBS and fixed in 2% 
PFA in hypertonic PBS (x1.4 PBS in ddH2O) and allowed to stand at RT for 20 mins. 
After washing in PBA, cells were incubated in PBS/0.1% BSA (w/v) / 0.1% sodium 
azide (w/v) / 0.5% saponin (w/v) (saponin buffer) for 10 mins at RT. After 
permeabilisation, antibodies directed against intracellular cytokines were added, 
and samples were incubated for 30 mins at RT. Samples were washed in saponin 
buffer and then PBS/0.2% BSA (w/v), before being resuspended in PBS and stored 
at 4°C for analysis the following day. Control samples for intracellular cytokine 
analysis were treated in exactly the same manner to ensure comparable forward 
and side scatter characteristics.  
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Dendritic cells were identified by the expression of CD11c and MHC II molecules. 
Alveolar macrophages also express CD11c, but can be distinguished from DCs by: 
1) High level of autofluorescence 
2) Low level of MHC II expression 
To differentiate macrophages from DCs, analysis was initially undertaken with 
appropriate gating according to forward and side scatter to exclude lymphocytes 
and dead cells. Highly autofluorescent cells corresponding to alveolar and interstitial 
macrophages were then excluded. Using this strategy, cells subsequently identified 
as being CD11c+/ MHC IIhi cells were considered DCs, as shown in Figure 2.2. 
T-lymphocytes were identified by the expression of CD4, CD8 and TCR-β. Analysis 
was initially undertaken with appropriate gating according to forward and side 
scatter to identify lymphocytes, as shown in Figure 2.3. Cells expressing CD4 and 
TCR-β were considered CD4+ T-lymphocytes and used for analysis of intracellular 
cytokine staining of IL-4 and IFN-γ, markers of Th2 and Th1 lymphocytes 
respectively.  
Data was acquired on a LSRII or LSR Fortessa (BD Biosciences, UK) and analysed 
using FloJo (TreeStar, USA). At least 30000 events were recorded for each sample.  
Fluorescence compensation settings for the above multi-colour flow cytometry was 
achieved using anti-rat IgGκ and anti-mouse IgGκ compensation bead kits, as per 
manufacturer’s instructions (BD Biosciences, UK). Anti-hamster compensation 
beads (Invitrogen, UK) were used where appropriate, according to the 
manufacturer’s instructions. Compensation adjustments were made using FlowJo 
software (TreeStar, UK).  
2.11. Histological analysis 
2.11.1. Preparation of slides 
Fresh human lung biopsy material was fixed in 4% PFA for 4 hrs before transfer to 
15% sucrose in PBS overnight. After being washed in 50% ethanol, specimens 
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Figure 2.2. Gating strategy 
employed to identify dendritic cells 
within lung single cell suspensions.  
Viable cells, excluding lymphocytes, 
were initially gated on forward and side 
scatter (A). Cells of high auto-
fluorescence in the FITC channel, 
corresponding to alveolar 
macrophages, were excluded (B) and 
dendritic cells were identified on the 
basis of being CD11c + / MHC IIhigh (C). 
Subsequent analysis for DC surface 
markers, including CD86 and OX40L, 
was performed on this cell population 
(R3).  
Viable cells, excluding lymphocytes, 
were initially gated on forward and side 
scatter (A). Cells of high auto-
fluorescence, corresponding to alveolar 
macrophages, in the FITC channel 
were excluded (B) and dendritic cells 
were identified on the basis of being 
CD11c + / MHC IIhigh (C). Subsequent 
analysis for DC surface markers, 
including CD86 and OX40L, was 
performed on this cell population (R3).  
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Figure 2.3 Gating strategy employed to identify CD4+/CD8+ T-lymphocytes within 
lung single cell suspensions.  
Lymphocytes were initially gated by forward and side scatter (A). T cells were labelled with 
anti-CD4, anti-CD8 and TCR-β. All cells identified as CD4+ (R2) or CD8+ (dashed gate) (B) 
were further identified as being TCR-β + (C). Only data for CD4+ cells are shown for clarity; 
CD8+ cells were analysed in the same manner. Subsequent analysis for intracellular 
cytokine staining was performed on this subset of CD4+ TCR-β + lymphocytes. 
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were transferred to 70% ethanol until required. Individual lobes of fixed mouse lungs 
or human biopsy material were placed in processing cassettes and dehydrated 
through a serial alcohol gradient on an automated tissue processor (Leica TP1050, 
Leica Microsystems, UK) before being manually embedded in paraffin wax blocks. 
Control lung sections for human TSLP and TSLPR immunostaining were cut from 
lung resection samples from patients with bronchial malignancies with no 
parenchymal fibrotic disease. Before immunostaining, 3 µm thick lung sections were 
dewaxed in xylene, rehydrated through decreasing concentrations of ethanol, and 
washed in TBS. 
2.11.2. Immunohistochemical localisation of TSLP and TSLPR 
For each antigen, four techniques of antigen extraction were performed to 
determine the optimum method of antigen retrieval for future studies: washing in 
TBS (2 x 5 mins); microwaving sections in 10 mM citrate buffer, pH 6.0 (2 x 10 
mins); incubation with 0.05% saponin (w/v) (Sigma, UK) in double-distilled water for 
30 mins at RT; incubation with proteinase K (10 µg/ml in 5 mM EDTA / 10 mM Tris, 
pH 7.4) for 10 mins. Human TSLP was unmasked by microwaving sections in 10 
mM citrate buffer, as described above. Human TSLPR required incubation with 
0.05% saponin (w/v), as described above. Murine TSLP and TSLPR did not require 
any antigen unmasking.  
After antigen retrieval, sections were washed twice in TBS for 5 mins, before 
incubation in 10% hydrogen peroxide (v/v) in H2O for 30 mins. Sections were 
washed again in TBS twice for 5 mins, and then incubated in 1:6 serum (dependent 
upon which species the secondary antibody had been raised in) in TBS, with 4 
drops/ml avidin blocking solution (Vector Laboratories, UK) for 20 mins. Thereafter, 
the blocking solution was tapped off, and the sections were incubated with the 
primary non biotinylated polyclonal antibody diluted in TBS/1% BSA (w/v)/1% serum 
(v/v) as described above and 4 drops/ml biotin blocking solution (Vector 
Laboratories, UK), overnight at 4°C. Sections were then washed in TBS (2 x 5 mins) 
before being incubated for 1 hour at RT with a biotinylated secondary antibody 
diluted 1:200 in TBS/1% BSA (w/v). Sections were again washed in TBS as 
described above, and then incubated with a streptavidin/peroxidise complex 
(Invitrogen, UK; 1:200 in TBS) for 30 mins. Sections were then washed in TBS (3 x 
5 mins) before a solution of 600 µg/ml of 3,3’diaminobenzidine tetrachloride (Vector 
Laboratories, UK) was added for 10 mins for colour development. Thereafter, 
sections were counterstained using Gill-2 haematoxylin (Thermo Shandon, USA), 
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dehydrated through a series of incubations in increasing concentrations of ethanol 
and then xylene, and mounted using a Sakura Coveraid automatic cover-slipping 
machine and Tissue-Tek cover-slipping film (Bayer Diagnostics, UK). Specificity of 
the signal obtained was confirmed by incubating control sections with an isotype 
specific, non-immune primary antibody. Further signal specificity was confirmed 
where possible by pre-incubating the primary antibody with a blocking peptide (at a 
concentration 6-fold greater than that of the primary antibody) overnight at 4°C. For 
biotinylated primary antibodies, sections were incubated with avidin for 15 mins, 
washed in TBS (1 x 5 mins) and then incubated in biotin for 15 mins before being 
washed in TBS (1 x 5 mins) prior to incubation with the primary antibody. No 
secondary antibody was required in this case. The detection antibody for human 
TSLP was a biotinylated primary antibody; all antibodies used were non-biotinylated 
antibodies. Sections were then visualized by microscopy (Leica DM500B 
microscope, Leica Microsystems, Germany) and images were captured using a 
Qiacam 12-bit colour fast camera using Q Capture software version 2.81 (QImaging 
Corporation, Canada).  
Optimum concentrations for primary antibodies are described in Table 2.1. 
2.11.3. Patient samples 
Lung biopsy specimens were obtained from 12 patients with IPF (obtained at 
diagnostic surgical lung biopsy) and 3 control patients (obtained from uninvolved 
tissue during cancer resection surgery). All biopsies used in this study were 
classified using the diagnostic criteria of the American Thoracic Society/European 
Respiratory Society Consensus (American Thoracic Society/European Respiratory 
Society International multidisciplinary consensus classification of the idiopathic 
interstitial pneumonias, 2002) demonstrating a pattern of usual interstitial 
pneumonia (UIP). Approval for the use of the material was obtained from the Royal 
Brompton, Harefield, NHLI and the UCL/UCLH ethic committee. Informed consent 
was obtained from each patient.  
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2.12. Cell biology 
2.12.1. Cell culture conditions 
All cells used for experimental work described in this thesis were maintained using 
standard cell culture techniques. pHLFs and pMLFs were grown in Dulbecco’s 
modified eagle’s medium (DMEM), supplemented with penicillin (200 units/ml), 
streptomycin (200 units/ml), glutamine (4 mM) and 10% (v/v) FBS. pHLFs used in 
siRNA transfection experiments were grown in media with no antibiotics to improve 
transfection efficiency. Cells were incubated in a humidified atmosphere containing 
10% CO2. The growth and maintenance of A549 and THP-1 cells has been 
described in Section 2.4. Primary Type II alveolar epithelial cells were seeded 
following preparation in DCCM-1 (Geneflow, UK) supplemented with penicillin (200 
units/ml), streptomycin (200 units/ml), glutamine (4 mM) and 10% (v/v) FBS, and 
used immediately for experimentation. Cells were routinely tested for mycoplasma 
contamination using a commercially available assay (MycoAlert; Cambre, UK). 
Upon reaching visual confluence (3-4 days), cells were sub-cultured (passaged) into 
new flasks: the medium was removed and the cell layer was washed with 0.05% 
trypsin (w/v)/0.02% EDTA (w/v) solution to remove any remaining culture medium. 
Cells were brought into suspension by adding 5mls of 0.05% trypsin (w/v)/0.02% 
EDTA (w/v) solution (for a T175 flask), and incubating the cells at 37°C until cell 
detachment was observed. Trypsin was neutralized by the addition of 15 mls of 
culture medium supplemented with 10% FBS. Cell suspensions were split at a ratio 
of 1 to 4-8. pHLFs and pMLFs were used at no more than passage 7 – cells of 
greater passage were observed to display characteristics of differentiation into 
myofibroblasts, thus precluding their use in the current studies. 
2.12.2. Preparation of agonists and inhibitors 
Preparation of hrTNF-α, hrTSLP, hrCCL2 and murine TSLP was as described in 
Section 2.2. All inhibitors were reconstituted in sterile tissue culture-tested DMSO 
(Invitrogen, UK) and stored at -80°C until use. Prior to use, the inhibitors were 
diluted in serum-free medium to achieve a final experimental DMSO concentration 
of 0.1%. For cell signalling studies, pHLFs were incubated with the inhibitor for 30 
mins at 37°C in 10% CO2, prior to stimulation with TNF-α. 
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2.12.3. Cell preparation for experiments 
A suspension of pHLFs trypsinised from one tissue culture flask was placed in a 50 
ml sterile polypropylene centrifuge tube. Cells were centrifuged at 300 g for 5 mins 
at RT using a bench centrifuge (MSE Mistral 3000, UK). The supernatant was 
discarded, and the cell pellet was brought into a single cell suspension with 10 ml 
DMEM/10% FBS (v/v) by gentle mixing. An aliquot of 7 µl of the suspension was 
removed under sterile conditions, and cells were counted on a haemocytometer. For 
each experiment, appropriate cell density of the cell suspension was then adjusted 
with DMEM/10% FBS (v/v) For collection of conditioned media for detection of 
secreted protein by ELISA, pHLFs were seeded at 1x105 cells/ml in 100 µl in 96 well 
plates. For collection of mRNA in TRIzol, cells were seeded at 1x104 cells/ml in 2 ml, 
in 6 well plates. For collection of cell lysates for Western blotting analysis, cells were 
seeded at 7.5x104 cells/ml in 1 ml in 12 well plates. Please refer to Section 2.14. for 
seeding densities for siRNA transfection experiments. Cells were seeded 48 hrs 
before assay. After 24 hrs in culture, and before confluence, cells were washed 
twice with serum-free DMEM, and the cells were quiesced in serum-free DMEM. 
Before each experiment, the starvation medium was removed and replaced with 
fresh serum-free DMEM, with or without mediators or inhibitors for a selected length 
of time (for details, please refer to individual experiments described in Results 
section). Plates were incubated in a humidified atmosphere containing 10% CO2 at 
37°C. For cytokine assays, serum-free conditioned media were collected from cell 
culture plates, spun to remove cell debris, and either used for ELISA immediately, or 
stored at -80°C and defrosted on ice before ELISA. A549 cells were treated in the 
same manner except that cells were incubated in 5% CO2 in F12K. 
2.13. Western blotting 
Western blotting was used to evaluate expression of proteins of interest. Samples 
were solubilised with detergents and reducing agents and separation of proteins 
from crude lysate was achieved by SDS-PAGE. Following transfer onto 
nitrocellulose membrane (GE Healthcare, UK), proteins were detected by enhanced 
chemiluminescence and quantified by using densitometry. The degree of protein 
phosphorylation was determined using specific antibodies directed against the 
phosphorylated form of the target protein. 
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2.13.1. Buffers 
Lysis buffer:   Phosphosafe (VWR, UK) 
Complete mini tablet protease inhibitor (Roche, UK) – 
1 in 20 dilution 
Laemmli buffer: 0.4M Tris pH 6.8; 12.5% SDS (w/v); 0.25 M glycerol; 
0.125 M DTT; bromophenol blue to colour;  
Running buffer (x10): 1M Tris base; 1M HEPES; 0.1% SDS (w/v); 
Transfer buffer (x10): 1M glycine; 0.125M Tris base; 0.375% SDS (w/v); 
Wash buffer (x20): 0.2M Tris base; 0.2M Tris HCl; 2.7M NaCl 
    Used as x1 TBS / 0.1% Tween 20 (TBST) 
Blocking buffer:  TBST / 5% w/v non-fat milk powder 
Stripping buffer:  62.5M Tris-HCl, pH 6.8; 2% SDS (w/v); 6.25 mM DTT  
 
2.13.2. Preparation of cell extracts 
pHLFs were seeded 48 hrs prior to treatment in 12 well plates. Cells were serum-
starved for 24 hrs before each treatment. After each treatment, cells were washed 
twice in ice-cold PBS on ice. Ice-cold lysis buffer (50 µl) was added to each well, on 
ice, and lysates were scraped and collected into ice-cold tubes. Whole cell extracts 
were stored at -80°C before use.  
2.13.3. BCA protein assay  
Protein concentrations of samples were assessed using the bicinchoninic acid 
(BCA) protein assay (Pierce, USA), as per the manufacturer’s instructions. Prior to 
use, an aliquot of BSA was thawed and diluted in serum-free medium. The amount 
of protein in samples can be derived by comparison with a bovine serum albumin 
standard curve. Briefly, 100 µl of freshly prepared BCA working reagent was added 
to 10 µl of each sample or standard (assayed in duplicate) in a 96 well plate. The 
plate was incubated at 37°C for 30 mins prior to reading the absorbance at 550nm 
on a Titertek Multiscan MCC/340 plate reader (Labsystems, Finland). Protein 
concentrations were determined by comparison with a standard curve of BSA 
ranging from 0-2000 µg/ml.  
 
  
 Chapter 2: Materials and Methods 
103 
 
2.13.4. Separation of proteins by reducing SDS-polyacrylamide gel 
electrophoresis 
Pre-cast LongLife gradient gels (8-16%; Nusep, Appleton Woods, UK) were used 
for all studies. Samples were mixed with Laemmli buffer and incubated at 100°C for 
5 mins before being loaded on to the SDS-PAGE gel. A pre-stained molecular mass 
ladder (PageRuler Plus, ThermoFisher, USA) was run in a separate lane for 
identification of appropriate molecular masses. Samples were electrophoresed at 
140 V for 40 mins in Nusep running buffer (Nusep, Appleton Woods, UK). 
2.13.5. Transfer of proteins onto nitrocellulose membrane 
Resolved proteins were transferred to a nitrocellulose membrane using a horizontal 
semi-dry transfer method. The nitrocellulose membrane was pre-equilibrated in 
transfer buffer for 15 mins prior to blotting. All other components were also soaked 
in transfer buffer before use. The membrane was placed on top of 10 pieces of 
Whatmann 3 mm filter paper and overlaid with a gel, taking care to remove air 
bubbles. A further 10 pieces of filter paper were placed on top of the gel. The 
cassette assembly was placed into the semi-dry transfer apparatus (Invitrogen, UK) 
and a constant voltage of 20 V was applied for 1 hour. Membranes were incubated 
in 2% Ponceau Red solution (Sigma, UK) solution to verify protein transfer.  
2.13.6. Detection of proteins by ECL 
Following transfer, the membrane was incubated in blocking buffer for at least 1 
hour with gentle agitation. The membrane was then incubated overnight at 4°C in 
blocking buffer containing an appropriate dilution of primary antibody. Thereafter, 
membranes were subjected to three 5 minute washes with wash buffer before 
incubation with HRP-conjugated secondary antibody, appropriately diluted in 
blocking buffer. After a further 3 washes, blots were developed by enhanced 
chemiluminescence (ECL) according to the manufacturer’s instructions (Amersham, 
UK). Immunoreactive bands were visualised by exposing Hyperfilm (GE Healthcare, 
UK) to the membrane. Exposure time was adjusted accordingly to ensure accurate 
quantification of protein bands. Films were then developed in an autoradiography 
film developer (Photon Imaging System, UK). Please refer to Table 2.2. for a full list 
of antibodies used for Western blotting in these studies. To confirm equal loading, 
membranes were incubated in stripping buffer for 20 mins at 50°C, followed by 
incubation in blocking buffer for 45 mins. They were then re-probed with either 
antibodies targeted against the non-phosphorylated form of the target protein or, in 
the case of siRNA transfection experiments, the housekeeping protein, total ERK2. 
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2.13.7. Quantification of protein bands 
Semi-quantitative analysis of Western blots was performed using densitometry. The 
blots underwent transmissive greyscale scanning at 300 dpi on a transmissive 
flatbed scanner (Epson, UK). The optical density of each band was calculated in 
Image J software (National Institutes of Health, USA) with reference to a calibration 
curve generated by scanning a Kodak photographic Step Tablet (Kodak, UK) with a 
known optical density gradient, using the same settings as described above. The 
optical density of the band for the target protein was normalised to the optical 
density of the non-phosphorylated form of the same protein, or total ERK2 for siRNA 
transfection experiments.  
2.14. Transfection of pHLFs with siRNA 
Primary human lung fibroblasts were seeded into 12 well plates on day 1 at a 
density such that 80% confluence would be reached by day 5 (3x104 cells/ml in 1 
ml). Antibiotics were omitted from all cultures involved in siRNA experiments to 
maximise transfection efficiency. On day 2, cells were serum-starved. Twenty four 
hrs later, cells were transfected with siRNA directed against either c-Jun, STAT3 or 
control scrambled siRNA at final concentrations of 100 nM. Further control cells 
were mock-transfected at the same time. siRNA (Dharmacon, USA) was transfected 
into cells using a gemini transfection reagent (a kind gift from GSK) in Optimem 
medium. Gemini surfactants are amphiphilic molecules which bind and compact 
dsRNA efficiently, resulting in the creation of a stable lipoplex. This is then able to 
penetrate the cell membrane into the cytoplasm within endosomes. Escape from the 
endosome, which is key for successful transfection, ensues as the pH falls within 
the cells, compared to the extracellular medium. This transfection reagent has 
previously been used successfully in the host laboratory. Cells were again serum-
starved on day 4 and allowed to quiesce for 24 hrs before subsequent stimulation. 
After each specific treatment, cell extracts were prepared as described in Section 
2.13.2., and Western blotting was used to evaluate expression of proteins of 
interest. In addition, time-point matched conditioned media were collected and 
analysed for TSLP and CCL2 protein release by ELISA, as described in Sections 
2.15. and 2.16. respectively.  
 
siRNA sequences for c-Jun and STAT3 are listed below in Table 2.7. 
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Target Sequence 
 
c-Jun 
 
GAGCGGACCUUAUGGCUAC 
STAT3 CAACAGAUUGCCUGCAUUG 
Scrambled controls Sequence not provided by Dharmacon 
 
Table 2.7. 
Sequences of siRNA used for transfection of pHLFs. 
 
 
 
2.15. Human TSLP ELISA 
Buffers used: PBS; Wash buffer: 0.05% Tween 20 ® in PBS; Reagent diluent: 
PBS/1% BSA (w/v); Stop solution: 1M H2SO4; Substrate solution: 
Tetramethylbenzidine (TMB; Invitrogen, UK) 
   
ELISA: Microtest TM 96-well ELISA plates were obtained from BD 
Biosciences, USA. The human TSLP Duoset ELISA set was purchased from R&D 
Systems, UK. The protocol followed was identical to that in the accompanying 
literature. Briefly, the Microtest TM 96-well ELISA plates were coated with 50 µl of 
anti-human TSLP capture antibody (800 ng/ml) diluted in PBS and were then left 
overnight at 4°C. After overnight incubation, plates were washed using an 
automated plate washer (Denley, UK) and blocked with 150 µl of reagent diluent for 
at least 1 hour at RT. After incubation, plates were again washed, and 50 µl of each 
sample or serial dilutions (0-2000 pg/ml) of human TSLP standard, diluted in serum-
free DMEM, were added to each well. After incubation for 2 hrs at RT, plates were 
again washed, before 50 µl of anti-human TSLP detection antibody (400 ng/ml) 
diluted in reagent diluent, was added to each well. Following a further incubation at 
RT for 2 hrs, plates were again washed, before the addition of streptavidin-HRP 
(1:200) in reagent diluent. Plates were incubated for 30 mins at RT before a further 
wash. 50 µl of substrate solution was then added to each well and incubated for 30 
min prior to the addition of stop solution. Absorbances were then read at 450 nm 
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and 540 nm with a plate reader (Multiskan MCC/340, Titertek) and TSLP 
concentrations were determined by comparison with a standard curve of TSLP 
ranging from 15 pg/ml to 2000 pg/ml.  
2.16. Human CCL2 ELISA 
Buffers used: Bicarbonate buffer (pH 9.6): 1.59 g Na2CO3 and 0.2 g NaN3 in 1L 
double-distilled water, filtered and stored at RT; Blocking buffer: PBS/1% BSA (w/v); 
Wash buffer: 0.05% Tween 20® in PBS; Stop solution: 1M H2SO4. 
 
ELISA: ELISA plates were coated with anti-human CCL2 capture antibody 
(400 ng/ml in bicarbonate buffer), 50 µl per well, and incubated overnight at 4°C. 
Plates were then washed as described above, and blocked with 150 µl of blocking 
buffer for at least 1 hour at RT. After incubation, plates were again washed, and 50 
µl of each sample (diluted 1 in 10) or serial dilutions (0-625 pg/ml) of human CCL2 
standard, diluted in serum-free DMEM, were added to each well. After incubation for 
2 hrs at RT, plates were washed before 50 µl of anti-human CCL2 detection 
antibody (400 ng/ml in blocking buffer), was added to each well. Following a further 
incubation at RT for 2 hrs, plates were again washed, before the addition of 
streptavidin-HRP (diluted 1:200 in PBS/0.1% BSA [w/v]). Plates were incubated for 
30 mins at RT before a further wash. 50 µl of substrate solution was then added to 
each well and incubated for 30 min prior to the addition of stop solution. 
Absorbances were then read at 450 nm and 540 nm with a plate reader (Multiskan 
MCC/340, Titertek) and CCL2 concentrations were determined by comparison with 
a standard curve of CCL2 ranging from 19.5 pg/ml to 625 pg/ml.  
2.17. Monocyte chemotaxis 
Chemotaxis of the human monocyte/macrophage cell line, THP-1, was evaluated in 
a 48-well Boyden chamber (Neuroprobe, USA). The ability of conditioned media 
from pHLFs to induce chemotaxis of THP-1 cells was compared to control medium 
alone and human recombinant CCL2, in the presence or absence of a neutralising 
anti-CCL2 antibody or isotype control antibody. Lower wells of the chamber were 
filled with 28 µl of chemotactic agent, controls or conditioned media. A 
polyvinylpyrrolidone (PVP) treated polycarbonate filter (8 µm pore size) 
(Neuroprobe, USA) was lowered onto the lower chambers, taking care not to 
introduce air bubbles, and a silicone gasket was applied to the filter, upon which the 
upper chambers would ultimately be positioned. THP-1 cells were prepared in 
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DMEM/10% FBS (v/v) at a concentration of 1 x 106 cells/ml, and 50 µl were added 
to the upper chambers, again taking great care not to introduce air bubbles. The 
chamber was then incubated at 37°C in humidified air with 5% CO2 for 2 hrs. After 
incubation, the filter was removed and non-migrated cells on the upper side of the 
filter were wiped clean using a wiper blade. The filter was then fixed in methanol, 
before being stained in Diff-Quik (Thermo Scientific, UK). The filter was then placed 
on a clear microscopic slide and allowed to dry, before migrated cells were counted. 
The mean number of cells per 5 high powered fields was determined, and each 
experimental condition was performed in triplicate. Each experiment was performed 
on three separate occasions.  
2.18. Immunocytofluorescence 
Immunocytofluorescence staining was performed to identify TSLPR and IL7Rα 
receptor chains on pHLFs grown in vitro. pHLFs were seeded in 8-well chamber 
slides (Millipore, UK) at 2x106 cells/ml in 250 µl DMEM and left overnight to adhere 
in a humidified atmosphere with 10% CO2 at 37°C. After 24 hrs, cells had reached 
semi-confluence, and were washed gently with PBS. Thereafter, cells were fixed 
with 4% PFA in PBS for fifteen mins. Following fixation, cells were washed with PBS 
three times. To avoid non-specific binding, cells were incubated in blocking buffer 
(PBS/10% FBS (v/v)/0.2% fish skin gelatin (v/v)) for 1 hour at RT. After a further 
three washes with PBS, cells were incubated with primary antibody (please refer to 
Table 2.4.) for 2 hrs at RT. Secondary antibodies, raised in donkey and conjugated 
with either AF488 or AF555 (Invitrogen, UK), were then added after three washes in 
PBS, and cells were incubated at RT in the dark for 1 hour. After this, the cells were 
washed again, and mounted using Prolong Gold Anti-Fade (Invitrogen, UK) 
containing 4’6-diamidino-2-phenylindole (DAPI), cover-slipped and left overnight at 
RT in the dark to cure. Slides were examined the following day and images 
captured using an upright fluorescence microscope (Zeiss Axioscop 2) with an 
attached camera (Olympus C-35DA-2).  
2.19. Data handling and statistical analysis 
All data presented are the mean ± standard errors of the mean (SEM) from 
triplicates (unless otherwise stated) of one experiment, and are 
representative of experiments performed on three independent occasions. 
Statistical comparison was performed between two treatment groups by 
student’s t-test, and between multiple treatment groups by ANOVA (one-way 
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or two-way, as indicated in the relevant figure legend) with Tukey post hoc 
testing. A p value of less than 0.05 was considered significant. Whilst it is not 
uncommon for data to be presented in this manner, I acknowledge that a 
more valid approach would be to perform multivariate statistical analysis on 
replicates from all independent experiments. To demonstrate my 
understanding of this, data in Figure 3.16 is presented in this manner.  
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CHAPTER 3: RESULTS 
 
Overview 
The experimental results of this thesis have been divided into four sections. The first 
section addresses the cellular immunolocalisation of TSLP and TSLPR in human 
fibrotic lung samples. The second section examines the regulation of TSLP 
expression by human alveolar epithelial cells and lung fibroblasts. The third section 
evaluates the effect of TSLP on human lung fibroblasts. The fourth section address 
the immunolocalisation of TSLP and TSLPR in murine lungs following bleomycin-
induced lung injury and further examines the role of TSLP in dendritic cell (DC) 
activation and the development of a Type-2 (T-2) immune response in this non-
allergen driven model of lung injury. This section also investigates the role of TSLP 
in the subsequent development of lung fibrosis in this model.  
3.1. The cellular immunolocalisation of TSLP and TSLPR in 
human lung fibrosis 
3.1.1. Introduction 
The expression of TSLP protein has been examined in a number of different 
conditions, all characterised by increased expression of T-2 cytokines (Taylor et al., 
2009; Ying et al., 2005; Yoo et al., 2005). In the lung, atopic asthma represents the 
archetypal T-2 inflammatory condition in which TSLP expression has been most 
extensively examined, both in terms of animal models and human disease, 
identifying bronchial epithelial cells and mast cells as potentially important sources 
of this cytokine. However, these cell types are not felt to significantly contribute to 
the pathogenesis of IPF, in contrast to alveolar epithelial cells and lung fibroblasts, 
as described in Section 1.3.2. 
Lung fibroblasts represent the key effector cells responsible for the excessive 
deposition of extracellular matrix proteins which underpins the parenchymal fibrosis 
of fibrotic lung disease (Scotton et al., 2007) and the airway remodelling 
characteristic of atopic asthma (Homer et al., 2005). However, their close proximity 
to the epithelium means that they are also in a unique position to relay signals of 
epithelial injury to immune cells, highlighting a potential duality of function: ECM 
deposition and the direction of immune cell trafficking.  
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Despite airway remodelling being a characteristic feature of chronic asthma (Homer 
et al., 2005), characterised by subepithelial fibrosis, no immunolocalisation of TSLP 
to fibroblasts has been reported in this condition. Moreover, to the best of my 
knowledge, the immunolocalisation of TSLP in IPF, a non-allergen driven lung 
disease also characterised by the increased expression of T-2 cytokines, has not 
been evaluated. 
3.1.2. Immunohistochemical localisation of TSLP and TSLPR in human 
fibrotic lung 
In order to determine the cellular localisation of TSLP and TSLPR in normal and 
fibrotic human lung, fibrotic and non-fibrotic lung sections were examined by 
immunohistochemistry. Lung biopsy specimens were obtained from 12 patients with 
IPF (obtained at diagnostic surgical lung biopsy) and 3 control patients (obtained 
from uninvolved tissue during cancer resection surgery). All biopsies used in this 
study were classified using the diagnostic criteria of the American Thoracic 
Society/European Respiratory Society Consensus (American Thoracic 
Society/European Respiratory Society International multidisciplinary consensus 
classification of the idiopathic interstitial pneumonias, 2002) demonstrating a pattern 
of Usual Interstitial Pneumonia (UIP).  
Initial studies focused upon determining the optimal antigen unmasking technique 
suitable for detection of both TSLP and TSLPR, as described in Materials and 
Methods. Following appropriate antigen unmasking (Section 2.11.2), optimization 
of the concentration of TSLP detecting antibody was established on lung tissue 
sections. A dilution series was constructed and lung tissue sections were incubated 
with a biotinylated polyclonal sheep anti-TSLP antibody overnight at 4oC at varying 
concentrations. Positive staining for TSLP was detected by incubating sections with 
an optimal concentration of biotinylated antibody (2 µg/ml), followed by a 
streptavidin/peroxidase complex and a solution of 3,3’- diaminobenzidine (DAB), 
which generates a brown reaction product.  
For optimization of the TSLPR detecting antibody, a similar protocol was observed. 
However, as the primary antibody was a non-biotinylated polyclonal rabbit anti-
TSLP antibody, an additional incubation with a biotinylated goat anti-rabbit 
secondary antibody, prior to incubation with the streptavidin/peroxidase complex, 
was required. Positive staining for TSLPR was detected with an optimal 
concentration of 5 µg/ml.  
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TSLP and TSLPR immunostaining was considered to reflect a specific signal as 
there was no discernible staining observed on serial control fibrotic tissue sections 
incubated with isotype specific, non-immune primary antibodies. 
Figure 3.1. shows the immunohistochemical localisation of TSLP in human fibrotic 
and non-fibrotic control lung samples. Tissue sections from control lungs showed 
weak positive staining, which was localised to occasional alveolar epithelial cells, 
and stronger staining associated to macrophages. However, tissue sections from 
fibrotic lung tissue showed widespread prominent staining which was predominantly 
associated with hyperplastic type II alveolar epithelial cells, macrophages and 
fibroblasts within fibrotic foci. Strong immunoreactivity for TSLP was also observed 
on fibroblasts in areas of established fibrosis. The degree of TSLP immunoreactivity 
localising to macrophages was similar in both non-fibrotic control lung and human 
IPF. The intensity of TSLP immunoreactivity for alveolar epithelial cells, fibroblasts 
and macrophages, from each of all 12 patients with IPF and the 3 control samples 
were graded from absent to very strong, and are summarised in Table 3.1. These 
data demonstrate that the pattern of immunoreactivity described above was a 
consistent finding. 
Figure 3.2. shows the immunohistochemical localisation of TSLPR in human fibrotic 
and non-fibrotic control lung samples. Tissue sections from control lungs 
demonstrated strong staining for bronchial epithelial cells and macrophages. 
Occasional staining was observed for alveolar epithelial cells, though the intensity 
for this cell type was variable. In contrast. sections from fibrotic lungs demonstrated 
intense staining for alveolar epithelial cells, fibroblasts and macrophages. In 
addition, strong immunoreactivity was observed for mononuclear cells with the 
morphological characteristics of lymphocytes. Such cells were generally organised 
in structures resembling lymphoid follicles, as has been described previously in IPF 
(Marchal-Somme et al., 2006). Moreover, cells with the morphological 
characteristics of DC were also observed to demonstrate staining for TSLPR. These 
cells were generally intercalated with mononuclear cells within the follicular 
structures described above.  
As described in Section 1.4.3., expression of TSLP is upregulated by a number of 
mediators, including TNF-α and IL-1β. Such cytokines may be regarded as early 
wave “alarm” cytokines, reflecting cellular injury in response to a variety of stimuli. 
To evaluate the structural relationship of cells immunoreactive for TNF-α, TSLP and 
DC, a major cellular target for TSLP, serial sections of human IPF lung were stained 
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Figure 3.1. 
TSLP immunostaining in Idiopathic pulmonary fibrosis (IPF) identifies 
epithelial cells, fibroblasts and macrophages as major cell types displaying 
strong immunoreactivity. 
Shown is immunostaining for TSLP (A-C) in normal non-fibrotic control lung (A) and 
IPF lung (B and C). In control lung (A), TSLP immunoreactivity is observed for 
macrophages (Mc); weak TSLP staining is also observed for alveolar epithelial cells 
(AEC). In contrast, in IPF lung (B,C), strong immunoreactivity for TSLP is observed 
for macrophages, cells with the morphology of fibroblasts (Fb) and alveolar 
epithelial cells. Fibroblasts in the IPF lung are located with a fibrotic focus (FFc, 
dotted area, seen at higher magnification in panel (C)), the characteristic histological 
feature of IPF. Serial IPF tissue section stained with isotype-specific non-immune 
primary antibody (D) shows no discernible staining. Original magnifications x20 A, 
C; x10 B, D. n=12 for IPF lungs and n=3 for normal lung. Sections shown are 
representative of all patients observed.  
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 Alveolar 
epithelial 
cell 
Fibroblasts 
within 
fibrotic foci 
Fibroblasts within 
areas of 
established 
fibrosis 
Macrophages 
1 ++ + +/- + 
2 + ++ + + 
3 ++ + + + 
4 ++ + + ++ 
5 + ++ + ++ 
6 -/+ + ++ ++ 
7 +++ ++ ++ +++ 
8 ++ ++ + + 
9 +++ ++ ++ ++ 
10 ++ + + +++ 
11 + +/- + ++ 
12 ++ + ++ ++ 
A - - n/a +++ 
B +/- - n/a + 
C - - n/a ++ 
 
Table 3.1.  
 
The immunolocalisation of TSLP in human IPF lung (samples 1-12) 
compared to non-fibrotic control lung (samples A-C). Data presented as 
– (absent) to very strong (+++) immunostaining for TSLP; n=12, IPF; n=3, 
control.  
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Figure 3.2. 
TSLPR immunostaining in Idiopathic pulmonary fibrosis (IPF) identifies epithelial 
cells, fibroblasts and immune cells as major cell types displaying strong 
immunoreactivity.  
Shown is immunostaining for TSLPR (A-D, G) in normal non-fibrotic control lung (A and B) and IPF 
lung (C and D). In control lung (A and B), TSLP immunoreactivity is observed for bronchial epithelium 
(BE) and macrophages (Mc). Weak TSLPR staining is also observed for alveolar epithelial cells 
(AEC). In contrast, in IPF lung (C and D), strong immunoreactivity for TSLP is observed for 
macrophages, cells with the morphology of fibroblasts (Fb) and alveolar epithelial cells, as well as 
smooth muscle cells (SMC). TSLP immunoreactivity is also observed on cells with the shape of 
dendritic cells (DC), as well as on mononuclear cells (Mo) within lymphoid aggregates (G). Serial IPF 
tissue section stained with isotype-specific non-immune primary antibody (E, F and H) shows no 
discernible staining. Original magnifications x10 A, B, C, E; x20 D, F-H. n=3 for IPF lungs and n=3 for 
normal lung. Sections shown are representative of all patients observed.  
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for the aforementioned ligands and for CD11c, a DC marker. Figure 3.3. 
demonstrates the immunolocalisation of TNF-α, TSLP and CD11c on serial human 
IPF sections. Strong immunoreactivity for TNF-α was observed for hyperplastic 
alveolar epithelium. This positive staining was observed to extend into the adjacent 
underlying extracellular matrix surrounding fibroblasts. Strong TSLP 
immunoreactivity was again observed for cells with the morphological 
characteristics of fibroblasts underlying hyperplastic epithelium, as well as for 
macrophages. In addition, mononuclear cells organised within lymphoid aggregates 
displayed positive TSLP staining. Finally, cells with the morphology of dendritic cells 
were observed to be strongly positive for CD11c. These cells were predominantly 
located within lymphoid follicles, though alveolar macrophages, which are also 
recognised to express CD11c, stained positive also, and were observed in alveolar 
spaces.
  
 
  ` 
Figure 3.3. Serial immunodetection of TNF-α, TSLP and CD11c demonstrates the structural proximity of TNF-α expressing epithelial cells, 
TSLP-expressing fibroblasts and dendritic cells in IPF. Strong immunoreactivity for TNF-α is observed for hyperplastic epithelial cells (AEC) and for 
fibroblast-associated matrix (A, D). Cells with morphology of fibroblasts (Fb) in close proximity display strong immunoreactivity for TSLP, in addition to 
macrophages (Mc) and mononuclear cells within lymphoid aggregates (LA) (B, E). Strongly positive CD11c cells, with the characteristic morphology of 
dendritic cells (DC) are observed within lymphoid aggregates in close proximity to TSLP immunoreactive cells (C). No discernible staining was observed for 
TNF-α, TSLP and CD11c in serial sections stained with isotype-specific non-immune primary antibodies (F-H). Original magnification x10 (A-C; F-H); x20 
(D, E).  
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3.1.3. Summary 
The results described in this section, examining the immunolocalisation and 
potential cellular sources of TSLP, as well as that of its receptor show that: 
 TSLP and TSLPR immunoreactivity is greater in fibrotic human lung 
tissue compared to non-fibrotic lung tissue; 
 in fibrotic human lung tissue, TSLP immunolocalises to alveolar type II 
epithelial cells (AECII), fibroblasts and macrophages, and TSLPR 
immunolocalises to AECII, fibroblasts, mononuclear cells and dendritic 
cells; 
 in fibrotic human lung tissue, alveolar epithelial cells, fibroblasts and 
dendritic cells, strongly immunoreactive for TNF-α, TSLP and CD11c 
respectively, are observed in close structural proximity; 
In summary, the results presented in this section show that TSLP and TSLPR 
immunolocalises to epithelial cells, fibroblasts and macrophages in human 
fibrotic lungs, with greater immunoreactivity observed in fibrotic compared to 
non-fibrotic lungs. In addition, TSLPR immunolocalises to cells with the 
morphology of dendritic cells in human fibrotic lung disease. These data suggest 
that expression of TSLP is upregulated in IPF, identifying for the first time 
alveolar epithelial cells and fibroblasts as possible cellular sources of this 
cytokine in human lung fibrosis. Moreover, they identify lung fibroblasts as a 
novel cell type expressing TSLPR in IPF, suggesting that human lung fibroblasts 
may represent a cellular target for TSLP in IPF. 
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3.2. The role of TNF-α in inducing TSLP expression in 
primary human lung fibroblasts and lung epithelial 
cells 
3.2.1. Introduction 
TSLP has traditionally been regarded as an epithelium-derived cytokine (Liu et 
al., 2007b), and its expression in the lung has been examined predominantly in 
airway epithelial cells (Allakhverdi et al., 2007a; Lee et al., 2007a), reflecting its 
perceived importance in the pathogenesis of atopic asthma. However, although 
bronchiolarization of the alveolar epithelium is a recognised feature of IPF 
(Kawanami et al., 1982), the alveolar, rather than airway, epithelium is felt to be 
the primary site of disease initiation in this condition, with the predominant 
downstream effector cell being the (myo)fibroblast. In light of the strong 
immunoreactivity observed for TSLP in human IPF on hyperplastic alveolar 
epithelial cells and fibroblasts, I was keen to determine which of these cell types 
represented the likely source of this cytokine in this disease. For these studies, I 
examined the effect of TNF-α on TSLP expression by lung epithelial cells and 
fibroblasts in vitro, as this master cytokine has previously been demonstrated to 
be a potent inducer of TSLP expression in other cell types (Lee et al., 2007a). 
Moreover, TNF-α expression is known to be upregulated in IPF (Ziegenhagen et 
al., 1998), and the present studies have demonstrated the close structural 
proximity of injured epithelium to fibroblasts within fibrotic foci, immunoreactive 
for TNF-α and TSLP respectively (Section 3.1.2.).  
3.2.2. Effect of TNF-α on TSLP protein production by lung epithelial 
cells 
In order to explore whether the alveolar epithelium represented a potential 
cellular source of TSLP in IPF, the effect of TNF-α on freshly isolated primary 
type II alveolar epithelial cells from donor lung and A549 cells was examined. 
Cells were exposed to TNF-α (10 ng/ml) and TSLP protein levels in culture 
supernatants were assessed by ELISA. TSLP protein in conditioned media (CM) 
was not detectable from any of these cell types at any of the time points chosen 
(0, 1, 2, 4, 8, 12 and 24 hours) following incubation with TNF-α. Data not shown. 
3.2.3. Effect of TNF-α on TSLP protein production by primary human 
lung fibroblasts (pHLFs) 
In addition to hyperplastic epithelial cells, fibroblasts, within fibrotic foci, 
demonstrated strong immunoreactivity for TSLP in IPF lung sections. In order to 
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explore the fibroblast as potential source of TSLP in this condition, baseline 
production and expression following exposure to TNF-α was examined using 
primary human lung fibroblasts (pHLFs) grown from explant cultures in our 
laboratory (please see Materials and Methods). pHLFs were exposed to 
varying concentrations of TNF-α, and TSLP protein levels in CM were assessed 
by ELISA.  
Initial studies (Figure 3.4. A-B) showed that baseline production of TSLP by 
pHLFs was low (between 25 and 30 pg/ml) and did not change over 24 hours 
(Panel A). In contrast, TNF-α (10 ng/ml) promoted TSLP protein release in a 
time-dependent manner. The sharpest increase in TSLP protein release was 
observed between 4 and 8 hours. Thereafter, the increase in TSLP protein 
release was maintained though blunted, although no plateau in this response 
was observed. Extending this time course to 72 hours (Panel B) confirmed that 
TSLP protein release in untreated cells remained constant and low (~50 pg/ml). 
However, in cells exposed to TNF-α, TSLP protein release continued beyond 24 
hours though the increase between 24 and 72 hours was less pronounced than 
that observed between 0 and 24 hours. These data therefore suggest that 
pHLFs remain responsive to TNF-α, with respect to TSLP protein release, up to 
72 hours after initial exposure. 
Having demonstrated that TNF-α promotes TSLP protein in a time-dependent 
manner, I was keen to investigate the kinetics of this interaction further by 
examining the concentration-response profile of this effect. As can be seen from 
Figure 3.4. (A), TNF-α induces a significant increase in TSLP protein release 
after a 4 hours incubation period, though a statistically more significant response 
was observed from 6 hours. Hence, this time-point was chosen to examine the 
concentration-dependent effect of TNF-α on TSLP protein release by pHLFs. 
Figure 3.5. shows that TNF-α promotes TSLP protein release in a 
concentration-dependent manner between 0.03 and 0.3 ng/ml. Concentrations 
of between 0.3 and 30 ng/ml did not induce any further increase in TSLP protein 
release. In contrast, concentrations of 100 ng/ml did promote further TSLP 
protein release. However, this concentration of TNF-α is of doubtful 
physiological or pathological relevance, and so for future studies, a 
concentration of 10 ng/ml was used 
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Figure 3.4. 
TNF-α stimulates TSLP protein release by primary human lung 
fibroblasts (pHLFs) in a time-dependent manner. 
Figure shows time course data for the effect of TNF-α on pHLF TSLP 
protein release into conditioned media performed over 24 hours (Panel 
A) or 72 hours (Panel B). pHLFs were exposed to TNF-α (10 ng/ml) for 
varying durations (A: 0-24 hours; B: 0-72 hours). Cell culture 
supernatants were analysed for TSLP protein release by ELISA. The 
amount of secreted TSLP is expressed as pg/ml, and each value 
represents the mean ± SEM, from triplicates. *p<0.05; ***p<0.001, 
comparison with time-point matched media control; two-way ANOVA. 
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Figure 3.5. 
TNF-α stimulates pHLF TSLP protein release in a concentration-
dependent manner. 
Figure shows concentration-response data for the effect of TNF-α on 
pHLF TSLP protein release into conditioned media. pHLFs were exposed 
to serum-free control medium or TNF-α (0.03 – 100 ng/ml) for 6 hours. 
Conditioned media were analysed for TSLP protein release by ELISA. 
The amount of secreted TSLP is expressed as pg/ml, and each value 
represents the mean ± SEM from triplicates. *p<0.05; ***p<0.001, 
comparison with unstimulated cells; one-way ANOVA. 
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3.2.4. Effect of TNF-α on TSLP mRNA levels in pHLFs 
The data obtained so far strongly indicate that TNF-α induces TSLP protein 
release from pHLFs in a concentration- and time-dependent manner. To 
determine if TNF-α exerts these effects by influencing Tslp gene expression, the 
effect of TNF-α on TSLP mRNA levels was assessed by qRT-PCR.  
pHLFs were found to express TSLP mRNA transcripts at baseline (Figure 3.6.).  
Exposure of cells to TNF-α (10 ng/ml) resulted in a significant increase in TSLP 
mRNA levels within 2 hours, with a maximal increase (over 50-fold relative to 
control) at 4 hours. TSLP mRNA levels diminished thereafter and returned to 
baseline by 24 hours. 
Two splice variants for human TSLP have previously been reported (Harada et 
al., 2009). The splice variants use different initiation methionine codons for 
protein translation. Previous expression studies (Kato et al., 2007; Lee et al., 
2007a) had not examined mRNA expression of the two splicing variants 
separately. The relative frequency of these splice variants has, to date, not been 
determined. To determine which splice variant of TSLP was induced by TNF-α 
in pHLFs, the effect of TNF-α on TSLP short and long splice transcript levels 
was assessed by qRT-PCR. Since the maximal fold induction in TSLP mRNA 
levels, relative to control, was observed at 4 hours, this time point was chosen 
for these studies. 
Figure 3.7. (A and B) shows that both short and long splice variants of TSLP 
transcripts were detected at baseline and that TNF-α (10 ng/ml) significantly 
increased the expression of the long TSLP splice variant only. 
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Figure 3.6. 
TNF-α increases TSLP mRNA levels in pHLFs. 
Figure shows time-course data for the effect of TNF-α on pHLF TSLP 
mRNA levels. pHLFs were exposed to serum-free control medium or 
TNF-α (10 ng/ml) for varying durations from 0-24 hours. TSLP mRNA 
levels at each time point were assessed by qRT-PCR. Data are 
expressed as fold-change relative to time zero, normalised to the house-
keeping gene hypoxanthinephosphoribosyltransferase (HPRT) mRNA 
levels (mean ± SEM from triplicates); **p<0.01; ***p<0.001, comparison 
with time-matched media controls; two-way ANOVA.  
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Figure 3.7. 
TNF-α only increases TSLP long splice variant mRNA levels in 
pHLFs. 
Panels shows the effect of TNF-α on pHLF TSLP mRNA levels (A- long 
splice variant; B- short splice variant). pHLFs were exposed to serum-free 
control medium or TNF-α (10 ng/ml) for 4 hours. TSLP mRNA levels were 
assessed by qRT-PCR. Data are expressed as fold change relative to 
time zero for each time point (mean ± SEM from triplicates) following 
normalization to HPRT mRNA levels. ***p<0.001, comparison with time-
matched medium control; one-way ANOVA.  
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3.2.5. Effect of NFκB inhibition on TNF-α-induced TSLP protein 
production in pHLFs 
Binding of TNF-α to its major receptor, TNFRI, ultimately results in the activation 
of two major transcription factors, NFκB and AP-1. Previous studies have 
suggested the importance of both these factors in mediating TSLP expression in 
epithelial cells, as discussed in Section 1.4.3. Studies were therefore performed 
to examine the role of NFκB in TNF-α induced TSLP expression in pHLFs using 
a highly specific inhibitor of IKK-2, SC-514, that has previously been shown to 
inhibit NFκB-dependent gene expression in fibroblasts (Kishore et al., 2003; 
Sullivan et al., 2009).  
3.2.5.1. Effect of TNF-α on NFκB signalling in pHLFs 
As discussed in Section 1.4.3.3., liberation of NFκB from its basal ternary 
complex with IκB proteins is achieved following phosphorylation, ubiquitination 
and degradation of IκB proteins, allowing the translocation of NFκB homodimers 
into the nucleus where they can bind to regulatory components of target genes. 
Loss of IκB signal on Western blotting therefore represents liberation of NFκB 
dimers for transcriptional regulation and initiation of this signalling pathway.  
Initial studies examined the effect of TNF-α on NFκB signalling. pHLFs were 
exposed to TNF-α (10 ng/ml) or control medium for varying durations, ranging 
from 0 to 60 minutes Cell lysates were analysed by Western blotting and probed 
with an anti-IκB antibody. As can be seen from Figure 3.8. (A), marked loss of 
the IκB signal, suggestive of NFκB signalling, was observed within 5 minutes of 
exposure of pHLFs to TNF-α. Recovery of the IκB signal was observed at 60 
minutes suggesting that NFκB signalling had returned to baseline. 
The effect of SC-514 on the NFκB pathway was then examined. Cells, pre-
incubated with increasing concentrations of SC-514 for 30 minutes, were 
exposed to TNF-α (10 ng/ml) for 15 minutes. Cell lysates were again examined 
by Western blotting as above. Figure 3.8. (B) shows that SC-514 inhibits TNF-
α-induced loss of the IκB signal in a concentration dependent manner, 
confirming that this molecule inhibits the NFκB pathway. Marked inhibition of 
NFκB signalling was observed for SC-514 concentrations of 1 µM (-log 6 M) 
upwards.  
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3.2.5.2. Effect of SC-514 on TNF-α induced TSLP protein 
production in pHLFs 
Having demonstrated that SC-514 is an effective inhibitor of IκB degradation at 
concentrations greater than 1 µM, I then examined the effect of SC-514 on TNF-
α-induced TSLP protein release. pHLFs were incubated with increasing 
concentrations of SC-514 (0 – 30 µM) for 30 minutes, prior to exposure to TNF-α 
(10 ng/ml) or control medium control medium for 6 hours. Conditioned media 
were then analysed for TSLP protein release by ELISA. Figure 3.9. shows that 
SC-514, up to concentrations of 3 µM (-log 5.5 M), had no effect on TNF-α 
induced TSLP protein release. Significant inhibition of TSLP protein release was 
only observed at SC-514 concentrations of 10 µM (-log 5 M) and above. Given 
that SC-514 already inhibits TNF-α induced degradation of IκB at concentrations 
around 1 µM, it is likely that the observed inhibition of TSLP protein release 
observed at higher concentrations reflect off-target effects of this inhibitor. These 
data therefore suggest that NFκB does not play a significant role in mediating 
TNF-α-induced TSLP protein release in pHLFs. 
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Figure 3.8. 
TNF-α induces activation of NFκB in a time-dependent manner and 
this effect is inhibited by SC-514 in pHLFs. 
Panel (A) shows that TNF-α induces the activation of NFκB signaling in a 
time-dependent manner. pHLFs were exposed to control medium or TNF-
α (10 ng/ml) for the indicated time periods. Activation of NFκB signaling 
was assessed by Western blotting using an anti-IκB antibody to detect 
IκB protein levels as an index of NFκB signaling (upper panel, A). 
Protein loading was confirmed by blotting with an anti-total ERK2 
antibody (lower panel, A). Panel (B) shows the effect of SC-514 on TNF-
α-induced NFκB activation. Cells were pre-incubated with varying 
concentrations of SC-514 for 30 minutes prior to exposure to control 
medium or TNF-α (10 ng/ml) for 15 minutes. IκB levels and protein 
loading was assessed as above. Data are representative of three 
separate experiments performed.  
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Figure 3.9. 
TNF-α-induced TSLP protein release in pHLFs is not attenuated in a 
concentration-dependent manner by the NFκB inhibitor, SC-514. 
Figure shows the effect of the specific NFκB inhibitor, SC-514, on TSLP protein 
release by pHLFs in response to TNF-α stimulation. Data are presented as a 
percentage of the maximal response obtained with TNF-α and drug vehicle 
alone (0.1% DMSO in DMEM). Cells were treated with increasing concentrations 
of SC-514 for 30 minutes prior to exposure to TNF-α (10 ng/ml) for 6 hours. 
Final concentrations of DMSO were kept constant for all experimental 
conditions. The first bar represents the TSLP response to control medium and 
drug vehicle alone. The second bar represents the highest concentration of SC-
514 examined and shows that this compound has no effect on basal TSLP 
release. Negative log of the concentrations of SC-514 are presented. Data 
represent the mean ± SEM, from triplicates. ns-non-significant; *p<0.05; 
**p<0.01, comparison with TNF alone; +++p<0.001, comparison with untreated 
cells; one-way ANOVA. 
Increasing [SC-514] 
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3.2.6. Effect of AP-1 inhibition on TNF-α-induced TSLP protein 
production in pHLFs 
As discussed in Section 1.4.3.2., AP-1 has been reported to play a role in 
mediating the expression of TSLP in epithelial cells (Harada et al., 2009). 
Moreover, AP-1 is a major transcription factor involved in mediating many of the 
cellular effects of TNF-α in a wide variety of cells, including lung fibroblasts 
(Sullivan et al., 2009). Therefore, the role of this transcription factor in mediating 
TNF-α induced TSLP expression in pHLFs was examined using an AP-1 
inhibitor, curcumin, which has previously been demonstrated to inhibit TNF-α-
induced AP-1 activity in lung fibroblasts (Sullivan et al., 2009). 
pHLFs were incubated with increasing concentrations of curcumin (0 – 30 µM) 
prior to exposure to TNF-α (10 ng/ml) or control medium for 6 hours. 
Conditioned media was analysed for TSLP protein release by ELISA. Figure 
3.10. shows that at concentrations of 3 µM (-log 5.5 M) and above, significant 
inhibition was observed with abrogation of TSLP protein release observed at 
curcumin concentrations around 30 µM (-log 4.5 M). 
Although capable of an impressive inhibitory effect on TNF-α-induced TSLP 
protein release, curcumin has been reported to influence the activity of a number 
of signalling pathways, in addition to AP-1 (Plummer et al., 1999), and so further 
studies were required before assigning a role for this factor in mediating this 
response. 
3.2.7. Effect of MAP kinase inhibition on TNF-α-induced TSLP 
protein production in pHLFs 
Differential phosphorylation of the components of AP-1, including c-Jun, is 
required to initiate AP-1 directed transcription of target genes, and this is 
mediated primarily by activated mitogen-activated protein kinases (MAPKs). 
TNF-α is known to exert many of its cellular effects via MAP kinase (p38, JNK 
and ERK1/2 kinases) pathways (Sullivan et al., 2005; Ventura et al., 2003). 
Moreover, previous studies have suggested that MAPK signalling may play a 
role in mediating TNF-α-induced TSLP expression in epithelial cells (Tu et al., 
2007; Zhang et al., 2007). Therefore, the following series of experiments were 
initiated to examine the role of MAPKs in mediating TNF-α-induced TSLP 
protein release in pHLFs. 
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Figure 3.10. 
TNF-α-induced TSLP protein release in pHLFs is attenuated in a 
concentration-dependent manner by the AP-1 inhibitor, curcumin. 
Figure shows the effect of the specific AP-1 inhibitor, curcumin, on TSLP protein 
release by pHLFs in response to TNF-α stimulation. Data are presented as a 
percentage of the maximal response obtained with TNF-α and drug vehicle 
alone (0.1% DMSO in DMEM). Cells were treated with increasing concentrations 
of curcumin for 30 minutes prior to exposure to TNF-α (10 ng/ml) for 6 hours. 
Final concentrations of DMSO were kept constant for all experimental 
conditions. The first bar represents the TSLP response to control medium and 
drug vehicle alone. The second bar represents the highest concentration of 
curcumin examined and shows that this compound has no effect on basal TSLP 
release. Negative log of the concentrations of curcumin are presented. Data 
represent the mean ± SEM from triplicates. ns-non significant; ***p<0.001, 
comparison with TNF-α alone; +++p<0.001, comparison with untreated cells; 
one-way ANOVA. 
Increasing [curcumin] 
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3.2.7.1. The effect of inhibition of p38 activity on TNF-α induced 
TSLP protein release in pHLFs 
The effect of inhibition of the p38 pathway on TNF-α induced TSLP protein 
release was examined using the specific inhibitor of p38 activity, SB203580. 
This compound has previously been demonstrated to inhibit p38 activity in 
fibroblasts (Reunanen et al., 2002). In the first instance, TNF-α-induced 
activation of the p38 signalling pathway in pHLFs was examined. Cells were 
exposed to TNF-α (10 ng/ml) or control medium for varying durations (0 – 60 
minutes). Activation of the p38 signalling pathway was examined by Western 
blotting using an anti-phospho heat shock protein (HSP) 27 antibody. HSP27 is 
a major downstream phosphorylation target of p38 MAP kinase and HSP27 
phosphorylation serves as a surrogate marker for p38 activity (Xu et al., 2006). 
Figure 3.11. (A) shows TNF-α induces the phosphorylation of HSP27 from 15 
mins onwards, with return to baseline by 60 minutes. 
The effect of SB203580 on p38 activity was then examined. Cells, pre-incubated 
with increasing concentrations of SB203580 (0 – 20 µM) for 30 minutes, were 
exposed to TNF-α (10 ng/ml) for 15 minutes. Cell lysates were again examined 
by Western blotting as above. Figure 3.11. (B) shows that SB203580 inhibits 
TNF-α-induced phosphorylation of HSP27 in a concentration-dependent 
manner. Marked inhibition of HSP27 phosphorylation was observed for 
SB203580 concentrations of 2 µM (-log 6.7 M) and above. 
Having demonstrated that SB20358 is an effective inhibitor of p38 activity, I then 
examined its effect on TNF-α-induced TSLP protein release. pHLFs were 
incubated with increasing concentrations of SB20358 (0 – 20 µM) for 30 
minutes, prior to exposure to TNF-α (10 ng/ml) or control medium for 6 hours 
and TSLP protein release into conditioned media was analysed by ELISA. 
Figure 3.12. shows that SB20358, up to concentrations of 20 µM (-log 7.7 M), 
had no effect on TNF-α induced or basal TSLP protein release. These data 
therefore suggest that p38 does not mediate TNF-α-induced TSLP expression in 
pHLFs. 
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Figure 3.11.  
TNF-α induces activation of p38 signalling (based on HSP27 
phosphorylation) in a time-dependent manner and this effect is 
inhibited by SB203580 in pHLFs. 
Panel (A) shows that TNF-α induces activation of the p38 signalling pathway in a time-
dependent manner. pHLFs were exposed to control medium or TNF-α (10 ng/ml) for the 
indicated time periods. Activation of the p38 pathway was assessed by Western blotting 
examining phosphorylation of HSP27 (upper panel, A). Protein loading was confirmed 
by blotting with an anti-total HSP27 antibody (lower panel, A). (B) shows the effect of 
SB203580 on TNF-α-induced p38 signalling. Cells were pre-incubated with varying 
concentrations of SB203580 for 30 minutes prior to exposure to control medium or TNF-
α (10 ng/ml) for 15 minutes. p38 signalling and protein loading was assessed as above. 
In this instance, the membrane was not stripped but a separate gel was run with 
identical protein concentrations (lower panel, B). Data are representative of three 
separate experiments performed. 
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Figure 3.12. 
TNF-α-induced TSLP protein release in pHLFs is not attenuated in a 
concentration-dependent manner by the p38 inhibitor, SB203580. 
Figure shows the effect of the specific p38 inhibitor, SB203580, on TSLP protein 
release by pHLFs in response to TNF-α stimulation. Data are presented as a 
percentage of the maximal response obtained with TNF-α and drug vehicle 
alone (0.1% DMSO in DMEM). Cells were treated with increasing concentrations 
of SB203580 for 30 minutes prior to exposure to TNF-α (10 ng/ml) for 6 hours. 
Final concentrations of DMSO were kept constant for all experimental 
conditions. The first bar represents the TSLP response to control medium and 
drug vehicle alone. The second bar represents the highest concentration of 
SB203580 examined and shows that this compound has no effect on basal 
TSLP release. Negative log of the concentrations of SB203580 are presented. 
Data represent the mean ± SEM, from triplicates, ns-non significant, comparison 
with TNF-α alone; +++p<0.001, comparison with untreated cells; one-way 
ANOVA.  
Increasing [SB203580] 
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3.2.7.2. The role of the ERK1/2 signalling pathway on TNF-α 
induced TSLP protein release in pHLFs 
I next examined the time-course of TNF-α-induced activation of the ERK1/2 
signalling pathway. Cells were exposed to TNF-α (10 ng/ml) or control medium 
for varying durations (0 – 60 minutes) and p42/44 phosphorylation was 
examined by Western blotting. Figure 3.13. (A) shows that marked 
phosphorylation of p42/44 in pHLFs occurs following stimulation with TNF-α. An 
initial response was observed within 5 minutes followed by a return to levels 
similar to time-matched controls at 15 minutes. Thereafter, a further significant 
increase in p42/44 phosphorylation is observed which is maintained at 60 
minutes following exposure to TNF-α.  
The effect of U0126, a MEK1/2 inhibitor, on p42/44 phosphorylation was then 
examined. Cells, pre-incubated with increasing concentrations of U0126 (0 – 10 
µM) for 30 minutes, were exposed to TNF-α (10 ng/ml) for 30 minutes. Figure 
3.13. (B) shows that U0126 inhibits TNF-α-induced phosphorylation of p42/44 in 
a concentration-dependent manner. Marked inhibition of p42/44 phosphorylation 
was observed for all concentrations of U0126 tested, though maximal inhibition, 
with almost complete loss of p42/44 phosphorylation was observed at 
concentrations of 3 µM (-log 5.5) and above. 
I next examined the effect of U0126 on TNF-α-induced TSLP protein release. 
pHLFs were pre-incubated with increasing concentrations of U0126 (0 – 10 µM) 
for 30 minutes, prior to exposure to TNF-α (10 ng/ml) or control medium control 
medium for 6 hours. Conditioned media was then analysed for TSLP protein 
release by ELISA. Figure 3.14. shows that no attenuation in the TSLP signal 
was observed at U0126 concentrations of 3 µM (-log 5.5 M) and below, although 
~40% inhibition was observed at relatively high concentrations of 10 µM (-log 5 
M). Collectively, these data therefore suggest that the inhibition of the TSLP 
signal observed at these concentrations reflects off-target effects of U0126, and 
that ERK1/2 pathway does not play a role in mediating TNF-α-induced TSLP 
expression. 
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Figure 3.13.  
TNF-α induces p42/44 phosphorylation in a time-dependent manner 
and this effect is inhibited by U0126 in pHLFs. 
Panel (A) shows that TNF-α induces p42/44 phosphorylation in a time-
dependent manner. pHLFs were exposed to control medium or TNF-α (10 
ng/ml) for the indicated time periods. Phosphorylation of p42/44 was 
assessed by Western blotting using an anti-phospho-p42/44 antibody 
(upper panel, A). Protein loading was confirmed by blotting with an anti-
total ERK2antibody (lower panel, A). Panel (B) shows the effect of 
U0126, on TNF-α-induced p42/44 phosphorylation. Cells were pre-
incubated with varying concentrations of U0126 for 30 minutes prior to 
exposure to control medium or TNF-α (10 ng/ml) for 30 minutes. p42/44 
phosphorylation and protein loading was assessed as above. Data are 
representative of three separate experiments performed. 
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Figure 3.14. 
TNF-α-induced TSLP protein release in pHLFs is not attenuated in a 
concentration-dependent manner by the MEK1/2 inhibitor U0126. 
Figure shows the effects of the specific MEK 1/2 inhibitor, U0126, on TSLP protein 
release by pHLFs in response to TNF-α stimulation. Data are presented as a percentage 
of the maximal response obtained with TNF-α and drug vehicle alone (0.1% DMSO in 
DMEM). Cells were treated with increasing concentrations of U0126 for 30 minutes prior 
to exposure to TNF-α (10 ng/ml) for 6 hours. Final concentrations of DMSO were kept 
constant for all experimental conditions. The first bar represents the TSLP response to 
control medium and drug vehicle alone. The second bar represents the highest 
concentration of inhibitor examined and shows that this compound has no effect on 
basal TSLP release. Negative log of inhibitor concentrations are presented. Data 
represent the mean ± SEM, from triplicates. ns-non-significant; ***p<0.001, comparison 
with TNF-α alone; +++p<0.001, comparison with untreated cells; one-way ANOVA. 
Increasing [U1026] 
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3.2.7.3. The role of JNK in TNF-α induced TSLP expression 
The third major MAPK involved in activating AP-1 is JNK, and the following 
series of experiments were designed to examine the role of this kinase in 
mediating TNF-α-induced TSLP expression. For these studies, I used two 
structurally unrelated inhibitors of JNK activity, SP600125 and TI-JIP.  
I first examined the time-course of TNF-α-induced phosphorylation of c-Jun in 
pHLFs. Cells were exposed to TNF-α (10 ng/ml) or control medium for varying 
durations (0 – 60 minutes) and c-Jun phosphorylation was assessed by Western 
blotting using an anti-phospho c-Jun antibody. Figure 3.15. shows that TNF-α 
induces marked phosphorylation of c-Jun from 15 minutes onwards and that this 
effect is maintained for at least 60 minutes. 
I then assessed the effect of SP600125, an inhibitor of JNK activity, on TNF-α-
induced c-Jun phosphorylation. Cells were pre-incubated with varying 
concentrations of SP600125 (0.3 – 10 µM) before exposure to TNF-α (10 ng/ml) 
or control medium for 30 minutes. As shown in Figure 3.16. (A-B), SP600125 
significantly inhibits TNF-α-induced c-Jun phosphorylation in a concentration-
dependent manner from 1 µM (-log 6 M) ( ~25% inhibition) upwards.   
Having demonstrated that SP600125 effectively inhibits TNF-α-induced c-Jun 
phosphorylation, I then examined the effect of this inhibitor on TNF-α-induced 
protein release. As previously, cells were exposed to varying concentrations of 
SP600125 (0 – 30 µM) for 30 minutes prior to stimulation with TNF-α (10 ng/ml) 
for 6 hours and TSLP protein release into CM was measured by ELISA. Figure 
3.17. shows that SP600125 significantly attenuated TNF-α-induced TSLP 
protein release in a concentration-dependent manner from 7 µM (-log 7M) 
onwards upwards.  
To strengthen the results obtained with SP600125, the effect of inhibiting JNK 
activity, using a structurally unrelated inhibitor, TI-JIP, on TNF-α-induced TSLP 
protein release was examined. As above, cells were pre-incubated with varying 
concentrations of TI-JIP for 30 minutes prior to exposure to TNF-α or control 
medium for 6 hours. Figure 3.18. shows that a significant inhibition of the TSLP 
signal was observed in a concentration-dependent manner from concentrations 
of TI-JIP of 0.1 µM (-log 7 M) onwards. 
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Figure 3.15. 
Time course of TNF-α-induced phosphorylation of c-Jun in pHLFs.  
Figure shows time-course data for the effect of TNF-α on pHLF c-Jun 
phosphorylation. pHLFs were exposed to control medium or TNF-α (10 
ng/ml) for the indicated time periods (0-60 minutes). Phosphorylated c-
Jun was assessed by Western blotting (upper panel). Protein loading 
was verified by blotting with an anti-total c-Jun antibody (lower panel). 
Data are representative of three independent experiments performed.  
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`Figure 3.16. 
TNF-α-induced c-Jun phosphorylation in pHLFs is attenuated in a 
concentration-dependent manner by the JNK inhibitor, SP600125. 
Figure shows the effect of the specific JNK inhibitor, SP600125, on TNF-α-induced c-
Jun phosphorylation. Cells were treated with control medium or with increasing 
concentrations of SP600125 for 30 minutes prior to exposure to TNF-α (10 ng/ml) for 30 
minutes. Final concentrations of DMSO were kept constant for all experimental 
conditions (0.1% DMSO in DMEM). Phosphorylation of c-Jun (upper panel, A) and 
protein loading (lower panel, A) was assessed by Western blotting as previously 
described. The blots are representative of three independent experiments performed. 
The relative expression of phospho-c-Jun normalized to total c-Jun was determined by 
performing quantitative densitometry (B). Data represent the mean ± SEM of duplicates 
from three independent experiments performed. +++p<0.001, comparison with 
unstimulated cells; ns-non significant, *p<0.05 **p<0.01, comparison to cells stimulated 
with TNF-α alone; one-way ANOVA.  
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Figure 3.17. 
TNF-α-induced TSLP protein release in pHLFs is attenuated in a 
concentration-dependent manner by the JNK inhibitor, SP600125. 
Figure shows the effect of the specific JNK inhibitor, SP600125, on TSLP 
protein release by pHLFs in response to TNF-α stimulation. Data are presented 
as a percentage of the maximal response obtained with TNF-α and drug vehicle 
alone (0.1% DMSO in DMEM). Cells were treated with increasing concentrations 
of SP600125 for 30 minutes prior to exposure to TNF-α (10 ng/ml) for 6 hours. 
Final concentrations of DMSO were kept constant for all experimental 
conditions. The first bar represents the TSLP response to control medium and 
drug vehicle alone. The second bar represents the highest concentration of 
SP600125 examined and shows that this compound has no effect on basal 
TSLP release. Negative log of the concentrations of SP600125 are presented. 
Data represent the mean ± SEM, from triplicates. *p<0.05; ***p<0.001, 
comparison with TNF-α alone; +++p<0.001, comparison with untreated cells; 
one-way ANOVA. 
Increasing [SP600125] 
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Figure 3.18. 
TNF-α-induced TSLP protein release in pHLFs is attenuated in a 
concentration-dependent manner by the JNK inhibitor, TI-JIP. 
Figure shows the effect of the specific JNK inhibitor, TI-JIP, on TSLP protein 
release by pHLFs in response to TNF-α stimulation. Data are presented as a 
percentage of the maximal response obtained with TNF-α and drug vehicle 
alone (0.1% DMSO in DMEM). Cells were treated with increasing concentrations 
of TI-JIP for 30 minutes prior to exposure to TNF-α (10 ng/ml) for 6 hours. Final 
concentrations of DMSO were kept constant for all experimental conditions. The 
first bar represents the TSLP response to control medium and drug vehicle 
alone. The second bar represents the highest concentration of TI-JIP examined 
and shows that this compound has no effect on basal TSLP release. Negative 
log of the concentrations of TI-JIP are presented. Data represent the mean ± 
SEM, from triplicates. *p<0.05; ***p<0.001, comparison with TNF-α alone; 
+++p<0.001, comparison with untreated cells; one-way ANOVA. 
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The data presented above suggest that TNF-α induces TSLP protein release in 
a JNK / c-Jun dependent manner. To determine whether JNK mediates these 
effects by influencing TSLP mRNA levels, the effect of SP600125 on TNF-α-
induced TSLP mRNA levels was examined. pHLFs were incubated with 
SP600125 (1 µM) for 30 minutes prior to exposure to TNF-α (10 ng/ml) for 4 
hours. TSLP mRNA levels were assessed as previously described in Section 
3.2.4. 
Figure 3.19. shows that at a concentration of 1 µM, SP600125 significantly 
inhibited the TNF-α-induced increase in TSLP mRNA levels by ~ 70%. At this 
concentration, SP600125 inhibits TNF-α-induced TSLP protein release by 
~40%. These data therefore suggest that TNF-α mediates its effects on TSLP 
protein and gene expression via the JNK/c-Jun signalling pathway.  
To confirm the importance of the JNK / c-Jun signalling pathway in TNF-α-
mediated TSLP production, a genetic approach was employed. pHLFs were 
transfected with siRNA targeted against c-Jun using a Gemini transfection 
reagent as described in Materials and Methods. Final concentrations of siRNA 
were 100 nM. Control cells were transfected with scrambled siRNA or mock-
transfected for 24 hours. Following transfection, and a further 24 hours 
quiescence, cells were exposed to TNF-α (10 ng/ml) for 4 hours. Cell lysates 
were collected and analysed by Western blotting for c-Jun expression. 
Membranes were stripped and re-probed with anti-total ERK2 antibody to 
ensure equal protein loading. Conditioned media from the same wells were 
collected and analysed for TSLP protein release by ELISA. As shown in Figure 
3.20., transfection of pHLFs with c-Jun siRNA resulted in a significant 
knockdown of c-Jun expression at the protein level, compared to cells 
transfected with scrambled control siRNA, or cells which had been mock-
transfected, at 4 hours following exposure to TNF-α. Figure 3.21. demonstrates 
this knockdown was associated with a significant (~50%) attenuation in TNF-α-
induced TSLP protein release, confirming the importance of the JNK/c-Jun 
signalling pathway in mediating this response in pHLFs.  
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Figure 3.19. 
Inhibition of TNF-α-induced upregulation of TSLP mRNA levels by 
the specific JNK inhibitor SP600125. 
Figure shows the effect of the specific JNK inhibitor, SP600125, on TNF-
α-induced TSLP mRNA levels. pHLFs were exposed to TNF-α (10 ng/ml) 
for 4 hours with or without pre-incubation with SP600125 (1µM) for 30 
minutes. TSLP mRNA levels were determined by qRT-PCR. Data are 
presented as fold change relative to time zero following normalization to 
HPRT mRNA levels. Final concentrations of DMSO were kept constant 
for all experimental conditions (0.1% DMSO in DMEM). Data represent 
the mean ± SEM, from triplicates. +++p<0.001, comparison with 
untreated cells; **p<0.01, comparison with TNF-α alone; one-way 
ANOVA.  
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Figure 3.20. 
Transfection of pHLFs with siRNA results in successful knock-down 
of c-Jun protein expression. 
Figure shows that transfection of pHLFs with c-Jun specific siRNA results in knockdown 
of c-Jun expression at the protein level. 48 hours following mock-transfection, or 
transfection with scrambled or c-Jun specific siRNA (100nM), pHLFs were exposed to 
TNF-α (10 ng/ml) for 6 hours. Expression of c-Jun was assessed by Western blotting of 
cell lysates (upper panel, A); protein loading was confirmed by blotting with an anti-
ERK2 antibody (lower panel, A). The relative expression of c-Jun normalized to total 
ERK2 was determined by performing quantitative densitometry (panel B). Data 
represent the mean ± SEM from triplicates and are representative of three separate 
experiments performed. ***p<0.001, comparison to mock-transfected cells; one-way 
ANOVA. 
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Figure 3.21. 
Transfection of pHLFs with siRNA targeted against c-Jun results in 
an attenuation of TNF-α-induced TSLP protein release. 
Figure shows the effect of transfection of pHLFs with c-Jun specific 
siRNA on TSLP-induced TSLP protein release. 48 hours after mock-
transfection, or transfection with scrambled siRNA or c-Jun-specific 
siRNA (100 nM), pHLFs were exposed to TNF-α (10 ng/ml) or control 
medium for 6 hours. Expression of c-Jun was assessed by Western 
blotting as shown in Figure 3.24. Time-matched supernatants were 
collected and analysed for TSLP protein release by ELISA. The amount 
of secreted TSLP is expressed as pg/ml, and each value represents the 
mean ± SEM, from triplicates. ns-non significant; *** p<0.001 comparison 
with mock-transfected cells; two-way ANOVA.  
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3.2.8. Summary 
The results described in this section, examining the expression of TSLP by 
human lung epithelial cells and primary adult human lung fibroblasts (pHLFs), 
showed that: 
 TNF-a does not induce TSLP production in primary type II alveolar 
epithelial cells derived from normal human lung, nor in the A549 
epithelial cell line; 
 TNF-α induces TSLP protein production and release in a concentration 
and time-dependent manner in pHLFs; 
 TNF-α upregulates TSLP mRNA levels in pHLFs in a time-dependent 
manner; 
 TNF-α increases the long-form splice variant TSLP mRNA levels in 
pHLFs; no effect on short-form splice variant TSLP mRNA levels is 
observed; 
 The NFκB, p38 and ERK1/2 pathways do not seem to play a role in 
mediating TNF-α induced TSLP protein release by pHLFs; 
 The JNK  / c-Jun pathway mediates TNF-α induced TSLP expression by 
pHLFs. 
In conclusion, the data presented indicate that TNF-α induces TSLP expression 
via the JNK / c-Jun pathway in pHLFs. Moreover, the data suggest that this 
occurs via transcription of the long- splice variant of TSLP. 
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3.3.     The effect of TSLP stimulation of primary human 
lung fibroblasts (pHLFs) 
3.3.1. Introduction 
The data presented in Section 3.1. demonstrates strong immunoreactivity for 
TSLPR associated with lung fibroblasts in IPF, findings which have not 
previously been reported. However, it is increasingly recognised that fibroblasts 
may serve as key immunoregulatory cells following tissue injury, both via the 
generation of chemokines / cytokines (Smith et al., 1997) and through their 
direct cell – cell interactions with immune cells (Yamamura et al., 2001). These 
observations led to the hypothesis that lung fibroblasts may represent a potential 
cellular target for TSLP and that the response of these cells to stimulation with 
TSLP would reflect their immunoregulatory capacity. The following section 
addresses this hypothesis by assessing expression of a TSLP/TSLPR signalling 
axis by pHLFs and examining the effect of TSLP on pHLFs in vitro. 
3.3.2. Expression of the TSLP receptor by lung fibroblasts in vitro. 
Expression of both components of the TSLP receptor complex was initially 
assessed by RT-PCR using RNA extracted from pHLFs and primary murine lung 
fibroblasts (pMLFs); primers were custom-designed as described in Materials 
and Methods. As can be seen in Figure 3.22., prominent PCR products were 
obtained for TSLPRα and IL-7Rα in both pHLFs and pMLFs. No-cDNA template 
controls served as negative controls in each adjacent lane, confirming that the 
PCR products were not the result of primer dimerization. These data 
demonstrate that lung fibroblasts have the potential to express the TSLP 
receptor complex. 
I next examined protein expression of the relevant receptor components by 
pHLFs in vitro by fluorescent immunocytochemistry. Figure 3.23. shows 
representative images of pHLFs incubated with anti-TSLPR and anti-IL-7Rα 
antibodies and counterstained with DAPI to enable visualisation of the nucleus, 
as described in Materials and Methods. Positive staining for both TSLPRα and 
IL-Rα chains was observed for pHLFs (panels A-B). Overlay of images 
demonstrated a strong degree of overlap, suggestive of co-localisation of these 
2 receptor chains (panel C). Signal specificity was demonstrated by loss of 
fluorescent signal upon substitution of anti-TSLPR and anti-IL-7Rα antibodies 
with isotype control antibodies (panels D-E). Separate chamber slides were 
incubated with either anti-TSLPRα or anti-IL7-Rα antibodies alone. Images were  
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Figure 3.22. 
Expression of TSLPR and IL-7Rα in primary murine and human lung 
fibroblasts. 
Figure shows the expression of TSLPR and IL-7Rα, as analysed by RT-PCR in 
whole cell lysates of primary murine lung fibroblasts (pMLFs) and primary 
human lung fibroblasts (pHLFs). 1 µg of cDNA was used for each set of primers 
and the same volume of final PCR products was run in a 1% agarose gel 
containing the nucleic acid gel stain, GelRed (1:10,000). No cDNA templates 
were run in each adjacent lane as negative controls, and expression of the 
housekeeping gene HPRT, specific for each species, was analysed as a positive 
control. (BP – base pairs) 
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captured for each such incubation in both fluorescent channels, and overlaid to 
ensure that any positive signal observed was not an artefact due to cross-over 
from the alternative channel. As can be seen in panels F-G, no such overlap 
was observed, further confirming the specificity of the signals obtained for each 
antibody targeted against its respective receptor chain. Collectively, these data 
allowed me to conclude that pHLFs express both components of the TSLP 
receptor complex. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B C D 
F G E 
Figure 3.23.  
Primary human lung fibroblasts express both components of the TSLP receptor complex. 
pHLFs were grown to 80% confluence and TSLPR and IL7Rα expression was analysed by means of dual immunofluoresence 
as described in Materials and Methods. pHLFs were stained with anti-TSLPR-AF488 (A), anti-IL7Rα-AF555 (B), and 
counterstained with DAPI to enable nuclear localisation. Staining overlap is demonstrated in panel (C). Substitution of anti-
TSLPR or anti-IL7Rα antibodies with appropriately matched isotype control antibodies (D and E respectively) eliminated the 
fluorescent staining. (F) represents an overlay of images obtained in both AF488 and AF555 channels following incubation 
with anti-TSLPR-AF488 only. (G) represents an overlay of images obtained in the same channels following incubation with 
anti-IL7Ra-AF555 only. Original magnifications x20.  
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3.3.3. Effect of TSLP on pHLF chemokine production 
Having demonstrated that pHLFs constitutively express both components of the 
TSLP receptor, I next examined whether the observed co-localisation of these 
chains reflected functionality of this receptor. The immunoregulatory role of 
fibroblasts may be ascribed to the elaboration of soluble factors, in particular 
chemokines (Buckley et al., 2001). Therefore, to evaluate this potential role, the 
effect of TSLP on pHLF chemokine expression was examined. Cells were exposed 
to TSLP (1 ng/ml) or control medium for varying durations (1, 2, 4, 8 and 24 hours). 
Conditioned media (CM) was collected and analysed for chemokine release using 
the MSD® electroluminescence detection platform. This platform is a multiplex 
immunoassay system permitting analysis of multiple chemokines simultaneously. 
The choice of chemokines assayed reflected those which have previously been 
implicated in the pathogenesis of pulmonary fibrosis, including CCL2, CCL7 and 
CCL22, as discussed in Section 1.7.4., but also included eotaxin and IP-10, 
chemokines elaborated by fibroblasts which are chemotactic for immune cells, 
including eosinophils (Wenzel et al., 2002), neutrophils (Hammond et al., 1995) and 
T-cells respectively (Dufour et al., 2002). As can be seen from Figure 3.24. (Panel 
A), TSLP promoted significant CCL2 protein release compared to control (1.5-fold 
increase at 24 hours). CCL2 protein levels were also observed to accumulate in CM 
of untreated control pHLFs, confirming previous reports of basal production of this 
chemokine (Deng et al., 2008), though no further increase was observed in these 
studies after 8 hours. Although pHLFs were found to produce a number of other 
mediators, no other chemokine release was demonstrated over this time course 
following exposure to TSLP (Figure 3.24. Panels B-E). Nonetheless, these data 
strongly suggest that pHLFs possess a functional TSLP receptor, and that they 
respond to TSLP by upregulating expression of CCL2. 
3.3.4. Effect of TSLP on pHLF CCL2 expression 
The previous findings support the notion that lung fibroblasts may represent an 
important immunomodulatory cell by releasing CCL2 in response to TSLP. To 
determine if TSLP exerts these effects by influencing Ccl2 gene expression, the 
effect of TSLP on CCL2 mRNA levels was assessed by qRT-PCR. Cells were 
exposed to TSLP (1 ng/ml) or control medium for varying durations (0 – 24 hours) 
and cell lysates collected for measurement of mRNA levels. Figure 3.25. 
demonstrates that exposure of pHLFs to TSLP resulted in a significant increase  
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Figure 3.24. 
Effect of TSLP on chemokine expression by pHLFS. 
Figure shows the time-course data for the effect of TSLP on pHLF 
chemokine protein release into conditioned media. pHLFs were exposed to 
TSLP (1 ng/ml) or control medium for varying durations (0-24 hours). 
Conditioned media was analysed for CCL2 (A); CCL17 (B); IP-10 (C); 
CCL22 (D) and eotaxin (E) protein release using the MSD ® 
electroluminescence detection platform. The amount of secreted chemokine 
is expressed as pg/ml and each value represents the mean ± SEM, from 
triplicates. ***p<0.001, comparison with time point-matched media control; 
two-way ANOVA.  
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Figure 3.25. 
TSLP increases CCL2 mRNA levels in pHLFs. 
Figure shows time-course data for the effect of TSLP on pHLF CCL2 mRNA 
levels. pHLFs were exposed to serum-free control medium or TSLP (1 ng/ml) 
for varying durations from 0-24 hours. TSLP mRNA levels at each time point 
were assessed by qRT-PCR. Data are expressed as fold-change relative to 
time zero following normalization to HPRT mRNA levels (mean ± SEM, from 
triplicates). ***p<0.001, comparison with time-matched media controls; two-
way ANOVA.  
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in CCL2 mRNA levels at 4 hours (~7-fold relative to control). CCL2 mRNA levels 
declined after this time-point and returned to baseline by 24 hours.  
TSLP-induced CCL2 expression at the protein level was further confirmed in an 
independent series of time-course and concentration-response experiments. Cells 
were exposed to varying concentrations of TSLP and CCL2 protein release into CM 
was analysed by ELISA at 0, 1, 2, 4, 8, 12 and 24 hours. Figure 3.26. shows TSLP 
(1 ng/ml) promotes CCL2 protein release in a time-dependent manner. Peak CCL2 
protein levels were reached 12 hours after exposure (1674 pg/ml ± 31 vs 890 pg/ml 
±13) with no further increase observed thereafter. Since the time-course studies had 
demonstrated a significant increase in TSLP-induced CCL2 protein release at 6 
hours, this time point was chosen for future concentration-response studies. As can 
be seen from Figure 3.27., TSLP promotes CCL2 protein release in a 
concentration-dependent manner from 0.03 ng/ml (-log 10.5 g/l) onwards. A 5-fold 
increase in CCL2 protein levels, relative to control, was observed with TSLP at a 
concentration of 1 ng/ml (-log -9 g/l) with no further increment in CCL2 protein 
release at higher concentrations (data not shown).  
CCL2 expression is exquisitely sensitive to endotoxin contamination. To confirm that 
the observed upregulation of CCL2 protein release in pHLFs exposed to TSLP was 
not the result of such contamination, the effect of neutralising TSLP, using a 
commercially available polyclonal sheep IgG anti-TSLP antibody, on this response 
was examined. Cells were exposed to TSLP (1 ng/ml) which had been pre-
incubated with varying concentrations of anti-TSLP antibody (0 – 1 µg/ml), isotype 
control antibody (1 µg/ml), control medium alone or respective antibodies alone (1 
µg/ml). CM was analysed for CCL2 protein release at 6 hours by ELISA. As can be 
seen from Figure 3.28., CCL2 production was attenuated in cells exposed to TSLP 
which had been pre-incubated with anti-TSLP antibody, in a concentration-
dependent manner from 0.1 µg/ml (-log 7 g/l) onwards. The TSLP-induced CCL2 
response was almost completely blocked at an anti-TSLP antibody concentration of 
1 µg/ml (-log 6 g/l). The ND50 of this antibody for this response was determined to 
be 0.25 µg/ml. Pre-incubation of TSLP with a maximal concentration of isotype 
control antibody did not result in any inhibition of the CCL2 response, and exposure 
to antibodies alone did not result in any significant CCL2 protein release. These 
data lend strong support to the conclusion that the effect of TSLP on CCL2 protein 
release is not mediated via a contaminant in the TSLP preparation.  
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Figure 3.26. 
TSLP stimulates pHLF CCL2 protein release in a time-dependent 
manner. 
Figure shows time course data for the effect of TSLP on pHLF CCL2 protein 
release into conditioned media. pHLFs were exposed to TSLP (1 ng/ml) for 
varying durations (0-24 hours). Cell cultures supernatants were analysed for 
CCL2 protein release by ELISA. The amount of secreted CCL2 is expressed 
as pg/ml, and each value represents the mean ± SEM, from triplicates. 
***p<0.001, comparison with time-point matched media control; two-way 
ANOVA. 
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Figure 3.27. 
TSLP stimulates pHLF CCL2 protein release in a concentration-
dependent manner. 
Figure shows concentration-response data for the effect of TSLP on pHLF 
CCL2 protein release into conditioned media. pHLFs were exposed to 
serum-free control medium or TSLP (0.01 – 1 ng/ml) for 6 hours. Cell culture 
supernatants were analysed for CCL2 protein release by ELISA. The amount 
of secreted CCL2 is expressed as pg/ml, and each value represents the 
mean ± SEM, from triplicates. ***p<0.001, comparison with unstimulated 
cells; one-way ANOVA. 
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Figure 3.28. 
TSLP-induced CCL2 protein release by pHLFs is inhibited by an anti-
TSLP antibody. 
Figure shows the effect of an anti-TSLP antibody on TSLP-induced CCL2 protein release. 
Data are presented as a percentage of the maximal response obtained with TSLP only. 
pHLFs were exposed for 6 hours to control medium; isotype control antibody only (1 µg/ml); 
anti-TSLP antibody only (1 µg/ml); TSLP (1 ng/ml) pre-incubated with isotype control 
antibody (1 µg/ml) or varying concentrations of anti-TSLP antibody (for 2 hours). Conditioned 
media were analysed for CCL2 protein release by ELISA. The first bar represents the 
response to control medium alone. The second bar represents the response to TSLP only. 
The final bars represent the response to isotype control and anti-TSLP antibodies 
respectively (1 µg/ml), and show that these antibodies had no effect on basal CCL2 release. 
Negative log of the concentrations of anti-TSLP antibody (g/l) are presented. Data represent 
the mean ± SEM, from triplicates. +++p<0.001, comparison with control medium; ns-non 
significant, ***p<0.001, comparison with TSLP alone.  
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3.3.5. Effect of TSLP on signal transducer and activator of transcription 
(STAT) phosphorylation in pHLFs 
Having demonstrated that TSLP upregulates expression of CCL2 in pHLFs, the next 
series of experiments was designed to investigate further the signalling mechanisms 
downstream of TSLP receptor ligation. Ligand-induced cross-linking of TSLPRα and 
IL-7Rα has previously been demonstrated to result in functional activation of both 
STAT5 and STAT3 in a number of different cell types (Isaksen et al., 1999; 
Wohlmann et al., 2010). Moreover, STAT3 has recently been reported to mediate 
transcription of CCL2 (Dauer et al., 2005). In light of these data, the following series 
of experiments examined the relative roles of STAT5 and STAT3 in mediating 
TSLP-induced CCL2 expression.  
I first examined the effect of TSLP on STAT5 and STAT3 phosphorylation in pHLFs. 
Cells were exposed to TSLP (1 ng/ml) or control medium for varying durations (0 – 
60 minutes) and cell lysates were assessed by Western blotting using anti-phospho 
STAT5 or anti-phospho STAT3 antibodies. As can be seen in Figure 3.29. (A), no 
induction of STAT5 phosphorylation was observed in either control cells or pHLFs 
exposed to TSLP over a period of 1 hour. In contrast, TSLP induced the 
phosphorylation of STAT3 in a time-dependent manner (Figure 3.29. (B)) from 15 
minutes onwards which was maintained for at least 60 minutes. No phosphorylation 
of STAT3 was observed in control cells exposed to media alone. 
To confirm the specificity of this response for TSLP, I examined the effect of 
neutralising TSLP on the STAT3 phosphorylation, using the same anti-TSLP 
antibody as described in Section 3.3.4. Cells were exposed to the same 
experimental conditions and STAT3 phosphorylation was assessed by Western 
blotting. As seen in Figure 3.30., pre-incubation of TSLP with anti-TSLP antibody 
resulted in a concentration-dependent inhibition of TSLP-induced STAT3 
phosphorylation assessed at 30 minutes at antibody concentrations of 0.03 µg/ml 
onwards. Abrogation of TSLP-induced STAT3 phosphorylation was observed in the 
presence of anti-TSLP antibody concentrations of 1 µg/ml. These data confirm that 
the observed phosphorylation of STAT3 in pHLFs exposed to TSLP is mediated by 
TSLP rather than a contaminant. Collectively, these findings demonstrate that TSLP 
induces STAT3 but not STAT5 phosphorylation in pHLFs. 
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Figure 3.29. 
TSLP induces STAT3, but not STAT5 phosphorylation in pHLFs. 
Panel (A) shows time-course data for the effect of TSLP on pHLF STAT5 
phosphorylation. pHLFs were exposed to control medium or TSLP (1 ng/ml) 
for the indicated time periods (0-60 minutes). Phosphorylated STAT5 was 
assessed by Western blotting (upper panel, A). Protein loading was verified 
by blotting with an anti-total STAT5 antibody (lower panel, A). (B) shows 
time-course data for the effect of TSLP on pHLF STAT3 phosphorylation. 
pHLFs were exposed to control medium or TSLP (1 ng/ml) as above. 
Phosphorylated STAT3 was assessed as above (upper panel, B) and 
protein loading was verified by blotting with an anti-total STAT3 antibody 
(lower panel, B). Data are representative of three independent experiments 
performed.  
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Figure 3.30. 
TSLP-induced phosphorylation of STAT3 in pHLFs is inhibited by an 
anti-TSLP antibody. 
Figure shows the effect of an anti-TSLP antibody on TSLP-induced STAT3 
phosphorylation in pHLFs at 30 minutes. pHLFs were exposed to control 
medium; isotype control antibody only (1 µg/ml); anti-TSLP antibody only (1 
µg/ml); TSLP (1 ng/ml) pre-incubated with isotype control antibody (1 µg/ml) 
or varying concentrations of anti-TSLP antibody for 2 hours. Phosphorylation 
of STAT3 was assessed by Western blotting of cell lysates (upper panel). 
Protein loading was verified by blotting with a total STAT3 antibody (lower 
panel). The blots are representative of three independent experiments 
performed.  
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3.3.6. The role of STAT3 in mediating TSLP-induced CCL2 protein 
release 
Having demonstrated that TSLP promotes both CCL2 protein production and 
STAT3 phosphorylation in pHLFs, I sought to determine if TSLP-induced CCL2 
expression in pHLFs was STAT3-dependent. For these studies, I used a specific 
inhibitor, S3I-201, which has previously been shown to specifically inhibit 
phosphorylation of STAT3 (Pang et al., 2010)  
I first examined the effect of S3I-201 on TSLP-induced STAT3 phosphorylation. 
Cells were incubated with increasing concentrations of S3I-201 (0 – 300 µM) prior to 
exposure to TSLP (1 ng/ml) or control medium. STAT3 phosphorylation was 
assessed at 30 minutes by Western blotting of cell lysates. Figure 3.31. (A) shows 
that S3I-201 inhibits TSLP-induced STAT3 phosphorylation in a concentration-
dependent manner from 10 µM (-log 5 M) onwards. At concentrations of 100 µM (-
log 4.0 M) onwards, TSLP-induced STAT3 phosphorylation was completely blocked.  
Having demonstrated that S3I-201 effectively inhibited TSLP-induced-STAT3 
phosphorylation, I next examined the effect of this inhibitor on TSLP-induced CCL2 
expression. Cells were exposed to the same experimental conditions as above and 
CM analysed for CCL2 protein release at 6 hours by ELISA. Figure 3.31 (B) shows 
that S3I-201 inhibits TSLP-induced CCL2 protein release in a concentration 
dependent manner from 10 µM (-log 5 M) onwards with complete inhibition of this 
response observed at a concentration of 300 µM (-log 3.5 M). The concentrations 
required to inhibit TSLP-induced CCL2 protein release in the present studies are 
compatible with previous work (Pang et al., 2010; Siddiquee et al., 2007) as well as 
the documented IC50 for this inhibitor (86 ± 33 µM, Calbiochem, USA). These data 
therefore suggest that TSLP-induced CCL2 expression in pHLFs is STAT3 
dependent. 
An inherent issue with using pharmacological inhibitors to investigate signalling 
pathways is the potential of off-target effects. Therefore, to confirm the importance 
of STAT3 in mediating TSLP-induced CCL2 expression, I again used a genetic 
approach. pHLFs were transfected with siRNA targeted against STAT3, scrambled 
siRNA or simply mock-transfected for 24 hours as described in Materials and 
Methods. Following 24 hours quiescence, cells were exposed to TSLP (1 ng/ml) for 
6 hours. Cell lysates were collected and assessed for STAT3 expression by 
Western blotting. Time-matched CM were analysed for CCL2 protein release by 
ELISA. As demonstrated in Figure 3.32. (A-B), transfection with STAT3 siRNA 
resulted in a significant reduction in STAT3 protein expression (~50%) compared to 
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control cells. This knockdown in STAT3 expression was associated with a 
significant inhibition (~50%) of TSLP-induced CCL2 protein release (Figure 3.33). 
These data, therefore, lend strong confirmation to the conclusion that TSLP-induced 
CCL2 release is STAT3 dependent. 
. 
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Figure 3.31. 
TSLP-induced STAT3 phosphorylation and CCL2 protein release in pHLFs is 
attenuated in a concentration-dependent manner by the STAT3, S3I-201. 
Figure shows the effect of the specific STAT3 inhibitor, S3I-201, on STAT3 phosphorylation (Panel A) 
and CCL2 protein release (Panel B) by pHLFs following exposure to TSLP. Cells were treated with 
increasing concentrations of S3I-201 for 30 minutes prior to exposure to TSLP (1 ng/ml) for 6 hours. 
Final concentrations of DMSO were kept constant for all experimental conditions (0.1% DMSO in 
DMEM). Phosphorylation of STAT3 (upper panel,A) and protein loading (lower panel, A) was 
assessed by Western blotting as previously described. The blots are representative of three 
independent experiments performed. Panel B: the first bar represents the CCL2 response to TSLP 
and drug vehicle alone. The second bar represents the response to control medium alone. The third 
bar represents highest concentration of S3I-201 examined and shows that this compound has no effect 
on basal CCL2 release. Negative log of the concentrations of S3I-201 are presented. Data represent 
the mean ± SEM, from triplicates. *p<0.05; ***p<0.001, comparison with TSLP alone; +++p<0.001, 
comparison with untreated cells; one-way ANOVA. 
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Figure 3.32. 
Transfection of pHLFs with siRNA results in successful knock-down of 
STAT3 protein expression. 
Figure shows that transfection of pHLFs with STAT3 specific siRNA results in knockdown of 
STAT3 expression at the protein level. 48 hours following mock-transfection, or transfection 
with scrambled or STAT3 specific siRNA (100nM), pHLFs were exposed to TSLP (1 ng/ml) 
for 6 hours. Expression of STAT3 was assessed by Western blotting of cell lysates (upper 
panel, A); protein loading was confirmed by blotting with an anti-ERK2 antibody (lower 
panel, A). The relative expression of STAT3 normalized to total ERK2 was determined by 
performing quantitative densitometry (Panel B). Data represent the mean ± SEM from 
triplicates and are representative of three separate experiments performed. *p<0.05, 
comparison to mock-transfected cells; one-way ANOVA.  
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Figure 3.33. 
Transfection of pHLFs with siRNA targeted against STAT3 results in an 
inhibition of TSLP-induced CCL2 protein release. 
Figure shows the effect of transfection of pHLFs with STAT3 siRNA on 
TSLP-induced CCL2 protein release. 48 hours after mock-transfection, or 
transfection with scrambled siRNA or STAT3-specific siRNA (100 nM), 
pHLFs were exposed to TSLP (1 ng/ml) or control medium for 6 hours. 
Expression of STAT3 was assessed by Western blotting as shown in Figure 
3.32. Time-matched supernatants were collected and analysed for CCL2 
protein release by ELISA. The amount of secreted CCL2 is expressed as 
pg/ml, and each value represents the mean ± SEM, from triplicates. * p<0.05 
comparison with mock-transfected cells; one-way ANOVA.  
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3.3.7. The effect of conditioned media of pHLFs exposed to TSLP 
on human monocyte chemotaxis 
The data presented in the preceding sections demonstrate that TSLP induces 
upregulation of CCL2 expression in pHLFs. CCL2 is a member of the CC 
chemokine family and is a potent chemoattractant for inflammatory cells, including 
mononuclear cells and T cells (Rose et al., 2003). Interestingly, recent evidence has 
also highlighted the importance of fibroblast-derived CCL2 in mediating dendritic cell 
trafficking into the lung (Kitamura et al., 2011)The next series of experiments was 
therefore designed to determine if CCL2 derived from TSLP-treated pHLFs was 
capable of inducing chemotaxis of human immune cells in vitro. 
3.3.7.1. Confirmation of CCL2 induced chemotaxis of human 
monocytes 
Chemotaxis of the human monocyte / macrophage cell line, THP-1, in response to 
human recombinant CCL2 (hrCCL2), was assessed using a Boyden chamber as 
described in Material and Methods. Briefly, monocytes were exposed to varying 
concentrations of hrCCL2 (0 – 100 ng/ml) and chemotaxis assessed by counting 
cells which had migrated across a 8 µm filter over a 2 hour incubation period using 
light microscopy. Data are presented as mean number of cells per 5 high powered 
fields (x40). As can be seen in Figure 3.34. (A) hrCCL2 induces significant 
chemotaxis of THP-1 cells, compared to control medium, in a concentration-
dependent manner between 0.1 ng/ml and 3 ng/ml (-log 10 g/ml to -log 8.5 g/l). The 
overall chemotactic response to hrCCL2 was bell-shaped with optimum chemotaxis 
(12-fold increase compared to control) induced at a concentration of 3 ng/ml (-log 
8.5 g/l).   
The specificity of this response for hrCCL2 was examined using a polyclonal goat 
IgG anti-CCL2 antibody. hrCCL2 (3 ng/ml) was pre-incubated with varying 
concentrations of anti-hCCL2 antibody (0 – 30 µg/ml) or isotype control (30 µg/ml) 
for 2 hours at 4°C prior to exposure to THP-1 cells. As can be seen in Figure 3.34. 
(B), neutralisation of CCL2 resulted in a significant concentration-dependent 
inhibition of monocyte chemotaxis from 3 µg/ml (-log 5.5 g/l) onwards, with 
abrogation of chemotaxis observed at an antibody concentration of 30 µg/ml (-log 
4.5 g/l). No such inhibition of chemotaxis was observed for cells exposed to hrCCL2 
pre-incubated with isotype control. The ND50 of this antibody for this response was 
determined to be 5.06 µg/ml 
. 
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Figure 3.34. 
CCL2 promotes chemotaxis of THP-1 mononuclear cells. 
Panel A shows the number of THP-1 mononuclear cells (visualized by light microscopy) in 
high powered fields (HPF) that have migrated towards varying concentrations of 
recombinant human CCL2 (hrCCL2) over a 2 hour period. Data are presented as the mean 
number of cells per 5 HPF ± SEM, from triplicates. *p<0.05; ***p<0.001, comparison with 
control medium only; one-way ANOVA. Panel B shows the effect of varying concentrations 
(0 – 30 µg/ml) of anti-CCL2 antibody (Ab) or isotype control Ab (IC) (30 µg/ml) on hrCCL2-
induced THP-1 cell chemotaxis (3 ng/ml). Data are presented as a percentage of the 
maximal response obtained with hrCCL2 alone. The first bar represents the response to 
control medium alone. The second bar represents the response to hrCCL2 pre-incubated 
with the maximum concentration of IC. The final two bars represent the response to 
maximum concentrations of Ab and IC alone and show that these antibodies had no effect 
on cell chemotaxis. Data represent the mean ± SEM, from triplicates; ***p<0.001, 
comparison with hrCCL2 alone; +++p<0.001, comparison with control medium alone; one-
way ANOVA. 
Reducing [anti-CCL2 
antibody] 
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3.3.7.2. Conditioned media of pHLFs exposed to TSLP induces 
chemotaxis of human monocytes in a CCL2-dependent 
manner 
Having confirmed the sensitivity of THP-1 cells to CCL2-induced chemotaxis, I next 
examined monocyte chemotaxis in response to CM from pHLFs exposed to TSLP 
(0 – 1 ng/ml) for 6 hours, using the same technique as above. Figure 3.35. (A) 
shows that no significant chemotaxis was observed in response to CM from pHLFs 
exposed to control media alone or TSLP at concentrations of 0.01- 0.3 ng/ml (-log 
11 g/l to -log 9.5 g/l). However, significant monocyte chemotaxis was induced by 
CM from pHLFs exposed to TSLP concentrations of 1 ng/ml (-log 9 g/l) (5-fold 
increase over control). This represents a ~65% induction compared with the 
hrCCL2-induced chemotactic response. 
I next assessed whether this response was mediated by CCL2 release into 
supernatants by pHLFs exposed to TSLP. CM from pHLFs exposed to TSLP (1 
ng/ml) for 6 hours was pre-incubated with anti-CCL2 antibody (30 µg/ml) or isotype 
control antibody (30 µg/ml) as described above, prior to exposure to monocytes. As 
can be seen from Figure 3.35. (B), monocyte chemotaxis in response to CM from 
pHLFs exposed to TSLP (1 ng/ml) was significantly attenuated (~40%) in the 
presence of an anti-CCL2 antibody; no inhibition was observed in the presence of 
an isotype control antibody. hrTSLP (1 ng/ml) exerted no chemotactic effect on 
THP-1 cells demonstrating that the observed chemotactic response was not due to 
direct stimulation by TSLP. Interestingly, neutralisation of CCL2 did not result in a 
complete inhibition of monocyte chemotaxis induced by CM from pHLFs exposed to 
TSLP, suggesting TSLP may induce the generation of other chemotactic agents by 
pHLFs. 
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Figure 3.35. 
Conditioned media from TSLP-treated pHLFs induces chemotaxis of 
THP-1 monoctyes via CCL2. 
Panel (A) shows the effect on chemotaxis of THP-1 monocytes induced by conditioned 
media collected from pHLFs exposed to control medium or varying concentrations of TSLP 
for 6 hours. The first bar represents the chemotactic response of cells to DMEM/BSA (1%, 
w/v) only. The second bar represents the chemotactic response of cells to hrCCL2 (3 ng/ml). 
Data are presented as the mean number of cells per 5 HPF ± SEM, from triplicates. *p<0.05, 
comparison with conditioned media from unstimulated cells; one-way ANOVA. Panel (B) 
shows the effect of an anti-CCL2 antibody (Ab) or isotype control (IC) (both at 30 µg/ml) on 
chemotaxis of THP-1 cells induced by conditioned media from pHLFs exposed to control 
medium or TSLP (1 ng/ml) for 6 hours. The first bar represents the chemotactic response of 
cells to human recombinant (hr) TSLP (1 ng/ml). Data are presented as Panel A. *p<0.05, 
comparison with conditioned media from TSLP-treated pHLFs not incubated with Ab or IC; 
one-way ANOVA. 
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3.3.8. Summary 
The results described in this section, examining the responsiveness of primary 
human lung fibroblasts (pHLFs) to TSLP, shows that: 
 pHLFs express both components of the TSLP receptor; 
 TSLP induces STAT3, but not STAT5 phosphorylation in pHLFs; 
 TSLP upregulates the expression of CCL2 in pHLFs in vitro in a time-
dependent manner;  
 STAT3 phosphorylation, subsequent to TSLPR ligation, mediates CCL2 
expression in pHLFs;  
 TSLP induces chemotaxis of human monocytes in vitro in a CCL2-
dependent manner 
Taken together, these data demonstrate for the first time that primary human lung 
fibroblasts express a functional TSLP-TSLP receptor signalling axis and that this 
leads to the upregulation of CCL2 release, an important immune-modulatory 
chemokine. Moreover, they highlight a novel role for TSLP in the generation of a 
fibroblast-derived chemokine gradient. 
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3.4. The role of TSLP in the development of Type-2 immune 
responses in the lung following non-allergen mediated 
lung injury 
3.4.1. Introduction 
The data presented so far in this thesis has demonstrated that lung fibroblasts 
represent both a potential cellular source and target of TSLP, an important T-2 
polarising cytokine, in IPF, a condition characterised by increased expression of 
pro-fibrotic T-2 cytokines (Wallace et al., 1995). The strong immunoreactivity for 
TSLP and TSLPR in IPF lung suggests a potential pathogenetic role for this 
cytokine in the development of lung fibrosis, and the next series of experiments 
were designed to explore this concept in an animal model of bleomycin-induced 
lung injury and fibrosis. This model cannot claim to faithfully recapitulate all the 
features of IPF. Nonetheless, it does share some important features which have 
allowed the identification of important pro-fibrotic pathways that have relevance in 
human disease. In particular, the development of inflammatory / immune responses 
in this model, and the subsequent development of fibrosis, do not seem dependent 
on allergen exposure, but rather follow epithelial injury. In the first instance, I 
examined the time-course of TSLP immunoreactivity in murine lung following 
bleomycin challenge over 28 days. I also examined TSLPR immunoreactivity during 
the fibrotic phase of this model. Thereafter, I performed FACS analysis on murine 
lung single cell suspensions following bleomycin challenge to profile local immune 
cell populations following lung injury in this model. In addition, concomitant studies 
were performed to determine the role of TSLP in the development of bleomycin-
induced immune responses. Finally, the contribution of TSLP to the development of 
bleomycin-induced lung fibrosis, as assessed by lung collagen deposition, was 
examined. For these studies, bleomycin (2 mg/kg body weight) or saline was 
administered via the oropharyngeal route to C57Bl/6 mice as described in Materials 
and Methods. To evaluate the role of TSLP in these responses, a rat monoclonal 
IgG neutralising anti-TSLP antibody (28F12), or isotype control (IC) was 
administered via the intra-peritoneal (i.p.) route at a dose of 15 mg/kg, every 4 days. 
These antibodies were kind gifts from GlaxoSmithKline (GSK, UK). This dosing 
schedule was chosen based on previous pharmacokinetic data made available by 
GSK, and a prophylactic regime was employed, with antibody intervention being 
initiated on day -1. Appropriate specificity and affinity of these antibodies had 
previously been confirmed on a Biacore Systems platform by GSK. The efficacy of 
28F12 to neutralise TSLP activity was further confirmed by demonstrating a 
concentration-dependent inhibition of TSLP-induced CCL2 protein release in 
primary murine lung fibroblasts (pMLFs) in vitro (please see Appendix A2). Serum 
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samples were taken from mice used in intervention studies and anti-TSLP and 
isotype control antibody levels were measured by ELISA at GSK. 
3.4.2. Immunohistochemical localisation of TSLP and TSLPR in 
bleomycin induced lung injury and fibrosis 
Having demonstrated significant TSLP immunoreactivity for injured hyperplastic 
epithelial cells and fibroblasts in IPF lung, I examined the cellular localisation of 
TSLP and TSLPR in the lungs of mice challenged with bleomycin over time to 
determine if a similar pattern was apparent in experimentally-induced fibrosis. Mice 
challenged with bleomycin (2 mg/kg) or saline were sacrificed at days 3, 7, 14, 21 
and 28. Sections were prepared as described in Materials and Methods and 
examined by immunohistochemistry using non-biotinylated polyclonal rabbit anti-
TSLP and anti-TSLPR antibodies. Antigen retrieval and optimal concentrations of 
the primary antibodies used for these studies are outlined in Table 2.1. 
Figures 3.36-3.38 show the immunohistochemical localisation of TSLP in control 
lung and in the bleomycin model of lung injury and fibrosis, respectively. Tissue 
sections from saline-treated animals (Figure 3.36) demonstrated predominantly 
weak staining throughout which was associated with alveolar epithelial cells, and 
macrophages. Occasional strongly positive alveolar epithelial cells and 
macrophages were observed, though there was no discernible geographical or 
temporal pattern to this. This pattern was observed at all time points following saline 
treatment. A similar pattern of immunoreactivity was observed in the lungs of mice 
harvested 3 days post bleomycin-challenge (Figure 3.37 Panel A). However, from 
day 7 onwards (Figure 3.37 Panels B-E), strong TSLP immunoreactivity was 
observed for cells with the morphological characteristics of fibroblasts, as well as 
alveolar epithelial cells and macrophages. Alveolar epithelial cell immunoreactivity 
was more pronounced in areas of increased matrix deposition. This pattern was 
maintained at all time points evaluated to day 28 post bleomycin-challenge. Figure 
3.38. (Panel A) shows Figure 3.36 Panel (C) at a higher magnification (X20). 
Spindle-shaped fibroblasts within areas of peri-bronchiolar matrix deposition can be 
observed to be strongly immunoreactive for TSLP, together with alveolar and 
bronchial epithelial cells. No discernible staining was observed on serial sections 
stained with isotype-specific non-immune primary antibody or primary antibody pre-
incubated with a TSLP blocking peptide (Panels B-C), as described in Materials 
and Methods, confirming specificity of the immunoreactive signal for TSLP. 
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Figure 3.36. 
Murine lung TSLP immunostaining in saline-treated mice. 
Shown is immunostaining for TSLP in mouse lung 7 (A), 14 (B), 21 (C) and 28 (D) days 
after saline treatment. In contrast to mice challenged with bleomycin (see Figure 3.37), 
immunoreactivity for TSLP is less extensive and is observed for macrophages (Mc) and 
occasional alveolar epithelial cells (AEC). Specific staining is depicted in brown; nuclei are 
stained blue with haematoxylin. n=3 for all groups; sections are representative for all mice; 
original magnification x20. For staining with isotype-specific non-immune primary antibody 
and anti-TSLP antibody pre-incubated with blocking peptide, please see Figure 3.37. 
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Shown is immunolocalisation of TSLP (A-E) in lung sections 3 (A), 7 (B), 14 (C), 21 (D), and 28 (E) days after oropharyngeal challenge with 
bleomycin (2 mg/kg). Murine lung TSLP immunoreactivity is weak/absent at day 3 post bleomycin-challenge (A). In contrast, strong 
immunoreactivity for TSLP is observed on cells with the morphology of fibroblasts (Fb), alveolar epithelial cells (AEC) and macrophages (Mc) from 
day 7 onwards (B, C, D, and E). Fibroblast immunoreactivity is more apparent in areas of increased matrix deposition, both peri-bronchiolar (C) 
and interstitial (D-E) which becomes more apparent with time post bleomycin challenge. No discernible staining for TSLP is observed on tissue 
sections, serial to (C) from bleomycin-challenged mice stained with isotype-specific non-immune primary antibody (F) or with anti-TSLP antibody 
pre-incubated with blocking peptide (1:6) (G). n=3 for all time points; sections shown are representative of all mice observed. Original 
magnifications x10. Increased magnification (x20) of section (C, F and G) are represented in Figure 3.38.(dotted area). 
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Figure 3.37. 
TSLP immunostaining in bleomycin-induced lung injury. 
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Figure 3.38. 
TSLP immunostaining in bleomycin-induced lung injury (2). 
Shown is immunolocalisation of TSLP (A) 14 days after oropharyngeal challenge with bleomycin (2 mg/kg). Strong immunoreactivity for 
TSLP is observed in fibroblasts (Fb) within areas of increased matrix deposition. TSLP immunoreactivity is also observed for epithelial 
cells (EC), both bronchial (dashed arrows) and alveolar (dotted arrows). No discernible staining is observed on serial tissue sections 
stained with isotype-specific non-immune primary antibody (B). Loss of signal is also observed in serial sections stained with primary anti-
TSLP antibody, pre-incubated with blocking peptide (1:6) (C). n=3 for bleomycin-challenged mice; sections shown are representative of all 
mice. Original magnification x20. 
 
A B C 
C
h
a
p
te
r 3
: R
e
s
u
lts
 
1
7
5
 
Chapter 3: Results 
176 
 
Figure 3.39. shows the immunohistochemical localisation of TSLPR in murine 
fibrotic lung at day 14 post-bleomycin challenge. Tissue sections from saline-
instilled animals demonstrated positive staining on alveolar epithelial cells (Panel 
A). However, a number of these cells also displayed small cytoplasmic stellate 
projections characteristic of immature DCs. Tissue sections from bleomycin-
challenged mice (Panels B-D) showed intense staining for TSLPR in areas of 
fibrosis, localising to bronchial epithelial cells, alveolar epithelial cells and 
fibroblasts. In addition, cells with the morphological characteristics of DCs, located 
within aggregates of mononuclear cells, were also observed to be strongly positive 
for TSLPR. These aggregates were typically organised in a bronchocentric pattern. 
Again, no discernible staining was observed for TSLPR on serial sections stained 
with isotype-specific non-immune primary antibody, demonstrating specificity of the 
immunoreactive signal for TSLPR (Panel E). 
These data therefore suggest that the immunolocalisation of TSLP might be similar 
in both experimentally-induced fibrosis and IPF, identifying epithelial cells and 
fibroblasts as potential cellular sources of this cytokine in lung fibrogenesis. 
Moreover, the increase in signal strength from day 3 onwards suggests a time-
dependent increase in TSLP expression following bleomycin-induced lung injury. In 
addition, these studies demonstrate that, in addition to immune cells organised 
within lymphoid aggregates in fibrotic lung, structural cells, including epithelial cells 
and fibroblasts, may be capable of responding to TSLP. These murine findings are 
consistent with the data presented in Section 3.3. demonstrating that pHLFs 
express a functional TSLP-TSLPR signalling axis. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.39. 
Immunohistochemical localization of TSLPR in bleomycin-induced lung injury and fibrosis. 
Shown is immunolocalization of TSLPR (A-D) in lung sections 14 days after saline administration (A) or bleomycin challenge (B-D). In saline-
treated control sections (A), TSLPR immunoreactivity is observed for alveolar epithelial cells (AEC). In lung sections from mice challenged with 
bleomycin (B-D), TSLPR immunoreactivity is observed for bronchial epithelial cells (BEC), fibroblasts (Fb), alveolar epithelial cells. In addition, 
strong TSLPR immunoreactivity is observed for cells with the characteristic shape of dendritic cells (DC) within lymphoid aggregates in bleomycin-
challenged mice (D). Serial sections of (B) were stained with isotype-specific non-immune primary antibody (E, F), and show no discernible 
immunoreactivity. Original magnifications x20 (A, C, D, F); x10 (B, E).  n=3 for all groups; sections shown are representative of all mice observed.  
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3.4.3. The effect of bleomycin-induced lung injury on the lung 
dendritic cell accumulation at day 7 
As discussed in Sections 1.46-1.47 key cellular targets for TSLP in the 
development of T-2 immune responses include dendritic cells (DCs) and T-
lymphocytes. Having demonstrated a time-dependent increase in TSLP 
immunoreactivity in murine lung following bleomycin-induced lung injury, I next 
examined the effect of such injury on lung DC accumulation during the 
inflammatory phase of this model. Mice challenged with bleomycin or saline 
were sacrificed at day 7 and lung harvested for the generation of single cell 
suspensions for FACS analysis, as described in Materials and Methods. This 
time point was chosen on the basis of previous experience with this model, 
suggesting the development of a lymphocytic alveolitis during the first 7 – 10 
days (Janick-Buckner et al., 1989). The development of lung fibrosis, in contrast, 
is observed by day 14. The gating strategy employed to identify DCs in lung 
single cells suspensions is described in detail in Materials and Methods. 
Briefly, however, cells were initially gated according to forward and side scatter 
characteristics to exclude debris and lymphocytes. Data are presented as the 
percentage of these cells which are DCs. DCs were identified as being 
CD11c+/MHC IIhi cells with low autofluoresence, thus excluding alveolar and 
interstitial macrophages from analysis.  
As can be seen from Figure 3.40., bleomycin challenge resulted in a significant 
increase in the lung DC population (3.2 % ± 0.14) compared to saline-instilled 
controls (< 1.5%) at day 7 post challenge. These results demonstrate that 
bleomycin-induced lung injury is associated with an accumulation of DCs in the 
lung during the first week post-challenge. 
3.4.4. The role of TSLP in influencing the lung dendritic cell 
population following bleomycin-induced lung injury at day 10 
and 28 
Having demonstrated that bleomycin challenge results in an accumulation of 
dendritic cells during the inflammatory phase of this model, I next examined if 
this response was maintained at later time points; furthermore, by neutralising 
TSLP activity in vivo, I examined the potential role of TSLP in mediating DC 
recruitment to the lung following bleomycin-induced lung injury. For this series of 
experiments, mice were challenged with bleomycin or saline, and anti-TSLP 
antibody (28F12) or IC antibodies administered as described in Section 3.4.1. 
Mice were sacrificed at day 10 and day 28 post-challenge, and FACS analysis 
performed on single cell suspensions. 
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Figure 3.40. 
Bleomycin-induced lung injury leads to an increase in the lung dendritic cell 
population at day 7 post injury. 
Figure shows the effect of bleomycin challenge on lung dendritic cell accumulation at 
day 7 post-injury. C57Bl/6 mice were instilled with saline or bleomycin (2 mg/kg) via the 
oropharyngeal (o.p.) route; lungs were harvested from mice for preparation of single cell 
lung suspensions as per Materials and Methods. Panel (A): Representative examples 
of fluorescence-activated cell-sorting (FACS) dot plots obtained from lung single cell 
suspensions. CD11c
+
/MHC II
hi
 cells of low autofluorescence were identified as dendritic 
cells (DCs) – R1. Panel (B): Percentage of dendritic cells (DCs) in lung homogenates of 
saline-treated mice or bleomycin-challenged mice at day 7 (R1). saline, n=3; bleomycin, 
n=4; data are presented as mean percentage of lung cells of low autofluoresence which 
are CD11c
+
/MHC II
hi 
± SEM; ***p<0.001 Student’s paired t-test.  
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3.4.4.1. Effect of 28F12 administration on bleomycin-induced 
lung dendritic cell accumulation 
As can be seen in Figure 3.41 (A-B)., the increase in lung DC population 
following bleomycin challenge, compared to saline control, at day 7 was 
maintained at day 10 (5.4% + 0.2 vs 1.1 ± 0.2). In fact, the percentage of DCs at 
this later time point in the BLM / IC group was greater than the percentage 
observed in the BLM group of the earlier experiment (5.4% ± 0.2 vs 3.2% ± 
0.12). These data therefore potentially suggest bleomycin induces lung DC 
accumulation in a time-dependent manner. The percentage of lung DCs in both 
groups of saline-instilled mice remained consistently less than 1.5%. The 
passive neutralisation of TSLP had no effect on bleomycin-induced lung DC 
accumulation at this time point (5.4% ± 0.2 vs 5.6% ± 2.1), suggesting that TSLP 
does not play a role in promoting dendritic cell accumulation to the lung following 
BLM-induced injury. 
Previous studies have suggested that peak expression of T-2 cytokines 
following bleomycin-induced fibrosis occurs between days 21 and 28. Moreover, 
a therapeutic benefit in attenuating lung fibrosis has been demonstrated in this 
model by targeting IL-13 responsive cells during the fibrotic phase of this model 
(Jakubzick et al., 2003). As shown in Section 3.4.2., immunoreactivity for TSLP 
remains strong during this phase of injury, suggesting potential activation of DCs 
into a T-2 polarising phenotype during this time. As can be seen from Figure 
3.42 (A-B), at this later time point, bleomycin challenge continued to be 
associated with an increase in the lung DC population, compared to saline 
control (10.6% ± 1.1 vs 5.9% ±0.45). These data therefore demonstrate that 
lung DC accumulation increases following bleomycin challenge between days 
10 and 28 (5.4% ± 0.2 vs 10.6% ± 0.2). Interestingly, at this later time point, the 
percentage of DCs in the lungs of saline-instilled mice also increased to 5.9% ± 
0.45, suggesting a baseline recruitment of DCs during the course of these 
studies.  However, as observed at day 10, the neutralisation of TSLP activity in 
vivo had no effect on the bleomycin-induced increase in lung DCs, suggesting 
that these cells are recruited to the lung in a TSLP-independent manner.  
3.4.4.2. Effect of 28F12 administration on bleomycin-induced 
lung dendritic cell activation 
Having demonstrated that bleomycin-induced lung injury is associated with an 
increase in the lung DC population that continues into the fibrotic phase, I 
sought to characterise the DC phenotype associated with bleomycin challenge 
further by determining their activation status, as assessed by CD86 expression.  
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Figure 3.41A. 
The bleomycin-induced increase in lung DCs at day 10 is not affected by 
administration of anti-TSLP antibody. 
Figure shows the effect of anti-TSLP antibody administration on bleomycin-
induced lung DC accumulation at day 10 post-challenge. C57Bl/6 mice were 
instilled with saline or bleomycin, and administered isotype control or anti-TSLP 
antibody i.p. as per Materials and Methods. Lungs were harvested for 
preparation of single cell lung suspensions and gating for DCs was performed 
as described in text. Data are presented as percentage of lung cells of low 
autofluorescence which are CD11c+/MHC IIhi ± SEM; n=3 in all groups; *** 
p<0.001, comparison with saline; ns – non significant, comparison with 
bleomycin / isotype; two-way ANOVA. 
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Figure 3.41B. 
 
The bleomycin-induced increase in lung DCs at day 10 is not affected by 
administration of anti-TSLP antibody. 
Figure shows representative FACS plots demonstrating the effect anti-TSLP 
administration on bleomycin-induced lung DC accumulation at day 10. C57Bl/6 mice 
were instilled with saline or bleomycin, and administered isotype control or anti-TSLP 
antibody i.p. as per Materials and Methods. Lungs were harvested for preparation of 
single cell lung suspensions as described in Materials and Methods.  CD11c
+
/MHC II
hi
 
cells of low autofluorescence were identified as dendritic cells (DCs) – R1. (A) saline 
and isotype control antibody; (B) saline and anti-TSLP antibody; (C) bleomycin and 
isotype control antibody; (D) bleomycin and anti-TSLP-antibody; n=3, all groups.  
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Figure 3.42A. 
The bleomycin-induced increase in lung DCs at day 28 is not affected by 
administration of anti-TSLP antibody. 
Figure shows the effect of anti-TSLP administration on bleomycin-induced lung 
DC accumulation at day 28 post challenge. C57Bl/6 mice were instilled with 
saline or bleomycin, and administered isotype control or anti-TSLP antibody i.p. 
as per Materials and Methods. Lungs were harvested for preparation of single 
cell lung suspensions and gating for DCs was performed as described in text. 
Data are presented as percentage of lung cells of low autofluorescence which 
are CD11c+/MHC IIhi ± SEM; n=3 in all groups; *** p<0.001, comparison with 
saline; ns – non significant, comparison with bleomycin / isotype; two-way 
ANOVA. 
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Figure 3.42B. 
 
The bleomycin-induced increase in lung DCs at day 28 is not affected by 
administration of anti-TSLP antibody. 
Figure shows representative FACS plots demonstrating the effect anti-TSLP 
administration on bleomycin-induced lung DC accumulation at day 28. C57Bl/6 mice 
were instilled with saline or bleomycin, and administered isotype control or anti-
TSLP antibody i.p. as per Materials and Methods. Lungs were harvested at 28 
days for preparation of single cell lung suspensions as described in Materials and 
Methods.  CD11c+/MHC IIhi cells of low autofluorescence were identified as 
dendritic cells (DCs) – R1. (A) saline and isotype control antibody; (B) saline and 
anti-TSLP antibody; (C) bleomycin and isotype control antibody; (D) bleomycin and 
anti-TSLP-antibody; n=3, all groups.  
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Maturation of DCs permit functional interactions with effector immune cells, 
including T-cells, and TSLP-activated DCs in particular promote the 
differentiation of naïve CD4+ T-cell into Th2 cells, capable of generating T-2 
cytokines. As shown in Figure 3.43 (A-B), bleomycin challenge is associated 
with a significantly greater proportion of DCs which express CD86, compared 
with saline controls at day 10 post injury (26.2% ± 0.9 vs 15.5% ± 3.4). 
Administration of 28F12 to mice challenged with bleomycin resulted in a 
significant reduction in the proportion of CD86+ DCs (26.2% ± 0.9 vs 9.8% ± 
2.2). No significant differences were observed in the percentage of CD86+ lung 
DCs in the two saline groups. These findings strongly suggest that bleomycin-
induced lung injury is associated with DC activation which in turn is TSLP-
dependent. No changes were observed in the activation status of splenic DCs 
following bleomycin challenge compared to saline control (please see Appendix 
A3), suggesting that the maturation of DCs following bleomycin-induced lung 
injury was limited to the site of injury. 
Having previously demonstrated that the lung DC population continues to 
increase into the fibrotic phase of the bleomycin model (Section 3.4.4.1.), I next 
examined the DC phenotype at this later time point to determine if they 
remained in an activated state. As well as assessing CD86 expression at this 
time-point, I also examined OX40L expression by DCs. Quiescent DCs do not 
express OX40L, but as discussed in Section 1.4.6., TSLP induces upregulation 
of OX40L expression by DCs; subsequent OX40L-OX40 interactions between 
TSLP-DCs and T-cells are key to the development of Th2 cells. Interestingly, at 
this time point, as shown in Figure 3.44., the vast majority of DCs were CD86+ 
in all groups examined, in contrast to the findings observed at day 10 (89.3% ± 
0.76 vs 15.1% ± 2.3). Moreover, no significant differences were observed 
between saline and bleomycin challenged mice (87.7% ± 1.1 vs 91% ± 2.2). In 
addition, at this later time point, neutralisation of TSLP activity in vivo had no 
effect on CD86 expression by lung DCs in either saline- or bleomycin-
challenged mice. This apparent global activation of lung DCs in all mouse 
groups was confirmed by examining DC OX40L expression. As can be seen in 
Figure 3.45, the majority of DCs in both saline and bleomycin mouse groups 
also expressed OX40L (64.3% ± 2.8 vs 66% ± 3.0). However, in contrast to 
CD86 expression, the administration of 28F12 resulted in a small but significant 
reduction in DC OX40L expression in both saline and bleomycin-challenged 
mice (69.6% ±2.7 vs 58.6% ± 1.5; 72.1% ± 1.3 vs 60.1% ± 2.8). 
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Figure 3.43A. 
Administration of anti-TSLP antibody reduces the bleomycin-induced 
increase in CD86+ lung dendritic cells at day 10. 
Figure shows the effect of anti-TSLP administration on CD86 expression by lung 
DCs following bleomycin-induced lung injury at day 10. C57Bl/6 mice were 
instilled with saline or bleomycin, and administered isotype control or anti-TSLP 
antibody i.p. as per Materials and Methods. Lungs were harvested for 
preparation of single cell lung suspensions as described in Materials and 
Methods.  Data are presented as percentage of lung dendritic cells (R1 – 
Figure 3.41B.) which are CD86+ ± SEM; n=3 in all groups; + p<0.05, 
comparison with saline / isotype; **p<0.01, comparison with bleomycin / isotype; 
two-way ANOVA. 
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Figure 3.43B. 
Administration of anti-TSLP antibody reduces the bleomycin-induced 
increase in CD86+ lung dendritic cells at day 10.  
Figure shows representative FACS plots demonstrating the effect anti-TSLP administration 
on bleomycin-induced increase in CD86+ DCs in the lung at day 10. C57Bl/6 mice were 
instilled with saline or bleomycin, and administered isotype control or anti-TSLP antibody i.p. 
as per Materials and Methods. Lungs were harvested for preparation of single cell lung 
suspensions as described in Materials and Methods.  CD86 staining was assessed in cells 
identified as DCs (R1 – Figure 3.41B). (A) saline and isotype control antibody ; (B) saline 
and anti-TSLP antibody; (C) bleomycin and isotype control antibody; (D) bleomycin and anti-
TSLP-antibody; n=3, all groups.  
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Figure 3.44. 
CD86 expression by lung DCs is similar for saline-treated and 
bleomycin-challenged mice at day 28. 
Figure shows the effect of anti-TSLP administration on CD86 expression by lung 
DCs following bleomycin-induced lung injury at day 28. C57Bl/6 mice were 
instilled with saline or bleomycin, and administered isotype control or anti-TSLP 
antibody i.p. as per Materials and Methods. Lungs were harvested for 
preparation of single cell lung suspensions as described in Materials and 
Methods. Panel A: representative FACS dot plots obtained for each 
experimental condition. CD86 staining was assessed in cells identified as DCs 
(R1 – Figure 3.42B). Panel B: percentage of DCs which are CD86+; data are 
presented as percentage of lung DCs (R1 – Figure 3.42B) which are CD86+ ± 
SEM; n=3 in all groups; ns, non-significant; two-way ANOVA.
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Figure 3.45. 
Administration of 28F12 attenuates OX40L expression by lung DCs at day 
28 following saline and bleomycin instillation. 
Figure shows the effect of anti-TSLP administration on OX40L expression by lung DCs 
following bleomycin-induced lung injury at day 28. C57Bl/6 mice were instilled with 
saline or bleomycin, and administered isotype control or anti-TSLP antibody i.p. as per 
Materials and Methods. Lungs were harvested for preparation of single cell lung 
suspensions as described in Materials and Methods. Panel A: representative FACS 
dot plots obtained for each experimental condition. OX40L staining was assessed in 
cells identified as DCs (R1 – Figure 3.42B). Panel B: percentage of DCs which are 
OX40L+; data are presented as percentage of lung DCs (R1 – Figure 3.42B) which are 
OX40L+ ± SEM; n=3 in all groups; ns, non-significant; *p<0.05, comparison with isotype; 
two-way ANOVA. 
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Collectively, these data suggest that the activation of DCs associated with 
bleomycin-induced lung injury at day 10 is TSLP-dependent. However, the 
current findings do not allow me to draw any firm conclusions regarding the role 
TSLP in promoting DC activation during the fibrotic phase of this model. In 
contrast, they suggest that during the later phase of these extended time-course 
studies, DC activation may have been influenced by the administration of rat IgG 
itself, independent of its target specificity. The implications of these findings will 
be discussed in Section 4.6.1. 
3.4.5. The effect of bleomycin-induced lung injury on the lung T cell 
profile at day 7 
TSLP-activated dendritic cells (TSLP-DCs) promote the development of T-2 
immune responses by inducing the differentiation of Th2 lymphocytes from 
naïve CD4+ cells (Ito et al., 2005), as well as by maintaining a population of 
effector Th2 cells (Wang et al., 2006). Although the importance of a T-2 immune 
phenotype in experimentally-induced fibrosis has been previously highlighted 
(Belperio et al., 2002), the precise profile of Th2 cells following bleomycin-
induced lung injury in mice is less clear. Having demonstrated that bleomycin 
challenge is associated with TSLP-mediated DC activation, at least during the 
inflammatory phase of this model, I next examined if this response was 
associated with an increase in the Th2 cell population in the lung. The gating 
strategy used to identify T lymphocytes is described in more detail in Materials 
and Methods. Briefly, however, lymphocytes were initially gated on forward and 
side scatter, before CD4, CD8 and TCR-β expression was used to identify sub-
populations for further analysis of intracellular cytokine staining. 
3.4.5.1. The effect of bleomycin-induced lung injury on T-cell 
accumulation in the lung 
I first examined the T-cell profile in the lung 7 days following bleomycin-induced 
lung injury. Mice were instilled with bleomycin (2 mg/kg) or saline as described 
in Materials and Methods. Mice were sacrificed at day 7 for FACS analysis of 
lung single cell suspensions. Data are presented as a percentage of cells 
identified as lymphocytes on forward and side scatter profile which are TCR-β 
+ve. As can be seen in Figure 3.46. (A), at this time point, no significant 
differences were observed in the total αβT-cell lung population in bleomycin-
challenged mice compared with saline control (26.2% ± 0.7 vs 20.7% ± 3.5). 
Moreover, analysis of αβ T-cell sub-populations (Figure 3.46. (B-C)) 
demonstrates that bleomycin-challenge did not result in any significant change 
in the CD4+ or CD8+ populations compared to saline control (9.8% ± 0.4 vs 
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Figure 3.46. 
Bleomycin challenge in mice does not result in an increase in the total, CD4 + 
or CD8 + T-cell lung populations at day 7. 
C57Bl/6 mice were instilled with saline or bleomycin, and lungs harvested as previously 
described. Lungs were harvested at day 7 for preparation of single cell suspensions, as 
described in Materials and Methods, for FACS analysis. (A) TCR-β + cells, expressed as 
percentage of lymphocytes gated on forward and side scatter, in lung homogenates of saline-
treated mice or bleomycin-challenged mice; (B) CD4+ cells, expressed as percentage of αβ T 
cells; (C) CD8+ expressed as percentage of αβ T-cells; saline, n=3; bleomycin, n=4; data are 
presented as mean percentage of designated population ± SEM; ns-non-significant, Student’s 
paired t-test. 
 Chapter 3: Results 
192 
 
9.0% ± 1.7; 7.5% ± 0.6 vs 6.3% ± 1.8 respectively; data presented as 
percentage of cells identified as lymphocytes on forward and side scatter which 
are TCR-β+, and CD4+ or CD8+). These data suggest that bleomycin challenge 
does not result in any changes in the total T cell population of the lung, or 
indeed the proportion of αβ T-cells which are CD4+ or CD8+. Representative 
FACS plots for CD4+ and CD8+ cells are presented in the Appendix A4.  
3.4.5.2. The effect of bleomycin-induced lung injury on Th1 and 
Th2 cells in the lung 
Having demonstrated that BLM challenge does not induce any changes in the 
overall T-cell population, including CD4+ and CD8+ subsets, at day 7 post-
injury, I performed further analyses of the CD4+ population to determine if 
bleomycin-induced lung injury was associated with a polarisation of the T-helper 
subset towards a T-2 phenotype. Data are presented as percentage of CD4+ / 
TCR-β+ lymphocytes which were either IL4+ or IFN-γ+, markers of Th2 and Th1 
cells respectively. 
As can be seen in Figure 3.47., bleomycin-challenge resulted in a significant 
increase in the proportion of CD4+ cells which display a Th2 phenotype 
(TCRβ+/CD4+/IL-4+) compared to saline control (34.1% ± 0.8 vs 26.6% ± 0.7) at 
day 7 post injury. However, no differences were observed in the Th1 cell 
population (TCRβ+/CD4+/IFN-γ+) between bleomycin-challenge and saline-
treatment (1.3% ± 0.2 vs 0.9% ± 0.3) (Figure 3.48.). Taken together, these data 
allowed me to conclude that bleomycin-challenge results in polarisation of the 
immune response, with respect to T-helper cells, towards a T-2 phenotype at 
this time point, an effect driven by an increase in the Th2 cell population.  
3.4.6. The role of TSLP in influencing the lung T cell profile 
following bleomycin-induced lung injury at day 10 and 28 
TSLP has previously been reported to play a critical role in promoting the 
development of T-2 immune responses in animal models of atopic asthma via its 
unique activation of DCs. However, its role in promoting such responses in non-
allergen driven lung injury is unknown. Having demonstrated that TSLP 
mediates bleomycin-associated DC activation, I next examined if neutralisation 
of TSLP activity in vivo would prevent the observed polarisation of the T-helper 
population in the lung. Mice were exposed to the same experimental conditions 
as described in Section 3.4.4. and the intracellular cytokine staining profile of 
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Figure 3.47. 
Bleomycin challenge results in an increase in the IL-4 producing CD4 + T cell 
population in the lung at day 7. 
Figure shows the effect of bleomycin-induced lung injury on the Th2 (IL-4+) cell 
population in the lung. C57/Bl6 mice were instilled with saline or bleomycin and lungs 
were harvested for preparation of single cell lung suspensions as described in 
Materials and Methods. (A) Representative FACS dot-plots obtained from single 
cell lung suspensions of mice instilled with saline (i) or bleomycin (ii). The gating 
strategy employed to identify TCR-β+/CD4+ cells for analysis of intra-cellular 
cytokine staining is described in Material and Methods.(B) Percentage of Th2 cells 
in single cell lung suspensions following bleomycin challenge (R3). Data presented 
as the mean percentage of CD4+ αβ T-cells which are IL-4+ ± SEM. Saline, n=3; 
bleomycin, n=4; **p<0.01 Student’s paired t-test.  
 
S
S
C
 
IL-4 
saline bleomycin 
S
S
C
 
IL-4 
R3 
R3 
 Chapter 3: Results 
194 
 
 
  
saline bleomycin
0.0
0.5
1.0
1.5
2.0
ns
IF
N
-
 +
 c
e
ll
s
(%
 o
f 
C
D
4
 +
 T
 c
e
ll
s
)
Ai          ii 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
Figure 3.48. 
Bleomycin challenge has no effect on the IFN-γ producing CD4 + T cell 
population in the lung at day 7. 
Figure shows the effect of bleomycin-induced lung injury on the Th1 (IFN-γ+) cell 
population in the lung. C57Bl/6 mice were instilled with saline or bleomycin and lungs 
were harvested for preparation of single cell lung suspensions as described in 
Materials and Methods. (A) Representative FACS dot-plots obtained from single 
cell lung suspensions of mice instilled with saline (i) or bleomycin (ii). The gating 
strategy employed to identify TCR-β+/CD4+ cells for analysis of intra-cellular 
cytokine staining is described in Material and Methods. (B) Percentage of Th1 cells 
in single cell lung suspensions following bleomycin challenge (R4). Data presented 
as the mean percentage of CD4+ αβ T-cells which are IFN-γ ± SEM. Saline, n=3; 
bleomycin, n=4; ns-non significant, Student’s paired t-test.  
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CD4+/TCR-β+ cells, as described in Materials and Methods, was examined by 
FACS analysis. 
 
3.4.6.1. Effect of 28F12 administration on lung CD4+ and CD8+ 
αβ T-lymphocytes  
As presented in Section 3.4.5.1., bleomycin challenge did not result in any 
significant change in the size of CD4+ and CD8+ T-lymphocyte populations, 
compared with saline control, at 7 days. Further analysis of these cell 
populations at days 10 and 28 in this model demonstrated that at these later 
time points, bleomycin challenge was again not associated with any significant 
differences in the size of these cell populations, compared with saline controls 
(data presented in Appendix A5). 
3.4.6.2. Effect of 28F12 administration on the bleomycin-
induced polarisation of the T-helper cell profile towards 
a T-2 phenotype 
Bleomycin-induced lung injury was demonstrated to be associated with 
polarisation of the T-helper cell population in the lung towards a T-2 phenotype 
at day 7 post injury (Section 3.4.5.2.). In light of previous reports suggesting 
persistent polarisation of the immune response during the fibrotic phase of the 
bleomycin model (Jakubzick et al., 2003), the following series of analyses were 
performed to determine if the early predominance of Th2 cells in the lung was 
maintained at later time points. In addition, the role of TSLP in this process was 
evaluated. Data are presented as the fold increase in percentage of CD4+ T-
cells which displayed a Th1 or Th2 phenotype compared to the saline/isotype 
control group. 
As can be seen in Figure 3.49., polarisation of lung CD4+ T-cells towards a T-2 
phenotype (IL-4+) was maintained at day 10 (Panel Ai: ~7-fold increase in Th2 
cells) and during the fibrotic phase of this model at day 28 (Panel Aii: ~3-fold 
increase in Th2 cells) following bleomycin-induced lung injury. In contrast, no 
significant differences were observed in Th1 cell populations (IFN-γ+) between 
the saline and bleomycin groups at either day 10 or day 28 (Panel B). 
Representative histograms for these data are presented in Figures 3.50-3.51. 
(days 10 and 28 respectively). The shift of the whole cell population, from lungs 
harvested at day 28 (Fig 3.51, panel A), towards IL-4+ suggests a degree of 
non-specific staining, and in this regard, one should interpret these data 
cautiously. 
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Neutralisation of TSLP activity resulted in an abrogation of this effect at both 
days 10 and 28 post bleomycin challenge. As demonstrated in Figure 3.49A, 
the fold increase in Th2 cells in bleomycin-challenged mice which received anti-
TSLP antibody was not significantly different compared to saline controls at days 
10 and 28 (1.03- and 1.28-fold change (3.49Ai and Aii respectively). The 
administration of anti-TSLP had no effect on the percentage of Th1 cells at 
either time point (Figure 3.49Bi-ii). Collectively, these data therefore suggest 
that bleomycin-induced lung injury is associated with TSLP-dependent 
polarisation of T-helper cells towards a T-2 phenotype which is seen as early as 
day 7, and which is maintained during the fibrotic phase of this model.  
No changes were observed in the splenic T-cell profiles of mice challenged with 
bleomycin compared to saline-treated controls at day 10 (data presented in 
Appendix A6), strongly suggesting that bleomycin-induced lung injury does not 
result in a systemic immune response, and that the polarisation of CD4+ cells 
observed in this model is a local phenomenon, restricted to the site of initial 
injury. 
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Figure 3.49. 
Administration of anti-TSLP antibody reduces the bleomycin-induced 
polarisation of T-cells in the lung towards a T-2 phenotype at day 10 and 28.  
Figure shows the effect of 28F12 administration on Th2 (IL-4+) (Panel A) and Th1 cells 
(IFN-γ) (Panel B) following bleomycin-induced lung injury at day 10 and day 28. C57Bl/6 
mice were instilled with saline or bleomycin, and administered isotype control or anti-TSLP 
antibody i.p.; lungs were harvested for preparation of single cell lung suspensions as 
described in Materials and Methods.  The gating strategy to identify TCR-β+/CD4+ cells for 
analysis of intra-cellular cytokine staining is described in Material and Methods. Data are 
presented as the mean fold change in percentage of Th2 cells at days 10 and 28 (Panel Ai-
ii) or of Th1 cells (Panel Bi-ii) relative to the saline/isotype group ± SEM; n=3 for all saline 
groups; n=5 and 3 for bleomycin groups (day 10 and 28 respectively). + p<0.05; ++p<0.01, 
comparison with saline; **p<0.01, comparison with bleomycin / isotype; two-way ANOVA. 
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Figure 3.50.  
Administration of anti-TSLP antibody reduces the bleomycin-induced 
polarisation of T-cells in the lung towards a T-2 phenotype at day 10.  
Figure shows representative histograms demonstrating the effect of 28F12 
administration on the Th2 (IL-4+) and Th1 (IFN-γ+) cell populations in the lung 
following bleomycin-induced lung injury at day 10. C57Bl/6 mice were instilled with 
saline or bleomycin, and administered isotype control or anti-TSLP antibody i.p.; 
lungs were harvested for preparation of single cell lung suspensions as described in 
Materials and Methods.  The gating strategy to identify TCR-β+/CD4+ cells for 
analysis of intra-cellular cytokine staining is described in Material and Methods. (A) 
Th2 cells; (B) Th1; n=3 for saline, 5 for bleomycin groups.  
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Figure 3.51. 
Administration of anti-TSLP antibody reduces the bleomycin-induced 
polarisation of T-cells in the lung towards a T-2 phenotype at day 28.  
Figure shows representative histograms demonstrating the effect of 28F12 
administration on the Th2 (IL-4+) and Th1 (IFN-γ+) cell populations in the lung 
following bleomycin-induced lung injury at day 28. C57Bl/6 mice were instilled with 
saline with bleomycin, and administered isotype control or anti-TSLP antibody i.p.; 
lungs were harvested for preparation of single cell lung suspensions as described in 
Materials and Methods.  The gating strategy to identify TCR-β+/CD4+ cells for 
analysis of intra-cellular cytokine staining is described in Material and Methods. (A) 
Th2 cells; (B) Th1; n=3 for all groups. 
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3.4.7. The role of TSLP in the development of bleomycin-induced 
lung fibrosis 
Previous studies have highlighted the importance of a T-2 immune response 
following lung injury in amplifying the dysregulated epithelial-mesenchymal crosstalk 
which contributes to lung fibrogenesis (reviewed in Section 1.7.1.). The data 
presented in the preceding section has highlighted the role of TSLP in promoting 
DC activation and polarisation of T-helper cells towards a T-2 phenotype following 
bleomycin-induced lung injury. Having demonstrated significantly greater TSLP 
immunoreactivity in both human and murine fibrotic lung, compared to control, I 
sought to determine whether the development of these TSLP-dependent T-2 
immune responses were associated with the subsequent development of lung 
fibrosis. The following series of experiments, therefore, were designed to investigate 
the pro-fibrotic potential of TSLP in the bleomycin model.  
3.4.7.1. The effect of 28F12 on bleomycin-induced lung collagen 
deposition 
Extensive studies in the host laboratory employing the bleomycin model to 
investigate lung fibrosis have demonstrated that significant lung collagen 
accumulation is observed at 2 weeks following lung injury (Howell et al., 2005; 
Scotton et al., 2009). Therefore, the effect of neutralising TSLP activity on lung 
collagen expression at both the mRNA and protein level was examined initially at 
day 14. Mice were exposed to the same experimental conditions as described in 
Section 3.4.1., and lungs were harvested for measurement of Col1A1 mRNA levels 
and total lung collagen, as described in Materials and Methods. To ensure that 
mice challenged with bleomycin had received appropriate lung injury, body weights 
were recorded regularly. As can be seen from Figure 3.52., all animals challenged 
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Figure 3.52. 
Effect of 28F12 administration on mouse body weights following bleomycin-
induced lung injury over 14 days. 
 
Figure shows the effect of 28F12 administration on mouse body weight following 
bleomycin challenge over 14 days. C57Bl/6 mice were instilled with saline or 
bleomycin (o.p.), and administered isotype control or anti-TSLP antibody i.p. as per 
Materials and Methods. Results are expressed as mean change in body weight as 
a percentage of the starting weight. ***p<0.001, comparison between saline and 
bleomycin; repeated measure ANOVA. 
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with bleomycin showed a characteristic and significant decrease in body weight 
from day 3 onwards. Following a nadir at around day 7, body weights in the 
bleomycin group demonstrated a characteristic recovery. Control mice administered 
saline displayed weight gain throughout the course of the experiment. Neutralisation 
of TSLP activity did not attenuate the extent of weight loss in bleomycin-challenged 
mice (Figure 3.52.) Consistent with previous studies (Howell et al., 2005; Krupiczojc 
et al., 2008) bleomycin challenge in resulted in a significant increase (~70% ) in total 
lung collagen, as measured by reverse-phase HPLC quantification of hydroxyproline 
in lung tissue, compared with saline control at day 14 post-injury (Figure 3.53). 
However, this increase was not inhibited by the administration of an anti-TSLP 
antibody, confirming that, in this model of lung injury, TSLP did not contribute to the 
development of lung fibrosis at day 14. In conjunction with the data presented in 
Section 3.4.6., these data also suggest that bleomycin-induced lung collagen 
deposition at this time point might be independent of the polarisation of T-helper 
cells in the lung towards a T-2 phenotype. 
Lung collagen mRNA levels may represent a more sensitive endpoint in this model, 
and I therefore looked at changes in Col1A1 mRNA levels between saline- and 
bleomycin-instilled mice. Figure 3.54., demonstrates that lung Col1A1 mRNA levels 
were significantly elevated in mice challenged with bleomycin (~3-fold increase 
relative to saline controls). However, the administration of 28F12 had no effect on 
bleomycin-induced Col1A1 mRNA levels, indicating that neutralisation of TSLP 
activity did not affect lung collagen I gene expression at day 14 post injury in this 
model.  
Although differences in lung Col1A1 mRNA levels from the two bleomycin-
challenged mouse groups (anti-TSLP and isotype) were not significant, there was 
nonetheless a “trend “ to reduction in mice treated with anti-TSLP antibody. 
Moreover, previous published studies have demonstrated that targeting IL-13 
responsive cells from day 21 onwards attenuates lung fibrosis in this model 
(Jakubzick et al., 2003). In light of the present findings that both TSLP 
immunoreactivity and the TSLP-mediated Th2 predominance of lung T-cells is 
maintained at day 28, further studies were performed to determine if neutralisation 
of TSLP activity and abrogation of the T-2 polarisation would attenuate lung 
collagen deposition beyond day 14.  
In the first instance, an extended time-course experiment was performed to 
determine if lung collagen accumulation continued beyond 14 days in the bleomycin 
model employed by the host lab. Mice were challenged with bleomycin or saline and 
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Figure 3.53. 
Effect of 28F12 administration on lung collagen accumulation in bleomycin-
induced lung injury and fibrosis at day 14. 
Figure shows the effect of anti-TSLP administration on bleomycin-induced lung 
collagen deposition. C57Bl/6 mice were instilled with saline or bleomycin, and 
administered isotype control or anti-TSLP antibody i.p. as per Materials and 
Methods. Mice were sacrificed at day 14 and lung collagen was measured by 
reverse phase HPLC quantification of hydroxyproline in acid hydrolysates of 
pulverised lung. The total amount of collagen in each lung was calculated assuming 
that lung collagen contains 12.2% w/w hydroxyproline as described in Materials 
and Methods. Data represent the mean ± SEM, n=8, apart from the 
bleomycin/isotype group, where n=6. ns-non significant; ***p<0.001; two-way 
ANOVA. 
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Figure 3.54. 
Effect of 28F12 administration on lung Col1a1 mRNA levels in bleomycin-
induced lung injury and fibrosis at day 14. 
Figure shows the effect of 28F12 administration on lung Col1A1 mRNA levels. 
C57Bl/6 mice were instilled with saline or bleomycin (o.p.), and administered isotype 
control or anti-TSLP antibody i.p. as per Materials and Methods. Col1a1 mRNA 
levels were assessed by qRT-PCR of whole lung homogenates. Data are expressed 
as mean fold-change ± SEM relative to saline-treated control, normalized to the 
housekeeping gene Hprt.  n=8 in all groups apart from the bleomycin/isotype group, 
where n=6. ns, non-significant **p<0.01, comparison with saline; two-way ANOVA. 
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total lung collagen was measured at days 7, 10, 14, 21 and 28. As can be seen from 
Figure 3.55., bleomycin-induced deposition of collagen in the lung continued to 
increase significantly up to day 28, compared with saline control, with the sharpest 
increase occurring between days 10 and 21. Mice treated with saline also 
demonstrate a significant increase in lung collagen at day 28 compared with day 7, 
which is likely to reflect an aging effect.  
Having demonstrated that lung collagen continues to accumulate beyond day 14 
and that a T-2 immune response persists at day 28 in this model, I sought to 
determine if the abrogation of the TSLP-induced Th2 cell predominance in the lung 
was associated with an attenuation in lung fibrosis at this later time point. For this 
analysis, mice were randomly chosen from the in vivo studies evaluating lung DC 
and T-cell populations at day 28, as described in Section 3.4.4. and 3.4.6. Body 
weight data from this experiment is presented in the Appendix (A7). As shown in 
Figure 3.56., total lung collagen was increased by ~80% following bleomycin 
challenge relative to saline control animals. However, administration of 28F12 had 
no significant effect on this increase. In conjunction with the findings described in 
Section 3.4.6., these data therefore suggest that the development of lung fibrosis 
following bleomycin-induced lung injury is independent of the TSLP-mediated 
polarisation of T-cells towards a Th2 phenotype. 
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Figure 3.55. 
Bleomycin-induced lung injury results in a time-dependent increase in lung collagen 
accumulation over 28 days. 
Figure shows the effect on lung collagen deposition following bleomycin challenge. C57Bl/6 
mice were instilled with saline or bleomycin (o.p.); lungs were harvested from mice at varying 
time-points (days 7, 10, 14, 21 and 28) and lung collagen was measured by reverse phase 
HPLC quantification of hydroxyproline in acid hydrolysates of pulverised lung. The total 
amount of collagen in each lung was calculated assuming that lung collagen contains 12.2% 
w/w hydroxyproline as described in Materials and Methods. Data represent the mean ± 
SEM; n=10, saline; n=11, bleomycin; ***p<0.001, comparison with saline controls, two-way 
ANOVA. 
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Figure 3.56. 
Effect of 28F12 administration on lung collagen accumulation in 
bleomycin-induced lung injury and fibrosis at day 28. 
Figure shows the effect of anti-TSLP administration on bleomycin-induced 
lung collagen deposition. C57Bl/6 mice were instilled with saline or 
bleomycin, and administered isotype control or anti-TSLP antibody i.p. as per 
Materials and Methods. Mice were sacrificed at day 28 and lung collagen 
was measured by reverse phase HPLC quantification of hydroxyproline in 
acid hydrolysates of pulverised lung. The total amount of collagen in each 
lung was calculated assuming that lung collagen contains 12.2% w/w 
hydroxyproline as described in Materials and Methods. Data represent the 
mean ± SEM, n=5, all saline groups; n=7, bleomycin/isotype; n=10, 
bleomycin/anti-TSLP; ns-non significant, comparison with isotype; 
***p<0.001, comparison saline; two-way ANOVA. 
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3.4.8. Summary 
The results described in this chapter, examining the role of TSLP in bleomycin-
induced changes in lung immune cell profiles and the development of lung fibrosis, 
showed that: 
 TSLP immunoreactivity, apparent from day 7 and maintained at day 28, is 
greater in bleomycin-challenged murine lung, compared to saline-treated 
controls, localising to alveolar epithelial cells (AECs), fibroblasts and 
macrophages 
 TSLPR immunolocalises to AECs, bronchial epithelial cells (BECs), 
fibroblasts and dendritic cells in murine fibrotic lung; 
 bleomycin challenge induced a significant time-dependent increase in the 
lung dendritic cell population which is independent of TSLP activity; 
 bleomycin-induced lung injury was associated with activation of lung 
dendritic cells at day 10 which was inhibited by the administration of anti-
TSLP antibody; 
 prolonged antibody dosing in extended time-course studies using this model 
was associated with general activation of lung DCs; 
 bleomycin-induced lung injury was not associated with an increase in the 
total, CD4+ or CD8+ T-cell populations in the lung at days 7, 10 and 28 but 
was associated with persistent polarisation of the CD4+ cell population 
towards a Th2 phenotype; 
 neutralisation of TSLP activity significantly inhibited the bleomycin-induced 
polarisation of the T-helper cell profile towards a T-2 phenotype during both 
the inflammatory and fibrotic phases of lung injury; 
 the administration of anti-TSLP antibody did not attenuate the bleomycin-
induced increase in total lung collagen deposition in the lung at day 14 post 
injury; 
 TSLP does not play a role in the development of lung fibrosis following 
bleomycin-induced lung injury at day 28; 
In conclusion, the reported findings suggest that bleomycin-induced lung injury is 
associated with increased TSLP expression. These data demonstrate for the first 
time that this injury is associated with predominance of Th2 lymphocytes in the lung, 
as well as the accumulation of activated DCs. Although DC accumulation appeared 
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independent of TSLP activity in this model, DC activation and polarisation of the T- 
helper population was demonstrated to be TSLP-dependent, highlighting a novel 
role for this cytokine in the development of T-2 immune responses following non-
allergen driven lung injury.  However, the development of lung fibrosis in this model 
appears independent of the bleomycin-induced polarisation of T-cells towards a T-2 
phenotype. Moreover, the findings described above suggest that TSLP does not 
contribute to the development of lung fibrosis following bleomycin challenge.  
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Overview 
Over the years, numerous animal and human studies have highlighted the 
importance of a polarised T-2 immune response to injury in amplifying the 
dysregulated cross-talk between the epithelium and mesenchyme in lung fibrosis 
(Belperio et al., 2002; Wallace et al., 1995). Redressing this polarisation may offer a 
more selective immunosuppressive effect than conventional anti-inflammatory 
therapy and has been demonstrated to attenuate experimentally-induced fibrosis 
(Jakubzick et al., 2003). This is reflected by a growing interest in the development of 
such therapeutic strategies in human fibrotic disease, including idiopathic pulmonary 
fibrosis (IPF). Sustained epithelial injury is regarded as a critical initiating factor in 
the pathogenesis of IPF (Selman et al., 2002), and it is increasingly recognised that 
danger signals released from injured epithelial cells are capable of engaging the 
adaptive immune response following injury (Pulendran, 2004), thus potentially 
promoting fibrogenesis. 
Thymic stromal lymphopoietin (TSLP) has recently emerged as a key cytokine 
involved in the development of T-2 immune responses in vivo (Taylor et al., 2009; 
Zhou et al., 2005) though this is not a universal finding, as the differentiation of Th2 
cells in TSLPR-/- mice infected with the helminth pathogens, Heligmosomoides 
polygyrus and Nippostrongylus brasiliensis, is unimpaired (Massacand et al., 2009). 
Nonetheless, its importance in the pathogenesis of atopic conditions, particularly in 
the lung, is well recognised (Al-Shami et al., 2005). However, its role in the 
development of non-allergen driven lung diseases, also characterised by increased 
expression of T-2 cytokines, such as IPF, is unknown.  
Although traditionally regarded as an epithelial-derived cytokine (Soumelis et al., 
2002), TSLP expression at the protein level has been reported for a number of other 
cell types, including airway smooth muscle cells (Redhu et al., 2011). Previous 
mRNA expression studies suggested that lung fibroblasts may also have the 
potential to produce TSLP (Soumelis et al., 2002). Lung fibroblasts represent the 
key effector cell responsible for the excessive deposition of extracellular matrix 
proteins which leads to the parenchymal fibrosis characteristic of interstitial lung 
disease (Scotton et al., 2007). However, their close proximity to the epithelium 
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means that they are also in a unique position to relay signals of epithelial injury to 
trafficking immune cells, potentially orchestrating local immune responses.  
This thesis therefore examined the hypothesis that the induction of TSLP 
following lung injury contributes to the development of pulmonary fibrosis by 
promoting a T-2 immune response. 
To address this hypothesis, initial experiments aimed first to establish whether 
TSLP is expressed in human disease by examining the cellular localisation of TSLP, 
and its receptor, in IPF lung by immunohistochemistry. These studies identified the 
lung fibroblast as a potential cellular source and target of TSLP in this condition. 
Similar analyses in the bleomycin model of fibrosis confirmed these findings, 
suggesting for the first time that TSLP expression increases following non-allergen 
driven lung injury. Subsequent experiments were performed to determine the 
signalling pathways involved in mediating TSLP expression by primary human lung 
fibroblasts (pHLFs) in vitro. In this regard, a central role for the JNK/c-Jun pathway 
was highlighted. In addition, the studies performed during the course of this doctoral 
work demonstrated for the first time that lung fibroblasts express a functional TSLP 
receptor signalling axis, and that TSLP induces the upregulation of CCL2 via a 
STAT3-dependent mechanism. TSLP was further shown to be capable of inducing 
chemotaxis of human monocytes via the generation of this immunomodulatory T-2 
chemokine. Thereafter, the role of TSLP in the development of a T-2 immune 
response and lung fibrosis in vivo was examined using a neutralising anti-TSLP 
antibody in the bleomycin model of lung injury and fibrosis. These studies 
demonstrated that passive neutralisation of TSLP activity following bleomycin-
induced lung injury inhibited the activation of dendritic cells and the concomitant 
polarisation of the immune response towards a T-2 phenotype. However, this effect 
was not associated with an attenuation in bleomycin-induced fibrosis, as measured 
by lung collagen accumulation. 
Taken together, these data demonstrate for the first time that: 
1. Lung fibroblasts represent both a source and cellular target of TSLP; 
2. TSLP contributes to DC activation and the development of T-2 immune 
responses following bleomycin-induced lung injury; 
3. TSLP does not contribute to lung collagen accumulation in this model.  
The following sections will discuss these findings and their implications in detail.  
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4.1. The cellular localisation of TSLP in lung fibrosis 
4.1.1. Introduction 
Immunohistochemical analysis of tissue sections has proved useful in highlighting 
potential cellular sources of TSLP T-2 dominated inflammatory conditions in 
humans. With respect to pulmonary disease, known cellular sources of TSLP 
include airway epithelial cells and smooth muscle cells (Ying et al., 2008; Zhang et 
al., 2007). However, these cell types are not felt to contribute significantly to the 
pathogenesis of lung fibrosis. In murine models of pulmonary disease, TSLP 
immunoreactivity has only been assessed in a single study localising this cytokine to 
the bronchial epithelium in a model of airway disease (Nakamura et al., 2008). 
Despite strong evidence suggesting a predominantly T-2 cytokine profile in IPF 
(Hancock et al., 1998; Wallace et al., 1995), the potential contribution of TSLP, an 
important promoter of such responses, has not previously been evaluated in this 
condition. The findings of the present studies, and their implications, will now be 
discussed in detail. 
4.1.2. Cellular immunolocalisation of TSLP in  IPF  
The results outlined in Section 3.1.2. demonstrate that in non-fibrotic human lung, 
positive immunostaining for TSLP is restricted to occasional alveolar epithelial cells 
and macrophages. In contrast, strong TSLP immunoreactivity is consistently 
observed in lung sections from IPF patients (n=12), localizing to hyperplastic 
alveolar epithelial cells, as well as spindle-shaped fibroblasts within fibrotic foci, and 
macrophages. TSLP has previously been localised to the human bronchial 
epithelium in asthma (Ying et al., 2005).  Expression of TSLP has been extensively 
reported in bronchial and small airway epithelial cells in response to stimuli with 
biological relevance to exacerbations of human airway disease, including TLR 
ligands, rhinovirus infection and pollutants (Bleck et al., 2008; Kato et al., 2007). In 
contrast, in the context of IPF, injury to alveolar, rather than bronchial, epithelial 
cells is regarded as the primary initiating event for subsequent fibrogenesis, and the 
demonstration of strong TSLP immunoreactivity for alveolar epithelial cells in lung 
fibrosis reported in this thesis represents the first such report. Moreover, in vitro 
expression of TSLP by such cells has not previously been reported, apart from in 
the A549 cell line (Lee et al., 2007a), and will be discussed further in Section 4.4. 
The identification of strong TSLP immunoreactivity for lung fibroblasts identifies for 
the first time a cellular source which is common to the pathology of both allergen 
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and non-allergen driven lung disease. This mesenchymal cell represents the key 
effector cell responsible for the excessive deposition of extracellular matrix protein 
leading to interstitial fibrosis (Scotton et al., 2007), as well as the airway remodelling 
characteristic of chronic asthma (Homer et al., 2005). The current observations are 
compatible with recent studies identifying fibroblasts as potentially important cellular 
sources of TSLP in non-pulmonary conditions such as nasal polyposis (Kimura et 
al., 2011). Moreover, lung fibroblasts have been reported to have the potential to 
express TSLP in vitro (Soumelis et al., 2002), though at the start of this PhD, 
expression at the protein level had not been reported. The current studies, 
therefore, suggest that the lung fibroblast may represent an important, and hitherto 
unrecognised, cellular source of TSLP in several conditions, including pulmonary 
diseases, characterised by the increased expression of T-2 cytokines. 
Strong TSLP immunoreactivity was also observed for mononuclear cells organised 
within peri-bronchiolar and peri-vascular aggregates in human IPF. These 
aggregates consist chiefly of T lymphocytes, as well as dendritic cells, suggesting a 
role for the adaptive immune system in the pathogenesis of IPF (Marchal-Somme et 
al., 2007a). However, TSLP expression by lymphocytes has not been reported. In 
contrast, it is well recognised that human lymphocytes express the TSLP receptor 
(Rochman et al., 2007). Indeed, recent studies have demonstrated that TSLP may 
induce programmes of proliferation and differentiation in activated T-cells directly 
(Rochman et al., 2007), in addition to via dendritic cells.  The observed 
immunoreactivity for such cells may therefore reflect localisation of extracellular 
TSLP bound to its receptor on lymphocytes. The T-cells that accumulate in such 
follicular structures in IPF are felt to be recently activated, as determined by 
increased expression of CD45L (Marchal-Somme et al., 2006). More recently, 
dendritic cells themselves have been reported to upregulate the expression of TSLP 
in response to TLR ligands in vitro (Kashyap et al., 2011). TSLP represents an 
extremely potent activator of DCs into a T-2 polarising phenotype (Section 1.4.6.). 
These recent findings may therefore reflect an autocrine signalling loop allowing 
amplification of an immune polarising signal at mucosal sites and / or a second 
pathway for the development of such responses, circumventing the need for 
alternative cellular sources of this cytokine. However, despite strong TSLP 
immunoreactivity for TSLP observed within lymphoid aggregates, due to the time 
constraints of the current studies, the confident immunolocalisation of TSLP to 
dendritic cells within these structures was not possible – such studies would 
represent an important part of future work in this area. 
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In the present IPF studies, no convincing TSLP immunoreactivity for human airway 
smooth muscle cells (HASMCs) was observed in contrast to previous reports in 
chronic obstructive pulmonary disease (COPD) (Zhang et al., 2007). Aside from 
technical variations, one possible explanation for these differences may be that 
TSLP immunoreactivity for this cell type was evaluated in biopsies derived from 
inflamed airways in COPD, which are not characteristic features of IPF. 
4.1.3. Cellular immunolocalisation of TSLP following bleomycin-
induced lung injury 
To determine if a similar pattern of cellular localisation was apparent in 
experimentally-induced fibrosis, immunohistochemical analysis was undertaken of 
lungs harvested from mice challenged with bleomycin. The bleomycin model 
represents the most widely used model for experimentally-induced lung fibrosis, and 
is described in detail in Section 1.3.1. 
The results presented in Section 3.4.2 demonstrate that immunoreactivity for TSLP 
in the lungs of saline-treated control mice is relatively weak at all time points 
evaluated from days 3 - 28 and is limited to occasional alveolar epithelial cells and 
macrophages, a pattern reminiscent of non-fibrotic human lung. In contrast, 
bleomycin challenge results in a time-dependent increase in TSLP 
immunoreactivity. At early time points, the pattern of immunoreactivity is similar to 
saline-treated animals. However, from day 7 onwards, the signal strength increases. 
In particular, the appearance of fibrotic lesions from day 10 post-challenge enabled 
the identification of fibroblasts as potential cellular sources of this cytokine, in 
addition to epithelial cells and macrophages. The observation that TSLP 
immunoreactivity increases in a time-dependent manner following bleomycin 
challenge is consistent with a role for TSLP in modulating of the immune response 
following epithelial cell injury in this model. The detection of TSLP at a time 
coincident with the onset of dendritic cell and T-lymphocyte recruitment (Bantsimba-
Malanda et al., 2010; Izbicki et al., 2002), key cellular targets for TSLP, raised the 
possibility that this cytokine may play a potential pathogenic role in this model. In 
contrast to human lung, however, TSLP immunoreactivity for mononuclear cells was 
not apparent in bleomycin-injured murine lung; this observation is more consistent 
with current evidence which has not identified the lymphocyte as a cellular source of 
TSLP in vivo or in vitro. In all other respects, however, the pattern of TSLP 
immunoreactivity in murine fibrotic lung is similar to that observed in human IPF 
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lung, suggesting that this cytokine may contribute to the pathogenesis of lung 
fibrosis. This concept will be further explored in Section 4.3. 
4.2. The cellular localisation of TSLP receptor in lung 
fibrosis 
As discussed in Section 1.4.2., the cellular effects of TSLP are initiated following 
ligand binding to the TSLP receptor complex and activation of downstream STAT 
signalling pathways. Quantitative PCR on a panel of human cDNA libraries has 
demonstrated TSLPR expression in vitro on a wide variety of cell populations of 
haematopoietic lineage, including dendritic cells and T lymphocytes (Reche et al., 
2001). Evaluation of human TSLPR expression in vivo has been hampered by 
technical difficulties relating to antibody specificity. However, recent studies have 
demonstrated strong TSLPR immunoreactivity for epithelial cells and smooth 
muscle cells in airways disease (Semlali et al., 2010; Shan et al., 2010). In contrast, 
localisation of TSLPR has not previously been examined in fibrotic lung disease, 
and this will now be discussed in more detail. 
4.2.1. Cellular immunolocalisation of TSLPR in IPF and bleomycin-
induced fibrosis 
The results presented in Section 3.1.2. demonstrate strong immunoreactivity 
TSLPR to bronchial epithelial cells (BEC) and macrophages in normal human lung. 
In addition, a weaker signal is observed for alveolar epithelial cells (AECs). A similar 
pattern of immunoreactivity was observed in the lungs of control mice given i.t. 
saline, though the BEC signal was far less apparent. In contrast, in IPF lung, the 
range of cells localising TSLPR was more extensive. In addition to AECs, 
mesenchymal cells, such as smooth muscle cells and fibroblasts, were also highly 
immunoreactive for TSLPR. These data support the notion that expression of the 
TSLP receptor is not limited to cells of haematopoietic lineage, and the functional 
implications of these findings will be discussed in Section 4.5. In addition, lymphoid 
aggregates, which in IPF have previously been demonstrated to consist of 
lymphocytes and dendritic cells, also demonstrated strong immunoreactivity for 
TSLPR. Within these structures, the high nuclear to cytoplasmic ratio of 
lymphocytes did not permit clear cell surface localisation of TSLPR to these cells, in 
contrast to cells with the morphology of dendritic cells. This pattern of surface 
localisation for TSLPR was also observed in the lungs of mice challenged with 
bleomycin, suggesting that the range of cells potentially capable of responding to 
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TSLP in fibrotic lung is similar in humans and mice. The significance of these 
findings will now be discussed. 
4.2.2. TSLPR immunolocalisation to immune cells in lung fibrosis 
The initial identification of TSLP as a factor in thymic stromal media (Friend et al., 
1994) influenced much of the early studies evaluating cellular responses to this 
cytokine, particularly examining the role of this cytokine in lymphocyte development. 
However, TSLP does not seem critical for B cell development in mice (Carpino et 
al., 2004) in contrast to T-cell lymphopoiesis and haematopoiesis (Al-Shami et al., 
2004). The discovery that immature DCs are potently activated by TSLP into a T-2 
promoting phenotype has evoked much speculation that this cytokine may represent 
a master switch, upstream of IL-4, in the development of pathological inflammatory 
responses characterised by increased T-2 cytokine expression (Ito et al., 2005)  
The demonstration of strong TSLPR immunoreactivity for DCs in human and murine 
fibrotic lung is consistent with the notion that TSLP-DCs may contribute to the 
pathogenesis of lung fibrosis by inducing a population of Th2 cells. The relevance of 
strong TSLPR immunoreactivity for lymphocytes in lung fibrosis is also of particular 
interest in light of increasing recognition that TSLP may exert direct proliferative and 
differentiating effects on T-cells themselves (Omori et al., 2007; Rochman et al., 
2007). These concepts suggest multiple pathways for TSLP to induce and maintain 
a population of Th2 effectors cells at sites of injury, and will be discussed in more 
detail in Section 4.3.3. 
4.2.3. TSLPR localisation to structural cells in lung fibrosis 
It is increasingly recognised that expression of a functional TSLP receptor is not 
limited to cells of a haematopoietic lineage (Semlali et al., 2010; Shan et al., 2010). 
The strong TSLPR immunoreactivity displayed by epithelial cells in both IPF and 
bleomycin-induced fibrosis in the present studies is consistent with recent reports 
suggesting a similar pattern in lung biopsies from human asthmatic lung (Semlali et 
al., 2010). Moreover, lung epithelial cells are capable of responding to TSLP in a 
functional manner in vitro - epithelial cell proliferation and repair is enhanced 
following exposure to TSLP in an IL-13 dependent manner (Semlali et al., 2010). 
Dysregulated epithelial cell proliferation following lung injury is felt to be central to 
the pathogenesis of IPF, and it is tempting to speculate that normal wound healing 
responses become increasingly aberrant in the face of persistent TSLP exposure. 
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In addition to epithelial cells, the present studies also demonstrated for the first time 
localisation of TSLPR to mesenchymal cells in IPF, including fibroblasts, suggesting 
that this cell type, critical to fibrogenesis, may express a functional TSLP-TSLP 
receptor signalling axis. The potential significance of these findings was explored in 
vitro by examining the expression and function of the TSLP receptor by pHLFs and 
will be discussed in detail in Section 4.5.  
4.3. Potential role for TSLP in lung fibrosis 
In light of the observations that both human and murine lung fibrosis is associated 
with increased immunoreactivity for TSLP and TSLPR, the potential role of this T-2 
promoting cytokine in fibrogenesis will now be discussed (Figure 4.1). 
4.3.1. TNF-α and TSLP in lung fibrosis 
Expression of TSLP has been reported in response to a number of mediators 
(Section 1.4.3.). It is of note that consistent upregulation of TSLP expression has 
been reported across a number of cell types in response to stimulation with TNF-α 
(see Table 1.3.). The role of this “early wave” alarm type cytokine in the 
pathogenesis of IPF was discussed earlier (Section 1.8.2.). Briefly, in lung fibrosis, 
injured and reparative epithelial cells are felt to be important sources of this cytokine 
(Nash et al., 1993; Oikonomou et al., 2006). The mechanisms through which TNF-α 
exerts its pro-fibrotic effects are multiple and include the upregulation of TGF-β 
activity (Sullivan et al., 2005). In addition, the capacity of TNF-α to promote 
lymphocyte recruitment in animal models of lung fibrosis is well recognised 
(Miyazaki et al., 1995; Oikonomou et al., 2006; Sime et al., 1998). These effects are 
likely to be mediated by secondary mediators of immune cell recruitment, survival 
and differentiation including mesenchyme-derived chemokines such as CCL2 
(Ohmori et al., 1993). However, the role of TNF-α in an adaptive immune response 
to tissue stress is not merely limited to cell recruitment. Previous studies have 
demonstrated an important function for this pleiotropic cytokine in the development 
of inflammatory responses characterised by increased expression of T-2 cytokines. 
TNF-receptor knockout mice are unable to mount protective T-2 immune responses 
and are therefore highly susceptible to Trichuris infection (Artis et al., 1999). The 
mechanisms underlying these effects remain unknown but have been postulated to 
include downstream effects on immune cells to augment T-2 effector cell responses.  
In light of this evidence, it was very interesting to observe the close structural 
proximity of injured, hyperplastic epithelium and fibroblasts, strongly 
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immunoreactive for TNF-α and TSLP respectively, to dendritic cells within lymphoid 
aggregates in serial sections of human IPF lung. Such proximity suggests there 
could be a functional interaction between these cell types, which may ultimately lead 
to the development of a pro-fibrotic T-2 microenvironment. One may postulate that, 
following epithelial injury, increased levels of epithelium-derived TNF-α would 
promote TSLP expression. Increased local concentrations of TSLP may then serve 
to polarise the immune response towards a T-2 phenotype. This may occur 
indirectly, via dendritic cells, or through direct effects on T-cells, and these two 
potential mechanisms will now be explored in detail with respect to the 
pathogenesis of IPF.  
4.3.2. Potential role of TSLP-activated DCs in lung fibrosis 
Recent studies have demonstrated that the IPF lung is heavily infiltrated by 
immature DCs (Section 1.5.). It has been proposed that, following recruitment to 
the lung from the vasculature along stromally-derived chemokine gradients, these 
cells are activated locally (Marchal-Somme et al., 2007b), though the mediators 
responsible for such maturation remain undefined. The interaction between 
activated DCs and naïve T-cells, resulting in T-cell priming and induction of 
differentiation, has historically been viewed to occur in local lymph nodes (von 
Andrian et al., 2000) to which maturing DCs traffic following initiation of maturation. 
Within this paradigm, it has traditionally been felt that only activated and/or memory 
T-cells access non-lymphoid peripheral tissue (Mackay et al., 1990) reflecting 
differential expression of tissue-specific chemokine receptors by such cells (Ebert et 
al., 2005). In this context, one may hypothesise that TSLP-DCs, activated following 
epithelial injury, migrate to draining lymph nodes to initiate a programme of T-2 
differentiation in naïve CD4+ T-cells. Thereafter, these activated Th2 cells, now 
expressing appropriate chemokine receptors, may traffic to the site of injury along 
chemokine gradients generated locally, with the subsequent development of a local 
pro-fibrotic T-2 cytokine milieu. This hypothesis is consistent with previous reports in 
the literature demonstrating that infiltrating T-cells in IPF are of an activated and 
memory phenotype (Marchal-Somme et al., 2006). Moreover, mediastinal 
lymphadenopathy is an increasingly recognised feature of idiopathic interstitial 
pneumonias, including IPF, though there remains uncertainty as to the pathological 
importance of these findings (Jung et al., 2000; Souza et al., 2006). It is tempting to 
speculate that this enlargement reflects, at least in part, a programme of 
proliferation and differentiation of naïve CD4+ T-cells following interaction with 
TSLP-DCs. However, such a hypothesis remains purely speculative at this time, 
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and further studies are required to evaluate the cellular composition of locally 
enlarged lymph nodes in IPF, in particular, focusing on the precise 
immunophenotype of constituent lymphocytes and DCs.  
In addition to immature DCs, IPF lung has been reported to be consistently 
infiltrated with mature DCs, organised within structures resembling lymphoid follicles 
(Marchal-Somme et al., 2006). The studies performed during the course of this 
thesis demonstrate that bleomycin-induced lung injury is associated with an 
increase in the proportion of activated DCs within the lung. These findings are 
consistent with a recent study published during the course of this thesis (Bantsimba-
Malanda et al., 2010). It is generally accepted that activated DCs do not traffic back 
to organs from lymph nodes. The present observations therefore suggest that 
resident or recruited immature DCs mature locally at sites of epithelial injury, 
following activation. Interestingly, locally released danger signals recently implicated 
in the pathogenesis of IPF, including uric acid and eATP (Gasse et al., 2009; Riteau 
et al., 2010), are potent activators of DCs, resulting in the subsequent development 
of T-2 immune responses. eATP, much like TSLP, induces the maturation of DCs 
into an IL-12lo phenotype, thus creating a local T-2 permissive microenvironment . 
Therefore, it is possible that TSLP-DCs interact with activated and memory T-cells 
locally to perpetuate a T-2 dominant environment. In this regard, long-lived memory 
Th2 cells have previously been proposed to play key roles at sites of T-2 
inflammation (Holt et al., 1999; Mojtabavi et al., 2002). Moreover, TSLP-DCs have 
been demonstrated to be capable of inducing an expansion of Th2 memory cells, 
which retain their Th2 commitment and capacity for effector cytokine function (Wang 
et al., 2006). Thus, TSLP may play a key role in maintaining the T-2 phenotype of 
recently recruited Th2 effector memory cells at sites of inflammation, thereby 
favouring the persistence of a microenvironment characterised by increased 
expression of T-2 cytokines. Such an interaction may be antigen-specific or related 
to bystander activation of memory T-cells primed during previously unrelated 
antigenic exposure, as discussed later in this section.  
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Figure 4.1. Proposed model for fibroblast-derived TSLP in the pathogenesis of lung 
fibrosis. TNF-α, released from injured epithelium (i), upregulates expression of TSLP by underlying 
fibroblasts (ii). TSLP promotes the development of a T-2 immune response, indirectly via the 
activation of dendritic cells (DC) (iii), or via a direct effect on T-cells (iv) in an antigen-specific manner. 
Engagement of naïve T-cells has traditionally been viewed to occur in the lymph nodes. However, as 
discussed in text, this standpoint has recently been challenged in light of recent evidence suggesting 
the potential importance of peripheral naïve CD4+ T-cells. A polarised T-2 immune response is 
characterised by increased expression of pro-fibrotic cytokines such as IL-4 and IL-13 (v).  
i 
ii 
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iv 
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As alluded to above, naïve CD4+ T-cells have not previously been regarded as a 
significant component of the overall T-cell population in non-lymphoid peripheral 
tissue, and their re-circulatory pathways have been thought to involve the lymphatic 
system exclusively. However, this concept has recently been challenged. Naïve T-
cells have been reported to be present in non-lymphoid organs in the context of 
inflammation (Krakowski et al., 2000; Weninger et al., 2003). More recently, 
significant numbers of naïve T-cells have been shown to traffic through peripheral 
tissue, including the lung, in a chemokine receptor-independent manner (Cose et 
al., 2006). Although the fraction of naïve T-cells in non-lymphoid organs is relatively 
low, it has been suggested that any such cell is likely to traffic through all such 
organs several times during its lifetime (Westermann et al., 2001). The precise 
function of naïve T-cells outside of lymph tissue remains unclear, though in light of 
their rapid transit, it has been proposed that they may play a role in 
immunosurveillance and the induction of peripheral tolerance [reviewed in (Cose, 
2007)]. 
It is, therefore, also possible that naïve CD4+ T-cells may be primed and activated 
in situ, a concept which represents a paradigm shift in our current understanding of 
T-cell differentiation. In support of this notion are the observations that T-cell priming 
in murine lung can occur in the absence of lymph nodes and spleens, suggesting a 
role for DC-T-cell interactions in peripheral tissue (Constant et al., 2002). Moreover, 
a very recent study demonstrated that T-cell differentiation and activation following 
bleomycin-induced lung injury may occur locally in the lung (Oh et al., 2011). This is 
consistent with reports of infiltration and activation of naïve T-cell in tumours 
(Thompson et al., 2010); such observations raise the intriguing possibility that naïve 
CD4+ T-cell migration, activation and differentiation may additionally occur at sites 
of epithelial injury following interactions with tissue-resident cells. Under such 
circumstances, therefore, one may tentatively hypothesise that TSLP-DCs interact 
with trafficking naïve CD4+ T-cells to induce activation and differentiation into 
effector Th2 cells. Although immunohistochemical analysis of IPF lung does not 
demonstrate a significant infiltration with naïve T-cells, such assessment is limited 
by its inherent snap-shot nature, and is intrinsically unable to offer insights into the 
potential presence of such cells at early stages of disease. The vast majority of 
patients with IPF present to physicians relatively late, when fibrosis is already well-
established and lung function tests demonstrate significant impairment of pulmonary 
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function (King et al., 2001). Further studies are clearly required to explore these 
concepts in this disease setting. 
It is not possible from the data presented in this thesis to draw any conclusions as to 
the site of Th2 cell differentiation following bleomycin-induced lung injury. However, 
one might address this question by examining the phenotype of lung T-cells in this 
model by FTY720 administration. FTY720 is an agonist of sphingosine-1-phosphate 
receptor 1, which selectively inhibits the migration of T-cells from lymph nodes 
(Worbs et al., 2006). If bleomycin-induced T-cell activation and differentiation 
occurred solely in lymph nodes, one would not expect to observe the predominance 
of Th2 cells in the lung following bleomycin challenge in FTY720-treated mice, as 
reported in the current studies. Such studies may be performed in parallel with 
analyses of phenotypes of T-cells derived from the mediastinal lymph nodes of IPF 
patients. In addition, useful insights into the importance of lymph nodes as sites of 
DC-T-cell interactions in the bleomycin model may be further assessed by 
evaluating T-cell phenotypes in lymphotoxin-α knockout mice (+/- splenectomy to 
exclude the spleen as a possible site for DC-T-cell interactions); these mice lack 
lymph nodes and therefore represent a useful tool to determine the importance of 
DC trafficking to lymph nodes for T-cell priming and subsequent differentiation. 
It is important to note that TSLP-DCs co-cultured with naïve CD4 T-cells in a 
syngeneic system do not induce differentiation of these lymphocytes into Th2 cells, 
but rather only promote proliferation (Watanabe et al., 2004). Induction of Th2 
differentiation in vitro is dependent on TSLP-DCs priming naïve T-cells in an 
antigen-specific manner (Soumelis et al., 2002). Thus, the suggestion that TSLP 
plays a role in the pathogenesis of IPF implies the presence of a pathogenic 
antigen. In fact, there is growing evidence that the pathogenicity of T-cells in IPF is 
indeed antigen-dependent. First, the lymphoid aggregates that have been recently 
identified in IPF lung are predominantly composed of recently activated and antigen-
experienced T-cells (Marchal-Somme et al., 2006). Second, as discussed in 
Section 1.6.2., the high proportion of circulating CD28-ve T-cells is extremely 
suggestive of an antigen-dependent T-cell response in IPF (Gilani et al., 2010). 
Third, abnormal CD4+ T cell clonal expansions, representing cellular immune 
responses to antigens, have been demonstrated in both serum and BALF of IPF 
patients (Feghali-Bostwick et al., 2007; Shimizudani et al., 2002). Furthermore, 
protein extracts from IPF lung have been shown to induce the proliferation of 
autologous T-cells in a manner suggesting the presence of an intra-pulmonary 
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antigen capable of activating the immune system. Moreover, repeated cycles of T-
cell stimulation with lung extract at 7 – 10 day intervals results in incrementally 
enhanced proliferation (Feghali-Bostwick et al., 2007), characteristic of responses to 
antigen. 
Is IPF an antigen-driven disease? 
The nature of the antigen(s) that drive(s) T-cell activation, differentiation and 
proliferation in IPF remains unclear. However, there are a number of different 
scenarios which may result in pathogenetic antigen presentation and subsequent 
engagement of the adaptive immune system. First, the source of antigen in IPF may 
be truly foreign and exogenous. The development of hypersensitivity pneumonitis 
(HP), for instance, is dependent on the inhalation of an environmental antigen which 
results in an exaggerated non-allergic immune response leading to alveolar 
inflammation and subsequent fibrosis (Girard et al., 2004). Although considered a 
separate disease to IPF, it is instructive that the histological pattern of UIP is found 
in a significant proportion of patients with chronic HP (Churg et al., 2009), 
suggesting an overlap of pro-fibrotic pathways in these two conditions. Second, the 
acquisition of somatic mutations may result in the expression of altered protein. 
Such proteins would then be regarded as “non-self” by the host with subsequent 
engagement of the adaptive immune response. These mutations may be 
spontaneous or induced by environmental factors. Moreover, an individual may be 
further genetically predisposed to the development of such mutations.  The most 
widely recognised environmental factor linking the development of somatic 
mutations to respiratory disease is cigarette smoking. The acquisition of somatic 
mutations has been proposed to play a role in the pathogenesis of lung cancer and 
COPD (Anderson et al., 2003; Roland et al., 1998). As discussed in Section 1.2., 
cigarette smoking is also a risk factor for the development of IPF (Baumgartner et 
al., 1997). More recently, cigarette smoking has further been shown to exert a 
negative influence on both morbidity and mortality of IPF patients (Antoniou et al., 
2008). Thus, one may postulate that chronic exposure to an environmental agent, 
capable of inducing somatic mutations, may result in the expression of a mutated 
protein that would activate the immune response in a pathological manner. 
Alternatively, environmentally-induced lung injury may result in the accessibility to 
the immune system of normally sequestered self-epitopes to which central and 
peripheral tolerance has never developed. For example, recent studies have 
demonstrated that cigarette smoking induces the release of proteolytic enzymes 
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from innate immune cells, liberating elastin fragments which induce an antigen-
specific immune response (Lee et al., 2007b). The structure of self-proteins may 
also be modified by reactive oxygen species (ROS). The ROS-induced modification 
of amino acids may occur in a number of ways, including the oxidation of sulphydril 
groups on cysteine residues to sulphenic or sulphinic derivatives, inducing protein 
dimerization (Thannickal et al., 2000). Such modification may then create an epitope 
to which the host has not previously developed tolerance, and would therefore 
initiate an adaptive immune response. Cigarette smoke is well recognised to contain 
reactive oxygen species in both the gas and tar phase (Church et al., 1985), which 
may serve to modify the structure of proteins in the lung. Very recent studies have 
demonstrated that chronic oxidative stress, which is associated with increased 
levels of highly reactive carbonyls in the lung, renders self-proteins immunogenic 
through carbonyl modification in COPD (Kirkham et al., 2011). Moreover, numerous 
studies have demonstrated the presence of an increased oxidative burden in IPF 
lung, irrespective of environmental influences (Jack et al., 1996; Montuschi et al., 
1998), characterised by an excess of ROS which overwhelm the host’s natural anti-
oxidant defences, including glutathione (Behr et al., 2002). A similar process may 
therefore occur in IPF; in susceptible individuals, therefore, cigarette smoking may 
initiate activation of the adaptive immune system, resulting in the inappropriate 
maturation of self-reactive T-lymphocytes targeted against previously “hidden” 
antigens. Finally, individuals with IPF may possess an inherent defect in the function 
of regulatory T-cells (Tregs). These cells are critical to the maintenance of self-
tolerance in the periphery (Valencia et al., 2007) and loss of the Treg-mediated 
suppressive effect on the immune system would permit the inappropriate 
presentation of self-peptides to immune cells, resulting in T-cell activation. In 
support of this notion is the recent demonstration of a quantitative and qualitative 
defect in Tregs from IPF patients (Kotsianidis et al., 2009), similar to that found in 
other auto-immune diseases, such as rheumatoid arthritis (Ehrenstein et al., 2004).  
Is IPF an autoimmune disease? 
The concept that IPF may represent an auto-immune disease is also gaining 
strength. The development of auto-immune pathology is ultimately controlled by 
genetic and environmental factors which interact to induce host susceptibility to the 
development of T- and B-cell responses directed against self-peptides.  
The generation of pathogenic auto-antibodies in humans is felt to be T-helper cell-
dependent, reliant on CD40 / CD40L interactions (Sempowski et al., 1997). It has 
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been suggested that T-2 cytokines, derived from Th2 cells, play a dominant role in 
promoting antibody-dependent autoimmune disease (Guo et al., 1999), though this 
is not a universal finding and is likely to vary from organ to organ (Elson et al., 
2000). The role of autoimmunity in the development of fibrosis is currently an area 
of fertile research and is discussed in more detail in Section 1.6.2. Briefly, however, 
a number of different circulating autoantibodies have been detected in IPF patients 
(Taille et al., 2010; Yang et al., 2002), though evidence demonstrating causality are 
lacking. Nonetheless, there remains strong circumstantial evidence in support of a 
role for pathogenic antibodies directed against self-antigen in IPF. Although the 
lymphoid aggregates observed in IPF lung are composed predominantly of antigen-
experienced T-cells, significant B-cell infiltration is also observed, suggesting the 
functional interactions between these lymphocytes relating to antigen-presentation 
(Marchal-Somme et al., 2006). Significant immune-complex deposition has also 
been reported in IPF lung (Magro et al., 2006) and the highly biased TCR β-chain 
variable region (TCRBV) repertoire in IPF T-cells (Feghali-Bostwick et al., 2007) 
supports the notion that the generation of antibodies directed against self-peptides, 
a T-helper cell-dependent process, contributes to the pathogenesis of IPF. The 
capacity for TSLP to induce an expansion in the population of previously activated 
Th2 cells, may therefore potentially promote subsequent T- and B- cell interactions, 
leading to increased pathogenetic autoantibody generation. However, these notions 
remain speculative, and further studies are required to determine whether the 
presence of auto-antibodies in IPF is an epiphenomenon or if they truly contribute to 
disease pathogenesis.  
Much attention has also focused on the potential pathogenetic role of viral infection 
in the development of IPF. A number of viruses have been implicated in this regard, 
including cytomegalovirus (Yonemaru et al., 1997) and hepatitis C (Meliconi et al., 
1996). More recently, members of the herpes virus family (Tang et al., 2003), 
including EBV (Sides et al., 2010; Stewart et al., 1999) and human herpesvirus-6 
(Pulkkinen et al., 2011), have been implicated in the pathogenesis of IPF. In light of 
the growing evidence in support of an auto-immune phenomenon in IPF, it is 
tempting to speculate that the T-cell dependent generation of antibodies generated 
against self-peptide may occur through “molecular mimicry” following viral infection. 
This concept proposes that cross-reactive anti-pathogen antibodies, generated 
following viral infection, bind to self-proteins of the host. These antibody-bound self-
proteins may then be processed by DCs, leading to their activation and subsequent 
functional engagement with T-cells resulting in an oligoclonal expansion of host-
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directed T-cells. Such DC activation in the context of increased expression of TSLP 
following sustained epithelial injury would promote an oligoclonal expansion of Th2 
cells, with potentially pro-fibrotic sequelae. There is growing evidence to support the 
notion that molecular mimicry following EBV infection plays a pathogenetic role in 
the development of auto-immune diseases such as systemic lupus erythematosus, 
a condition associated with interstitial lung disease, in humans (Poole et al., 2006). 
However, one must acknowledge that although a number of antibody targets have 
been identified in IPF (Dobashi et al., 2000; Taille et al., 2010; Yang et al., 2002), no 
cross-reactivity has yet been demonstrated to any proteins derived from viruses 
implicated in the pathogenesis of IPF. Further studies are required to evaluate this 
concept in this disease context. 
It is also important to acknowledge that while the proposed T-cell dependent 
immunopathology outlined herein is antigen-dependent, disease initiation and 
progression may be dependent on exposure of the host to multiple antigens. In this 
regard, molecular mimicry between viral and host antigen may result in the 
generation of autoreactive T-cells without clinical consequence - autoimmunity 
without disease - which reflects the need for a critical number of autoreactive T-cells 
to be generated before disease occurs (Sevilla et al., 2000). In these circumstances, 
activation of DCs by TSLP at sites of epithelial injury could potentially result in DC-
mediated bystander activation of antigen-experienced resident T-cells in the lung, 
resulting in the expansion of an effector population of Th2 cells specific to a historic, 
possibly silent, “priming” antigenic stimulus. It is also plausible that this aberrant 
immunopathology may be further compounded following subsequent viral infections 
by host heterologous immunity mediated by cross-reactive mechanisms, a 
phenomenon previously reported in inflammatory diseases of the lung. For instance, 
acute vaccinia virus (VV) infection of naïve mice results in a severe neutrophilic 
bronchiolitis with a high degree of mortality. In contrast, VV infection of lymphocytic 
choriomeningitis virus (LCMV)-immune mice is associated with increased survival, 
though at the expense of the development of bronchocentric fibrosis, suggesting 
modulation of the immune response, dependent on previous priming events (Chen 
et al., 2001; Chen et al., 2003). Interestingly, polarisation of the immune response 
towards a T-2 phenotype is observed in this model, supporting the notion that 
heterologous immunity may be influenced by the initial skewing of resident memory 
T-cells. These exciting concepts require further evaluation in both murine models of 
lung fibrosis and human disease but may help reconcile a number of seemingly 
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disparate hypotheses regarding the pathogenesis of IPF, including epithelial injury, 
aberrant cytokine phenotypes and viral infections.  
DC-derived chemokines in IPF 
As discussed in Section 1.4.6., TSLP induces the upregulation of OX40L 
expression by DCs to promote the differentiation of inflammatory Th2 cells. In 
addition, TSLP promotes the generation of T-2 chemokines, including CCL17 and 
CCL22 by DCs (Soumelis et al., 2002). These chemokines have previously been 
shown to be important in the pathogenesis of bleomycin-induced fibrosis by 
mediating the recruitment of lymphocytes to the lung following injury (Belperio et al., 
2004). Moreover, CCL17 has also been demonstrated to be a strong 
chemoattractant for CCR4-expressing human Th2 lymphocytes in the context of 
pulmonary inflammation (Katoh et al., 2003). The recruitment of T-cells has been 
demonstrated to be a prerequisite for the transition from an inflammatory response 
to the development of fibrosis in the bleomycin model (Oikonomou et al., 2006). 
Thus, increased expression of TSLP, in response to signals received from an 
injured epithelium, may drive the further recruitment to the lung of immune cells, 
such as lymphocytes, capable of pro-fibrotic T-2 cytokine generation, along DC-
derived chemokine gradients.  
In conclusion, my data, together with current evidence in the literature, has led me 
to propose the hypothesis that in IPF, TSLP-DCs prime T-cells in an antigen-
specific manner to induce their differentiation into effector Th2 cells. Although this is 
likely to occur in locally draining lymph nodes, recent evidence suggests that local 
activation and differentiation may also be important. Moreover, TSLP-DCs may also 
promote an expansion of antigen-experienced Th2 memory cells in situ, thus 
playing a key role in the maintenance and polarisation of Th2 cells at sites of injury. 
The precise nature of the antigen(s) remain(s) unknown though, as has been 
discussed above, there a number of biologically plausible candidates, reflecting both 
exogenous and endogenous sources. Finally, it is tempting to speculate that TSLP 
may further contribute to the pathogenesis of lung fibrosis through the generation of 
DC-derived chemokine gradients, which may serve to amplify the recruitment of 
effector Th2 cells to sites of injury. However, recent evidence suggests that TSLP 
may also act directly on T-cells themselves, and this concept, in the context of lung 
fibrosis, will now be explored.  
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4.3.3. Direct effects of TSLP on T-cells in lung fibrosis 
There is increasing evidence that TSLP may contribute to the development of a T-2 
immune response via direct effects on T-cells (Section 1.4.7.). As well as being 
capable of inducing a programme of differentiation and proliferation of naïve T-cells 
into Th2 cells (Omori et al., 2007; Rochman et al., 2007), TSLP can enhance TCR-
mediated expression of T-2 cytokines by Th2 memory cells (Kitajima et al., 2011). 
The strong TSLPR immunoreactivity for lymphocytes within ectopic lymphoid 
aggregates in IPF lung observed in the current studies is therefore of particular 
interest. The potential importance of T-cells to the pathogenesis of IPF has been 
discussed in Section.1.7. While acknowledging contradictory results in animal 
models, there is increasing circumstantial evidence supporting their pathogenicity in 
human disease (Luzina et al., 2008; Pignatti et al., 2006). Human T-cells have been 
shown to proliferate in response to exposure to TSLP, though this effect is greater in 
activated cells, in comparison to resting lymphocytes (Rochman et al., 2007). This is 
consistent with the notion that TSLP expression is upregulated in an inflammatory 
cytokine milieu which is likely to be associated with T-cell activation. Moreover, T-
cells organised in lymphoid aggregates in IPF lung display an activated phenotype, 
which would render them more susceptible to the effects of TSLP (Marchal-Somme 
et al., 2006). In addition, TSLP induces upregulation of the IL-2Rα receptor chain 
expression in human T-cells, thereby increasing their sensitivity to low 
concentrations of IL-2 (Rochman et al., 2007). This is important since Th2 
differentiation in vitro is dependent on the presence of IL-2, in addition to IL-4 (Cote-
Sierra et al., 2004). Recent evidence suggests that IL-2-induced STAT5 activation is 
critical to maintain accessibility at the DNase hypersensitivity sites of the Il4 locus, 
and this collaboration is required for full Th2 differentiation in vitro (Zhu et al., 2003). 
Thus, a direct effect of TSLP on T-cells to upregulate expression of IL2Rα would 
offer a further mechanism for amplifying the development of a T-2 immune 
response, by increasing their sensitivity to IL-2. The strong TSLPR immunoreactivity 
for lymphocytes is therefore compatible with the hypothesis that TSLP may exert 
direct effects on lymphocytes in the fibrotic lung to induce and maintain a 
functioning Th2 cell population. 
Does TSLP influence Treg function? 
The studies presented in this thesis did not explore the recently proposed concept 
that Tregs may play a role in the pathogenesis of IPF. Analysis of serum and BALF 
specimens from IPF patients revealed a deficit in Treg number and function 
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(Kotsianidis et al., 2009). These cells are critical for the control of immunological 
tolerance, and impairment of their function is associated with the development of 
autoimmune conditions such as rheumatoid arthritis (Chavele et al., 2011), which is 
associated with a UIP histological pattern of lung fibrosis. However, during the 
course of this PhD, in vitro studies demonstrated that TSLP directly impairs the 
immunosuppressive capability of Tregs (Nguyen et al.) and as well as Treg 
development (Lei et al., 2011). One might speculate, therefore, that locally-derived 
TSLP may serve to impair Treg function in the lung, thus attenuating the 
immunosuppressive influence of this sub-population of T cells. Indeed, Tregs 
isolated from IPF lung display a deficit in suppressing T-2 cytokine expression in 
vitro (Kotsianidis et al., 2009), which is consistent with previous studies 
demonstrating that mice deficient in Tregs display increased airway hyper-
responsiveness in models of airway inflammation (Doganci et al., 2005) – this effect 
is reversed, together with suppression of T-2 cytokine expression, by the adoptive 
transfer of Tregs (Kearley et al., 2005). Furthermore, the absence of Tregs has 
been demonstrated to promote a fundamental T-2 bias in mice (Wan et al., 2007) 
suggesting that TSLP-induced defective Treg function may contribute to polarisation 
of the immune response towards a T-2 phenotype by ineffective suppression of 
existing T-cell function. However, the relationship between TSLP and Treg function 
is far from clear, as other groups have reported that TSLP-DCs promote the 
development of Tregs in vitro (Watanabe et al., 2005). It is likely that the influence of 
TSLP on Treg development and/or function is dependent on the presence or 
absence of an associated inflammatory microenvironment, and further studies are 
required to evaluate this relationship in IPF.  
Is there a role for Th17 cells in IPF? 
Th17 cells represent a novel subset of T-lymphocytes which have been 
demonstrated to play a key role in inflammation associated with neutrophil 
infiltration. The Th17 response in the lung has been most extensively investigated 
following infectious injury (Korn et al., 2009), though recent studies have also 
demonstrated its importance in immune cell recruitment following non-infectious 
injury (Lo Re et al., 2010). The prophylactic administration of anti-IL17R antibodies 
attenuates bleomycin-induced fibrosis, reflecting an impairment of immune cell 
recruitment in the first week after injury. Interestingly, these studies also 
demonstrated that differentiation of Th17 cells occurred in the lung following injury, 
and not in local lymph nodes, suggesting the development of a tissue 
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microenvironment conducive to influencing T-cell behaviour in situ (Oh et al., 2011). 
In light of recent evidence suggesting a role for TSLP in the development of such 
cells (Tanaka et al., 2009), one may tentatively speculate that locally recruited T-
cells to sites of injury may be exposed to a Th17-promoting microenvironment 
characterised by increased TSLP expression. Their subsequent differentiation into 
this subset would promote the recruitment of effector cells, such as neutrophils 
during the inflammatory phase of bleomycin-induced injury, the actions of which 
contribute to fibrogenesis (Chua et al., 2007). However, much more work is required 
to draw any firm conclusions regarding the role of this cytokine in Th17 cell 
differentiation, let alone the contribution of this T-cell subset to the pathogenesis of 
lung fibrosis.  
In conclusion, therefore, the data presented in this thesis support the notion TSLP 
may contribute to the pathogenesis of IPF by inducing and maintaining a population 
of effector Th2 cells, capable of elaborating pro-fibrotic T-2 cytokines at sites of 
epithelial injury. Having demonstrated potential human disease relevance for TSLP 
with respect to the pathogenesis of IPF, the potential contributory role of TSLP to 
the development of lung fibrosis was explored in the bleomycin model, and these 
findings will be discussed in Section 4.7. However, the present studies, to the best 
of my knowledge, represent the first to highlight the fibroblast as a potential cellular 
source of this cytokine in the lung, supporting the notion that this cell possesses 
important immunoregulatory functions, and these concepts will now be discussed in 
more detail. 
4.4. TSLP production by structural lung cells in vitro 
As discussed in Section 4.1., strong immunoreactivity for TSLP was observed for 
epithelial cells and fibroblasts in fibrotic lung disease. Immunohistochemical 
techniques do not, however, offer definitive evidence of cellular expression, but 
instead suggest cellular localisation. To corroborate these findings, the expression 
of TSLP by these cell types was evaluated in vitro.  
4.4.1. TSLP expression by alveolar epithelial cells 
Despite strong immunoreactivity for TSLP in the fibrotic human lung, we were 
unable to demonstrate that TSLP was secreted by either A549 epithelial cells or 
primary type II epithelial cells freshly isolated from donor lung. There are several 
potential explanations for these findings. First, our in vitro studies were performed 
using cells derived from non-fibrotic human lung tissue or from young donors with 
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no obvious lung pathology. TSLP immunoreactivity for alveolar epithelial cells in 
control human lung was relatively weak and occasional, in contrast to the strong 
signal observed in fibrotic disease. Therefore, the lack of baseline or inducible 
expression may reflect a change in the transcriptional profile of reparative 
hyperplastic epithelial cells as compared to normal epithelium, reflecting chronic and 
sustained injury. This phenomenon is increasingly recognised in a number of other 
cell types, including mesenchymal cells, and will be discussed in more detail in 
Section 4.4.2. Ideally, TSLP expression would have been further assessed in AECs 
derived from fibrotic lung. However, the preparation of primary type II AECs requires 
a large amount of fibrotic tissue (>150 g), which is much greater than that obtained 
from lung biopsies. One is therefore reliant on explanted lung from IPF patients 
undergoing transplantation, and the relative lack of such patients precluded further 
studies in primary type II alveolar epithelial cells during the course of this PhD. 
Although the lung epithelial cell line, A549, is a useful tool to initiate investigations 
into epithelial cell biology, it cannot be relied on to provide definitive evidence of 
functional and biologically relevant responses. Moreover, A549 cells are well-known 
to display functional variability in in vitro assessments, which may explain the 
discrepancies between the current findings and reports of inducible TSLP 
expression by this cell line (Lee et al., 2007a). In light of these findings, the focus of 
the current studies shifted to evaluate baseline and inducible expression of TSLP by 
primary adult human lung fibroblasts (pHLFs), also identified by 
immunohistochemical techniques as a possible novel cellular source of TSLP in the 
context of IPF as well as other respiratory conditions.  
4.4.2. TSLP expression by primary adult human lung fibroblasts 
Although lung fibroblasts represent a key effector cell common to airway and 
parenchymal lung disease, their ability to express TSLP has, until recently, not been 
formally evaluated. This is in contrast to fibroblasts in other organ pathologies, 
including nasal polyp and synovial fibroblasts. (Koyama et al., 2007; Nonaka et al., 
2010). In addition, a role for fibroblast-derived TSLP has been postulated in the 
development of a GATA-3hi lymphoid infiltrate in pancreatic cancer which is 
associated with a poor prognosis (De Monte et al.).  
The studies presented in this thesis demonstrate that lung fibroblasts are capable of 
elaborating TSLP in response to stimulation with TNF-α in a time- and 
concentration-dependent manner; this is most likely to occur via transcription of the 
long splice variant of the Tslp gene. The potential clinical relevance of TSLP 
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variants is highlighted by studies demonstrating that a single nucleotide 
polymorphism (SNP) in the promoter region of the long splice variant, which is 
associated with enhanced TSLP expression in vitro, (Harada et al., 2009) is 
significantly associated with disease susceptibility in asthma (Harada et al., 2011). 
However, the relationship of this SNP to lung fibrosis has not been examined; such 
studies may offer further insights into the potential importance of this cytokine in the 
pathogenesis if IPF.  
In the present studies, TNF-α was found to induce TSLP expression at both the 
protein and mRNA levels, but the magnitude of the mRNA response was not 
mirrored by such an impressive induction at the protein level. Such discrepancy 
between the abundance of protein and mRNA has been documented previously in 
other systems (Garrison et al., 2010; Ralphe et al., 2005) and represents low 
translational efficiency for this gene. It is possible that TSLP protein synthesis in 
pHLFs is tightly regulated by post-translational protein modification to ensure that 
extracellular functional TSLP concentrations are maintained within a small effective 
window. Elevated levels of circulating TSLP during murine neonatal haematopoiesis 
has been shown to lead to  a significant expansion of B cell precursor populations, 
resulting in a lethal infiltrative B cell lymphoproliferative disorder (Demehri et al., 
2008), suggesting that TSLP may have severe systemic effects at high 
concentrations. Moreover, systemic overexpression of TSLP has also been reported 
to result in a severe global inflammatory response secondary to cryoglobulinaemia 
(Taneda et al., 2001), further highlighting the importance of the need for tight local 
regulation of this cytokine. In addition, this discrepancy may be explained by post-
transcriptional modification of mRNA-binding regulatory factors. In this regard, it is 
possible that interactions between RNA binding proteins and cognate cis-elements 
in untranslated regions of TSLP mRNA may influence the translation of TSLP 
mRNA.  
In summary, the data presented in this thesis support the notion that TNF-α, a 
danger signal reflecting tissue injury, is capable of modulating the nature of the 
immune response by inducing TSLP production by pHLFs. Moreover, they highlight 
the potential for fibroblasts to function in an immunoregulatory capacity, promoting 
the switch from innate to adaptive immunity via elaboration of this key T-2 polarising 
cytokine. There is increasing recognition of the ability of mesenchymal cells to 
influence immune responses, and evidence suggests that such interactions may be 
mediated by direct cell-cell interactions or indirectly, in particular by chemokines. 
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Direct regulation of haematopoietic cells by fibroblasts has previously been reported 
to be mediated by CD40-CD40L interactions (Sempowski et al., 1997). Such a bi-
directional relationship would serve to promote activation of CD40 expressing 
fibroblasts leading to the generation of chemokine gradients, serving to enhance 
further recruitment of immune cells. The generation of such stromally-derived 
chemokine gradients will be discussed in more detail in Section 4.5.1. Importantly, 
recent studies have suggested that chemokines also possess direct immune-
modulatory effects (Luther et al., 2001), and this concept will also be discussed in 
Section 4.5.1. In addition, there exists strong evidence that fibroblasts comprise a 
heterogeneous population, with in vitro functional differences in migratory capacity 
and ECM production dependent on the site of isolation (Fries et al., 1994). In fact, 
such differences appear dependent upon the presence or absence of inflammation. 
Global gene expression studies have demonstrated that the transcriptional profile of 
fibroblasts may be modified by inflammatory stimuli, such as TNF-α, towards a more 
immuno-centric phenotype (Parsonage et al., 2003). For instance, murine lung 
fibroblasts derived from Th2-induced granuloma spontaneously elaborate 
significantly higher quantities of the immunomodulatory chemokine, CCL2, than 
their Th1-derived counterparts (Hogaboam et al., 1999). It has been postulated that 
fibroblasts may be broadly divided into possessing peripheral or lymphoid 
characteristics, and TNF-α seems to promote a more lymphoid transcriptional profile 
(Parsonage et al., 2003). In this regard, it is interesting to reflect on the presence of 
lymphoid aggregates in IPF lung tissue, a condition characterised by increased 
expression of TNF-α. The presence of such tertiary lymphoid tissue (Ruddle, 1999) 
is well described in chronic inflammatory conditions, such as auto-immune thyroid 
disease (Armengol et al., 2003) and rheumatoid arthritis where the continued 
recruitment of inflammatory cells is associated with persistent fibroblast activation 
(Buckley, 2003). Ideally, interactions between recruited immune effector cells and 
stromal cells at sites of injury would ultimately result in resolution of the 
inflammatory response, in part due to the withdrawal of stromally-derived survival or 
chemokine factors (Buckley et al., 2001). An inflammation-induced change in the 
nature of the fibroblast towards a lymphoid phenotype, with associated changes in 
chemokine/adhesion molecule expression, may therefore promote the development 
of stroma more akin to that found in classical lymphoid organs. In turn, this would be 
capable of supporting retained effector lymphocytes within a tertiary lymphoid 
structure, promoting a persistent immune response.  
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4.4.3. Delineation of the signalling pathways involved in TNF-α induced 
TSLP production by pHLFs 
Signal transduction plays a critical role in converting extracellular stimuli into 
appropriate cellular responses. Understanding the mechanisms by which 
extracellular stimuli modify the function of cells not only provides valuable insight 
into the pathogenesis of disease, but may also lead to the identification of novel 
therapeutic targets for pharmacological intervention. A number of tools are available 
to delineate signalling pathways. The present studies employed both 
pharmacological tools and genetic approaches to identify those pathways important 
in mediating TNF-α-induced expression of TSLP in pHLFs.   
During the course of these studies, the potential roles of the transcription factors, 
NFκB and AP-1, as well as members of the MAPK family, were evaluated. Despite 
engagement with their respective targets, as demonstrated by Western blotting, 
inhibitors of NFκB, p38 and ERK1/2 did not exert a concentration-dependent 
attenuation of TNF-α-induced TSLP protein release, enabling the confident 
exclusion of these signalling pathways in mediating this response. Any inhibitory 
effects observed are therefore likely to represent off-target effects of the inhibitors 
used. These findings are in contrast to previous reports demonstrating the 
importance of these pathways in mediating TSLP expression in lung epithelial lines, 
bronchial epithelial cells and HASMCs. However, it is plausible that different 
signalling pathways predominate in different cell types. In contrast, a central role for 
the JNK/c-Jun signalling pathway in mediating TNF-α-induced TSLP expression 
was identified, and these findings will now be discussed in more detail.  
4.4.3.1. Role of JNK pathway 
JNK is a member of the MAPK family and, as discussed in Section 1.4.3.1., only 
JNK1 and JNK2 are relevant to respiratory disease. JNK is the enzyme responsible 
for phosphorylating critical serine residues in the N-terminus of c-Jun, a component 
of AP-1. Pharmacological inhibition of the JNK pathway has been shown to reduce 
the degree of eosinophilic inflammation and airway hyper-responsiveness in a 
murine model of asthma (Nath et al., 2005), and JNK1 knockout (JNK1-/-) mice are 
protected from bleomycin induced lung fibrosis (Alcorn et al., 2009).  
There is good evidence to support a role for AP-1, a major target of JNK, in 
mediating the expression of TSLP (Section 1.4.3.2.). To investigate the role of JNK 
MAPK, and its target transcription factor, AP-1, the effect of two pharmacologically 
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distinct inhibitors of JNK activity, SP600125 and TI-JIP, on TNF-α-induced TSLP 
expression was examined. SP600125 is a reversible ATP competitive inhibitor of 
JNK activity. TI-JIP is a peptide corresponding to the amino acid sequence of the 
JNK interacting protein-1 scaffold protein that potently inhibits JNK activity in a 
manner that is non-competitive for ATP (Barr et al., 2004). In the present studies, 
significant concentration-dependent attenuation of TNF-α-induced TSLP protein 
release was observed using both inhibitors. Moreover, TNF-α-induced increases in 
TSLP mRNA levels are inhibited by SP600125, supporting the notion that Tslp gene 
transcription in pHLFs is dependent on JNK, most likely via activation of AP-1. 
Indeed, TNF-α-induced TSLP protein release was also significantly inhibited in the 
presence of the AP-1 inhibitor, curcumin. However, although pharmacological 
inhibition of signalling pathway components is a useful tool, non-specific effects of 
inhibitors cannot be excluded completely. RNA interference was therefore employed 
to confirm these findings.  
RNA interference (RNAi) is a highly conserved genetic surveillance mechanism 
which permits post-transcriptional down-regulation of target genes in a sequence-
specific manner. Briefly, the RNAi pathway is initiated by Dicer, an 
endoribonuclease which cleaves long dsRNA molecules into short interfering RNA 
molecules (siRNA). This dsRNA may be exogenous, such as viral, or endogenous, 
such as microRNAs (miRNA) which are genomically coded non-coding mRNA 
molecules. It is increasingly recognised that such miRNAs play critical roles in 
organogenesis via post-transcriptional regulation of target gene expression (Stefani 
et al., 2008) and dysregulation of miRNA expression is increasingly implicated in a 
number of disease processes, including IPF (Pandit et al., 2010). Following 
unwinding of the siRNA molecule into 2 single-stranded RNA molecules in an ATP-
dependent manner, the guide strand is then incorporated into a multi-protein RNA-
silencing complex (RISC). This anti-sense guide strand then directs the entire 
complex to an mRNA molecule bearing a complementary sequence, the target 
mRNA, which is subsequently degraded by catalytic components of RISC, thus 
preventing its translation. Such post-transcriptional gene silencing ultimately leads 
to a reduction in the functional levels of target protein levels within the cell.  
Experimental RNAi exploits this mechanism to allow specific knock-down of protein 
expression in cells, enabling their importance to particular pathways to be 
evaluated. However, a significant problem of introducing long dsRNA molecules into 
eukaryotic cells is the initiation of an anti-viral apoptotic pathway, leading to cell 
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loss. This issue may be circumvented by the transfection of siRNA, specific for the 
target mRNA of interest. The introduction of siRNA into cells may be achieved by 
direct transfection or by using plasmid or viral vectors. In the current studies, 
transfection was achieved using a “Gemini reagent”, a kind gift from GSK, which 
has previously been used in the host laboratory to good effect.  
The role of c-Jun in mediating TNF-α-induced TSLP expression was confirmed by 
transfecting pHLFs with siRNA targeted against c-Jun mRNA. Successful knock-
down of c-Jun protein expression, under conditions of TNF-α exposure, was 
confirmed by Western blotting. This knock-down led to a significant inhibition of the 
TNF-α-induced TSLP signal, confirming the importance of the JNK / c-Jun pathway 
in regulating this response. 
During the course of my studies, upregulation of TSLP expression at the protein 
level was reported for normal human lung fibroblasts (NHLFs) following exposure to 
TNF-α (Futamura et al., 2010). This effect was enhanced by β-agonists and c-AMP 
elevating agents and attenuated by steroids in a cAMP-independent manner 
(Futamura et al., 2010). However, the signalling mechanisms underlying TNF-α-
mediated TSLP expression were not further evaluated in these studies. β-agonists 
act on G-protein coupled receptors (GPCRs), a major group of transmembrane 
receptors responsible for detecting extracellular signals. GPCRs, particularly those 
coupled to Gαi and Gαq families of proteins are strongly linked to the activation of 
JNK. GPCRs coupled to Gαs, including the β-agonist receptor, induce the 
generation of cAMP. In an effort to reconcile these observations, it could be 
hypothesized that cAMP positively regulates JNK activity. Indeed, this has 
previously been demonstrated in a number of different cell types (Kanno et al., 
2004; Yamauchi et al., 2001). However, this was not a universal finding, and there 
are reports of JNK activity being inhibited by elevated cAMP levels (Zhang et al., 
2008). Therefore, it is possible that the regulation of JNK activity by cAMP is cell-
specific. 
TNF-α-induced TSLP expression in fibroblasts has also been demonstrated to be 
inhibited by fluticasone (Futamura et al., 2010). Glucocorticoids (GCs), including 
fluticasone, exert the vast majority of their actions by binding to intracellular 
glucocorticoid receptors (GRs). The most well-described mechanism through which 
they influence gene transcription is via the bindings of these receptors to responsive 
elements in the regulatory sequences of target genes. However, cross-talk between 
GRs and other transcription factors is also recognised, and GR antagonism of NFκB 
 Chapter 4: Discussion 
237 
 
and AP-1 is thought to underlie the anti-inflammatory actions of steroids (Herrlich, 
2001). GRs may interfere with AP-1 directly, preventing effective interactions 
between AP-1 and the transcriptional machinery. However, GCs have also been 
demonstrated to repress AP-1-mediated transcription of genes by inhibiting 
phosphorylation of JNK (Bruna et al., 2003). Thus inhibition of TNF-α-induced TSLP 
expression in fibroblasts by glucocorticoids is consistent with their known ability to 
inhibit AP-1 activity. These observations are therefore compatible with the present 
studies highlighting the importance of the JNK / AP-1 signalling pathway in 
mediating the expression of TSLP in pHLFs. 
4.5. pHLFs express a functional TSLP receptor signalling 
axis 
As discussed in Section 4.2., the current studies demonstrated immunolocalisation 
of TSLPR to fibroblasts in both murine and human fibrotic lung, suggesting that this 
cell type may represent a novel cellular target for TSLP. These findings are 
consistent with studies published during the course of this thesis which showed that 
mesenchymal cells, such as human airway smooth muscle cells, also express a 
functional TSLP receptor (Shan et al., 2010). The expression of both components of 
the TSLP receptor was therefore confirmed at both the mRNA and protein level in 
pHLFs before functionality was examined in vitro. In light of the increasing 
importance attached to the generation of stromally-derived chemokine gradients in 
inflammatory disease, chemokine expression by pHLFs following exposure to TSLP 
was evaluated. These studies demonstrated that TSLP upregulates the expression 
of CCL2 in pHLFs in a time- and concentration-dependent manner. The implications 
of these observations will now be discussed.  
4.5.1. TSLP induces the expression of CCL2 in pHLFs 
CCL2 is a member of the CC chemokine family with a wide range of cellular sources 
including lung fibroblasts (Deng et al., 2008). There is strong evidence suggesting a 
pathogenic role for this chemokine in lung fibrosis via a number of potential 
mechanisms. First, CCL2 is a potent chemoattractant for immune cells, including T-
cells and dendritic cells (Carr et al., 1994; Xu et al., 1996). The present studies 
showed that TSLP is capable of inducing chemotaxis of immune cells in a CCL2-
dependent manner, suggesting that TSLP may represent an important mediator of 
immune cell trafficking. In fact, the expression of chemokines by structural cells is 
key to effective DC trafficking murine lung. In particular, the interstitial location of 
fibroblasts suggests that, in addition to matrix deposition, they may serve to 
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influence immune cell migration out of the vasculature. Very recent studies have 
demonstrated the importance of fibroblast-derived CCL2 in mediating DC trafficking 
in lung inflammation in vivo (Kitamura et al., 2011). Moreover, fibroblasts exposed to 
TNF-α are capable of promoting DC migration in vitro via the generation of 
secondary mediators (Saalbach et al., 2010), suggesting that these cells are 
capable of actively participating in the development of an immune response at sites 
of injury. This generation of a stromally-derived chemokine gradient is increasingly 
recognised as crucial to the accumulation, differentiation and survival of immune 
cells in non-lymphoid organs (Buckley et al., 2001). Conversely, withdrawal of such 
signals has been postulated to be important in the resolution of inflammation. 
Increased expression of chemokines, including CCL19, CCL22 and CXCL12 has 
been reported in IPF lung, localising to fibroblasts and epithelial cells. CCL19, in 
particular, has been reported to be an important chemoattractant for DCs (Scandella 
et al., 2004), while the major function of CCL22 is to promote recruitment of 
activated T-cells, particularly Th2 cells (Andrew et al., 1998). CXCL12, on the other 
hand, is important for the successful trans-endothelial migration of DCs (de la Rosa 
et al., 2003). The close structural proximity of immune cells to stromal cells 
expressing these chemokines in IPF is suggestive of a functional interaction, as is 
found in chronic inflammatory conditions, such as rheumatoid arthritis. These 
conditions are characterised by the persistent recruitment of immune cells ultimately 
resulting in the development of tertiary lymphoid structures within a stable but 
disordered matrix, such as has been recently reported in IPF (Marchal-Somme et 
al., 2006). The present findings suggest an additional novel role for TSLP in the 
generation of stromally-derived chemokine, particularly CCL2, serving to attract 
effector immune cells, such as monocytes/macrophages, to sites of injury. Further in 
vitro studies are required to examine the role of TSLP in promoting T-cell and DC 
chemotaxis: subsequent functional interactions between these cell types, in the 
presence of fibroblast-derived TSLP, would serve to promote a local T-2 dominated 
cytokine milieu. It must be noted, however, that conditioned media from pHLFs 
exposed to TSLP retained some chemotactic properties for human monocytes 
despite neutralisation of CCL2. These data suggest the elaboration of further 
chemokines by pHLFs in response to stimulation with TSLP. The current work 
attempted to identify the nature of these additional mediators using the MSD 
platform to examine TSLP-induced chemokine protein release. However, this was 
not fruitful and requires further studies.  
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As suggested above, the mechanisms by which CCL2 promotes fibrosis are likely to 
extend beyond its chemoattractant properties and include upregulation of TGF-β 
expression and possibly that of the IL-13 receptor chain IL-13Rα1/2 by fibroblasts 
(Gharaee-Kermani et al., 1996; Murray et al., 2008). In light of the current findings, I 
would propose that TSLP may represent an alternative mediator of CCL2 
expression in pHLFs, which would serve to promote the fibrotic response.  
In addition to the effects described above, it is increasingly recognised that 
chemokines possesses important immunoregulatory capabilities, including the 
regulation of T-cell differentiation. Exposure of T-cells to CCL2 in vitro results in 
increased T-2 cytokine expression (Karpus et al., 1997), an effect which is 
enhanced in recently-activated or memory T-cells. This is consistent with the 
observation that CCR2 is not expressed by naïve T-cells, but rather on recently 
activated CD4+ cells (Loetscher et al., 1996; Qin et al., 1996). As previously 
discussed, the majority of T-cells organised within lymphoid aggregates in IPF 
display an activated phenotype, thus rendering them susceptible to further 
modulation by CCL2. In addition, neutralisation of fibroblast-derived CCL2 has been 
shown to attenuate CD4+ IL-4 production, with a concomitant increase in IFNγ 
expression (Hogaboam et al., 1998), suggesting that CCL2 is capable of modulating 
CD4+ T-cell behaviour directly. However, CCL2 may promote the development of 
Th2 cells via the generation of a Th2-permissive milieu, much like the effects of 
TSLP on DCs. The differentiation of Th2 cells requires an IL-12lo microenvironment, 
and CCL2 has been demonstrated to downregulate the expression of this T-1 
polarising cytokine by activated monocytes in vitro (Chensue et al., 1996). These in 
vitro findings have been translated to animal models of disease, where CCL2 knock-
out mice are unable to mount a protective T-2 immune response to Leishmania 
major infection, despite normal lymphocyte trafficking (Gu et al., 2000).  
4.5.2. TSLP-induced CCL2 expression in pHLFs is STAT3-dependent 
The present studies identified STAT3 as the major signalling pathway involved in 
mediating CCL2 expression in pHLFs exposed to TSLP. Critical to STAT activation 
is the dimerization of two STAT monomers. This dimerization is dependent upon the 
binding of the -SH2 domain of one monomer to a Pro-pTyr-Leu-Lys-Thr-Lys 
sequence on the complementary monomer. However, prior to this, STAT monomers 
must bind to tyrosine motifs on the receptor which have been phosphorylated by 
receptor-associated JAKs. S3I-201 is a non-peptide small molecule which targets 
the -SH2 domain and prevents STAT3 from binding to the pTyr residues of the 
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receptor, thus blocking de novo phosphorylation by receptor-associated JAKs 
(Siddiquee et al., 2007). The relatively high concentrations of S3I-201 used in the 
current studies is comparable to previous reports (Pang et al., 2010). Nonetheless, 
it was important to confirm the role of STAT3 in mediating TSLP-induced CCL2 
expression using a genetic approach. These studies showed that knockdown of 
STAT3 expression using siRNA attenuated TSLP-induced CCL2 expression. 
The current findings are consistent with very recent reports published during the 
course of these PhD studies showing that ligation of the TSLP receptor also results 
in STAT3 activation in other mesenchymal cells, such as airway smooth muscle 
cells, with subsequent upregulation of chemokine expression (Shan et al., 2010). 
Activation of STAT5 has also been implicated in mediating the cellular effects of 
TSLP in haematopoietic cells (Isaksen et al., 1999). However, STAT5 was not found 
to be phosphorylated in pHLFs following TSLP exposure. These differences in 
STAT phosphorylation may reflect mesenchymal cell-specific signalling events 
downstream of TSLP receptor ligation, as TSLP does not induce STAT5 
phosphorylation in HASMCs either (Shan et al., 2010).The present reported findings 
are also consistent with previous observations demonstrating that STAT3 activation 
is important in mediating CCL2 expression in a variety of cell types (Kujawski et al., 
2008; Lee et al., 2011; Schroer et al., 2011). Moreover, using a combination of 
oligonucleotide gene arrays and qRT-PCR, a group of genes involved in chemotaxis 
and wound healing has recently been identified whose transcription is mediated by 
STAT3, including CCL2 (Dauer et al., 2005).  
In conclusion, the findings discussed in this section show for the first time that lung 
fibroblasts are capable of responding to TSLP, further highlighting the potential 
immunoregulatory importance of these cells. It is tempting to speculate that TSLP 
acts in an autocrine manner on fibroblasts to upregulate CCL2 expression, and that 
aside from its pro-fibrotic effects, CCL2 might promote the recruitment of dendritic 
cells and T-cells, in addition to macrophages. The well-described T-2 promoting 
properties of TSLP may then be further amplified by the immunomodulatory effects 
of CCL2 on recruited naïve, recently activated and/or memory T-cells. However, it is 
clear that additional work is required to definitively assign a mechanistic role for 
TSLP-induced CCL2, derived from lung fibroblasts, in fibroproliferative lung disease.  
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4.6. Role of TSLP in modulating innate and adaptive 
immune cell populations following bleomycin-
induced lung injury 
The role of TSLP in the development of atopic lung disease is well described (Zhou 
et al., 2005). Such conditions are characterised by increased expression of T-2 
cytokines. However, such an immune phenotype is not exclusive to atopic disease 
and may develop in the absence of allergy.  This aspect of TSLP biology has not 
previously been examined in the lung, and so the next logical step of this research 
study was to explore the functional role of this cytokine in an animal model of 
fibrosis. As discussed in Section 1.3.1., the bleomycin model of lung injury was 
chosen for these exploratory studies. 
4.6.1. TSLP mediates bleomycin-induced dendritic cell activation but 
not recruitment to the lung 
A central theme of this thesis has been that, following epithelial injury, activation of 
dendritic cells by TSLP promotes a pro-fibrotic immune response. The data 
discussed in Section 4.1. established potential human disease relevance for this 
hypothesis by demonstrating increased TSLP immunoreactivity for cells in close 
proximity to dendritic cells, a major cellular target for this cytokine. During the 
course of this PhD, bleomycin-induced lung injury was reported to lead to an 
accumulation of dendritic cells and increased local expression of DC-attracting 
chemokines, including CCL2 (Bantsimba-Malanda et al., 2010). Further analysis of 
these lung DCs revealed that they were of a mature and activated phenotype, as 
evidenced by increased cell surface expression of CD86. The nature of bleomycin-
induced lung injury is felt to reflect DNA scission in epithelial cells (Harrison et al., 
1989), with subsequent apoptosis. This change in alveolar epithelial cell phenotype 
is well recognised in IFP (Kuwano et al., 1996). These observations are compatible 
with the notion that dendritic cells may be activated by danger signals as previously 
discussed in Section 4.3.2. Such signals, for example uric acid and eATP which 
have both been implicated in the pathogenesis of IPF (Gasse et al., 2009; Riteau et 
al., 2010)., may be directly released from injured cells. However, DC maturation 
may also be mediated by heparin sulphate proteoglycans, which are important 
mediators of fibroblast-matrix interactions (Johnson et al., 2002). The mediators of 
DC activation following bleomycin-induced lung injury, however, remain unknown. In 
light of the T-2 polarising phenotype of TSLP-DCs, and the evidence that this model 
is associated with a T-2 immune response, this PhD examined the hypothesis that 
lung DC activation following bleomycin challenge is mediated by TSLP.  
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In the first instance, the present studies demonstrated that lung injury initiated by a 
single instillation of bleomycin via the oropharyngeal route results in an 
accumulation of lung DCs which continues into the fibrotic phase of this model. 
These observations are consistent with previous reports that local expression of 
chemokines known to attract DCs, including CCL19 and CXCL12 (de la Rosa et al., 
2003; Scandella et al., 2004) is upregulated from day 14 post bleomycin challenge. 
Moreover, they are compatible with the presence of both immature and mature DCs 
in IPF lung, suggesting continued recruitment in the presence of established fibrosis 
(Marchal-Somme et al., 2007b; Marchal-Somme et al., 2006). 
I next examined the role of TSLP in promoting DC recruitment in response to 
bleomycin-induced lung injury, using a neutralising anti-TSLP antibody (a kind gift 
from GSK). Previous animal studies designed to examine the role of TSLP in 
inflammatory lung disease have employed a variety of techniques, including the use 
of Tslpr -/- mice (Zhou et al., 2005) and the administration of a blocking anti-TSLPR 
(Shi et al., 2008) or neutralising anti-TSLP antibody (Li et al., 2010). For the current 
studies, antibody-mediated neutralisation was chosen to block TSLP signalling in 
vivo, since we did not have access to Tslp or Tslpr -/- mice and were moreover keen 
to avoid the potential development of compensatory immune mechanisms 
associated with knock-out mice. The dosing regime and route of administration of 
the anti-TSLP antibody, 28F12, was based on detailed pharmacokinetic data 
provided by GSK. Serum samples were taken from mice during the evolution of the 
bleomycin response to assay antibody concentrations. The efficacy of 28F12 in 
neutralising TSLP activity in vitro was also examined prior to the in vivo studies. A 
concentration-dependent inhibition of TSLP-induced CCL2 protein release by 
primary murine lung fibroblasts (pMLFs) was observed in vitro, with complete 
inhibition of the CCL2 signal observed at a concentration of 30 ng/ml. Serum 
concentrations of 28F12 achieved with the outlined dosing schedule were in the 
range of 100 µg/ml  (data presented in Appendix A1). These data provided a high 
degree of confidence that adequate neutralisation of TSLP activity could be 
achieved. 
The chemoattractive properties of TSLP have not been extensively studied. DC 
migration involves a complex interplay between cell-intrinsic and extrinsic factors. 
Current evidence suggests that danger signals may induce the upregulation of 
chemokine receptors on DCs, which are then more receptive to chemokine 
gradients generated within inflamed tissue [reviewed in (Banchereau et al., 2000)]. 
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During the course of this PhD, TSLP was reported to act as a DC chemoattractant 
in vitro (Fernandez et al., 2011). These findings support a previous observation that 
anti-TSLPR administration in a murine model of asthma is associated with reduced 
recruitment of DCs to airways (Shi et al., 2008). In the present studies, 
neutralisation of TSLP activity did not inhibit the bleomycin-induced accumulation of 
DCs at day 10 or 28 following lung injury. One plausible explanation to reconcile 
these findings might be that the role of TSLP as a DC chemoattractant is injury- and 
context-dependent. In the bleomycin model, DC chemotaxis may be governed by 
the generation of TSLP-independent chemokine gradients, in contrast to airway 
disease. Furthermore, it is possible that TSLP-dependent chemotaxis is important 
for DC migration to lymph nodes, rather than directly from the vasculature to the 
lung parenchyma, as has been postulated to occur in the bleomycin-induced lung 
injury and in IPF (Bantsimba-Malanda et al., 2010; Marchal-Somme et al., 2007b).  
The current studies confirmed that bleomycin-induced injury is associated with a 
higher proportion of lung DCs exhibiting an activated phenotype (CD86+) at day 10 
post-injury. In contrast, this model of lung injury is not associated with splenic DC 
activation suggesting that bleomycin challenge is not associated with a systemic 
immune response, but rather one which is limited to the site of epithelial injury. The 
observation that lung DC activation following bleomycin-induced lung injury is 
inhibited in mice administered an anti-TSLP antibody provides strong proof-of-
concept that TSLP plays a non-redundant role in mediating local DC maturation 
during the inflammatory phase of this non-allergen driven model of lung injury. 
These findings, therefore, extend the role of TSLP as a signal for DC activation to 
inflammatory conditions beyond allergen-driven inflammation, and identify for the 
first time a mediator involved in DC activation in the bleomycin model. As discussed 
in Section 1.4.5., activation of DCs is critical to their subsequent interactions with T-
cells. The upregulation of co-stimulatory cell surface proteins, such as CD86, are 
critical for the activation and differentiation of naïve T-cells into Th2 cells (van Rijt et 
al., 2004). Indeed, blocking CD86 co-stimulation inhibits reactivation of Th2 memory 
cells in vivo (Keane-Myers et al., 1997). Given the importance of CD86-expressing 
DCs in T-2 polarisation, and in light of the additional unique T-2 polarising 
capabilities of TSLP-DCs, it is tempting to speculate that inhibition of TSLP-induced 
DC activation would inhibit the development of a T-2 immune response in this 
model. This inhibition may be further compounded by the prevention of direct effects 
of TSLP on naïve or memory T-cells.  
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In contrast, it is not currently possible to draw any conclusions regarding the role of 
TSLP in promoting DC maturation during the fibrotic phase of this model (14-28 
days post injury). By this time point, the vast majority of lung DCs examined in all 
mouse groups were CD86+, with no discernible differences observed between the 
saline-treated and bleomycin-challenged mice. Over the course of 28 days, each 
mouse received 8 doses of rat IgG, in contrast to 3 doses during the course of 10 
days. The apparent global activation of DCs seen in all groups of mice receiving 
such dosing may reflect an effect of the interventional rat IgG, in inducing DC 
maturation. Although, the rat antibodies used in the current studies were designed 
to be minimally immunogenic in mice, they nonetheless represent foreign protein, 
and therefore may induce a humoral immune response. DCs are well recognised to 
express receptors for the Fc domain of immunoglobulins, including FcγR (Sallusto 
et al., 1994), which binds IgG. Moreover, previous studies have demonstrated that 
FcγR-mediated internalisation of immune complexes by DCs, consisting of 
circulating antibody bound to foreign antigen, is associated with DC activation 
(Regnault et al., 1999). The generation of murine IgG to foreign antigen has been 
demonstrated to occur within 1-2 weeks following antigen exposure (Wang et al., 
2000). It is therefore possible that, over the course of 28 days, the mice may have 
mounted an IgG response to the dosed antibody. The resultant immune complexes, 
consisting of murine IgG bound to rat IgG, may then have activated murine DCs via 
FcγRs, resulting in the observed widespread DC maturation, as evaluated by CD86 
expression, in all experimental groups, regardless of the specificity of the rat IgG.  
OX40L expression by DCs was also assessed at day 28 following bleomycin 
challenge or saline treatment. OX40L is not expressed by immature or quiescent 
DCs, but is upregulated following activation (Redmond et al., 2009). The mediators 
and mechanisms regulating OX40L expression by DCs remain poorly defined. TSLP 
represents the only known cytokine capable of upregulating DC OX40L expression, 
though ligation of CD40 receptor on DCs by its cognate ligand, CD40L, expressed 
by activated T-cells, has been reported to result in increased OX40L expression 
(Ohshima et al., 1997). The present observation of high OX40L expression in all 
experimental groups, including saline, again suggests an effect mediated by the 
administration of rat IgG, over a prolonged dosing schedule, which has resulted in 
widespread DC activation. However, given that TSLP has recently been identified 
as a key inducer of OX40L expression by DCs, the reduction in the proportion of 
OX40L+ DCs in mice receiving anti-TSLP antibody potentially suggests successful 
target engagement in this model. Despite this, however, no reduction in CD86 
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expression was observed in mice receiving anti-TSLP antibody. This may be 
explained by the presence of multiple inducers of CD86 expression during this 
phase of lung remodelling, which may include other danger signals, including uric 
acid and eATP, or endogenous proteins rendered immunogenic following lung 
injury. Further studies are required to conclusively demonstrate that DC activation 
following bleomycin-induced lung injury is maintained during later time points, and 
furthermore, to identify possible candidates responsible for such activation.  
In summary, although the present studies demonstrate the importance of TSLP in 
mediating bleomycin-induced DC activation during the inflammatory phase of this 
model, it is currently not possible to draw similar conclusions regarding the role of 
TSLP in DC activation during the later fibrotic phase of this model. 
4.6.2. TSLP mediates bleomycin-induced polarisation of the immune 
response towards a T-2 phenotype 
There is strong evidence that bleomycin-induced lung injury results in polarisation of 
the immune response towards a T-2 phenotype and targeting this polarisation 
attenuates bleomycin-induced lung fibrosis (Belperio et al., 2002). Although 
numerous studies have demonstrated the importance of T-cells to the pathogenesis 
of experimentally-induced fibrosis, these findings are not universal (Helene et al., 
1999; Piguet et al., 1989). However, a recent study demonstrated that mice deficient 
in Nrf2, a key transcriptional regulator of cellular anti-oxidant defences, developed 
worse fibrosis following bleomycin-induced lung injury than their wild-type controls - 
this effect was associated with an increase in lung Th2 cells (Kikuchi et al.). 
Induction of a Th2 bias in mice overexpressing GATA-3, the master Th2 
transcription factor, was also associated with a worsening of experimentally-induced 
fibrosis (Kimura et al., 2006). Nonetheless, polarisation of T-cell subsets into Th1 or 
Th2 phenotypes has not been extensively evaluated in these models. Although 
human studies have hinted at a polarisation of T-cell subsets in IPF towards a T-2 
phenotype (Pignatti et al., 2006), a causal relationship between Th2 cells and lung 
fibrogenesis remains to be established. 
To the best of my knowledge, the findings from the current studies demonstrate for 
the first time clear polarisation of the T-helper population towards a T-2 phenotype 
following bleomycin-induced injury. This response is observed during both the 
inflammatory and fibrotic phases of this model. The observed polarisation is local 
and limited to the lung, as no such differences were observed in splenic T-cells of 
injured mice and importantly was TSLP-dependent. As described in Section 4.6.1., 
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the majority of DCs expressed OX40L in both saline-treated and bleomycin-
challenged mouse groups. However, only bleomycin-challenged mice demonstrated 
an accumulation of Th2 cells in the lung. Despite the importance of OX40L-
expressing DCs in inducing Th2 cell differentiation, these findings may be 
reconciled considering the antigen-specific nature of this interaction. As discussed 
in Section 4.3.2., it is possible that bleomycin-induced lung injury induces 
accessibility of previously sequestered cellular antigen. Only under these 
circumstances would TSLP-DCs, expressing OX40L, be in a position to induce a 
programme of Th2 differentiation. In contrast, the immunogenicity of mice receiving 
saline treatment is likely to be unchanged and thus OX40L-expressing DCs in this 
scenario would be unable to induce T-2 polarisation.  
These data further, therefore, highlight for the first time the importance of TSLP in 
the development of a T-2 immune response in the context of non-allergen driven 
lung disease. As has been discussed previously, TSLP may promote expansion and 
differentiation of Th2 cells indirectly, via DCs, or via direct actions on naïve or 
memory T-cells.  At the current time, it is not possible to determine which pathway 
predominates in this model. The observation that inhibition of TSLP activity in vivo is 
associated with a concomitant reduction in the proportion of activated DCs at day 10 
post bleomycin-induced injury suggests that TSLP-DCs are at least in part involved 
in directing the local T-helper response. This issue will be further explored in 
Section 4.9.1. 
 Although bleomycin challenge induced a TSLP-dependent increase in the 
proportion of Th2 CD4+ cells, no changes were observed in the total TCRβ+ T-cell, 
nor the total CD4 or CD8 cell populations. This is in contrast to previous studies 
demonstrating an increase in lung T-cells following bleomycin challenge (Zhu et al., 
1996) . This discrepancy may be explained by the fact that in the present study, T-
cells were assessed in whole lung homogenates, in contrast to BALF specimens 
used in previous studies. The use of BALF specimens circumvents the problem of 
contamination of samples by circulating T-cells derived from the vasculature at the 
time of harvest, but do not permit analysis of effector T-cells organised within 
aggregates in areas of fibrotic lung parenchyma, as found in fibrotic lung. Moreover, 
the cellular yield is much lower, which limits the extent of FACS analysis. In the 
current studies, each mouse lung was used for the preparation of cells for positive 
and negative controls, as well as for both DC and T-cell analysis. Moreover, cell 
loss following stimulation of cells with PMA and ionomycin was a major issue during 
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the course of these experiments. Lung perfusion via the pulmonary vasculature is 
often used to enable the generation of single cell suspensions from lung 
homogenates which are not contaminated by vascular-derived cells. However, the 
pattern of lung damage following bleomycin-induced injury makes it highly unlikely 
that any lung perfusion would be uniform and consistent. In view of the requirement 
of sufficient cell numbers to analyse Th1 and Th2 cell populations, as well as DCs, 
single cell preparations were generated from non-perfused lung homogenates as 
described in Materials and Methods.  
 
In summary, the present studies demonstrate for the first time that bleomycin-
induced lung injury is associated with a polarisation of the T-helper population 
during the inflammatory phase, which is maintained during the fibrotic phase of this 
model. Moreover, they provide evidence for a role for TSLP as a master switch for 
the development of T-2 immune responses beyond allergic inflammation. In light of 
the strong evidence suggesting that the development of such responses is 
associated with the development of fibrosis, the effect of redressing this polarisation 
of T-helper cells on the development of lung fibrosis following bleomycin-induced 
lung injury will now be discussed.  
4.7. The role of TSLP in the pathogenesis of bleomycin-
induced lung fibrosis 
The present studies have identified lung fibroblasts as a potential source of TSLP 
and cellular target in both IPF and bleomycin-induced lung fibrosis. As discussed in 
Section 4.3., there are multiple pathways via which TSLP may play a role in the 
pathogenesis of lung fibrosis. In particular, the current findings demonstrate that 
neutralisation of TSLP activity abrogates bleomycin-induced T-2 polarisation of T-
helper cells, thereby inhibiting the development of a key cellular source of T-2 
cytokines. In light of the strong evidence suggesting that the development of lung 
fibrosis is dependent, to a greater or lesser degree, on the expression of such pro-
fibrotic T-2 cytokines (Belperio et al., 2002), I hypothesised that this abrogation 
would be associated with an attenuation in bleomycin-induced lung fibrosis in mice. 
The results described in Section 3.4.7. will now be discussed in more detail.  
4.7.1. The effect of 28F12 administration on bleomycin-induced lung f
 fibrosis 
Contrary to our expectations, neutralisation of TSLP activity in vivo, despite 
reducing the presence of Th2 cells in the lung, was not associated with an 
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attenuation in bleomycin-induced lung fibrosis, as assessed by total lung collagen at 
days 14 or 28 (Section 3.4.7.). These observations suggest that TSLP does not 
contribute to lung collagen accumulation in this model. However, it is important to 
interpret these findings with a degree of caution as these data may be confounded 
by the overwhelming activation of DCs seen in the context of repeated antibody 
dosing over 28 days. Aside from inducing T-cell differentiation and proliferation, 
activated DCs may potentially contribute to the development of fibrosis by 
alternative mechanisms, including the generation of chemokine gradients (Section 
4.3.2.). However, if these data do represent a true negative result, they are 
unexpected for a number of reasons. T-2 cytokine activity has previously been 
demonstrated to be required for the development of bleomycin-induced fibrosis in 
vivo (Belperio et al., 2002), and the downstream effects of TSLP have been shown 
to be mediated by these cytokines (Zhou et al., 2008). Moreover, both IL-4 and IL-
13 have been shown to exert strong pro-fibrotic effects in vitro (Saito et al., 2003). 
Reducing the predominance of Th2 cells in the lung by neutralising TSLP activity in 
vivo may therefore have been expected to reduce the local elaboration of such pro-
fibrotic cytokines. 
The lack of protection afforded by the administration of 28F12 from bleomycin-
induced fibrosis, despite apparent successful engagement with TSLP, may have a 
number of explanations. First, it is possible that in this particular model, the 
development of lung fibrosis is independent of the phenotype of the immune 
response. Previous studies targeting T-2 cytokine activity have been performed in 
mice administered bleomycin via the intra-tracheal (i.t.) route (Belperio et al., 2002; 
Jakubzick et al., 2003), rather than via the oro-pharyngeal (o.p.) route employed in 
the current studies. Although bleomycin is administered via the airways in both 
models, it is clear that the pattern of fibrosis is different. Following a surgical 
procedure, i.t. administration results in a more bronchocentric pattern of lung 
fibrosis, in contrast to the more peripheral and sub-pleural pattern observed 
following o.p. challenge, which does not involve surgical trauma to the airway. The 
o.p. model was chosen for the current studies, as the pattern of fibrosis was felt to 
more faithfully mirror that found in human IPF. However, the spatial and temporal 
heterogeneity of IPF is critical to its diagnosis, and different geographical patterns of 
fibrosis in humans often reflect different underlying pathogenetic mechanisms, 
including the relative predominance of immune responses. This concept may be 
translated back to murine models of disease, and reflects an inherent issue of 
generating meaningful comparisons between different studies. For instance, 
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depending on the route of administration, bleomycin-induced lung fibrosis has been 
reported to either completely resolve by 6 weeks or be maintained at 6 months 
following injury (Scotton et al., 2010). These differences are profound and are likely 
to reflect the predominance of certain molecular pathways in different versions of 
the “same model”.  
In addition, the difficulty in comparing data from different studies is further 
compounded by variations in dose, mouse strain and measurements of fibrosis 
outcomes. Previous studies demonstrating an attenuation in bleomycin-induced 
fibrosis following interference in T-2 cytokine signalling have employed CBA/J mice 
(Belperio et al., 2002; Jakubzick et al., 2003), in contrast to the present studies 
which employed C57Bl/6 mice challenged with bleomycin. These mice were chosen 
for the present studies in light of their well-characterised response to bleomycin in 
the host laboratory. However, significant differences in the immune responses in 
these two strains have been reported in models where the nature of the immune 
response is arguably more directly related to the pathogenesis of the target 
condition, for instance in infection models. For example, mice of a C57Bl 
background generate significantly lower quantities of IL-4 than CBA/J mice following 
Leishmania infection (Rosas et al., 2005). In addition, C57Bl mice are relatively 
resistant to infection with Mycobacterial tuberculosis, a characteristic related in part 
to differential expression of IL-10, an important immunomodulatory cytokine (Turner 
et al., 2001). Further differences between mouse strains which may have impacted 
on the present studies, include variability in T-cell recruitment and maintenance in 
the lung (Chackerian et al., 2003), and strain-dependent differences in DCs have 
also been reported to influence CD4+ T-cell polarisation (Filippi et al., 2003).  
In the current studies, lung collagen was assessed by measuring hydroxyproline 
content in lung powder by reverse-phase HPLC. Previous studies evaluating the 
importance of T-2 immune responses have utilised colometric assays to measure 
collagen (Belperio et al., 2002). A major issue with such assays is that they 
measure only soluble collagen, in contrast to HPLC which takes into account 
insoluble collagen, arguably a more biologically relevant readout in the context of 
fibrotic lung disease. Ongoing studies within the host laboratory have revealed that 
these two read-outs do not necessarily correlate over the time course of the 
bleomycin model (Scotton et al., manuscript in preparation). Thus, it is apparent that 
there a number of reasons, both operator-dependent and -independent, which may 
potentially explain the differences between the current studies and previous reports 
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highlighting the importance of a T-2 immune response in the pathogenesis of 
bleomycin-induced fibrosis.  
Alternative cellular sources of T-2 cytokines may also explain the lack of protection 
afforded by reducing the predominance of Th2 cells in this model. IL-13 was 
originally described as a T-cell derived cytokine (Minty et al., 1993), though it is now 
well recognised that other cells are capable of generating IL-13, including mast cells 
(Toru et al., 1998), basophils (Li et al., 1996), eosinophils (Schmid-Grendelmeier et 
al., 2002), macrophages (Hancock et al., 1998) and epithelial cells (Allahverdian et 
al., 2008). More recently, a novel innate leukocyte effector cell, termed a nuocyte 
(Neill et al., 2011), has been described as an important cellular source of this 
cytokine. It is possible that in the pathogenesis of lung fibrosis, Th2 cells are not the 
predominant source of T-2 cytokines. The predominant cellular source of T-2 
cytokines in this model may therefore include cells whose expression of these 
cytokines is not ultimately regulated by TSLP. Of these, no pathogenetic role for 
nuocytes has yet been suggested in the development of lung fibrosis. The 
importance ascribed to the macrophage in lung fibrogenesis has waxed and waned 
over recent years, though there is now renewed interest in this effector cell in IPF 
(Baran et al., 2007; Prasse et al., 2006). In addition, it has been proposed that the 
macrophage represents a major cellular source of TGF-β in experimentally-induced 
fibrosis (Khalil et al., 1989). In particular, alternatively activated macrophages, a 
phenotype preferentially induced by T-2 cytokines (Stein et al., 1992), are 
associated with the development of fibrosis in both human disease and animal 
models (Varin et al., 2009; Wynn, 2004), including lung fibrosis (Murray et al.). With 
relevance to the present studies, there are reports that macrophages may represent 
an important source of IL-13 in fibrosis (Hancock et al., 1998), though the regulation 
of macrophage IL-13 production remains unclear. Epithelial cells have also been 
reported to be capable of expressing IL-13 in response to mechanical injury 
(Allahverdian et al., 2008), which is of particular interest given the perceived 
importance of epithelial injury in initiating both experimentally-induced fibrosis and 
IPF. Eosinophils have also been demonstrated to be a major source of T-2 
cytokines in the bleomycin model (Huaux et al., 2003b), and may therefore 
represent another cell type whose expression of pro-fibrotic T-2 cytokines might be 
unaffected by neutralising TSLP activity in vivo. To the best of my knowledge, the 
current studies are the first to demonstrate clear polarisation of the T-helper cell 
populations in the lung following bleomycin-induced lung injury. However, the 
current studies did not evaluate the expression of T-2 cytokines at the protein level 
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in this model. Thus, while neutralisation of TSLP activity in vivo may reduce the 
prevalence of effector Th2 cells in the lung following bleomycin injury, one would not 
expect this intervention to inhibit the continued local production of T-2 cytokines by 
macrophages, epithelial cells and eosinophils, which may continue to promote a 
pro-fibrotic microenvironment. The current findings are compatible with findings from 
studies evaluating the role of TSLP in certain helminth-induced T-2 immune 
responses. In these studies, despite a significant reduction in T-2 cytokine 
expression by Th2 cells in TSLPR-/- mice undergoing secondary granuloma 
formation in the lung, the size of granuloma was unaffected compared to wild-type 
controls (Ramalingam et al., 2009). 
In summary, the present studies suggest that the development of bleomycin-
induced fibrosis is independent of both TSLP activity and the phenotype of T-helper 
cells in the lung. However, it is not possible at the current time to draw any 
conclusions regarding the dependence of fibrogenesis in this model to a T-2 
phenotype in general. Further studies evaluating protein expression of T-2 cytokines 
would be needed to address this issue and will be discussed in Section 4.9.1. 
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4.8. Conclusion and implications 
This thesis examined the hypothesis that TSLP is upregulated in the fibrotic lung 
and contributes to fibrogenesis by promoting the development of a T-2 immune 
response following epithelial injury. The work presented herein reports for the first 
time strong TSLP and TSLPR immunoreactivity in bleomycin-induced lung fibrosis 
and IPF. These findings were extended in vitro to demonstrate that the human lung 
fibroblast may represent an important cellular source of TSLP in response to signals 
relayed from an injured epithelium. Moreover, the present studies demonstrate the 
presence of a hitherto unreported functional TSLP-TSLPR signalling axis in lung 
fibroblasts, further highlighting the potential of this cell to act in an immunoregulatory 
manner. The importance of TSLP as a key mediator of immune responses 
characterised by a predominance of Th2 cells was extended beyond non-allergen 
driven lung disease, and TSLP was identified as a critical mediator of DC activation 
following bleomycin-induced lung injury. However, these studies revealed that the 
development of lung fibrosis in this model is independent of a predominance of Th2 
cells in the lung, and suggest that, while a T-2 immune response to lung injury may 
be pro-fibrotic, alternative cellular sources of T-2 cytokines may contribute to the 
pathogenesis of lung fibrosis. 
The pathogenetic role of T-cells in lung fibrosis remains a contentious issue, with 
different studies in animals yielding contradictory results. Moreover, despite reports 
of functional differences in T-cell populations from IPF and control patients, a causal 
relationship between the adaptive immune system and the pathogenesis of fibrosis 
has yet to be defined in this condition. It is increasingly clear, however, that the 
heterogeneity of mechanisms through which T-cells may participate in the immune 
response to epithelial injury, means that universal depletion or suppression of T-cell 
activity is unlikely to be beneficial to patients. Rather, phenotypic modulation of T-
cells in the lung may offer more promise as a therapeutic strategy. Although the 
current studies failed to demonstrate such an effect in bleomycin-induced lung 
fibrosis, it is important to acknowledge the difficulties in translating results from 
animal models to human disease. The bleomycin model is a useful model to 
delineate the relative importance of potential pro-fibrotic mechanisms but, as has 
been well documented, is by no means an accurate representation of all the 
features of IPF (Scotton et al., 2010). Aside from pirfenidone and NAC, optimism 
that targets derived from attenuation of experimentally-induced fibrosis would 
translate into a clinical benefit in IPF has not yet been realized. Nonetheless, the 
current studies suggest that in IPF, T-cells may not represent the predominant 
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cellular source of pro-fibrotic cytokines. As has been described, both alveolar 
epithelial cells and macrophages are capable of elaborating IL-13, and the relative 
importance of these cellular sources in IPF remains undefined. However, 
modulation of the immune phenotype in this condition remains a potentially 
successful therapeutic option and trials evaluating the use of an anti-IL-13 antibody 
in IPF are currently ongoing (QAX576; Novartis, Switzerland). 
While the current studies have failed to demonstrate a clear pathogenetic role for 
TSLP in the development of bleomycin-induced lung fibrosis, they do support the 
notion that the lung fibroblast represents a potential immunoregulatory cell, capable 
of modulating the nature of the immune phenotype at sites of injury. In particular, 
the work presented in this thesis supports the notion that fibroblasts are capable of 
acting as sentinel cells, responding to tissue injury by influencing immune cell 
recruitment; the scientific rationale for targeting this aspect of fibroblast biology in 
inflammatory lung diseases characterised by excessive activity of the adaptive 
immune system is rapidly gaining strength.  
In conclusion, IPF remains a devastating and progressive condition with an 
appalling prognosis. It is clear that the fibroproliferative response to injury seen in 
this condition reflects an extremely complex interplay between a number of different 
cellular and signalling mechanisms, with an unknown degree of redundancy. By 
demonstrating the independence of bleomycin-induced fibrosis from T-cell 
polarisation, the work presented in this thesis contributes to this field of knowledge 
by suggesting that the pro-fibrotic “T-2 immune phenotype” perceived as 
characteristic of IPF may in fact be mediated by cells other than T-lymphocytes. 
Indeed, the present findings highlight the need for further human studies to 
determine the relative importance of T-cells to the development of such phenotypes 
in this condition.  
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4.9. Future work 
4.9.1. Animal models of lung fibrosis 
The findings presented in this thesis have provided evidence that the development 
of bleomycin-induced lung fibrosis is independent of TSLP-mediated DC activation 
and polarisation of T-helper cells towards a T-2 phenotype. To reconcile these 
findings with previous reports highlighting the importance of T-2 cytokines in lung 
fibrosis, further studies would be required to examine the expression of T-2 
cytokines in this model. Quantitative evaluation of IL-13 protein expression is 
technically challenging in murine lung homogenates and to the best of my 
knowledge has not been reported in the bleomycin model. While it is possible to 
measure expression at the mRNA level, the interpretation of such studies are 
hampered in this model by the potential dilution of signal by mRNA emanating from 
the massive cellular infiltrate into the lung following bleomycin injury. Nonetheless, 
such studies may help determine if the development of a T-2 immune phenotype 
occurs independently of T-cells. Concomitant immunostaining for T-2 cytokines in 
this model may also help resolve this issue but was not attempted due to time 
constraints. An alternative approach would be to examine T-2 cytokine expression 
in mice deficient in T- and B-cells challenged with bleomycin. Such depletion may 
be achieved by anti-CD3 therapy administration to wild type mice or by using mice 
devoid or T- and B-cells, such as rag-/- mice.  
While the present studies have demonstrated the importance of TSLP in promoting 
the predominance of Th2 cells in the lung following bleomycin-induced lung injury, it 
is not clear whether this effect is mediated by TSLP-DCs, or via a direct effect on T-
cells. To resolve this issue, future studies may examine the effect of conditional 
depletion of lung DCs (van Rijt et al., 2005) in the bleomycin model. Such 
experiments may also confirm the independence of bleomycin-induced fibrosis from 
DC activation, as has been suggested by the present studies.  
The findings presented in this thesis have demonstrated that immunoreactivity for 
TSLP in the lung is greater in bleomycin-challenged mice compared to saline-
instilled controls, localising to alveolar epithelial cells as well as fibroblasts. From the 
present studies, it is not possible to determine which of these cell types represents 
the predominant cellular source in promoting DC activation and the promotion of 
Th2-dominant lymphocyte population in the lung following bleomycin-induced injury. 
This question may be addressed by the generation of mice containing a conditional 
fibroblast-specific deletion of Tslp. C57Bl/6 mice which carry an inducible Cre-
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recombinase under the control of a fibroblast-specific regulatory sequence, for 
instance from the proα2(I) collagen gene, could be crossed with mice that carry a 
floxed TSLP allele. The use of such mice has not, to the best of my knowledge, 
been reported in the literature but would represent an exciting opportunity to 
determine the functionally dominant cellular source of TSLP following bleomycin-
induced lung injury. 
Finally, to address the relative importance of TSLP in mediating DC activation in this 
model during the fibrotic phase, further studies may be performed using a small 
molecular weight antagonist of TSLP. Although such a compound is not currently 
commercially available, the success of such a molecule (developed by Actimis 
Pharmaceuticals Inc, USA) in attenuating cutaneous allergic inflammation suggests 
that it may offer an alternative effective mechanism to neutralise TSLP activity in 
vivo. Such experiments would circumvent the problems highlighted with repeated 
antibody dosing in this model and may indeed offer a more complete neutralisation 
of TSLP activity in the bleomycin model. 
4.9.2. Human disease 
While the present studies have demonstrated strong immunoreactivity for TSLP and 
TSLPR in IPF, future studies would be directed towards assaying expression at the 
protein level in this condition. Although neutralisation of TSLP activity had no effect 
in an animal model of lung fibrosis, the observation of increased levels of TSLP in 
IPF patients would corroborate the present immunohistochemical data and 
strengthen the notion that this cytokine might contribute to the pathogenesis of 
human disease. In addition, qRT-PCR could be performed on laser-capture 
microdissected IPF lung tissue to confirm that fibroblasts represent an important 
source of TSLP in this disease. An alternative approach to confirm the cellular 
provenance of TSLP in this condition would be to perform combined in-situ 
hybridisation studies with immunohistochemical analysis of IPF sections. 
4.9.3. Cell biology 
The mechanisms involved in mediating STAT phosphorylation following ligation of 
the TSLP receptor complex remain unclear. Although the present studies have 
demonstrated that TSLP induces phosphorylation of STAT3 in pHLFs, the relative 
importance of JAKs was not addressed and would form a major part of future 
studies to delineate the signalling pathways downstream of TSLP in this cell type.  
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APPENDICES 
 
 
 
 
A1 Serum concentrations at day 14 of anti-TSLP and isotype control 
antibodies following intra-peritoneal injection in mice instilled 
with saline or bleomycin. 
Figure shows the serum concentrations of the monoclonal rat anti-mouse IgG2a 
TSLP antibody, 28F12, and the isotype control antibody achieved following intra-
peritoneal injections (15 mg/kg mouse weight). C57Bl/6 mice were instilled with 
saline or bleomycin at day 0 as described in Materials and Methods. Antibody 
administration was commenced at day -1, and continued every 4 days until the time 
of sacrifice at day 14. Serum samples were taken from mice and analysed for 
antibody levels by ELISA (kindly performed by GSK). The concentration of antibody 
is expressed as µg/ml, and each bar represents the mean ± SEM of all mice in each 
group (n=8, saline/isotype; n=8, saline/anti-TSLP; n=6, bleomycin/isotype; n=8, 
bleomycin/anti-TSLP). 
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A2 TSLP-induced CCL2 protein release by primary murine lung 
fibroblasts (pMLFs) is inhibited by the rat monoclonal anti-
mTSLP antibody, 28F12.  
Figure shows the effect of an anti-mTSLP antibody, 28F12, on TSLP-induced CCL2 
protein release by pMLFs. Data are presented as a percentage of the maximal 
response obtained with mTSLP only. pMLFs were exposed for 6 hours to control 
medium; isotype control antibody only (30 ng/ml); 28F12 only (30 ng/ml); mTSLP (1 
ng/ml) pre-incubated with isotype control antibody (30 ng/ml) or varying 
concentrations of 28F12 (for 2 hours). Conditioned media were analysed for CCL2 
protein release by ELISA. The first bar represents the response to control medium 
alone. The second bar represents the response to mTSLP only. The final bars 
represent the response to isotype control and 28F12 antibodies respectively (30 
ng/ml), and show that these antibodies had no effect on basal CCL2 release. 
Negative log of the concentrations of 28F12 (g/l) are presented. Data represent the 
mean ± SEM, from triplicates. +++p<0.001, comparison with control; ns-non 
significant medium, **p<0.01, ***p<0.001, comparison with mTSLP alone.  
Reducing [28F12] 
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A3 CD86 expression by splenic DCs is similar for saline-treated and 
bleomycin-challenged mice at day 10. 
Figure shows the effect of anti-TSLP administration on CD86 expression by splenic 
DCs following saline or bleomycin instillation. C57Bl/6 mice were instilled with saline 
or bleomycin, and administered isotype control or anti-TSLP antibody i.p. as per 
Materials and Methods. Spleens were harvested for preparation of single cell 
splenic suspensions as described in Materials and Methods.  Data are presented 
as percentage of splenic dendritic cells (identified by an identical gating strategy to 
that employed for lung DCs) which are CD86+ ± SEM; n=3, all groups; ns – non 
significant, two-way ANOVA. 
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A4 Bleomycin challenge in mice does not result in an increase in the 
total, CD4+ or CD8+ lung T-cell populations at day 7. 
Figure shows representative FACS plots demonstrating lung αβ T-cell populations 7 
days following saline or bleomycin instillation. C57Bl/6 mice were instilled with 
saline or bleomycin; lungs were harvested at day 7 for preparation of single cell 
suspensions, as described in Materials and Methods, for FACS analysis. Cells 
were initially gated according to forward and side scatter to identify lymphocytes and 
exclude debris. CD4 (Panel A) and CD8 staining (Panel B) was then assessed in 
TCR-β+ cells derived from murine lung instilled with saline (i and iii) or bleomycin (ii 
and iv); saline, n=3; bleomycin, n=4. 
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A5 Bleomycin-induced lung injury in mice does not result in an 
increase in the lung CD4+ or CD8+ T-cell populations at day 10 or 
day 28.  
Figure shows the effect of bleomycin challenge on the CD4+ and CD8+ T-cell 
populations at day 10 and day 28. C57Bl/6 mice were instilled with saline or 
bleomycin, and administered isotype control or anti-TSLP antibody i.p.; lungs were 
harvested at day 10 (Panel A) or day 28 (Panel B) for preparation of single cell lung 
suspensions as described in Materials and Methods. Cells were initially gated on 
forward and side scatter to identify lymphocytes, before being gated according to 
TCR-β and CD4 or CD8 staining. Data are presented as percentage of lymphocytes 
which are TCR-β+ and CD4 +ve (Ai, Bi) or CD8 +ve (Aii, Bii) ± SEM.; n=3, saline 
groups; n=5, bleomycin (day 10); n=3, bleomycin (day 28); ns – non-significant, two-
way ANOVA. 
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A6 Bleomycin-induced lung injury does not result in a change in the 
Th1 or Th2 phenotype of splenic CD4+ T-cells at day 10 post 
injury.  
Figure shows the effect of bleomycin challenge on IFN-γ-producing/Th1 (Panel A) 
and IL-4-producing/Th2 (Panel B) splenic CD4+ T-cells at day 10. C57Bl/6 mice 
were instilled with saline or bleomycin, and administered isotype control or anti-
TSLP antibody i.p.; spleens were harvested for preparation of single cell splenic 
suspensions as described in Materials and Methods. The gating strategy 
employed to identify TCR-β+/CD4+ cells for analysis of intra-cellular cytokine 
staining was identical to that used for lung T-cells. Data are presented as the mean 
percentage of TCR-β+/CD4+ cells which are IFN-γ+ (Panel A) or IL-4+ (Panel B) ± 
SEM.; n=3, saline groups; n=5, bleomycin; ns – non-significant, two-way ANOVA. 
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A7 Effect of 28F12 administration on mouse body weights following 
bleomycin-induced lung injury over 28 days. 
Figure shows the effect of 28F12 administration on mouse body weight following 
bleomycin challenge over 28 days. C57Bl/6 mice were instilled with saline or 
bleomycin, and administered isotype control or anti-TSLP antibody i.p. as per 
Materials and Methods. Results are expressed as mean change in body weight as 
a percentage of the starting weight. ***p<0.001, comparison between saline and 
bleomycin; repeated measure ANOVA. 
 
 Appendix 
319 
 
A8 Publications and awards arising from this thesis: 
 
Review articles: 
Novel therapeutic approaches for pulmonary fibrosis. A Datta, CJ Scotton 
and RC Chambers. British Journal of Pharmacology. (2011). Novel 
therapeutic approaches for pulmonary fibrosis. Br J Pharmacol, 163, 141-72. 
 
Abstracts: 
TSLP plays a key role in the development of T-2 immune responses in a 
model of fibrotic lung injury. A Datta, A Williams, R Alexander, CJ Scotton 
and RC Chambers Am J Resp Crit Care Med ATS supp 2012; 
 
TNF-α induces TSLP expression by human lung fibroblasts in an AP-1 / JNK 
dependent manner. A Datta, CJ Scotton, A Ortiz-Stern, RJ McAnulty and RC 
Chambers. Am J Resp Crit Care Med ATS supp 2009; 
 
Manuscripts in preparation: 
Human lung fibroblasts express a functional TSLP-TSLPR signalling axis. A 
Datta, CJ Scotton, A Ortiz-Stern, RJ McAnulty and RC Chambers 
 
TSLP mediates lung dendritic cell activation and polarisation of the immune 
response towards a T-2 phenotype following non-allergen driven lung injury. 
A Datta, A Williams, A Ortiz-Stern, R Alexander, CJ Scotton and RC 
Chambers  
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Presentations: 
Forthcoming abstract and poster discussion: TSLP plays a key role in 
the development of T-2 immune responses in a model of fibrotic lung injury; 
American Thoracic Society conference, 2012; 
 
Abstract and oral presentation: The role of TSLP in the development of T-
2 immune responses following bleomycin-induced lung injury; UK 
Respiratory Research Collaborative Meeting, Royal Society of Medicine 
2012; 
 
Abstract and oral presentation: Human lung fibroblasts express a 
functional TSLP-TSLPR signalling axis; British Association for Lung 
Research (BALR) Meeting 2011. 
 
Academic achievements: 
 
Winner of Clinical Science Oral Communication Prize, UK Respiratory 
Research Collaborative Meeting, Royal Society of Medicine (2012); 
 
Runner up BALR Young Researcher of the Year (2011); 
 
Wellcome Clinical Research Training Fellowship (2008). 
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